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ABSTRACT 
Background: Health workers (HWs) are exposed to a wide range of chemicals used for 
cleaning and disinfection. This has been largely attributed to the ever-increasing demand for 
effective cleaning and disinfection in hospital settings in an effort to prevent healthcare 
associated infections. Over the last two decades, there has been increasing evidence linking 
cleaning agents to adverse work-related health effects such as rhinitis, asthma and contact 
dermatitis. There is however little information on the specific cleaning agents and tasks 
associated with various asthma-related outcomes. Furthermore, limited information exists 
regarding exposure-response relationships between the frequency of exposure to specific 
cleaning agents and asthma-related outcomes. This study investigated the prevalence and 
risk factors for work-related asthma (WRA) among HWs exposed to diverse cleaning agents 
in two academic tertiary public hospitals in southern Africa - South Africa and Tanzania. 
Methods: A cross-sectional study of 699 HWs was conducted. Exposure assessment 
included systematic workplace observations, environmental sampling for aldehydes (ortho-
phthalaldehyde-OPA, glutaraldehyde and formaldehyde) and urine biomonitoring for 
chlorhexidine. Environmental sampling for aldehydes was conducted more extensively in the 
South African hospital (SAH). A pilot sampling in the Tanzanian hospital (TAH) revealed very 
low detectable levels of OPA and glutaraldehyde and as a result extensive measurements 
were not done. In the SAH, a total of 269 full-shift passive personal samples were collected 
from 164 HWs randomly selected from 17 different clinical departments. Passive sampling 
used TraceAir® AT580 monitors (Assay Technology, Livermore, CA). Biomonitoring for 
chlorhexidine was only conducted in the SAH since none of the HWs in the TAH used 
chlorhexidine. For the health outcome assessment, a total of 697 HWs completed interviews 
using the ECRHS questionnaire adapted for occupational contexts, which contained in-depth 
information on asthma, as well as detailed information on tasks and chemicals used during 
the course of their work. Sera was successfully collected from 682 HWs and analysed for 
specific immunoglobulin E (sIgE) antibody reactivity to common aero-allergens (Phadiatop) 
and specific occupational allergens (NRL - Hevea brasiliensis (Hev b5, Hev b6.02), 
chlorhexidine and OPA). Methacholine challenge tests (MCT) were performed on all South 
African HWs (n=318), based on standard inclusion criteria. Spirometry, accompanied by a 
post-bronchodilator (post-BD) test was conducted on all Tanzanian HWs (n=329) and a 
small proportion (n=25) of South African HWs where MCT was contraindicated. All HWs 
from both hospitals (n=654) underwent fractional exhaled nitric oxide (FeNO) testing during 
the working day prior to spirometry.  
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Results: The prevalence of current asthma was 10% (atopic asthma 6%, non-atopic asthma 
4%), while 2% had WRA. The prevalence of atopy was 43%, with 4% of workers being 
sensitised to OPA, 2% to NRL and only 1% to chlorhexidine. Environmental sampling 
demonstrated that OPA was detectable in 6 (2%) samples, all samples (Geometric mean 
(GM) = 0.010 ppm) being higher than the ACGIH exposure limit (0.0001 ppm). Workers with 
detectable OPA were found to have a longer duration of OPA use (OR = 1.28; 95% CI: 1.10 
– 1.50). Formaldehyde was detectable in 103 (38%) samples (GM = 0.005 ppm), with 1% of 
samples having levels higher than the NIOSH TWA exposure limit (0.016 ppm). Asthma-
related outcomes (increasing asthma symptom score and FeNO) demonstrated consistent 
positive associations with certain medical instrument cleaning agents (OPA, QACs and 
enzymatic cleaners) and tasks (pre-cleaning of medical instruments, changing sterilisation 
solutions and manual disinfection of medical instruments) as well as certain patient care 
activities (disinfection prior to procedures, cleaning/disinfecting wounds, application of 
wound dressing, usage of adhesives and adhesive removing solvents). A particularly 
pronounced dose-response relationship was observed between work-related ocular-nasal 
symptoms and medical instrument cleaning agents (OPA, glutaraldehdye, QACs, enzymatic 
cleaners, alcohols and bleach; OR range: 2.50 – 12.08) and tasks (OR range: 2.58 – 3.97). 
Furthermore, a strong association was observed between higher asthma symptom scores 
and use of more sprays than wipes for fixed surface cleaning activities (mean ratio = 3.00; 
95% CI: 1.50 – 5.98). 
Conclusion: This study has demonstrated that detectable exposures to OPA are higher and 
more isolated to certain departments than the more widespread low-level formaldehyde 
exposures present throughout the hospitals. Furthermore, cleaning agents have replaced 
NRL as important causes for WRA in health settings. Finally, specific cleaning agents such 
as OPA, quaternary ammonium compounds and enzymatic cleaners associated with 
medical instrument cleaning/disinfection as well as patient care activities and the use of 
sprays for fixed surface cleaning, are important environmental risk factors for various 
asthma-related outcomes among HWs in health care settings. 
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1.1. INTRODUCTION 
Work-related asthma (WRA) is commonly classified as occupational asthma (OA), caused 
by a particular workplace agent or work-exacerbated asthma (WEA), which is a preexisting 
asthma worsened by workplace agents (1). Previous studies have shown that the proportion 
of adult-onset asthma attributable to occupational exposure is between 10-15% of the 
population (2). Studies in the past decade (1,3,4) indicate that the population-attributable risk 
of 10-25% for adult asthma related to occupation exceeds that of previously reported 
studies. More recently, in a British postal survey among adults with asthma, 33% reported 
work-aggravation of their asthma symptoms (5). Furthermore, studies have shown that 
occupational asthma is under-recognised in clinical practice (1,6). Occupational exposure as 
a cause of adult onset asthma may therefore be more common than is appreciated. In the 
South African setting, a population attributable fraction of 13% has previously been 
estimated (7) with occupational asthma ranked as the second most common occupational 
lung disease after the pneumoconioses (8).  
Health workers (HWs) are among the high risk occupational groups for developing WRA, 
and accounting for 16% of WRA patients in a US surveillance study (9). It is well known that 
natural rubber latex (NRL) has historically been a common cause of WRA in HWs (10–13). 
However, studies in the past decade have reported a decrease in NRL allergy among HWs 
due to substitution with less allergenic alternatives or a reduction in powder and protein 
content of gloves with the incidence of sensitisation to NRL allergens having decreased to 
1% in countries that have promoted latex avoidance (10,14–17). Nevertheless, powdered 
NRL gloves continue to be widely used in developing countries due to economic reasons, 
posing an increased risk for allergic sensitisation and asthma.  
With the global decline in the incidence of NRL allergic asthma, cleaning agents have 
increasingly been considered a major risk factor for WRA in the health care setting (17–19). 
Cleaning agents have been shown to cause work-related asthma-like symptoms, new onset 
asthma with or without latency and may also exacerbate asthma symptoms in asthmatic 
individuals (20,21). It is estimated that 12% of WRA is related to the use of cleaning products 
among patients reported in a US surveillance registry (22). Furthermore, among the causes 
of work-related reactive airways dysfunction syndrome (RADS), cleaning agents constituted 
the largest group (15% of the cases) reported by the same surveillance program for WRA 
(23).  
In recent years, there has been an increasing demand for effective cleaning and disinfection 
in hospital settings in order to prevent healthcare associated infections, particularly those 
caused by the multi-drug resistant organisms (24). These efforts have resulted in strict 
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infection prevention guidelines requiring extensive use of various types of cleaning agents in 
hospital settings (25). As a result, HWs are exposed to higher concentrations of a wider 
range of cleaning agents, some known to be potent respiratory sensitisers and irritants. 
Most cleaning agents are irritants but some have sensitising properties as well (20). Major 
groupings of potential sensitisers and irritants that are present in health care settings include 
medical instrument cleaning and disinfecting products (e.g. glutaraldehyde and ortho-
phthalaldehyde - OPA); fixed surface cleaning products (e.g. bleach); floor finishing products 
(stripping, waxing & buffing e.g. ethanolamine); specimen preparation products (e.g. 
formaldehyde); patients‘ skin / wound cleaning & disinfecting products (e.g. chlorhexidine 
and povidone iodine) and hand washing / sanitising products (e.g. chlorhexidine and 
alcohols). Other potential sensitisers and irritants in health care settings include NRL, 
aerosolised medications (e.g. pentamidine), methacrylates in dental and surgical cements, 
micro-organisms and mildew (20,25,26). While previous studies have reported on the 
association between respiratory symptoms or asthma and these broad categories of 
cleaning-related exposures in health care settings (20,21,27,28), only a few epidemiological 
studies and case reports have identified specific cleaning agents associated with these 
outcomes (29–31).  
Little is known about the magnitude of asthma burden among HWs in South Africa. A few 
studies among HWs in South Africa have focused mainly on NRL and exposures such as 
endotoxins, but none on cleaning agents (32–37). The South African study of dental HWs 
(37) reported a 6.9% prevalence of atopic asthma and a slightly lower proportion (5.9%) with 
non-atopic asthma. In this occupational group, WEA was reported in 4% of the study 
population. On the other hand, the prevalence of asthma specifically among HWs in 
Tanzania is unknown. 
Exposure assessment for cleaning agents has historically been a challenge since various 
cleaning agents with different ingredients are used simultaneously, resulting in airborne 
exposures that are usually a complex mixture of various chemicals with different physico-
chemical properties that require multiple sampling techniques (38). Furthermore, the type of 
product used, the frequency and duration of its use, varies depending on the specific 
cleaning task performed (25,38). Frequently, several cleaning tasks are performed in an 
isolated room and may be repeated several times a day. Furthermore, various HWs may use 
the same cleaning agent in different ways resulting in variable degrees of exposure. As a 
result only a few studies have been reported on quantitative exposure assessment for 
cleaning agents in general, and aldehydes such as glutaraldehyde and OPA in particular.  
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This study was prompted by the increasing number of HWs with WRA and skin complaints 
presenting to the Occupational Medicine clinic at Groote Schuur Hospital. The study was 
conducted to determine the contribution of cleaning agents towards the development of 
WRA among HWs in two southern African health care settings, South Africa and Tanzania, 
since little recent information was available with regard to the magnitude of asthma among 
HWs and specifically, the contribution of cleaning agents in relation to WRA among HWs. 
Furthermore, while some studies in other parts of the world, had reported on quantitative 
exposure assessment for cleaning agents, none had been reported from southern Africa. 
Moreover, little information exists on the specific cleaning agents and tasks associated with 
various asthma phenotypes and limited evidence regarding specific dose-response 
relationships. It was also important to determine the residual contribution of NRL to WRA 
following a reduction in latex glove usage practices in the South African Hospital. 
Furthermore, there was also a need to better understand the association between WRA and 
host-related risk factors that could modify these risks in exposed workers. It was envisaged 
that the specific information obtained from this study would contribute towards the 
development of appropriate preventive strategies for WRA associated with exposure to 
cleaning agents in the health care settings in general and the African setting in particular. 
 
1.2. STUDY AIM 
To determine prevalence and risk factors for work-related asthma among health workers in a 
South African and Tanzanian tertiary academic public hospital with widespread use of 
cleaning agents. 
 
1.3. OBJECTIVES 
1) To characterise the exposure of health workers to major categories of cleaning 
agents (e.g. medical instrument cleaning/disinfection and fixed surfaces cleaning) in 
relation to specific chemicals used, frequency and duration of use, job type, specific 
tasks and protective measures in place. 
2) To characterise predominantly dermal exposure to chlorhexidine-containing cleaning 
products through determination of urinary levels of chlorhexidine and its metabolites. 
3) To characterise inhalational exposure to OPA (a high-level disinfectant used for 
medical instruments) through personal environmental sampling and investigate the 
determinants of exposure variability (e.g. jobs, tasks) in this health care setting. 
4) To determine the prevalence of work-related respiratory and skin symptoms, allergic 
sensitisation and lung function abnormalities in health workers of these two hospitals. 
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5) To describe various asthma phenotypes (non-work-related and work-related) based 
on the presence of respiratory symptoms, allergic sensitisation, airway obstruction, 
nonspecific bronchial hyperresponsiveness and airway inflammation, and determine 
their association with host risk factors. 
6) To determine the association between various asthma-related outcomes (general 
and work-related) and environmental risk factors, controlling for potential 
confounders. 
 
1.4. STRUCTURE OF THE THESIS 
Chapter 2 is a comprehensive literature review focussing on the relationship between 
exposure to cleaning agents and asthma-related outcomes in health care settings. The 
chapter includes information on the working populations at risk of developing adverse health 
effects due to cleaning agents, exposure characterisation for cleaning agents, epidemiology 
of asthma related to cleaning agents, pathophysiological mechanisms of asthma related to 
cleaning agents, workplace environmental risk factors and causative agents, host-associated 
risk factors and preventive strategies for WRA associated with cleaning agents in the health 
care settings. 
Chapter 3 gives a detailed description of the methods used for this study. The chapter 
describes the study design, population and sampling strategy, the various exposure 
assessment strategies employed and a detailed description of the various methods used for 
the health outcome assessment of the epidemiological study. 
Chapter 4 describes the detailed characterisation of health workers‘ exposure to cleaning 
agents in the two hospitals. It includes information on the systematic workplace observations 
that were conducted, environmental sampling for aldehydes (OPA, glutaraldehyde and 
formaldehyde) and biomonitoring for chlorhexidine. It also investigates the determinants of 
exposure variability, especially for the measured aldehyde levels, in order to identify specific 
risk factors that could be targeted for prevention. 
Chapter 5 describes the prevalence of work-related respiratory and skin symptoms, allergic 
sensitisation profiles and various lung function indices used to identify airway obstruction, 
non-specific bronchial hyperresponsiveness and airway inflammation among health workers 
in the two hospitals. 
Chapter 6 describes the various asthma phenotypes identified among this group of health 
workers and provides a detailed exploration of their relationship with host-associated risk 
factors. 
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Chapter 7 provides a detailed description of the environmental risk factors (specific cleaning 
agents and tasks) including exposure-response relationships for the association between the 
various asthma-related outcomes among these health workers.  
Chapter summarises the most important findings of this study. Strengths and limitations of 
the study are discussed and practical preventive strategies for reducing the burden of work-
related asthma related to cleaning agents in heath care settings are presented. 
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2.1. Background 
Various studies have demonstrated that health workers (HWs) are at increased risk of 
developing work-related asthma due to their exposure to various agents that are respiratory 
sensitisers or irritants such as cleaning agents, natural rubber latex (NRL), diisocyanates, 
methacrylates, medications and mildew (1–4). Exposure to cleaning agents has become of 
particular importance in health care settings due to the extensive use of various types of 
cleaning chemicals so as to comply with strict infection prevention standards that have been 
implemented to prevent healthcare associated infections (3,5). In the past two decades, an 
increasing number of case reports, epidemiological and surveillance studies have reported 
an increased risk of asthma, rhinitis and contact dermatitis associated with cleaning-related 
exposures in health care settings  (3,5–8). However, only a limited number of studies have 
investigated the specific cleaning agents associated with work-related asthma in HWs.  
Search strategy 
Several electronic literature sources were searched including PubMed, Google Scholar and 
Embase for relevant articles using various key words: allergy, asthma, occupational asthma, 
work-related asthma, cleaning agents, cleaning products, disinfectants, sterilants, 
chlorhexidine, ortho-phthalaldehyde, glutaraldehyde. Reference lists from the articles 
obtained were also screened for relevant publications. Selection of articles to be included in 
the review was not restricted to any time period. However, epidemiological studies that 
investigated work-related asthma associated with cleaning agents in the health care setting 
during the last 15 years (2004 to 2019) were summarised in Table 2.1. 
2.2. Working populations at risk  
Based on occupations in the health care sector, workers considered to be potentially at 
increased risk include nurses, cleaners, physicians, respiratory therapists and occupational 
therapists (9–12). Nursing professions typically consist of a number of sub-groups, such as 
registered nurses, licensed practical nurses, licensed vocational nurses, nurse aides, nurse 
practitioners and nurse trainers (12). Arif et al (12) demonstrated that among nurses, 
registered nurses had the highest prevalence of reported asthma (10.2%), followed by 
licensed vocational nurses (8%) and nurse practitioners and nurse aides (6.9%). The 
reason/s for difference in the prevalence of reported asthma among these groups of nurses 
in this study (12) was not explained by the authors and perhaps not well understood at the 
time. 
Other studies have also demonstrated that cleaners  in hospitals also have a higher odds 
(odds ratio (OR) = 2.1; 95% CI: 1.1 to 4.2) of having current asthma when compared to 
those who have never done a cleaning job or those cleaners that had not worked in any 
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listed high risk workplaces (industries, hospitals, kitchens, laboratories, schools, outdoors, 
private homes, common areas in apartment buildings, other healthcare settings), most likely 
due to their increased likelihood of exposure to irritant cleaning products (13). 
2.3. Exposure characterisation for cleaning agents 
Exposure assessment for cleaning agents has been challenging partly due to the fact that 
many cleaning agents having different ingredients are used simultaneously in the health care 
setting. Airborne exposures generated in these settings are commonly a complex mixture of 
various chemicals with different physicochemical properties requiring different sampling 
techniques (14,15). Another challenge is that the type of product used, its frequency and 
duration of use usually varies depending on the specific cleaning task performed (14,16). 
Commonly, several cleaning tasks are performed in a single room and may be repeated 
several times a day. Furthermore, HWs may use cleaning agents differently, resulting in 
varying amounts of chemical exposures for a single category of HWs. As a result, very few 
studies have conducted quantitative exposure assessments for cleaning agents in the health 
care setting. In a case-control study among Spanish domestic cleaners, quantitative 
exposure assessment for chlorine and ammonia was conducted in a sub-group of 10 
participants (17). In this study, airborne exposure levels of both chlorine (median: 0–0.4 
ppm) and ammonia (median: 0.6–6.4 ppm) were detectable during domestic cleaning using 
cleaning products containing bleach and ammonia.  
There is limited information regarding assessment of environmental exposure to aldehydes 
such as glutaraldehyde (GTA) and ortho-phthalaldehyde (OPA). In a study of various 
endoscopy units in an Italian hospital (18), detectable GTA levels (mean = 0.005 ppm) were 
slightly higher than in the US study (19) of HWs from eight health care facilities (range: not 
detected – 0.005 ppm). However, much higher GTA levels (geometric mean (GM) = 0.025 
ppm) were reported in a Canadian study of five hospitals (20).  
A literature search revealed few studies that have conducted measurement of OPA 
exposure in air (19,21–26). The mean OPA concentration reported in a previous Italian study 
among HWs in endoscopy units was 0.0015 ppm (18). A Japanese study that conducted air 
measurements for OPA in an endoscopy unit reported OPA concentrations in the range of 
0.0006 – 0.002 ppm (27). The highest concentration (0.002 ppm) was found when a bucket 
containing OPA was left open without a lid while an endoscope washing machine was 
operating (27). A later Japanese study conducted air measurements for OPA in 9 manual 
disinfection rooms and in 8 rooms using automatic endoscope washers (24). The TWA 
concentration of OPA in this Japanese study was higher in the manual group (median = 
0.0007 ppm) than in the automatic endoscopic washer group (median = 0.0003 ppm) (24). In 
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the US study, the average OPA concentrations were higher (GM = 0.00006 ppm) in the 
group of workers from the departments using OPA than in the comparison group (GM = 
0.00003 ppm) where OPA was not used (19). 
Literature on the development of sampling and analytical methods for the determination of 
airborne OPA concentrations is even more scant. A study by Uchiyama et al. published a 
method for the determination of OPA in air using 2,4-dinitrophenylhydrazine (DNPH)-
impregnated silica cartridges and high-performance liquid chromatography (HPLC) (22). 
Subsequently, Tucker reported a method for determining OPA concentration in air and two 
methods for measuring OPA exposure on surfaces (23). A more recent study by Tucker 
reported two partially validated methods for determination of OPA in air, one (DNPH-HPLC 
method) being an improvement of his previous method (26).  
Despite the presence of commercially available passive samplers, a literature search did not 
find any study that has measured OPA in the air using the passive method. However, 
studies on passive sampling for formaldehyde and GTA have been reported (28,29). 
Previous studies comparing the performance of passive and active sampling methods for 
formaldehyde have shown good agreement between the two assessment methods (28). 
However, a recent study demonstrated that passive sampling generally overestimated the 
formaldehyde concentrations when compared to the active method (30). In this study, the 
median formaldehyde concentration reported ranged from 0.04 ppm using the active method 
to 0.05 ppm for the passive method. Passive samplers are sometimes preferred over active 
ones for several reasons in that they are convenient since they are small and lightweight; 
can be used by most people with minimal training; are less expensive; and often do not 
interfere with the usual workers‘ routine (30).     
Chlorhexidine is one of the most commonly used agents for hand hygiene and patient care 
activities such as disinfection of wounds and patients‘ skin prior to various medical 
procedures (31). The most appropriate method of estimating exposure to chlorhexidine is to 
conduct biological exposure monitoring. Environmental air sampling is considered 
inappropriate since chlorhexidine has a low likelihood of being aerosolised given its very 
lower vapour pressure. Again, few studies have conducted chlorhexidine biomonitoring (32). 
Some of these researchers have been able to identify chlorhexidine and its metabolites (p-
chloroaniline and 1-chloro-4-nitrobenzene) in biological fluids but challenges have arisen in 
quantifying the concentration of these chemicals (32–34) . 
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2.4. Epidemiology of asthma related to cleaning agents  
Few epidemiological studies have investigated the magnitude of asthma among HWs 
exposed to various cleaning agents (Table 2.1). In an international prospective population-
based study [European Community Respiratory Health Survey-II (ECRHS-II)], the 
prevalence of new-onset asthma (asthma attack or taking asthma medication in the past 12 
months) among nurses was found to be 4.8% (35). A more detailed analysis of HWs from 
this study (36) reported a slightly higher prevalence (6%) of new-onset asthma (currently 
taking asthma medication, asthma attack or woken up by an attack of shortness of breath in 
last 12 months), most likely due to different asthma definitions used. These findings are 
similar to the that of a US study among HWs (n=3650) with active professional licenses (1), 
which demonstrated an overall prevalence of doctor-diagnosed asthma with onset after entry 
into the healthcare profession to be 6.6%. The highest prevalence was observed among 
nurses (7.3%) followed by respiratory therapists (5.6%), occupational therapists (4.5%) and 
doctors (4.2%). However, a study published 2 years later of the same US population of HWs 
reported a much higher prevalence of diagnosed asthma with onset after entry into the 
healthcare profession (9.8%) among nurses based on the longest job held (12). Overall, the 
prevalence of asthma in HWs exposed to cleaning agents has ranged between 4.4% and 
11.2% (current asthma: 4.8% – 11%; doctor-diagnosed asthma: 9 – 11.2% and doctor-
diagnosed asthma with onset after entry into the healthcare profession: 4.4% – 9.8%) 
(1,12,13,35–37). Little is known about the magnitude of asthma in HWs in South Africa. 
However, in a recent South African study among dental HWs (38), the prevalence of atopic 
asthma was 6.9%, non-atopic asthma 5.9% and work-exacerbated asthma 4%. On the other 
hand, the prevalence of asthma among Tanzanian HWs is unknown. 
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Table 2.1: Recent epidemiological studies on work-related asthma associated with cleaning agents in the health care setting 
Author/ year Population 
(n) 
Prevalence of asthma 
phenotypes / symptoms 
High risk activities 
significantly associated 
with asthma 
OR / RR (95% CI) 
Cleaning agents significantly 
associated with asthma  
OR/RR / MR (95% CI) 
Tools used for 
assessment of 
exposure and 
asthma-related 
outcomes  
Dumas et al, 
2018 (31) 
Nurses  
(n = 4055) 
Prevalence not specified. Asthma 
control was defined by Asthma 
Control Test (ACT) 
Surgical hand/arm hygiene:  
≥1 time/day: 1.96(1.52-2.51); 
<1 time/day: 1.38(1.06-1.80) 
Not specified Questionnaire 
 
 
Dumas et al, 
2017 (39) 
Nurses  
(n = 4102) 
Prevalence not specified. Asthma 
control was defined by Asthma 
Control Test (ACT) 
Use of disinfectants for 
medical instruments:  
1.88 (1.38-2.56) 
Formaldehyde: 1.33 (1.05-1.68) 
Enzymatic cleaners: 1.33 (1.12-1.57) 
Hydrogen peroxide: 1.19 (1.04-1.36) 
Glutaraldehyde: 1.18 (1.03-1.34) 
Hypochlorite bleach: 1.18 (1.03-1.36) 
Questionnaire 
 
Job-task-exposure 
matrix 
Lee et al, 2014 
(40) 
Hospital 
cleaners  
(n = 183) 
Prevalence not specified. 
Chemical-related symptoms 
(respiratory, ocular, dermal, 
neurological and gastrointestinal) in 
the past 12 months  
Sprays: 2.82(1.16-6.82) Carpet cleaners: 2.98 (1.28-6.92) 
Solvents: 2.71 (1.20-6.15) 
Multi-purpose cleaners: 2.58 (1.13-
6.92) 
Questionnaire 
 
Gonzalez et al, 
2014 (37) 
Health 
workers  
(n = 543) 
Physician diagnosed asthma: 
11.2% 
Physician-diagnosed asthma with 
onset after entry in the healthcare 
sector (new-onset asthma): 4.4% 
Dilution of disinfectants: 
4.01(1.34-12.00)  
General disinfection tasks: 
3.16(1.17-8.52) 
Quaternary ammonium compounds: 
7.56 (1.84-31.05) 
Questionnaire 
 
Workplace 
observations 
Arif and 
Delclos, 2012 
(41) 
Health 
workers 
(n = 3650) 
WRAS: 3.3% 
 
WEA: 1.1%  
 
OA: 0.8% 
Not specified  Chloramines: 4.81(1.28-18.06) 
Cleaners for restrooms and toilets: 
4.60(2.12-9.95)  
Bleach: 3.72(1.70-8.12)  
Ethylene oxide: 2.97(1.21-7.33) 
Detergents: 2.84(1.33-6.08) 
Formaldehyde: 2.66(1.03-6.86) 
Cleaners/abrasives: 2.50(1.19-5.25) 
Ammonia: 2.45(1.28-4.69) 
Glutaraldehyde/OPA: 2.18(1.17-4.07) 
Questionnaire 
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Table 2.1 (continued): Recent epidemiological studies on work-related asthma associated with cleaning agents in the health care 
setting  
Author/ year Population 
(n) 
Prevalence of asthma 
phenotypes / symptoms 
High risk activities 
significantly associated 
with asthma 
OR / RR (95% CI) 
Cleaning agents significantly 
associated with asthma  
OR/RR / MR (95% CI) 
Tools used for 
assessment of 
exposure and 
asthma-related 
outcomes 
Dumas et al, 
2012 (42) 
Health 
workers 
(n=724) 
Asthma and report of asthma 
attacks, respiratory symptoms or 
asthma treatment in the last 12 
months: 
 
Men: 39.5%   
Women: 31.6% 
 
General cleaning/ 
disinfecting tasks: 2.32(1.11-
4.86) 
Ammonia: 3.05(1.19-7.82) 
 
Sprays: 2.87(1.02-8.11)  
 
Decalcifiers: 2.32(1.01-5.31) 
 
Questionnaire 
 
Expert assessment 
 
Asthma-specific 
JEM 
Vizcaya et al, 
2011 (13) 
Professional 
cleaners 
including 
hospital 
cleaners 
(n=917) 
Doctor-diagnosed asthma: 9% 
 
Asthma attack in the last 12months 
or woken by an attack of shortness 
of breath in last 12 months or 
currently taking any medicine for 
asthma: 11% 
 
Asthma with the first asthma attack 
at the age of 16 years or later: 5% 
 
Hospital cleaners (activities 
not specified):  2.1(1.1-4.2) 
Carpet cleaners: 2.2(1.0-5.1) 
Hydrochloric acid: 1.7(1.1-2.6);  
Ammonia: 1.6(1.0-2.5)  
Degreasers: 1.6(1.0-2.4)  
Multiple purpose products: 1.6(1.0-
2.5)  
Waxes: 1.6(1.0-2.6)  
Air fresheners: 1.5(1.0-2.4) 
Perfumed products: 1.5(1.0-2.4)  
 
Questionnaire 
Arif et al, 2009 
(12) 
Health 
workers 
(n=3634) 
Doctor-diagnosed asthma with 
onset after entry into the healthcare 
profession: 9.8% among nurses 
 
BHR-related symptoms: 31.3% 
among nurses 
Building surface cleaning: 
1.72(1.00-2.94) 
 
Medical instrument cleaning: 
1.67(1.06-2.62) 
 
Adhesives, glues and/or solvents for 
patient care: 1.51(1.08-2.12) 
Questionnaire 
 
Job exposure 
matrix 
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Table 2.1 (continued): Recent epidemiological studies on work-related asthma associated with cleaning agents in the health care  
Author/ year Population 
(n) 
Prevalence of asthma 
phenotypes / symptoms 
High risk activities 
significantly associated 
with asthma 
OR / RR (95% CI) 
Cleaning agents significantly 
associated with asthma  
OR/RR / MR (95% CI) 
Tools used for 
assessment of 
exposure and 
asthma-related 
outcomes 
 
Delclos et al, 
2007 (1) 
 
Health 
workers 
(n=3650) 
 
Doctor-diagnosed asthma with 
onset after entry into the healthcare 
profession:  
Overall: 6.6%  
Nurses: 7.3% 
Respiratory therapists: 5.6%  
Occupational therapists: 4.5% 
Physicians: 4.2%  
BHR-related symptoms: overall 
27.4% 
 
 
Medical instrument cleaning: 
2.22(1.34-3.67) 
 
Building surface cleaning: 
2.02(1.20-3.40) 
 
 
Chemical spills: 2.02(1.28-3.21) 
 
Adhesives for patients care: 
1.65(1.22-2.24) 
 
 
 
Questionnaire 
 
Job exposure 
matrix 
Kogevinas et 
al, 2007 (35) 
General 
population  
(n = 6837) 
Asthma attack or taking asthma 
medication in the past 12 months: 
4.8% among nurses 
Acute symptomatic 
inhalational event: 
3.33(1·00-11·13) 
 
Nursing (activities not 
specified): 2.22(1.25-3.96) 
 
 
 Questionnaire 
 
Job exposure 
matrix 
 
Expert assessment 
 
Methacholine 
challenge test 
Mirabelli et al, 
2007 (36) 
General 
population  
(n = 2813) 
Asthma attack in the last 12 
months or woken by an attack of 
shortness of 
breath in last 12 months or 
currently 
taking any medicine for asthma: 
6% among nurses 
Not specified Ammonia and / or Bleach: 2.16(1.03-
4.53) 
Questionnaire 
 
IgE test to common 
aeroallergens 
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Table 2.1 (continued): Recent epidemiological studies on work-related asthma associated with cleaning agents in the health care 
setting  
Author/ year Population 
(n) 
Prevalence of asthma 
phenotypes / symptoms 
High risk activities 
significantly associated 
with asthma 
OR / RR (95% CI) 
Cleaning agents significantly 
associated with asthma  
OR / RR / MR (95% CI) 
Tools used for 
assessment of 
exposure and 
asthma-related 
outcomes 
Delclos et al, 
2006 (43) 
Health 
workers 
(n=118) 
Self-reported history of asthma: 
22.9% 
 
Prior physician diagnosis of 
asthma: 20.3% 
 
PC20 ≤8 mg/ml: 55.1% 
 
PC20 ≤4 mg/ml: 48.3% 
Not specified Not specified Questionnaire 
 
Industrial hygienist 
interview 
 
Methacholine 
challenge test 
 
IgE test to common 
aeroallergens 
 
IgE test to latex 
Bronchial hyper-responsiveness (BHR)-related symptoms: combination of eight questions on asthma and allergy symptoms that had exhibited the best combination of sensitivity and specificity 
when compared to non-specific bronchial challenge testing with methacholine 
WRAS (work-related asthma symptom): wheezing or whistling OR shortness of breath at work that gets better when away from work or worsens on return to work 
WEA (work exacerbated asthma): wheezing or whistling OR shortness of breath at work that gets better when away from work or worsens on return to work AND physician diagnosis of asthma AND 
onset of asthma before entry into health care profession 
OA (occupational asthma): wheezing or whistling OR shortness of breath at work that gets better when away from work or worsens on return to work AND physician diagnosis of asthma AND onset 
of asthma after entry into health care profession 
PC20: provocative concentration of methacholine that produced a 20% or greater decrease in forced expired volume in one second (FEV1) from the baseline 
JEM: job exposure matrix; IgE: Immunoglobulin E; OR: odds ratio; RR: risk ratio; MR: mean ratio 
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2.5. Pathophysiological mechanisms 
The pathophysiology of asthma associated with cleaning agents is not well characterized. It 
is widely accepted that high molecular weight (HMW) agents, which are commonly proteins 
such as NRL (commonly associated with donning gloves when using cleaning agents) and 
proteolytic enzymes cause asthma through immunoglobulin E (IgE)-mediated mechanism 
(44,45). IgE-mediated immunological mechanisms are also believed to play a major role in 
occupational asthma induced by some low molecular weight (LMW) agents in non-health 
care settings (44). However, only a small proportion of individuals with occupational asthma 
due to most LMW agents have specific IgE in the serum suggesting an IgE-independent 
immunological mechanism (probably involving cell-mediated and mixed Th1 and Th2 
responses) may be playing a greater role (44,46). The mechanism of asthma caused by 
non-immunological (irritant) mechanisms is not clearly understood. However, it is believed 
that irritants (such as common cleaning agents - bleach and ammonia) can destroy bronchial 
epithelium thereby exposing nerve endings and subsequently trigger a neurogenic 
inflammation characterized by bronchoconstriction, increased mucus secretion and oedema, 
which are typical features of asthma (44,47). Oxidative stress resulting from persistent 
imbalance between antioxidants and pro-oxidants as well as the dual irritant and adjuvant 
effects of some of these chemicals (e.g. formaldehyde and OPA) are also thought to play a 
role in the pathogenesis of irritant-induced asthma (3,48–50). It is therefore likely that IgE-
independent immunological and irritant mechanisms play a greater role in asthma 
associated with cleaning agents as most cleaning agents are of LMW. 
Some animal and human data are available for common disinfectants such as GTA and 
OPA (25). Experimental studies in mice have shown that GTA and OPA are both dermal and 
respiratory irritants and sensitizers. Interestingly, OPA was found to be more irritant than 
GTA in both in-vitro EpiDerm Skin Irritation Test and in-vivo tests (51). The in-vitro EpiDerm 
Skin Irritation Test is a test used to assess dermal corrosion potential of chemicals and 
utilizes a normal, human cell-derived, metabolically active skin model closely mimicking the 
human epidermis (51). There was a concentration-dependent increase in lymphocyte 
proliferation in the draining lymph nodes of the mice in all three studies reported from the US 
(51–53), B lymphocytes being the majority in one study (53). In addition, a population of B 
lymphocytes expressing IgE was also increased in all these studies, in which mice were 
exposed to GTA (52) and OPA (51,53). Another finding supporting the immunological 
mechanism caused by OPA and GTA was a predominant expression of Th2 cytokines (IL-4, 
IL-5 and IL-13) (51–53). The two mice studies reported from Japan also demonstrated the 
production of specific IgE to OPA (54,55). In the US studies, there was a significantly 
increase in specific IgE to OPA in mice that were dermally exposed (51), but they were not 
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detected in those exposed through the inhalational route (53). Total serum IgE was also 
elevated in two studies (51,52). 
In some clinical case reports of patients with anaphylaxis due to OPA, skin prick and 
intracutaneous tests have been used to confirm the presence of sensitization (56–59). More 
importantly, OPA specific IgE was detected by ELISA in all three patients who developed 
anaphylaxis due to OPA (59). Furthermore, histamine was released from the basophils of 
these patients but not from healthy controls (59). However, when basophils from the healthy 
controls were sensitized to the patient‘s serum and then exposed to OPA, these cells also 
released histamine (58). This suggests the presence of an OPA specific heat sensitive 
component (OPA specific IgE) in the patient‘s serum capable of sensitising control basophils 
(58). Recently, a team of National Institute for Occupational Safety and Health (NIOSH) 
conducted skin prick tests (SPT) and specific IgE and IgG assessment for OPA among 129 
US health workers (19). In this US study, 5 (4%) HWs had positive skin responses to SPTs 
with OPA solution but none had detectable specific IgE and IgG antibodies in any of the 
blood samples tested (19). 
In addition to these immunological data, the clinical history in the case reports of asthma due 
to OPA and GTA also demonstrated a latency period between first exposure to these agents 
and development of symptoms implying immunologic response associated with these agents 
(59,60). Late reactions were also observed in patients that underwent specific inhalation 
challenge test to GTA, alluding to an underlying allergic mechanism (60). 
Nagendran et al. identified 4 cases of occupational IgE-mediated allergy to chlorhexidine 
among 53 HWs in the United Kingdom (UK) hospital (61). Urticaria was reported in all 4 
cases identified and in addition one case reporting  rhinitis while the other diagnosed with 
contact dermatitis (61). In this study by Nagendran et al., all 3 cases had positive reactions 
to skin prick tests, while 2 had positive sIgE tests (61). Wittczak et al. also described 3 cases 
of occupational allergy among HWs confirmed by placebo-controlled specific bronchial 
challenge testing (62). One was diagnosed with occupational asthma, the other having both 
occupational asthma and rhinitis, while the third had an anaphylactic reaction to 
chlorhexidine (62). While serum sIgE test to chlorhexidine was positive in all 3 identified 
cases, only 2 had a positive skin prick test (62). There have been no African studies that 
have conducted immunological assessment for chlorhexidine in health workers. 
2.6. Asthma phenotypes 
It is well-known that asthma is a heterogeneous disease with diverse clinical, physiological 
and inflammatory characteristics (63–65). A number of studies have reported various 
phenotypes for non-work-related asthma, with significant efforts directed towards 
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characterising the severe asthma phenotypes (64,65). However, studies that have 
investigated occupational asthma phenotypes are quite limited and most of them have only 
characterised occupational asthma based on its aetiological agent (e.g. high molecular 
weight and low molecular weight agents) or according to allergic versus irritant mechanisms 
(4,63,66,67). The published literature on asthma phenotypes in HWs exposed to cleaning 
agents is even more scant (3).  
2.7. Workplace environmental risk factors and causative agents 
The extent of exposure to substances in the health care setting for substances other than 
NRL and its association with WRA is not well characterised. However, there are a few recent 
studies in the US and Europe that have attempted to address this issue (36,41). Cross-
sectional studies in the US have reported that aside from powdered latex glove usage (pre-
2000), occupational exposure to cleaning substances (e.g. instrument cleaning, surface 
cleaning) and the use of adhesives / solvents are related to asthma after entry into the health 
care profession (1,12).  
2.7.1. Potential hazardous workplace activities 
Patient care activities performed by nurses include cleaning surgical and non-surgical 
instruments, drawing blood, providing wound care and respiratory care, mixing and 
administering medications, mopping floors, assisting with invasive and other medical 
procedures and assisting with anaesthesia (12). These activities often involve handling of 
chemical products or the release of air contaminants, which may pose a potential health risk.  
Some population based studies have applied a job exposure matrix (JEM) to categorise 
chemical agents and workplace activities in the health care sector (1,12,35,68). These 
studies have identified a number of broad categories of chemical exposures associated with 
cleaning related activities such as medical instrument cleaning and disinfection; fixed 
surfaces cleaning and disinfection; floor finishing tasks (stripping, waxing & buffing); patients‘ 
skin / wound cleaning and disinfection; specimen preparation; hand hygiene and exposure to 
aerosolised medications such as pentamidine (12,31,39). Furthermore, accidental chemical 
exposures and spills are also another exposure context for high-risk workplace exposures 
(12). 
2.7.2. Potential causative agents (asthmagens) 
Various studies indicate that the development of occupational asthma is primarily related to 
the level of exposure to a specific agent in the workplace, and less so to individual host 
factors such as atopy and smoking, which have produced inconsistent results in a number of 
studies (69). Broad groups of potential sensitisers and irritants present in health care 
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settings include surface cleaning products (e.g. bleach); disinfectants and sterilants (e.g. 
glutaraldehyde (GTA) and ortho-phthalaldehyde (OPA)); adhesives/solvents and hand 
cleaners (e.g. chlorhexidine, triclosan); aerosolised medications (e.g. pentamidine); 
methacrylates in dental and surgical cements; NRL products; micro-organisms and mildew 
(11,43,70).  
Health workers are commonly exposed to cleaning products that contain respiratory irritants 
and sensitizers. Most cleaning agents are irritants, however, some have both irritant and 
sensitising properties. Some of the known irritants in cleaning agents include chlorine, 
ammonia, hydrochloric acid, monochloramine, sodium hydroxide, quaternary ammonium 
compounds (e.g. benzalkonium chloride), monoethanolamine (6). Sensitisers known to be 
present in cleaning agents include, but are not limited to, amine compounds (e.g. 
monoethanolamine), disinfectants (e.g. GTA and OPA), quaternary ammonium compounds 
(QACs), scents (e.g. pinene, d-limonene, eugenol), preservatives (e.g. isothiazolinones and 
formaldehyde) (6). 
Delclos et al (1) in their studies of asthma in health workers further classified chemical 
products and agents in the health care sector into three main groups, i.e. instrument 
cleaning agents, fixed surface cleaners and adhesives/solvents/gases (Table 2.2). However, 
while the specific inventories of chemical products used in the health care setting may not 
always be generalisable across hospitals in different countries, the active ingredients in 
these cleaning products are often similar across hospitals. 
Medical instrument cleaning / disinfecting agents 
Health workers, especially nursing personnel, are exposed to cleaning agents used for high-
level disinfection of heat sensitive medical instruments such as endoscopes. Of particular 
interest are the two aldehydes, GTA and OPA. GTA has been used for over 40 years in 
health care settings not only for the disinfection of medical instruments but also as a fixative 
for electron microscopy and x-ray films. Several clinical case reports have been reported in 
the literature linking GTA and various health effects such as occupational asthma (71,72) 
and allergic contact dermatitis (73). In 1999, Food and Drug Administration (FDA) approved 
OPA to be used as a high-level disinfectant. Subsequently, OPA was considered a safer 
replacement for GTA and is increasingly being used (25). However, OPA has also been 
recently reported to cause occupational asthma (21,74) and anaphylaxis (56–59) in various 
case reports, including patients undergoing instrument procedures. In a Japanese study 
among 70 HWs responsible for endoscope disinfection, 24% had work-related skin, 
respiratory or eye symptoms due to OPA (27). Work-related symptoms due to OPA were 
also reported in another Japanese study among 80 female HWs from endoscopy units, with 
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respiratory symptoms being the majority (16%), followed by skin (10%) and eye (9%) 
symptoms (24).  
Other cleaning agents used for disinfection of medical instruments include QACs, hydrogen 
peroxide, a mixture of hydrogen peroxide and peracetic acid and a mixture of hydrogen 
peroxide, peracetic acid and acetic acid. Respiratory and ocular symptoms have been 
reported in individuals exposed to hydrogen peroxide and a mixture of hydrogen peroxide, 
peracetic acid and acetic (75,76). In recent years, there has been an increase in the use of 
enzymatic cleaners for pre-cleaning of medical instruments prior to high-level disinfection in 
health care settings (1,77). Two studies have reported cases of occupational asthma and 
rhinitis among HWs using enzymatic cleaners (77,78). Exposure to proteolytic enzymes has 
long been recognised as a cause of allergic respiratory and skin symptoms particularly 
among detergent manufacturing workers (1,77).  
The association between asthma and cleaning agents used for medical instrument 
disinfection has also been demonstrated in epidemiological studies and surveillance systems 
(12,39,79,80). In a recent study among US nurses (39), medical instrument disinfection (OR 
= 1.88; 95% CI: 1.38 to 2.56) and exposure to formaldehyde, glutaraldehyde, hypochlorite 
bleach, hydrogen peroxide and enzymatic cleaners was associated with poor asthma 
control. A study by Arif et al (12) reported a significantly higher odds of reported asthma 
among HWs exposed to medical instrument cleaning agents (OR = 1.67; 95% CI: 1.06 to 
2.62). Six percent of occupational asthma cases reported to a surveillance system in the 
United Kingdom were attributable to GTA (79). Although not specified, it is probable that 
most, if not all of these cases were from heath care settings, where GTA was commonly 
used.  
Fixed surface cleaning agents 
Fixed surface cleaning is an inherent aspect of activities performed in the health care setting. 
Cleaners and janitors are widely reported to be high-risk occupations in both industrialised 
and developing countries (3,81–83). In a US surveillance study (84), janitors, cleaners and 
housekeepers formed the largest (22%) occupational group in which exposure to cleaning 
products was associated with WRA, followed by a group of nurses and nurse aides (20%). In 
this study, the health sector had the highest number (39%) of patients with WRA due to 
cleaning products.  
For general cleaning purposes, Medina-Ramon et al (85) found bleach, ammonia and 
hydrochloric acid as the most commonly used irritant cleaning products used in a diluted or 
undiluted form, with airborne chlorine and ammonia detected during cleaning activities. A 
Spanish study among cleaning workers also reported an increased risk of asthma symptoms 
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in workers that used hydrochloric acid (mean ratio [MR] = 1.7; 95% CI: 1.1 to 2.6), 
degreasers (MR = 1.6; 95% CI: 1.0 to 2.4), air fresheners (MR = 1.5; 95% CI: 1.0 to 2.4) or 
ammonia (MR = 1.6; 95% CI: 1.0 to 2.5) in the last year (13). A number of studies have 
demonstrated a positive association between use of cleaning sprays and asthma or 
respiratory symptoms (39,40,42,86–90). Use of sprays generates more aerosols and hence 
facilitates inhalational exposure. 
Cleaning agents comprised the most common group of agents reported (20.5%) among 
individuals with suspected occupational asthma presenting with acute asthma symptoms to 
the emergency units of the two large public tertiary referral hospitals in Cape Town (91). The 
study by Kogevinas et al (35) demonstrated a 1.8 fold (RR = 1.80; 95% CI: 1.01 to 3.18) 
increased relative risk for asthma with the use of cleaning products (including different 
occupations and sectors in the analysis). A similar finding was observed among nurses in a 
study by Arif et al (12) that showed a significantly higher odds of reported asthma for 
exposure to general building cleaning agents and disinfectants (adjusted OR = 1.72; 95% CI: 
1.00 to 2.94). According to a large scale European based study, nurses that reported using 
ammonia and / or bleach were found to have a more than two-fold (RR = 2.16; 95% CI: 1.03 
to 4.53) increased risk of developing new-onset asthma (36). An increased relative risk for 
asthma (RR = 1.51; 95% CI: 1.36 – 1.66) has also been reported among cleaners in the 
Finish health care setting (92).  
Apart from the individual effect of cleaning agents, newly produced  asthmagens can be 
produced when different cleaning agents are mixed together (6). Chloramines may be 
released when hypochlorite from bleach is mixed with ammonium salts from cleaning 
products or body fluids (6). Chloramines have been reported to cause occupational asthma 
among pool workers (93). Recently, increased numbers of occupational asthma cases have 
been reported among cleaners that used chlorine-based cleaning agents (sodium 
hypochlorite and sodium dichloroisocyanurate) (80). Interestingly, specific bronchial 
challenge tests to these cleaning agents were negative and only became positive when 
challenged with a mixture of urine and chlorine-based cleaning agents (and hence producing 
chloramines) (94). On the other hand, chlorine, a common respiratory irritant is generated 
when acid is mixed with bleach (84). Application of some cleaning agents can also yield high 
levels of volatile organic compounds (VOC) that can also act as airway irritants (6,95). This 
suggests that there is potential for multiple exposures among workers who are involved in 
cleaning-related tasks.  
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Agents used for patient skin / wound cleaning and disinfection 
Chlorhexidine, povidone iodine and alcohols are one of the most commonly used agents for 
disinfection of wounds and patients‘ skin prior to various medical procedures. Walk-through 
surveys performed by occupational hygienists in US hospitals revealed that routine patient 
care activities performed by nurses often included the use of adhesives and adhesive 
removers, particularly in surgical and intensive care units (1,12). These compounds are used 
to apply and/or remove dressings and adhesive bandages, as well in case of stoma care. 
The compounds may contain respiratory irritants such as dimethyl ether, dipropylene glycol 
methyl ether and isoparaffinic hydrocarbons, and may be administered in an aerosolised 
form. Arif et al (12) also found an almost twofold increased odds of asthma among nursing 
professionals that were exposed to adhesives, adhesive removers and / or solvents. 
Furthermore, Pechter et al (70) reported that exposure to solvents accounted for 7% of 
reported WRA, and various chemicals (including glues and solvents) were associated with 
asthma among 29% of aides and therapists in the US. 
Agents used for hand hygiene (hand washing/sanitising) 
Exposure to chemicals contained in hand hygiene products is quite common in hospital 
settings since HWs are required to wash and disinfect their hands several times per day in 
order to comply with infection control standards. Alcohols and chlorhexidine are the most 
commonly used agents for hand hygiene in hospital settings (31,61,62). Chlorhexidine is a 
known sensitiser and irritant to both the skin and airways (31). There have been a few 
published reports of asthma and dermatitis due to chlorhexidine, mostly among patients and 
few occurring in HWs (61,62,96–98). Povidone iodine is also used commonly for hand 
washing (31). Povidone iodine is a well-known skin irritant but its sensitising properties have 
not been well characterised (99). Triclosan, also used as hand cleaner in the health care 
setting, has been implicated in the causation of adverse health effects affecting the skin such 
as allergic contact dermatitis and contact urticaria as well as occupational asthma (100–
103).  
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Table 2.2: Cleaning agents associated with work-related asthma in health care 
workers 
Instrument 
cleaning/disinfection 
Fixed surface cleaners Adhesive removers and hand 
cleaners / disinfectants  
 
Glutaraldehyde 
Hydrogen peroxide 
Isopropanol 
Ortho-phthalaldehyde 
Quaternary ammonium 
compounds 
Sodium sesquicarbonate 
Subtilisins (enzymatic 
cleaners) 
 
Acetic acid/acetic acid anhydride 
Ammonia/ammonium hydroxide 
Bleach 
Butyl paraben, ethyl paraben, 
methyl paraben 
Diethanolamine 
Diethylene-glycol n-butyl ether 
Hydrochloric acid 
Isoparaffinic hydrocarbons 
Phosphoric acid 
Quaternary ammonium 
compounds  
Sodium sulfate 
Sulfuric acid 
 
Adhesive removers 
 Acetone 
 Dipropylene glycol 
methyl ether 
 Ethanol 
 Isoparaffinic 
hydrocarbons 
 Isopropanol 
Stoma care products 
 Carboxymethyl ether 
 Hexane-based skin 
bond 
 Methylbenzene 
Hand cleaners / disinfectants 
 Chlorhexidine 
 Alcohols 
 Povidone iodine 
 Triclosan 
Other 
 Methylene chloride 
 Trichloroethane 
 
 
Source: Modified from (1) 
 
2.7.3 Dose-response relationships 
Little is known regarding exposure-response relationships between exposure to specific 
cleaning agents and asthma-related outcomes. A few studies have only reported exposure-
response relationships for broad categories of cleaning-related exposures with very limited 
information on specific cleaning agents (41). Arif et al. demonstrated exposure-response 
relationships for work-exacerbated asthma in HWs who used disinfectants for medical 
instrument disinfection as well as for work-related asthma symptoms in HWs who used 
cleaning agents for fixed surfaces cleaning/disinfection (41). Medina-Ramon et al. 
demonstrated dose-response relationship between use of bleach and asthma among 
domestic cleaners in Spain (17). Similarly, Zock et al. demonstrated dose-response 
relationships for asthma with the frequency of use of cleaning sprays as well as with 
increasing number of the types of sprays used (86). In a recent study by Dumas et al., poor 
asthma control was positively associated with increased frequency of hand hygiene 
practices among US nurses, with clear dose-response relationship demonstrated for surgical 
hand/arm hygiene (31). 
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2.8. Host-associated risk factors 
Common host-associated factors that have been associated with asthma include age, 
gender, seniority, smoking status and atopy (1,12). Delclos et al (1) demonstrated that 
increasing seniority was positively associated with reported asthma. The study by Kogevinas 
et al (35) of workers across different industries, demonstrated that atopic individuals had a 
significantly higher relative risk (RR = 2.9; p-value = 0.019) for new-onset asthma than non-
atopics. The study also demonstrated an increased risk of new-onset asthma in participants 
with a parental history of asthma (RR = 2.1) and in non-smokers (RR = 1.8) compared to 
current smokers.  
There is inconsistent evidence with regard to the association between smoking and asthma 
in general and with occupational asthma in particular (3,63,104). While some studies have 
demonstrated that smoking at baseline increased the risk of incident asthma in adulthood, 
no significant association was reported in a follow-up cross-sectional analysis (105). 
Furthermore, very limited specific information is available on the risk of smoking in relation to 
asthma among HWs exposed to cleaning agents (104,106). The study by Zock et al. in 
cleaning workers did not demonstrate any association between smoking and asthma (106).  
Risk factors for non work-related adult-onset asthma and occupational asthma have also 
been reviewed in a comparative manner (63). This review found that while host associated 
factors (e.g age, gender, genetics, atopy and obesity) did not differ for these two broad 
asthma phenotypes, environmental factors appeared to play a very important role in 
occupational asthma. Recently, Rava et al. (107) identified novel genes associated with 
adult asthma related to occupational exposure to LMW agents / irritants in three large 
European cohorts (Epidemiological family-based study of the Genetics and Environment of 
Asthma, Swiss Cohort Study on Air Pollution and Lung and Heart Diseases in Adults and 
ECRHS). 
Female HWs appear to be more affected than men. In a study (41) of US HWs, females had 
a higher prevalence of all asthma phenotypes that included WRA symptoms (3.6% vs 1.8%), 
work exacerbated asthma (1.3% vs 0.3%) and occupational asthma (1.0% vs 0.1%) than 
their male counterparts. Similar findings were reported in a large population European study 
(35) that found a slightly higher relative risk of new-onset asthma among women (RR = 1.13) 
compared to men. It is likely that the gendered distribution of work plays a role. Interestingly, 
female sex hormones have been implicated in the pathogenesis (63).  
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2.9. Prevention 
Several studies have proposed preventive strategies for work-related asthma related to 
cleaning agents (3,5,108). However, not enough effort has been directed towards the 
implementation of the suggested preventive strategies that target relevant stakeholders such 
as government agencies, manufacturers of cleaning products, suppliers and commercial 
cleaning companies (3,5). 
Primary prevention is usually the most effective strategy but not always feasible (109). Some 
of the primary prevention strategies that have been proposed include substitution of certain 
cleaning agents such as glutaraldehyde, QACs, bleach and ammonia with less hazardous 
agents (3,5). One of the challenges of this method has been the difficulties associated with 
finding the proper alternative cleaning agent/s and the lack of information regarding health 
effects of the newer cleaning agents. This has lead to replacement of a known hazard, such 
as GTA, with a potentially unknown hazard (e.g. OPA), that was later demonstrated to cause 
similar health effects (25). Quantitative structure-activity software that can predict 
sensitisation potential of chemicals may be very useful for decisions regarding new cleaning 
agents to be introduced in the workplaces (110). Avoidance of mixing cleaning products 
such as bleach and ammonia has also been strongly advocated (5,6).  
Engineering controls are very important in reducing cleaning-related exposures. Ideally, 
proper ventilation should be maintained in all areas where cleaning agents are used. 
However, this is quite rare since cleaning agents are used almost everywhere. Local exhaust 
ventilation (LEV) systems should be installed in certain dedicated areas where a specific 
cleaning and disinfection is performed on a regular basis such as in areas where medical 
instrument cleaning and disinfection is taking place. A recent US study (19) has proposed 
specific ventilation standards for areas where OPA is used for high-level disinfection of 
medical instruments. Since exposure to cleaning sprays is an important risk factor for work-
related asthma (86), use of wipes rather than sprays could be very effective in reducing the 
burden of work-related asthma due to cleaning agents. 
Administrative controls such as provision of occupational health and safety (OHS) education; 
establishing written policies on how to properly use cleaning agents; supervision to make 
sure proper work practices are followed while working with cleaning agents; and preventive 
maintenance of the ventilation systems are also very important in the prevention of work-
related asthma associated with cleaning agents. However, little is known regarding the 
effectiveness of the suggested administrative control measures in reducing incidence of 
WRA related to cleaning agents. An intervention involving collaboration between a cleaners‘ 
union and other stakeholders including OHS technical personnel in the US was successful in 
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eliminating the use of the most hazardous cleaning agents, reducing the number of different 
cleaning agents used, banning mixing of cleaning agents, and enhancing safety training 
(111). 
It is well known that the use of personal protective equipment (PPE) is the least effective 
method for the control of work-related hazards. Full support of the employer with 
involvement and commitment of employees is required to ensure the proper use of PPE. 
Use of PPE is usually advised since the most effective means for controlling cleaning-related 
exposures such as engineering methods are usually absent in most workplaces. Some of 
the PPE advised for controlling cleaning-related exposures include use of proper respirators 
with vapour and gas cartridges, eye protection (e.g. goggles or face shields), fluid repellent 
gowns or aprons, proper gloves (e.g. nitrile gloves) and proper shoes (19). 
Medical surveillance for HWs that work regularly with cleaning agents is also recommended. 
The aim of this mode of secondary prevention is to detect the disease at an early stage in 
order to prevent the development of severe adverse health effects. Occupational health 
practitioners can use medical surveillance information to determine the effectiveness of the 
available preventive measures. Questionnaire interviews and spirometry are commonly used 
for medical surveillance in various workplaces. However,  the use of immunological tests can 
be very helpful in the surveillance of HWs using  cleaning agents with sensitising properties 
(112,113).  
2.10. Conclusion  
Cleaning agents have become the major causative agent of WRA among HWs due to their 
extensive use in the health care settings. More efforts need to be directed towards 
characterising cleaning-related exposure in a more detailed manner so as to obtain more 
specific information such as cleaning agents and tasks associated with WRA in HWs as well 
as the frequency and duration of use. Furthermore, future studies need to use more 
objective measures of exposure assessment for cleaning agents in the health care setting. 
There is a need for larger prospective studies in HWs exposed to cleaning agents using 
various clinical, physiological and inflammatory markers such as Fractional exhaled nitric 
oxide (FeNO) test, serum specific IgE or skin prick tests, sputum eosinophils, serum 
periostin and lung function testing in order to further characterise the asthma phenotypes in 
these workers. In addition, more efforts need to be directed towards characterising 
exposure-response relationships and host-associated risk factors (e.g. atopy, gender, and 
smoking) in HWs exposed to cleaning agents. More studies are needed to have a better 
understanding of the association between novel genes and adult-onset asthma due to 
occupational exposure to low-molecular weight agents/irritants in order to develop more 
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specific preventive strategies for WRA associated with cleaning agents in health care 
settings.   
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3.1. Study design, Population and Sampling 
 A cross-sectional study of 699 HWs was conducted in two large tertiary academic hospitals 
(346 from a South Africa hospital – SAH and 353 from Tanzanian hospital - TAH) during the 
period July 2014 and March 2018. Following meetings with several key stakeholders and 
walk-through inspections by the investigators of both hospitals, specific departments were 
identified as potentially high-risk exposure settings for cleaning agents. Health workers in 
these high-risk departments used significant amounts of cleaning agents at a frequency 
much higher than other departments. The departments identified in the SAH included out-
patient clinics, intensive care units (ICUs), operating theaters, emergency units, ENT ward, 
vascular radiology and the haemodialysis unit. The out-patient clinics, ICUs, operating 
theaters, emergency unit, Central Sterile Services Department (CSSD) and haemodialysis 
unit were identified in the TAH (Table 3.1 and 3.2). 
 
Table 3.1: Permanently employed health workers in high risk areas at the South 
African Hospital 
 Nurses Cleaners Technicians Porters Clerks Total 
Out-patient clinics 63 8 17 5 11 104 
Intensive care units 225 26 8 1 10 270 
Operating theaters 152 3 29 18 3 205 
Emergency units 81 11 0 0 11 103 
ENT ward 11 4 0 0 1 16 
Vascular radiology 10 6 4 6 0 26 
Hemodialysis unit 19 4 8 0 4 35 
Total 561 62 66 30 40 759 
 
Table 3.2: Permanently employed health workers in the high risk areas at the 
Tanzanian Hospital 
 Registered 
nurses 
Enrolled 
nurses 
Health 
attendants 
Cleaners Technicians Clerks Total 
Out-patient clinics 16 7 17 28 1 3 72 
Intensive care units 68 8 25 15 0 1 117 
Operating theatres 93 23 69 5 0 3 193 
Emergency unit 43 9 38 12 0 25 127 
Central Sterile 
Services Department 
3 6 12 0 3 0 24 
Hemodialysis unit 17 1 6 2 0 1 27 
Total 240 54 167 62 4 33 560 
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Sampling strategy 
All permanently employed HWs in the high-risk departments constituted the sampling frame 
of the study. Doctors were excluded from the sampling frame as they were more likely to 
work in multiple different exposure settings across the hospital. A list of all permanently 
employed HWs in the high-risk departments was obtained from their respective managers. 
Study participants were selected from these departments through stratified random sampling 
according to job title, choosing up to five HWs from each high-risk department. For 
departments having more than five HWs with the same job title, a random sample of five 
workers was selected. For departments having less than five workers, all workers were 
selected to participate in the study. Selected HWs who could not participate in the study 
were replaced by fellow HWs using a similar method (stratified random sampling). The 
overall response rate was 53%, with a higher response rate in the TAH (63%) compared to 
the SAH (46%) (Appendix J).  
Sample size calculation 
Based on information from the literature the estimated sample size was calculated using a 
mean prevalence of 6% based on a prevalence of 4.8 – 7.3% for work-related asthma 
reported in the literature (1,2). The following parameters were used to obtain an estimated 
sample size of 347 for each hospital as outlined in Table 3.3. 
 
Table 3.3: Sample size parameters used in calculations 
Parameter value 
Anticipated proportion of work-related asthma 0.06 
Expected precision 0.025 
Alpha level 0.05 
 
3.2. Exposure assessment 
3.2.1. General exposure assessment 
A list of cleaning agents used in the two hospitals was obtained from the supply chain 
department of the respective hospital. Information was also obtained about the type and 
volume of chemicals used in the various departments of the hospital to confirm a priori high-
risk departments. The most recent safety data sheets (SDS) of the cleaning products were 
obtained from the supply chain department and/or from suppliers/manufacturers directly. 
Walk-through surveys were conducted in both hospitals using a proforma checklist. The 
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surveys were conducted by a team that included an occupational hygienist and occupational 
medicine specialist. The team members also conducted short interviews with the operational 
managers of the respective work area. During the walk-through survey, each member of the 
team conducted their own independent evaluation. After evaluating each specific work area 
(department), the team members convened for a short discussion to have a consensus 
decision on the relevant exposures pertaining to that department. Discrepancies in findings 
were resolved by consensus and the findings recorded on the checklist. The research team 
also communicated with the supply chain departments and nurse managers on a regular 
basis to ensure that any new products that were introduced during the study period also 
formed part of the assessment.  
3.2.2. Environmental sampling of aldehydes 
Measurement of aldehyde concentrations in the air was initially conducted in the SAH. A 
subsequent pilot sampling study in the TAH revealed very low levels of OPA and 
glutaraldehyde and as a result extensive environmental sampling was not done in this 
hospital. In the SAH, measurements of aldehydes were conducted in the 17 departments 
where OPA and enzymatic cleaners were used for cleaning and disinfection of medical 
instruments. This decision was informed by the initial walk-through survey findings. Selection 
of workers for OPA monitoring was limited to those on a day-shift for logistical reasons. On 
the earmarked sampling day, workers in each department were classified into high, medium 
and low/no exposure based on the results of the walk-through survey. Workers working 
directly with OPA were classified into a high exposure group; workers performing patient 
care activities were classified into a medium exposure group; and administrative workers 
were classified into a low/no exposure group. A random sampling strategy was employed to 
select workers in each stratum (high, medium, low/no exposure) for OPA air monitoring in 
each department. The random selection was based on using sample size calculations of the 
top 20%, employing a 95 percent confidence level (3). A total of 269 full-shift passive 
personal samples were collected from 164 HWs randomly selected from 17 different 
departments. Among the 164 workers selected, 70 (43%) were sampled once, 83 (50%) 
sampled twice and 11 (7%) were sampled thrice.  
Passive sampling used TraceAir® AT580 monitors (Assay Technology, Livermore, CA). 
TraceAir® AT580 monitors containing a fibreglass strip treated with 2,4-
dinitrophenylhydrazine (DNPH) for sampling aldehydes including OPA. The OPA reacts with 
DNPH in the monitor to yield an OPA-DNPH derivative. Field blanks were included in every 
day of passive sampling. All samples were stored at 4 degrees Celsius after collection until 
analysed. Analysis was conducted within four weeks of sample collection. 
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Samples were analysed for OPA, glutaraldehyde and formaldehyde using OSHA method 64 
and NIOSH method 2016 in a South African National Accreditation System (SANAS) 
accredited laboratory (Chemtech laboratory services). Two millilitres of 
Acetonitrile:dimethylsulfoxide (90:10) was added to extract the OPA-DNPH derivative from 
the monitors. The samples were left to desorb for 30 minutes, to ensure that all the analytes 
were dissolved in solution. Samples were analysed using an Agilent 1100 series High 
Performance Liquid Chromatography (HPLC) with a Variable Wavelength Detector (VWD). 
The column used was a Phenomonex Luna 5um C18 reversed phase. An acetate buffer was 
used, which contained 5 g of ammonium acetate adjusted to pH 6 with acetic acid. 
Acetonitrile was used as the organic solvent.  The method used was 19.00 minutes in length. 
The flow rate was 1.5 ml/min. An isocratic mixture of buffer: acetonitrile (30:70) was used as 
the mobile phase. The injection volume was 20 µl, and the column temperature was 
controlled at 40C. The VWD was set to 360 nm. Samples were integrated with 
Chemstation, where a calibration was setup beforehand. The calibration was setup by 
means of an external standard. A calibration stock of OPA-DNPH derivatives were obtained 
from Supelco. Calibration standards ranged from 1ppm to 10 ppm. A linear calibration curve 
was constructed and was forced through 0, with a regression of 0.99910. 
3.2.3. Biomonitoring for chlorhexidine 
Chlorhexidine biomonitoring was conducted in the SAH only since none of the HWs in the 
TAH used chlorhexidine. Urine samples for chlorhexidine biomonitoring were collected from 
the study participants during their health outcome assessment visit to the study venue. Spot 
urine samples (50 ml) were collected from 336 participants in a clean indoor toilet using a 
plastic container topped with a plastic cap. To avoid contamination, participants were 
instructed on specific precautions on washing hands before handling containers; not 
touching the inside of the container; collecting the midstream urine and covering the 
containers immediately after producing the sample. The samples were stored in the 
refrigerator at 4 degrees Celsius at the study venue and then transported on dry ice to the 
permanent storage facility on the same day of sample collection. The samples were stored 
at -80 degrees Celsius before being analysed at the Clinical Pharmacology laboratory at the 
University of Cape Town by a team led by Dr Lubbe Wiesner. 
While the initial plan of the biomonitoring component was to develop a multiplex assay for 
the determination of chlorhexidine and its metabolites (p-chloroaniline and 1-chloro-4-
nitrobenzene) in urine, due to logistical reasons it was only possible to develop a method for 
p-chloroaniline (PCA). The urine samples were analysed using a LC-MS/MS method 
developed in-house based on the detection of PCA. The samples were thawed at room 
temperature and extracted with 4 volumes of a 1:1 mix of 0.1% formic acid and acetonitrile, 
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containing 62.5ng/ml p-bromoaniline as internal standard. The supernatant following 
centrifugation was transferred to a 96-well plate for LC-MS/MS analysis. Calibration 
standards and quality control samples were prepared by spiking PCA in blank urine to give 
final concentrations between 1 – 3125ng/ml. These were then extracted as described and 
analysed together with the patient samples to provide a standard curve from which patient 
PCA levels were determined.  LC-MS/MS was performed on an ABSciex 4000Qtrap® mass 
spectrometer coupled to an Agilent 1200 Rapid Resolution HPLC system. Chromatography 
was achieved using a Kinetex F5 column (100 x 4.6mm, 2.6µ) using 0.1% formic acid as the 
aqueous mobile phase and 0.1% formic acid in acetonitrile as the organic phase. An 
isocratic method at 0.8ml/min was run, with a 1:1 split between the MS and waste. Carry 
over was avoided using a needle wash consisting water, acetonitrile, methanol, isopropanol 
and formic acid (30:30:30:10:0.1). Analyst 1.6 software was used for instrument control, data 
acquisition and analyte quantitation. 
3.3. Health outcome assessment 
3.3.1. Questionnaire 
A total of 697 participants completed the questionnaire interviews (344 from SAH and 353 
from TAH). Each participant answered a modified questionnaire for the investigation of 
asthma as contained in the Protocol for the European Community Respiratory Health Survey 
(4). The study questionnaire also included validated questions from the NIOSH specific 
questionnaire for cleaning agents in the health care setting (5). The questionnaire was 
administered by trained interviewers in English language for South African health workers 
(SAHWs) and in Swahili language for Tanzanian health workers (TAHWs). The translated 
Swahili questionnaire was back-translated to ensure validity and repeatability. 
3.3.2. Immunological assessment  
Blood samples were collected from 682 participants (339 SAHWs and 343 TAHWs). Specific 
IgE antibody reactivity to common aero-allergens (Phadiatop) and specific occupational 
allergens was evaluated. The quantification of specific IgE antibodies to specific 
occupational allergens: NRL (Hevea brasiliensis - Hev b5, Hev b6.02), chlorhexidine and 
OPA was performed using the UniCAP system (Phadia, Uppsala, Sweden). Immunological 
assessment for chlorhexidine was only done on sera of SAHWs since chlorhexidine 
containing chemicals were not used in the TAH.  
Commercial ImmunoCAPs containing Phadiatop (Phad), Chlorhexidine (C8), rHev b5 (K218) 
and rHev b6.02 (K220) allergens were obtained from Thermo Scientific. Serum samples 
were tested at the National Institute for Occupational Health (NIOH) Immunology laboratory 
(Dr Tanusha Singh) using the UNICAP 250 machine supplied by Thermo Scientific 
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according to the manufacturer manual. This instrument uses the fluorescent enzyme 
immunoassay (FEIA) technique in an automated process. Briefly, serum is added to allergen 
of interest that is covalently coupled to ImmunoCAP. If specific IgE is present in the serum 
being tested, it will bind to the antigen and form an antigen–antibody complex. After washing 
away non-specific IgE, a fluorescent labelled anti human immunoglobulin is added that binds 
to the unwashed antigen–antibody complex. The fluorescent colour is converted into specific 
IgE concentrations by the machine software. 
Since the OPA test was not readily available commercially, it required further development. 
Ortho-phthalaldehyde (OPA) was coupled to albumin using a modification of the ELISA 
method by Suzukawa et al., 2007, Anderson et al., 2010 and Johnson et al., 2011 (6–8).  A 
4% (40mg in 1ml) solution of bovine serum albumin (BSA) (GE healthcare life sciences, cat 
no: SH30574.02) was prepared in phosphate buffered saline (PBS) (Roche, cat no: 
11 418 165 001) and a 2.2 % (22mg in 1ml) solution of OPA (Sigma, cat no: P1378-5G) was 
prepared in sterile water. Equal amounts (500μl) of BSA and OPA solutions were mixed 
resulting in a final concentration of 2 % BSA and 1.1 % OPA.  
This mixture was labelled with Biotin and separated on a Sephadex G-25 column using the 
Biotin labelling kit from Roche according to the manufacturer‘s instructions (Roche, cat no: 
11 418 165 001). Briefly 6.7µl of Biotin-7-NHS was added to the BSA/OPA mix and 
incubated for 2 hours at 15-250C while stirring. The Sephadex G-25 column was prepared by 
adding 5 ml of blocking solution to the column and allowed to flow through. Thereafter, the 
column was rinsed 6 times with 5ml of PBS. The biotin labelled protein mixture was added to 
the column. This was then eluted with 3.5ml of PBS and 40 drops of labelled protein was 
collected and used as the allergen. 
The ImmunoCAPs were then washed and placed in a 2ml Eppendorf with a pipette tip. 
These were then centrifuged to get rid of the glycerol for 2 min 1450g. ImmunoCAPs were 
washed and centrifuged 4 times with 50 μl ImmunoCAP Washing solution. Washed 
ImmunoCAPs were placed in a microtiter plate and 50 µl of biotinylated allergen was added 
into each ImmunoCAP. After 30 minutes the ImmunoCAPs were put into a carrier and 
loaded into the Phadia250 machine. Specific IgE antibodies to prepared OPA allergens were 
then measured using the UNICAP 250 machine according to manufacturer‘s procedure.   
 3.3.3. Spirometry (pre and post-bronchodilator) only 
Three hundred and thirty one (331) participants from the TAH and, as explained further in 
the next section, only 25 participants from the SAH performed spirometry (pre- and post-
bronchodilator). The latter group did not proceed to methacholine challenge testing (see 
below) due to contra-indications (e.g. FEV1 below 1.5 litres or 70% predicted, pregnant and 
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breastfeeding women). Spirometry was conducted according to guidelines of the American 
Thoracic Society/European Respiratory Society (ATS/ERS) (9) using EasyOne World 
spirometer (ndd Medical Technologies, Zurich, Switzerland) at the TAH and Jaeger Aerosol 
Provocation System (APS) Pro apparatus connected to a computer at the SAH, according to 
the manufacturer‘s instructions. In the SAH, spirometry was conducted by an experienced 
technologist in the same pulmonary function laboratory, where methacholine challenge tests 
were also performed. Since a portable EasyOne spirometer was used in the TAH, spirometry 
was conducted by experienced nurses in the pulmonary function laboratory as well as in the 
respective departments. Spirometers were calibrated at least twice a day with a three-liter 
syringe. The temperature and humidity were monitored on a daily basis. Spirometry was 
performed in a sitting position with nose clips. Each HW performed no more than eight trials 
to produce three acceptable curves. The lung function indices of primary interest were forced 
vital capacity (FVC) and forced expiratory volume in one second (FEV1). The best FEV1 and 
FVC were used regardless of whether they belong to the same tracing. Special instructions 
were given to health workers to abstain from smoking tobacco (at least 2 hours before) 
taking any anti-asthmatic inhalers (12 hours before) or oral asthma medications (48 hours 
before) prior to the test. The Global Lung Function Initiative (GLI) 2012 reference values 
using ―other‖ ethnic group were used for grading degree of impairment of spirometry (10). A 
change in FEV1 of ≥200 milliliters and ≥12% 10 minutes after the administration of 
bronchodilator (400 µg of salbutamol) was considered to be significant bronchial reversibility. 
To achieve additional quality control for the Tanzanian group that did not perform 
methacholine challenge tests (due to logistical considerations), each spirometric test was 
evaluated for the quality according to the ATS standards (11) as outlined in Table 3.4, which 
compares grading between the Easyone spirometer output and the ATS grading. All 
spirometric tests with ATS quality grade F were not included in the analysis. Three (3) 
participants with ATS quality grade F on their pre-bronchodilator (pre-BD) tests were not 
allowed to proceed to post-BD testing (Table 3.4). Data from 182 participants were available 
after excluding those with ATS grade D, E and F on pre-bronchodilator (pre-BD) tests.  
 
Table 3.4: Spirometry quality grades of health workers in the Tanzanian hospital 
 Pre-BD Easyone grade 
n (%) 
Pre-BD ATS grade  
n (%) 
Post-BD Easyone grade 
n (%) 
Post-BD ATS grade 
n (%) 
A 86 (26) 129 (39) 132 (41) 175 (54) 
B 43 (13) 69 (21) 43 (13) 40 (12) 
C 102 (31) 34 (10) 57 (18) 18 (6) 
D 97 (29) 9 (3) 75 (23) 13 (4) 
E  87 (26)  61 (19) 
F 3 (1) 3 (1) 18 (6) 18 (6) 
Total 331 331 325 325 
Note: Those with ≥2 acceptable tests with repeatability of > 0.250 L were assigned ATS grade E 
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3.3.4. Methacholine challenge tests including spirometry 
Methacholine challenge testing (MCT) was only performed in the South African study site 
due to logistical considerations. The tests were conducted in a pulmonary function laboratory 
that was well equipped with appropriate resuscitation facilities. Among 318 participants who 
underwent spirometry, 239 performed interpretable PD20 methacholine results while 52 
participants had ≥10% decrease in FEV1 after administration of saline diluent and were 
therefore not considered for MCT. MCT was discontinued in two participants who requested 
the test to be stopped. As explained above, 25 participants underwent post-bronchodilator 
spirometry, since MCT was contraindicated. MCT was conducted under the supervision of 
an experienced technologist according to an abbreviated protocol used in epidemiological 
surveys. The Medic Aid Pro Nebulizer dosimeter method involved a protocol of increasing 
numbers of breaths to achieve pre-defined cumulative doses of methacholine (12). The 
doses were delivered by the Jaeger APS MedicAid Side Stream APS-Nebulizer according to 
the manufacturer‘s instructions, commencing with the lowest dose of 0.026 mg. The dose 
was increased to a maximum of 2.048 mg methacholine if a positive endpoint (fall in FEV1 of 
20% or more) was not obtained. The results of the MCT were interpreted as follows: 
borderline defined as 0.4mg <PD20M<1.0 mg; mild = 0.08 mg < PD20M <0.4mg; 
moderate/severe = PD20M< 0.08mg. Borderline values for PD20M were considered negative 
in the definition of non-specific bronchial hyper responsiveness (NSBH). These cut-offs for 
the APS system are based on the results from a validation study performed on 40 hyper-
responsive bakery workers that confirmed a satisfactory correlation between the APS 
cumulative PD20M method and the standard VMAX (Sensormedics) method (13). A urine 
pregnancy test was offered to women prior to the administration of methacholine, while 
pregnant women and nursing mothers were automatically excluded from testing. 
3.3.5. Fractional exhaled nitric oxide (FeNO) 
A total of 654 participants performed FeNO tests (334 from SAH and 320 from TAH). A 
hand-held portable exhaled nitric oxide sampling device (NIOX MINO® Airway Inflammation 
Monitor (NIOX MINO); Aerocrine AB, Solna, Sweden) was used. Under guidance of clinical 
personnel, all HWs inhaled NO-free air close to total lung capacity and exhale for 10 
seconds at a flow rate of 50 ml/sec according to the manufacturer‘s instructions. Two 
technically adequate measurements were performed in line with the current American 
Thoracic Society /European Respiratory Society recommendations (14). A third maneuver 
was performed if the difference between the first two measurements was more than 10 ppb. 
The FeNO test was done during the work shift before spirometry / MCT. Special instructions 
were provided to workers to ensure that tested individuals did not smoke tobacco, eat or 
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drink (at least 1 hour before) prior to the test. Ambient NO and temperature were also 
recorded. 
3.3.6. Operational definitions of asthma phenotypes and predictor variables 
Information on which the asthma phenotypes were based was obtained from the 
questionnaire, immunological tests, spirometry (pre- and post-bronchodilator), methacholine 
challenge tests and FeNO levels. An asthma symptom score was computed based on the 
sum of answers (0=no, 1=yes) to five questions on asthma-like symptoms in the past 12 
months (short of breath while wheezing, woken up with chest tightness, attack of shortness 
of breath at rest, attack of shortness of breath after exercise, woken up by attack of 
shortness of breath), as has been described previously (15–18). A binary variable was 
created from these five asthma-like symptoms (≥ 2 symptoms vs 0-1 symptom). Having≥ 2 
asthma-like symptoms was considered ‗more symptomatic‘ and 0-1 asthma-like symptom 
‗less symptomatic‘. 
Current asthma was defined as either having an asthma attack in the past 12 months, 
current use of asthma medication or woken up by an attack of shortness of breath in the past 
12 months (17,19,20). Atopic asthma was defined as either having an asthma attack in the 
past 12 months, current use of asthma medication or woken up by an attack of shortness of 
breath in the past 12 months; and presence of atopy. Nonatopic asthma was defined as 
either having an asthma attack in the past 12 months, current use of asthma medication or 
woken up by an attack of shortness of breath in the past 12 months; and being nonatopic. 
Work-related asthma was defined as either having an asthma attack in the past 12 months, 
current use of asthma medication or woken up by an attack of shortness of breath in the past 
12 months; and work-related chest symptoms in the past 12 months that gets better when 
away from work or worsen on return to work. 
Work-relatedness of asthma symptoms was determined based on the positive responses to 
the following questions (Figure 3.1): ―Does being at work ever make your chest tight, 
wheezy, or short of breath? If Yes: In the last 12 months, have you experienced these chest 
symptoms while you were at work at any time? If Yes: While you were away from work (for 
e.g. on weekends, off-shift, or on vacations) at any time in the last 12 months, did your chest 
symptoms seem better, worse, or the same? After returning to your work at any time in the 
last 12 months, did your chest symptoms seem better, worse, or the same?‖ (21). Work-
relatedness of ocular-nasal and skin symptoms was determined using a similar approach 
(Figure 3.1). 
Individuals with sensitization to specific occupational allergens were identified based on sIgE 
≥ 0.35 KU/L. A variable was created for sensitisation to at least one occupational allergen 
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(OPA, Chlorhexidine or NRL). A categorical variable for NSBH was defined as any of the 
following two criteria: positive methacholine challenge test (PD20 methacholine < 0.4 mg) or 
significant bronchial reversibility (≥12% and ≥ 200 ml increase in FEV1 after administration of 
a bronchodilator). Two continuous indices of NSBH (continuous index of responsiveness 
(CIR) and dose-response slope (DRS)) were also calculated. CIR = (Post-diluent FEV1 – 
FEV1 at the last dose of methacoline) ÷ Post-diluent FEV1 and DRS = (Post-diluent FEV1 – 
FEV1 at the last dose of methacoline) ÷ (Post-diluent FEV1 x Last methacholine dose). CIR 
and DRS were all multiplied by 100 to convert them into percentages. FeNO results were 
interpreted as follows: low < 25ppb; elevated for values 25 - 50ppb; and high for values > 
50ppb (22). In addition to the numerical variable for FeNO, two categorical variables (FeNO 
≥ 25 ppb and FeNO ≥ 50 ppb) were also computed. 
Further information on the host-associated risk factors was based on information obtained 
from the questionnaire and immunological tests (atopy). Body mass index (BMI) was 
calculated as weight in kilograms divided by height in metres squared. Two categorical 
variables were created for smoking history. One was a binary variable: ever smokers 
(current smokers and ex-smokers) vs never smokers. The second smoking variable was a 
nominal variable with three categories (current smokers, ex-smokers and never smokers). 
Family history of allergy was defined as a positive answer to the question ―do or did any 
member of your family (blood relatives) ever have any kind of allergies?‖. Individuals with 
atopy were defined as those having a positive Phadiatop test. Hay fever was defined as a 
positive response to the question ―have you ever had any nose or eye problems or allergies 
such as hay fever?‖. Childhood-onset asthma was defined as doctor-diagnosed asthma at 
the age of 16 years or younger. Adult-onset asthma was defined as doctor-diagnosed 
asthma at the age of 17 years or older. Frequency of domestic cleaning was categorised as 
≥1 day/week vs <1 day/week. 
Further information on the environmental risk factors was based on information obtained 
from the questionnaire, which had detailed information on use of cleaning agents and related 
tasks in the past 12 months. This included information on the duration of use per day for 
each cleaning agent and number of days used per week (5). For cleaning tasks, the 
questionnaire included information on the typical duration of each individual task, number of 
times per day that the task was performed and the number of days per week an individual 
HW performed the task in question (5). Furthermore, for each cleaning agent, frequency of 
use per week was calculated by multiplying duration of use per day and number of days 
used per week. Similarly, for each cleaning task, frequency of task performance per week 
was calculated by multiplying duration of the task, number of times the task was performed 
per day and number of days the task was performed per week. For exposure-response 
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analyses, cleaning-related predictor variables were categorised into 3 levels (cleaning 
product not used; use of a cleaning product for up to 99 minutes per week and use of a 
cleaning product for ≥ 100 minutes per week). 
 
Figure 3.1: Case definitions for work-related symptoms used in the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4. Human subjects and ethical issues 
Ethics approval was obtained from the Human Research Ethics Committee (HREC) of the 
University of Cape Town (HREC Ref: 212/2013), Muhimbili University of Health and Allied 
Sciences (MUHAS) Institutional Review Board and University of Michigan Medical School 
Institutional Review Board (HUM00083115). Informed written consent was sought prior to 
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(n = 697) 
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the questionnaire interview or any tests that was performed. All testing were done on a 
voluntary basis during working time at no direct cost to the worker. All the study participants 
have been provided with a written copy of their own results with interpretation. Individual 
results have been treated with a high degree of confidentiality. All workers with abnormal 
results were offered appropriate referrals for further evaluation. 
3.5. Statistical analysis 
All data analysis was performed using statistical software STATA version 14 (StataCorp, 
College Station, Texas, USA). Frequencies of categorical variables were compared between 
the two hospitals using Chi-squared test or Fisher‘s exact test where appropriate. Numerical 
variables were summarised using median and range, since not all variables followed a 
normal distribution. Scatter plots, Spearman rank correlation and unadjusted linear 
regression models were used to assess association between numerical variables (CIR, DRS 
and FeNO). Numerical variables were compared between the two hospitals using Wilcoxon 
sum rank test. Exposure data followed a log-normal distribution, therefore geometric mean 
and geometric standard deviation were used to summarise measured concentrations of 
aldehydes and p-chloroaniline (PCA). Unadjusted logistic and linear regression models were 
used to examine the association between measured aldehyde levels and predictor variables 
as well as between health outcomes (e.g. asthma-like symptoms, NSBH, FeNO, current 
asthma, atopic asthma, non-atopic asthma, work-related asthma) and host-related risk 
factors (e.g. age, gender, BMI, atopy). Multivariate logistic and linear saturated regression 
models adjusted for atopy, gender and smoking were used to evaluate the association 
between asthma-related outcomes (and other relevant clinical endpoints) and cleaning-
related risk factors (specific cleaning agents and tasks). For linear regression analyses, log 
transformed values of DRS and FeNO were used, with geometric mean ratios and 95% 
confidence intervals. A negative binomial regression analysis was used for the association 
between asthma symptom score (a count outcome variable) and cleaning-related risk 
factors. Negative binomial regression models were used for this analysis instead of Poisson 
regression since the mean score (0.58) was lower than the standard deviation (1.11). The 
results of the negative binomial regression models were reported as mean ratios with 95% 
confidence intervals. For some regression models the regression coefficient was not 
calculable due to small numbers, the respective cell for that separate regression model was 
annotated as ―not calculable‖ (NC) in the relevant table.  
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CHAPTER 4 
Characterisation of exposure to cleaning agents among health workers in two large tertiary 
hospitals in South Africa and Tanzania 
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ABSTRACT 
Background: Over the past two decades, there has been growing evidence linking cleaning 
agents to adverse health effects such as rhinitis, asthma and contact dermatitis. Although 
cleaning agents are commonly used in workplaces and homes, health workers (HWs) are at 
higher risk due to a wide range of chemicals with significantly higher concentrations that are 
used in order to prevent healthcare associated infections. Exposure assessment for cleaning 
agents has been challenging partly because many cleaning agents are used simultaneously 
resulting in complex airborne exposures with various chemicals requiring different sampling 
techniques. The main objective of this study was to characterize exposures of HWs to 
various cleaning agents in the two tertiary academic hospitals in sub-Saharan Africa. 
Methods: A cross-sectional study of HWs was conducted in two large tertiary hospitals. 
Systematic workplace observations and interviews with key personnel were conducted in the 
two hospitals using a proforma checklist. Environmental sampling for aldehydes (ortho-
phthalaldehyde - OPA, glutaraldehyde and formaldehyde) was initially conducted in the 
South African hospital (SAH). A pilot sampling in the Tanzanian hospital (TAH) revealed very 
low detectable levels of OPA and glutaraldehyde and consequently full measurements were 
not done in this hospital. In the SAH, a total of 269 full-shift passive personal samples were 
collected from 164 HWs randomly selected from 17 different clinical departments. Passive 
sampling used TraceAir® AT580 monitors (Assay Technology, Livermore, CA). Samples 
were analysed for aldehydes using OSHA method 64 and NIOSH method 2016 by a South 
African National Accreditation System (SANAS) accredited laboratory. Biomonitoring for 
chlorhexidine was only conducted in the SAH since none of the HWs in the TAH used 
chlorhexidine. Spot urine samples from 336 participants were collected and analysed by the 
University of Cape Town (UCT) Clinical Pharmacology laboratory. While the study was 
initially set up to determine the concentration of chlorhexidine and its metabolites (p-
chloroaniline (PCA) and 1-chloro-4-nitrobenzene), it proved feasible to develop an assay 
only for PCA. 
Results: OPA was detectable in 6 (2%) of all samples analysed. These detectable samples 
were all collected in the gastrointestinal (GI) unit (GM = 0.010 ppm; range: 0.005 – 0.027). 
All 6 detectable samples had OPA levels higher than the newly proposed ACGIH‘s TLV-
Ceiling Limit of 0.0001 ppm. All detectable samples were collected from HWs who used 
OPA. Health workers exposed to detectable OPA levels had a longer duration of OPA use 
(OR = 1.28; 95% CI: 1.10 – 1.50). While samples collected from nurses had the highest 
mean OPA exposure levels (GM = 0.014 ppm), sterilising operators had greater odds of 
having detectable exposures than nurses (OR = 22.43; 95% CI: 3.82 – 131.72). 
Formaldehyde was detectable in 103 (38%) samples (GM = 0.005 ppm; range: 0.003 – 
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0.027). Three (1%) samples had formaldehyde levels higher than the NIOSH recommended 
exposure limit (REL) of 0.016 ppm TWA but none greater than the ACGIH TLV-TWA (0.1 
ppm). Formaldehyde exposure was positively associated with working in an Ear, Nose & 
Throat (ENT) ward (OR = 6.28; 95% CI: 1.65–23.82). Unlike OPA, job title, personal use of 
formaldehyde and duration of formaldehyde use were not associated with detectable 
formaldehyde levels. Glutaraldehyde was not detectable in the SAH. In the pilot sampling 
conducted in the TAH, glutaraldehyde was detectable in eight (73%) of the eleven samples 
collected (GM = 0.006 ppm; range: 0.001 – 0.028). Glutaraldehyde levels that were 
detectable were all below the ACGIH‘s TLV-Ceiling Limit of 0.05 ppm. PCA was detectable 
in 13 (4%) of the 336 urine samples collected and analysed (GM = 2.41 ng/ml range: 1.00 – 
25.80).  
Conclusion: Cleaning agents used in this study were similar to those used in health care 
settings beyond sub-Saharan Africa, but the frequency and duration of use differs depending 
on the setting. Workplace controls for reducing exposure to cleaning agents were deficient in 
both exposure contexts. The study concluded that mean detectable exposures to OPA are 
higher and more isolated to certain departments and are dependent on the personal use of 
OPA, duration of use and job title in contrast to the more widespread low-level formaldehyde 
exposures present throughout the hospitals. There is a need for more standardized, 
sensitive and validated assays for the determination of chlorhexidine and its metabolites 
(PCA and 1-chloro-4-nitrobenzene) in biological fluids. 
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4.1. INTRODUCTION 
Various studies have demonstrated an association between exposure to cleaning agents 
and adverse health effects such as rhinitis, asthma and contact dermatitis(1). Exposure to 
cleaning agents is common in different workplaces as well as in domestic settings (2). Health 
workers (HWs) are particularly at higher risk since higher concentrations of a wide range of 
cleaning agents are used in order to prevent healthcare associated infections (3). 
Most cleaning agents are irritants but some have both irritant and sensitising properties (4). 
Broad groups of potential sensitisers and irritants that are present in health care settings 
include medical instrument cleaning and disinfecting products (e.g. glutaraldehyde and 
ortho-phthalaldehyde (OPA)); fixed surfaces cleaning products (e.g. bleach); floor finishing 
products (stripping, waxing & buffing e.g. ethanolamine); specimen preparation products 
(e.g. formaldehyde); patients‘ skin / wound cleaning & disinfecting products (e.g. 
chlorhexidine and povidone iodine); hand washing / sanitising products (e.g. chlorhexidine 
and alcohols); aerosolised medications (e.g. pentamidine); methacrylates in dental and 
surgical cements; natural rubber latex products; micro-organisms and mildew(4–6). 
The use of high-level disinfectants such as OPA and glutaraldehyde for heat-sensitive 
reusable semi-critical medical instruments such as endoscopes, bronchoscopes and 
respiratory therapy equipment generally follows a pre-cleaning phase to remove gross 
contaminants using products such as enzymatic cleaners .Glutaraldehyde has historically 
been used for over 40 years in health care settings not only for high-level disinfection of 
medical instruments but also as a fixative for electron microscopy and x-ray films. Several 
studies have linked glutaraldehyde and various health effects such as occupational asthma 
and allergic contact dermatitis (7,8). In some countries such as the United Kingdom (UK), it 
has been banned for this purpose (9). In 1999, the Food and Drug Administration (FDA) 
approved OPA to be used as a high-level disinfectant. OPA was subsequently considered a 
safer replacement for glutaraldehyde in some health care settings. Recently, OPA has also 
been reported to cause occupational asthma, contact dermatitis and anaphylaxis (10,11).   
Hand hygiene and  skin/wound disinfection of patients in hospital settings has been effected 
commonly using chlorhexidine (12–14). Since chlorhexidine is also present in several 
common household products such as tooth pastes, mouthwashes, ointments, eye and nose 
drops it is ubiquitous in the domestic setting. Chlorhexidine is well known for its sensitising 
and irritating properties to both the skin and airways (12–14). Previous studies have reported 
cases of occupational asthma and dermatitis due to chlorhexidine (12–14) and anaphylaxis 
among patients undergoing surgery/invasive procedures (15,16).  
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Exposure assessment for cleaning agents has historically posed a challenge since many 
cleaning agents with different ingredients are used simultaneously resulting in airborne 
exposures that are usually a complex mixture of various chemicals with different physico-
chemical properties requiring multiple sampling techniques (17). Another challenge has been 
the type of product used, frequency and duration of use that all vary depending on the 
specific cleaning task performed (6,17). Frequently, several cleaning tasks are performed in 
a single room and may be repeated several times a day. Furthermore, HWs may use the 
same cleaning agents in different ways resulting in variable degrees of chemical exposures. 
It is not surprising that only a few studies have been reported on quantitative exposure 
assessment for cleaning agents in general, and aldehydes such as glutaraldehyde and OPA 
in particular.  
A detailed literature search revealed studies that have focussed mainly on measurement of 
OPA exposures in air (18–23). The literature on development of sampling and analytical 
methods for the determination of OPA concentrations in air is even more scant. Uchiyama et 
al (19) published a method for the determination of OPA in air using 2,4-
dinitrophenylhydrazine (DNPH)-impregnated silica cartridges and high-performance liquid 
chromatography (HPLC) in 2006. In 2008, Tucker reported a method for determining OPA 
concentration in air and two methods for measuring OPA exposure on surfaces (20). More 
recently, Tucker reported two partially validated methods for determination of OPA in air, one 
(DNPH-HPLC method) being an improvement of the previous method (22).  
Despite the commercial availability of samplers, no studies were identifiable that used 
passive method for determining airborne OPA exposures. However, studies on passive 
sampling of formaldehyde and glutaraldehyde have been reported (24,25). Previous studies 
comparing the performance of passive and active sampling methods for formaldehyde have 
shown good agreement between the two assessment methods (24). However, a recent 
study demonstrated that passive sampling generally overestimated the formaldehyde 
concentrations as compared to the active method (26). Passive samplers are occasionally 
preferred over active methods in that they are convenient due to being small and lightweight; 
can be used by most individuals, often with minimal training; are less expensive; and often 
do not interfere with the workers‘ usual routine (26).  
The most appropriate method for estimating exposure to chlorhexidine is to conduct 
biological monitoring. Environmental air sampling is considered inappropriate since 
chlorhexidine has a low likelihood of becoming airborne due to its very low vapour pressure. 
Few studies have used chlorhexidine biomonitoring to evaluate exposure (27). While some  
of these studies have successfully identified chlorhexidine and/or its metabolites (p-
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chloroaniline and 1-chloro-4-nitrobenzene) in biological fluids, challenges exist in quantifying 
exposure (27–29). 
This study was conducted to characterise exposures of HWs to major categories of cleaning 
agents used in two large tertiary hospitals in South Africa and Tanzania, and to identify 
important exposure determinants. This arose following a few incidents of anaphylaxis in 
patients following the use of OPA for high-level disinfection of medical instruments and some 
HWs reporting respiratory and skin symptoms when cleaning and disinfecting these 
instruments. 
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4.2. METHODS 
4.2.1. Study population 
A cross-sectional study of different categories of HWs was conducted in the two large 
tertiary hospitals. Following meetings with several key stakeholders and walk-through 
inspections by the investigators of both hospitals, specific departments were identified as 
potentially high-risk exposure settings for cleaning agents. Health workers in these high-risk 
departments used significant amounts of cleaning agents at a frequency much higher than 
other departments. The departments identified in the SAH included out-patient clinics, 
intensive care units (ICUs), operating theaters, emergency units, ENT ward, vascular 
radiology and the haemodialysis unit. The out-patient clinics, ICUs, operating theaters, 
emergency unit, Central Sterile Services Department (CSSD) and haemodialysis unit were 
identified in the TAH. Ethics approval was obtained from the Human Research Ethics 
Committee (HREC) of the University of Cape Town (HREC Ref: 212/2013), Muhimbili 
University of Health and Allied Sciences (MUHAS) Institutional Review Board and University 
of Michigan Medical School Institutional Review Board (HUM00083115). 
4.2.2. General exposure assessment 
A list of cleaning agents used in the two hospitals was obtained from the supply chain 
department of the respective hospital. Information was also obtained about the type and 
volume of chemicals used in the various departments of the hospital to confirm a priori high-
risk departments. The most recent safety data sheets (SDS) of the cleaning products were 
obtained from the supply chain department and/or from suppliers/manufacturers directly. 
Walk-through surveys were conducted in both hospitals using a proforma checklist. The 
surveys were conducted by a team that included an occupational hygienist and occupational 
medicine specialist. The team members also conducted short interviews with the operational 
managers of the respective work area. During the walk-through survey, each member of the 
team conducted their own independent evaluation. After evaluating each specific work area 
(department), the team members convened for a short discussion to have a consensus 
decision on the relevant exposures pertaining to that department. Discrepancies in findings 
were resolved by consensus and the findings recorded on the checklist. The research team 
also communicated with the supply chain departments and nurse managers on a regular 
basis to ensure that any new products that were introduced during the study period also 
formed part of the assessment.  
4.2.3. Environmental sampling of aldehydes 
Measurement of aldehyde concentrations in the air was initially conducted in the SAH. A 
subsequent pilot sampling study in the TAH revealed very low levels of OPA and 
glutaraldehyde and as a result extensive environmental sampling was not done in this 
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hospital. In the SAH, measurements of aldehydes were conducted in the 17 departments 
where OPA and enzymatic cleaners were used for cleaning and disinfection of medical 
instruments. This decision was informed by the initial walk-through survey findings. Selection 
of workers for OPA monitoring was limited to those on a day-shift for logistical reasons. On 
the earmarked sampling day, workers in each department were classified into high, medium 
and low/no exposure based on the results of the walk-through survey. Workers working 
directly with OPA were classified into a high exposure group; workers performing patient 
care activities were classified into a medium exposure group; and administrative workers 
were classified into a low/no exposure group. A random sampling strategy was employed to 
select workers in each stratum (high, medium, low/no exposure) for OPA air monitoring in 
each department. The random selection was based on using sample size calculations of the 
top 20%, employing a 95 percent confidence level (30). A total of 269 full-shift passive 
personal samples were collected from 164 HWs randomly selected from 17 different 
departments. Among the 164 workers selected, 70 (43%) were sampled once, 83 (50%) 
sampled twice and 11 (7%) were sampled thrice.  
Passive sampling used TraceAir® AT580 monitors (Assay Technology, Livermore, CA). 
TraceAir® AT580 monitors containing a fibreglass strip treated with 2,4-
dinitrophenylhydrazine (DNPH) for sampling aldehydes including OPA. The OPA reacts with 
DNPH in the monitor to yield an OPA-DNPH derivative. Field blanks were included in every 
day of passive sampling. All samples were stored at 4 degrees Celsius after collection until 
analysed. Analysis was conducted within four weeks of sample collection. 
Samples were analysed for OPA, glutaraldehyde and formaldehyde using OSHA method 64 
and NIOSH method 2016 in a South African National Accreditation System (SANAS) 
accredited laboratory. Two millilitres of Acetonitrile:dimethylsulfoxide (90:10) was added to 
extract the OPA-DNPH derivative from the monitors. The samples were left to desorb for 30 
minutes, to ensure that all the analytes were dissolved in solution. Samples were analysed 
using an Agilent 1100 series High Performance Liquid Chromatography (HPLC) with a 
Variable Wavelength Detector (VWD). The column used was a Phenomonex Luna 5um C18 
reversed phase. An acetate buffer was used, which contained 5 g of ammonium acetate 
adjusted to pH 6 with acetic acid. Acetonitrile was used as the organic solvent.  The method 
used was 19.00 minutes in length. The flow rate was 1.5 ml/min. An isocratic mixture of 
buffer: acetonitrile (30:70) was used as the mobile phase. The injection volume was 20 µl, 
and the column temperature was controlled at 40C. The VWD was set to 360 nm. Samples 
were integrated with Chemstation, where a calibration was setup beforehand. The calibration 
was setup by means of an external standard. A calibration stock of OPA-DNPH derivatives 
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were obtained from Supelco. Calibration standards ranged from 1ppm to 10 ppm. A linear 
calibration curve was constructed and was forced through 0, with a regression of 0.99910. 
4.2.4. Biomonitoring for chlorhexidine 
Chlorhexidine biomonitoring was conducted in the SAH only since none of the HWs in the 
TAH used chlorhexidine. Urine samples for chlorhexidine biomonitoring were collected from 
the study participants during their health outcome assessment visit to the study venue. Spot 
urine samples (50 ml) were collected from 336 participants in a clean indoor toilet using a 
plastic container topped with a plastic cap. To avoid contamination, participants were 
instructed on specific precautions on washing hands before handling containers; not 
touching the inside of the container; collecting the midstream urine and covering the 
containers immediately after producing the sample. The samples were stored in the 
refrigerator at 4 degrees Celsius at the study venue and then transported on dry ice to the 
permanent storage facility on the same day of sample collection. The samples were stored 
at -80 degrees Celsius before being analysed at the Clinical Pharmacology laboratory at the 
University of Cape Town. 
While the initial plan of the biomonitoring component was to develop a multiplex assay for 
the determination of chlorhexidine and its metabolites (p-chloroaniline and 1-chloro-4-
nitrobenzene) in urine, due to logistical reasons it was only possible to develop a method for 
p-chloroaniline (PCA). The urine samples were analysed using a LC-MS/MS method 
developed in-house based on the detection of PCA. The samples were thawed at room 
temperature and extracted with 4 volumes of a 1:1 mix of 0.1% formic acid and acetonitrile, 
containing 62.5ng/ml p-bromoaniline as internal standard. The supernatant following 
centrifugation was transferred to a 96-well plate for LC-MS/MS analysis. Calibration 
standards and quality control samples were prepared by spiking PCA in blank urine to give 
final concentrations between 1 – 3125ng/ml. These were then extracted as described and 
analysed together with the patient samples to provide a standard curve from which patient 
PCA levels were determined.  LC-MS/MS was performed on an ABSciex 4000Qtrap® mass 
spectrometer coupled to an Agilent 1200 Rapid Resolution HPLC system. Chromatography 
was achieved using a Kinetex F5 column (100 x 4.6mm, 2.6µ) using 0.1% formic acid as the 
aqueous mobile phase and 0.1% formic acid in acetonitrile as the organic phase. An 
isocratic method at 0.8ml/min was run, with a 1:1 split between the MS and waste. Carry 
over was avoided using a needle wash consisting water, acetonitrile, methanol, isopropanol 
and formic acid (30:30:30:10:0.1). Analyst 1.6 software was used for instrument control, data 
acquisition and analyte quantitation. 
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4.2.5. Statistical analyses 
All data analyses were performed using statistical package STATA version 14 (StataCorp, 
College Station, Texas). Frequencies of categorical variables such as major categories of 
cleaning/disinfecting tasks, specific control measures uptake and common cleaning products 
used were calculated. Numerical variables were summarised using median and range, since 
some of the variables did not follow a normal distribution. Predictably, exposure data 
followed a log-normal distribution, and as a result geometric mean and geometric standard 
deviation were used to summarise the measured concentrations of aldehydes and p-
chloroaniline (PCA). Univariate logistic regression analyses were used to examine the 
association between the outcomes of interest (aldehyde levels & PCA) and the predictor 
variables (e.g. job title, department). 
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4.3. RESULTS 
4.3.1. General exposure assessment 
The results of the walk-through inspections and nurse manager interviews indicate that a 
slightly larger number of departments were investigated in the SAH than the TAH. The major 
categories of cleaning-related tasks that were performed in these two hospitals included 
medical instruments cleaning and disinfection, fixed surfaces cleaning and disinfection, floor 
finishing tasks (stripping, waxing and buffing), specimen preparation, patients‘ skin / wound 
cleaning and disinfection and hand washing / sanitising (Table 4.1). Most HWs in the 
departments sampled used more wipes than aerosolised sprays when handling various 
cleaning agents.  
There were no local exhaust ventilation (LEV) systems present for cleaning-related tasks in 
both hospitals. A greater proportion of departments in the SAH (83%) than the TAH (15%) 
had ceiling extractor fans. A low proportion of HWs (44% in South Africa and 23% in 
Tanzania) had received training on adverse health effects due to cleaning agents. None of 
the HWs were observed wearing an appropriate respirator (e.g. half-face respirator with 
vapour cartridges) when performing their cleaning and disinfecting tasks. Furthermore, both 
hospitals reported that there were no specific medical surveillance programs for workers 
working with cleaning agents. 
Among the 36 nurse managers in South Africa and 13 nurse managers who were 
interviewed in Tanzania, 8 (22%) in the former and 7 (54%) in the latter hospital respectively 
reported at least one HW in their department with adverse health effects due to cleaning 
agents in the last 12 months. The reported number of HWs who experienced these adverse 
health effects was higher in the TAH, 39 (7%), when compared to 16 (2%) individuals from 
the SAH. While nurse managers in Tanzania reported mainly ocular symptoms, airway 
(nasal, throat, and chest) and skin symptoms were more commonly reported from South 
Africa. The cleaning agents suspected of being responsible for these adverse health effects 
included the most common products used for medical instrument and fixed surfaces cleaning 
and disinfection (Figure 4.1). While enzymatic cleaners and ortho-phthalaldehyde (OPA) 
were reported by nurse managers in both hospitals, chlorhexidine, a quaternary ammonium 
product, and a high-level disinfectant containing acetic acid, peracetic acid and hydrogen 
peroxide were only reported by the SAH (Figure 4.1). On the other hand, glutaraldehyde and 
chlorine-based products (sodium dichloroisocyanurate ―Troclosene sodium‖ tablets and 
liquid hypochlorite bleach) were only reported by the TAH (Figure 4.1). 
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Table 4.1: Cleaning-related tasks performed, control measures uptake and health 
effects reported by nurse managers in the two tertiary hospitals 
 Tertiary Hospital 
– South Africa 
(SAH) 
N (%) 
Tertiary Hospital 
–Tanzania (TAH) 
 
N (%) 
Number of health workers (HWs) in the selected 
departments 
n = 759 n = 560 
Departments investigated n = 36 n = 13 
Cleaning-related tasks performed   
Hand washing / sanitising 36 (100) 13 (100) 
Fixed surfaces cleaning and disinfection 35 (97) 13 (100) 
Medical instruments cleaning and disinfection 20 (56) 13 (100) 
Patients‘ skin / wound cleaning and disinfection 31 (86) 12 (92) 
Floor finishing tasks (stripping, waxing & buffing) 36 (100) 0 (0) 
Specimen preparation 19 (53) 8 (62) 
The manner of cleaning products use: used more 
sprays or more wipes 
  
More wipes than sprays 32 (89) 13 (100) 
More sprays than wipes 3 (8) 0 (0) 
Use sprays and wipes about equally 1 (3) 0 (0) 
Control measures uptake   
Engineering controls present   
Extractor fans in the ceiling 30 (83) 2 (15) 
Local exhaust ventilation system 0 (0) 0 (0) 
Administrative controls present   
Training on adverse health effects due to cleaning 
agents 
16 (44) 3 (23) 
Availability of Standard Operating Procedures 
(SOP) document/s on how to use cleaning agents 
13 (36) 11 (85) 
Housekeeping: Chemical spill / release observed 0 (0) 1 (8) 
Personal protective equipment use   
Gloves 36 (100) 13 (100) 
Protective clothing (aprons, overalls) 29 (81) 3 (23) 
Eye protection (goggles, face shields) 2 (6) 0 (0) 
Foot protection (safety/gum boots) 1 (3) 3 (23) 
Air purifying half face respirator 0 (0) 0 (0) 
Medical surveillance 0 (0) 0 (0) 
No. of nurse managers reporting at least one of their 
HCWs in their department experienced health 
effects due to cleaning agents in the last 12 months 
8 (22%) 7 (54%) 
Total number of HCWs who experienced health 
effects in the last 12 months as reported by their 
nurse managers  
16 (2) 39 (7) 
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Figure 4.1: Cleaning agents responsible for symptoms as reported by nurse managers 
in the two tertiary hospitals 
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Table 4.2 presents the most common (top 5) cleaning agents used in the two tertiary 
hospitals. The most common high-level disinfectant used for heat-sensitive medical 
instruments in South Africa was OPA (36%), followed by hydrogen peroxide (14%). Whilst 
OPA (23%) was also used in Tanzania, glutaraldehyde (31%) was more commonly used. 
Glutaraldehyde was not used for medical instruments cleaning and disinfection in the SAH. 
Enzymatic cleaners were also used in both hospitals for cleaning medical instruments prior 
to disinfection. In South Africa, enzymatic cleaners (median: 300 minutes/week; range: 8 – 
1800 minutes/week) and alcohols (median: 300 minutes/week; range: 2 – 600 
minutes/week) had the longest average duration of use for medical instruments cleaning and 
disinfection, while in Tanzania, an all-purpose cleaner (median: 368 minutes/week; range: 95 
– 1500 minutes/week) and chlorine-based bleach products (median: 248 minutes/week; 
range: 70 – 490 minutes/week) were used for the longest average duration (Table 4.3A). 
Out-patient clinics and operating theatres in both hospitals used most of the products for 
medical instruments cleaning and disinfection. 
Bleach was the most common product used for fixed surfaces cleaning and disinfection in 
both hospitals (Table 4.2). Bleach had also the longest average duration of use for fixed 
surfaces cleaning and disinfection in both hospitals (South Africa = median: 1020 
minutes/week; range: 140 – 4200 minutes/week and Tanzania = median: 1200 
minutes/week; range: 900 – 1800 minutes/week). Intensive care units (median: 2100 
minutes/week; range: 140 – 2520 minutes/week) in South Africa and out-patient clinics 
(median: 1440 minutes/week; range: 900 – 1800 minutes/week) in Tanzania had the longest 
duration of bleach use for fixed surfaces cleaning and disinfection (Table 4.3B). Other 
common products used for fixed surfaces cleaning and disinfection were ammonia (92%), 
alcohols (86%) and a dishwashing liquid (81%) in SAH and an all-purpose cleaner (100%) in 
the TAH.  
Floor finishing tasks were not performed by HWs in the TAH. While floor strippers and waxes 
were used only once a year in each department in the SAH, buff sprays (diluted floor waxes) 
were used more frequently (median: 2 times/week; range: 1 – 5 times/week). The 
haemodialysis unit had the longest average duration use of buff sprays (median: 360 
minutes/week; range: 360 – 360 minutes/week) compared to other departments. 
Formalin (10%) solution was commonly used in both hospitals for specimen preparation 
(tissue fixation). Vascular radiology (median: 70 minutes/week; range: 70 – 70 
minutes/week) and operating theatres (median: 49 minutes/week; range: 2 – 100 
minutes/week) in the SAH as well as operating theatres (median: 8 minutes/week; range: 2 – 
15 minutes/week) in Tanzania had the longest duration of formalin use for tissue fixation 
(Table 4.3C). Health workers in the SAH reported a higher duration of formalin use (median: 
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33 minutes/week; range: 2 – 300 minutes/week) than their Tanzanian counterparts (median: 
6 minutes/week; range: 2 – 50 minutes/week). The other common product used for 
specimen preparation in the South African hospital was an alcohol-based spray for 
cytological specimens.  
Alcohols and povidone iodine were used commonly in both hospitals for disinfection of 
patients‘ surfaces before a surgical or instrument procedure or for wound care. Notably, 
chlorhexidine containing products were commonly used (61%) in the SAH for patients‘ 
surfaces disinfection and wound care but not in Tanzania. HWs in the emergency units of 
both hospitals had the longest average duration of alcohol usage for disinfection of patients‘ 
surfaces and wound care compared to other departments. The longest duration of povidone 
iodine use was recorded in the operating theatres (median: 222 minutes/week; range: 100 – 
350 minutes/week) in South Africa while in Tanzania, intensive care units (median: 150 
minutes/week; range: 150 – 150 minutes/week) and operating theatres (median: 125 
minutes/week; range: 50 – 300 minutes/week) had the longest duration of povidone iodine 
use. 
Liquid products for hand washing and/or sanitising were used quite commonly by HWs in all 
the departments studied in both hospitals although South African HWs reported much higher 
frequency of use. Chlorhexidine containing products (100%), liquid hand soap (92%) and 
alcohol sanitisers (75%) were the most common hand products used in South Africa (Table 
4.2). In Tanzania, a diluted all-purpose cleaner (92%) was the most commonly used hand 
product, followed by an alcohol sanitiser (62%). Alcohol sanitisers (median: 60 times/day; 
range: 10 – 140 times/day), followed by chlorhexidine containing products (median: 55 
times/day; range: 3 – 120 times/day) were the most frequently used hand products in South 
Africa. In Tanzania, a diluted all-purpose cleaner (median: 30 times/day; range: 10 – 40 
times/day) followed by an alcohol sanitiser (median: 23 times/day; range: 5 – 35 times/day) 
were the most frequently used products for hand washing/sanitising.  
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Table 4.2: The most common cleaning products used in the two tertiary hospitals 
 Tertiary Hospital – South Africa 
N = 36 
Tertiary Hospital –Tanzania 
N = 13 
Medical instruments cleaning 
& disinfection 
n = 20 n (%) n = 13 n (%) 
Enzymatic cleaners 15 (42) Bleach 10 (77) 
Ortho-phthalaldehyde 13 (36) All-purpose cleaner 10 (77) 
Alcohols 7 (19) Enzymatic cleaners 5 (39) 
Chlorhexidine 6 (17) Glutaraldehyde 4 (31) 
Hydrogen peroxide 5 (14) Ortho-phthalaldehyde 3 (23) 
Fixed surfaces cleaning & 
disinfection 
n = 35 n (%) n = 13 n (%) 
Bleach 34 (94) Bleach 13 (100) 
Ammonia 33 (92) All-purpose cleaner 13 (100) 
Alcohols 31 (86) Glass cleaner 7 (54) 
Dishwashing liquid 29 (81) Floor cleaner  2 (15) 
Air freshener 21 (58)   
Floor finishing tasks 
(stripping, waxing & buffing) 
n = 36 n (%) n = 0 n (%) 
Floor stripper 36 (100)   
Floor wax 36 (100)   
Specimen preparation n = 19 n (%) n = 8 n (%) 
Formalin 10% solution 18 (50) Formalin 10% solution 8 (62) 
Cytological fixative spray 14 (39)   
Alcohol solution 3 (8)   
Glutaraldehyde 1 (3)   
Patients’ skin / wound 
cleaning & disinfection 
n = 31 n (%) n = 12 n (%) 
Alcohols 27 (75) Alcohols 12 (92) 
Chlorhexidine 22 (61) Povidone iodine 11 (85) 
Povidone iodine 15 (42) Chloroxylenol 4 (31) 
Ether 6 (17) Hydrogen peroxide mouthwash 1 (8) 
Acetone 2 (6)   
Hand washing / sanitising n = 36 n (%) n =12 n (%) 
Chlorhexidine 36 (100) All-purpose cleaner (diluted) 12 (92) 
Liquid hand soap 33 (92) Alcohol sanitiser 8 (62) 
Alcohol sanitiser 27 (75) Hand wash liquid soap 1 (8) 
Povidone iodine 6 (17)   
N = number of departments assessed; n = number of departments conducting the task/s 
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Table 4.3A: Duration of cleaning products use for medical instrument cleaning and disinfection classified by department in the two 
tertiary hospitals 
 Medical instruments cleaning and disinfection 
Tertiary Hospital – South Africa (N = 36) Tertiary Hospital –Tanzania (N = 13) 
Department N Enzymatic OPA Alcohol Chlorhexidine Hydrogen peroxide Department N Bleach All-purpose cleaner Enzymatic Glutaraldehyde OPA 
 n Mins /week 
median (range) 
n Mins /week 
median (range) 
n Mins /week 
median 
(range) 
n Mins /week 
median (range) 
n Mins /week 
median 
(range) 
 n Mins /week 
median (range) 
n Mins /week 
median (range) 
n Mins /week 
median (range) 
n Mins /week 
median (range) 
n Mins /week 
median (range) 
Out-patient 
clinics (n=9) 
9 6 1050 (150-1800) 6 720 (60–1800) 4 300 (30-600) 3 300 (150-1200) 2 163 (25-300) Out-patient 
clinics (n=3) 
3 1 95 (95 – 95) 3 630 (95 – 1500) 2 430 (90 – 770) 2 420 (90 – 750) 0  
Intensive care 
units (n=9) 
0 0  0  0  0  0  Intensive care 
units (n=3) 
3 3 330 (70 – 490) 3 320 (145 – 490) 0  0  0  
Operating 
theatres (n=11) 
7 6 165 (8-400) 4 15 (5–150) 2 301 (2-600) 1 400 (400-400) 1 400 (400-400) Operating 
theatres (n=4) 
4 4 248 (110 – 280) 2 433 (215 – 650) 3 215 (70 – 270) 2 35 (20 – 50) 2 265 (30 – 500) 
Emergency 
units (n=3) 
1 1 35 (35-35) 1 35 (35-35) 1 70 (70-70) 1 70 (70-70) 0  Emergency 
units (n=1) 
1 1 415 (415 – 415) 1 415 (415 – 415) 0  0  1 100 (100 – 100) 
ENT ward 
(n=1) 
1 1 50 (50-50) 1 30 (30–30) 0  0  1 75 (75-75)             
Vascular 
radiology (n=1) 
1 1 210 (210-210) 1 105 (105–105) 0  1 210 (210-210) 1 210 (210-210) CSSD (n=1) 1 1 70 (70 – 70) 1 145 (145 – 145) 0  0  0  
Haemodialysis 
(n=2) 
1 0  0  0  0  0  Haemodialysis 
(n=1) 
1 0  0  0  0  0  
Overall (n=36) 20 15 300 (8-1800) 13 75 (5–1800) 7 300 (2-600) 6 255 (70-1200) 5 210 (25-400) Overall (n=13) 13 10 248 (70 – 490) 1
0 
368 (95 – 1500) 5  215 (70 – 770) 4 70 (20 – 750) 3 100 (30 – 500) 
n = number of departments using the product; N = number of departments doing the task 
 
 
 
 
 
 
 
 
86 
 
 
Table 4.3B: Duration of cleaning products use for fixed surfaces cleaning and disinfection classified by department in the two tertiary 
hospitals 
 Fixed surfaces cleaning and disinfection 
Tertiary Hospital – South Africa (N = 36) Tertiary Hospital –Tanzania (N = 13) 
Department N Bleach Ammonia Alcohol Dishwashing liquid Department N Bleach All-purpose cleaner Glass cleaner Floor cleaner 
 n Mins /week 
median (range) 
n Mins /week 
median (range) 
n Mins /week 
median (range) 
n Mins /week 
median (range) 
 n Mins /week median 
(range) 
n Mins /week median 
(range) 
n Mins /week 
median (range) 
n Mins /week 
median (range) 
Out-patient 
clinics (n=9) 
9 9 600 (600-1260) 9 600 (210-1200) 9 420 (90-1800) 5 1260 (900-1800) Out-patient 
clinics (n=3) 
3 3 1440 (900 – 1800) 3 1440 (900 – 1800) 2 125 (100 – 150) 0  
Intensive 
care units 
(n=9) 
9 9 2100 (140-2520) 8 420 (140-2520) 9 420 (210-2520) 9 105 (70-2100) Intensive 
care units 
(n=3) 
3 3 1200 (900 – 1200) 3 1200 (900 – 1200) 3 150 (30 – 150) 2 120 (120 – 120) 
Operating 
theatres 
(n=11) 
1
0 
1
0 
1200 (180-4200) 10 2010 (50-2520) 8 220 (50-420) 9 4200 (50-4200) Operating 
theatres 
(n=4) 
4 4 900 (900 – 900) 4 750 (150 – 900) 1 150 (150 – 150) 0  
Emergency 
units (n=3) 
3 3 420 (210-3360) 3 420 (210-420) 3 210 (210-210) 3 70 (70-420) Emergency 
units (n=1) 
1 1 1200 (1200 – 1200) 1 1200 (1200 – 1200) 0  0  
ENT ward 
(n=1) 
1 1 420 (420-420) 1 1260 (1260-1260) 0  1 1260 (1260-1260)           
Vascular 
radiology 
(n=1) 
1 1 210 (210-210) 1 210 (210-210) 1 210 (210-210) 1 70 (70-70) CSSD (n=1) 1 1 900 (900 – 900) 1 900 (900 – 900) 0  0  
Haemodialys
is (n=2) 
1 1 840 (840-840) 1 840 (840-840) 1 420 (420-420) 1 840 (840-840) Haemodialys
is (n=1) 
1 1 1200 (1200 – 1200) 1 1200 (1200 – 1200) 1 30 (30 – 30) 0  
Overall 
(n=36) 
3
4 
3
4 
1020 (140-4200) 33 600 (50-2520) 31 300 (50–2520) 29 840 (50-4200) Overall 
(n=13) 
1
3 
13 1200 (900 – 1800) 13 900 (150 – 1800) 7 150 (30 – 150) 2 120 (120 – 120) 
n = number of departments using the product; N = number of departments doing the task 
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Table 4.3C: Duration of cleaning products use for other tasks classified by department in the two tertiary hospitals 
 Tertiary Hospital – South Africa (N = 36) Tertiary Hospital –Tanzania (N = 13) 
Department Floor finishing 
products 
Products for specimen preparation Hand sanitisers and hand washing products Department Products for 
specimen 
preparation 
Hand sanitisers and hand washing products 
Buff sprays  
(diluted floor waxes) 
 Formalin 10% 
solution 
Cytological fixative 
spray 
Chlorhexidine Liquid hand soap Alcohol sanitiser Formalin 10% 
solution 
All-purpose cleaner 
(diluted) 
Alcohol 
sanitiser 
Hand wash 
liquid soap 
n Mins / week  
median (range) 
n n Mins / 
week  
median 
(range) 
n Mins / week  
median 
(range) 
n Times / day 
median 
(range) 
n Times / day 
median 
(range) 
n Times / day 
median 
(range) 
n Mins / 
week  
median 
(range) 
n Times / day  
median 
(range) 
n Times / day 
median 
(range) 
n Times / day  
median 
(range) 
Out-patient 
clinics (n=9) 
9 150 (120 – 150) 8 7 15 (3–300) 7 25 (2–300) 9 40 (10 – 80) 9 40 (2–100) 8 50 (10–80) Out-patient 
clinics (n=3) 
3 6 (6 – 50) 2 20 (10 – 25) 0  1 10 (10 – 10) 
Intensive care 
units (n=9) 
9 240 (120 – 900) 1 1 15 (15–15) 1 2 (2–2) 9 80 (50 – 120) 9 15 (6–50) 7 100(75–140) Intensive care 
units (n=3) 
0  3 30 (30 – 35) 3 30 (30 – 35) 0  
Operating 
theatres (n=11) 
11 240 (60 – 240) 8 8 49 (2–100) 4 49 (40–100) 11 30 (3 – 100) 10 10 (5–30) 6 47 (30–100) Operating 
theatres (n=4) 
4 8 (2 – 15) 4 30 (20 – 30) 2 8 (5 – 10) 0  
Emergency 
units (n=3) 
3 180 (120 – 450) 1 1 7 (7–7) 1 7 (7–7) 3 70 (20 – 100) 2 12 (8–15) 3 70 (35–115) Emergency 
units (n=1) 
0  1 30 (30 – 30) 1 20 (20 – 20) 0  
ENT ward (n=1) 0  0 0  0  1 50 (50 – 50) 1 100 (100–100) 1 50 (50–50)          
Vascular 
radiology (n=1) 
1 30 (30 – 30) 1 1 70 (70–70) 1 10 (10–10) 1 30 (30 – 30) 1 20 (20–20) 1 30 (30–30) CSSD (n=1) 0  1 30 (30 – 30) 1 10 (10 – 10) 0  
Haemodialysis 
(n=2) 
2 360 (360 – 360) 0 0  0  2 45 (10 – 80) 1 10 (10–10) 1 10 (10–10) Haemodialysis 
(n=1) 
1 3 (3 – 3) 1 40 (40 – 40) 1 25 (25 – 25) 0  
Overall (n=36) 35 150 (30 – 900) 19 18 33 (2–300) 14 28 (2–300) 36 55 (3 – 120) 33 15 (2–100) 27 60 (10–140) Overall (n=13) 8 6 (2 – 50) 12 30 (10 – 40) 8 23 (5 – 35) 1 10 (10 – 10) 
n = number of departments using the product/s; N = number of departments doing the task 
Floor strippers and waxes were used only once a year in each department at GSH. Floor strippers and waxes were not used at MNH  
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Table 4.3D: Duration of cleaning products use for patients’ skin / wound cleaning and disinfection classified by department in the two 
tertiary hospitals 
 Patients’ skin / wound cleaning and disinfection 
Tertiary Hospital – South Africa (N = 36) Tertiary Hospital –Tanzania (N = 13) 
Department N Alcohols Chlorhexidine Povidone iodine Ether Department N Alcohols Povidone iodine Chloroxylenol 
 n Mins /week 
median (range) 
n Mins /week 
median (range) 
n Mins /week 
median (range) 
n Mins /week 
median (range) 
 n Mins /week 
median (range) 
n Mins /week 
median (range) 
n Mins /week 
median (range) 
Out-patient clinics 
(n=9) 
7 5 202 (15-1000) 3 202 (15–700) 6 114 (12-200) 1 12 (12-12) Out-patient clinics 
(n=3) 
3 3 150 (50-180) 2 105 (60-150) 0  
Intensive care 
units (n=9) 
9 9 140 (56-735) 9 84 (15-455) 0  3 126 (70-280) Intensive care 
units (n=3) 
3 3 150 (150-150) 3 150 (150-150) 1 75 (75-75) 
Operating 
theatres (n=11) 
10 9 150 (7-500) 8 132 (3-300) 6 222 (100-350) 2 50 (50-50) Operating 
theatres (n=4) 
4 4 100 (25-300) 4 125 (50-300) 3 150 (75-300) 
Emergency units 
(n=3) 
3 3 525 (56-560) 1 315 (315-315) 3 56 (2-156) 0  Emergency units 
(n=1) 
1 1 300 (300-300) 1 75 (75-75) 0  
ENT ward (n=1) 0 0  0  0  0          
Vascular 
radiology (n=1) 
1 0  0  0  0  CSSD (n=1) 0 0  0  0  
Haemodialysis 
(n=2) 
1 1 200 (200-200) 1 200 (200-200) 0  0  Haemodialysis 
(n=1) 
1 1 30 (30-30) 1 30 (30-30) 0  
Overall (n=36) 31 27 200 (7-1000) 22 130 (3 – 700) 15 144 (2-350) 6 60 (12-280) Overall (n=13) 12 12 150 (25-300) 11 150 (30-300) 4 113 (75-300) 
n = number of departments using the product; N = number of departments doing the task 
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4.3.2. Environmental sampling for aldehydes 
OPA was detectable in 6 (2%) of all samples analysed (Table 4.4). These detectable 
samples were all collected in the gastrointestinal (GI) unit (GM = 0.010 ppm; range: 0.005 – 
0.027) of SAH. All the 6 detectable samples had OPA levels higher than the newly proposed 
ACGIH‘s TLV-Ceiling Limit of 0.0001 ppm (31). All detectable samples were collected from 
HWs who used OPA. While samples collected from nurses had the highest mean OPA 
exposure levels (GM = 0.014 ppm) (Table 4.5), sterilising operators had greater odds of 
having detectable exposures than nurses (OR = 22.43; 95% CI: 3.82 – 131.72). Health 
workers exposed to detectable OPA levels had an increased odds of having a longer 
duration of OPA use (OR = 1.28; 95% CI: 1.10 – 1.50) (Table 4.6). Overall, department, job 
title, personal use of OPA and duration of OPA use were the important predictors of 
detectable OPA exposures (Table 4.6).  
Formaldehyde, on the other hand was detectable in a greater proportion (38%) of the 269 
collected samples (GM = 0.005 ppm; range: 0.003 – 0.027). Three (1%) samples had 
formaldehyde levels higher than the NIOSH recommended exposure limit (REL) of 0.016 
ppm TWA, but none greater than the ACGIH TLV-TWA (0.1 ppm). Formaldehyde exposure 
was positively associated with working in an Ear, Nose & Throat (ENT) ward (OR = 6.28; 
95% CI: 1.65–23.82) and a longer duration of passive sampling (OR = 1.01; 95% CI: 1.00 – 
1.01). Unlike OPA, job title, personal use of formaldehyde and duration of formaldehyde use 
were not associated with detectable formaldehyde levels (Table 4.7). 
Glutaraldehyde was not detectable in the SAH. In the pilot sampling that was conducted in 
the TAH, glutaraldehyde was detectable in eight (73%) of the eleven samples collected (GM 
= 0.006 ppm; range: 0.001 – 0.028). Glutaraldehyde levels detectable in this study were all 
below the ACGIH‘s TLV-Ceiling Limit of 0.05 ppm.  
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Table 4.4: Personal aldehyde exposure levels classified by department in a South African tertiary hospital 
Department K N Formaldehyde (ppm) Ortho-phthalaldehyde (ppm) 
Detectable 
samples 
 Detectable 
samples 
 
n (%) AM GM GSD Range n (%) AM GM GSD Range 
Out-patient clinics 75 147 51 (35) 0.005 0.004 1.282 0.003 – 0.008 6 (4) 0.013 0.010 2.085 0.005 – 0.027 
Intensive care units 0 0    
 
All < LOD 
Operating theatres 59 79 25 (32) 0.005 0.005 1.582 0.003 – 0.020 
Emergency units 3 3 3 (100) 0.004 0.004 1.292 0.003 – 0.005 
ENT ward 7 13 10 (77) 0.007 0.006 1.818 0.004 – 0.027 
Vascular radiology 20 27 14 (52) 0.006 0.005 1.690 0.003 – 0.018 
Haemodialysis 0 0  
Overall 164 269 103 (38) 0.005 0.005 1.484 0.003 – 0.027 6 (2) 0.013 0.010 2.085 0.005 – 0.027 
K = no. of workers sampled; N = no. of samples collected; n = no. of samples with detectable levels; AM=arithmetic mean; GM=geometric mean; GSD=geometric standard 
deviation; LOD = limit of detection; LOD for formaldehyde = 0.10µg; LOD for OPA = 0.01µg; ENT = ear, nose and throat; ppm = parts per million 
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Table 4.5: Personal aldehyde exposure levels classified by job title in a South African tertiary hospital 
Job title K N Formaldehyde (ppm) Ortho-phthalaldehyde (ppm) 
Detectable 
samples 
 Detectable 
samples 
 
n (%) AM GM GSD Range n (%) AM GM GSD Range 
Nurses (RN, EN & NA) 94 160 60 (38) 0.005 0.005 1.463 0.003 – 0.020 3 (2) 0.018 0.014 2.638 0.005 – 0.027 
Sterilising operators 6 10 3 (30) 0.004 0.004 1.181 0.003 – 0.004 3 (30) 0.007 0.007 1.408 0.005 – 0.009 
Doctors 5 7 4 (57) 0.010 0.007 2.478 0.004 – 0.027   
All < LOD Cleaners 19 32 10 (31) 0.004 0.004 1.283 0.003 – 0.007 
Others
#
 40 60 26 (43) 0.005 0.005 1.434 0.003 – 0.018 
Overall 164 269 103 (38) 0.005 0.005 1.484 0.003 – 0.027 6 (2) 0.013 0.010 2.141 0.005 – 0.027 
K = no. of workers sampled; N = no. of samples collected; n = no. of samples with detectable levels; RN = Registered nurse; EN = Enrolled nurse; NA = Nurse assistant 
AM=arithmetic mean; GM=geometric mean; GSD=geometric standard deviation; #Others= clerks, porters, technologists, ECG technicians & radiographers; LOD = limit of 
detection; LOD for formaldehyde = 0.10µg; LOD for OPA = 0.01µg;ppm = parts per million 
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Table 4.6: Predictors of personal ortho-phthalaldehyde (OPA) exposure levels in a 
South African tertiary hospital 
 Ortho-phthalaldehyde (ppm) 
 Detectable vs Undetectable 
OR (95% CI) 
Duration of sampling 0.99 (0.98 - 1.00) 
Job title*# 
Sterilising operators (n = 6) vs Nurses (n = 94) 
22.43 (3.82 - 131.72)** 
Personal OPA use## NC 
Personal OPA use duration (minutes / day) 1.28 (1.10 - 1.50)** 
**p-value < 0.01; OR = odds ratio; NC = not calculable; CI = confidence interval; ppm = parts per million; 
*Reference group = nurses; #OPA levels were undetectable for the remaining job titles (Cleaners, Clerks, Porters, 
Radiographers, Technologists, ECG Technicians and Doctors); ##All workers with detectable OPA levels used 
OPA; LOD for OPA = 0.01µg; n = no. of workers sampled 
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Table 4.7: Predictors of personal formaldehyde exposure levels in a South African 
tertiary hospital 
 Formaldehyde (ppm) 
 Detectable vs Undetectable 
OR (95% CI) 
Duration of sampling (minutes) 1.01 (1.00 - 1.01)** 
Department#  
Operating theatres 0.89 (0.50 – 1.59) 
Emergency units NC€ 
ENT ward 6.28 (1.65 – 23.82)** 
Vascular radiology 2.03 (0.89 – 4.64) 
Job title##  
Nurses (RN, EN & NA) 1.40 (0.35 – 5.62) 
Doctors 3.11 (0.41 – 23.39) 
Cleaners 1.06 (0.23– 4.97) 
Others (Clerks, Porters, Radiographers, 
Technologists & ECG Technicians) 
1.84 (0.43 – 7.81) 
Personal formalin use 1.54 (0.53- 4.48) 
Personal formalin use duration (minutes / 
day) 
0.80 (0.54- 1.20) 
Formalin used in the department 0.73 (0.43 - 1.24) 
**p-value < 0.01; NC = Not calculable; OR = Odds ratio; CI = Confidence interval; ECG = Electrocardiogram; ppm 
= parts per million; ENT = ear, nose and throat; RN = registered nurse; EN = enrolled nurse; NA = nurse 
assistant; #Reference group =Out-patient clinics; ##Reference group = Sterilising operators; €All sampled workers 
had detectable formaldehyde levels; LOD for formaldehyde = 0.10µg 
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4.3.3. Biomonitoring for chlorhexidine 
PCA, a metabolite of chlorhexidine, was detectable in 13 (4%) of all 336 urine samples that 
were analysed (GM = 2.41 ng/ml range: 1.00 – 25.80), which did not appear to differ by 
department or job type (Tables 4.8 and 4.9). The highest concentration (25.80 ng/ml) 
measured was obtained from a technician in the Haemodialysis unit and a registered nurse 
(6.47 ng/ml) in the Vascular Radiology department  
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Table 4.8: p-Chloroaniline urine levels classified by department in a South African 
tertiary hospital 
Department N p-Chloroaniline (ng/ml) 
Detectable 
samples 
 
n (%) AM GM GSD Range 
Out-patient clinics 52 0 (0) All < LOQ 
Intensive care units 106 5 (5) 1.37 1.33 1.30 1.00 – 1.94 
Operating theatres 89 4 (5) 2.88 2.32 2.18 1.08 – 5.42 
Emergency units 34 2 (6) 2.13 2.13 1.08 2.01 – 2.25 
ENT ward 12 0 (0) All < LOQ 
Vascular radiology 25 1 (4) 6.47 6.47 NC 6.47 – 6.47 
Haemodialysis 18 1 (6) 25.80 25.80 NC 25.80 – 25.80 
Overall 336 13 (4) 4.22 2.41 2.55 1.00 – 25.80 
N = no. of samples collected; n = no. of samples with detectable levels; NC = Not calculable; 
AM=arithmetic mean; GM=geometric mean; GSD=geometric standard deviation; LOQ = limit of quantification; 
ENT = ear, nose and throat; ng/ml = nanograms/millilitre; LOQ for p-chloroaniline = 1 ng/ml 
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Table 4.9: p-Chloroaniline urine levels classified by job title in a South African tertiary 
hospital 
Job title N p-Chloroaniline (ng/ml) 
Detectable 
samples 
 
n (%) AM GM GSD Range 
Nurses 234 10 (4) 2.63 2.11 1.97 1.00 – 6.47 
Registered nurses 129 6 (5) 3.32 2.67 2.11 1.11 – 6.47 
Enrolled nurses 46 2 (4) 1.67 1.56 1.68 1.08 – 2.25 
Nurse assistants 59 2 (3) 1.51 1.42 1.64 1.00 – 2.01 
Cleaners 44 2 (4) 1.42 1.42 1.08 1.34 – 1.50 
Technicians 32 1 (3) 25.80 25.80 NC 25.80 – 25.80 
Clerks 12 0 (0) All < LOQ 
Porters 14 0 (0) 
Overall 336 13 (4) 4.22 2.41 2.55 1.00 – 25.80 
N = no. of samples collected; n = no. of samples with detectable levels; RN = Registered nurse; EN = Enrolled 
nurse; NA = Nurse assistant; 
AM=arithmetic mean; GM=geometric mean; GSD=geometric standard deviation; LOQ = limit of quantification; 
ng/ml = nanograms/millilitre; NC = Not calculable; LOQ for p-chloroaniline = 1 ng/ml 
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4.4. DISCUSSION 
The results of this study demonstrate that a wide variety of agents are used for cleaning and 
disinfection in hospital settings located in Southern Africa. Although, cleaning agents used in 
this study were similar to those used in health care settings elsewhere, the frequency and 
duration of use differed. The mean detectable exposures to OPA were higher and more 
isolated to certain departments and were dependent on the personal use of OPA, duration of 
use and job title in contrast to the more widespread low-level formaldehyde exposures 
present throughout the hospitals. The study also highlighted that workplace controls for 
reducing exposure to cleaning agents were not adequate. 
The most common high-level disinfectant used in the South African (SAH) was OPA. 
However, in the Tanzanian hospital (TAH), glutaraldehyde was more commonly used. 
Formaldehyde was not used for medical instrument cleaning and disinfection in both the 
SAH and the TAH. This is contrary to other hospital settings as in the USA and Saudi Arabia 
where formaldehyde continues to be used for medical instrument cleaning and disinfection, 
although at a lower frequency compared to other agents (32,33).  
Quaternary ammonium compounds were not used in the TAH but were used at a much 
lower frequency (8%) in the SAH for medical instrument disinfection. In contrast, quaternary 
ammonium compounds were the leading cleaning agents used by my most nurses (93%) for 
cleaning and disinfection of medical instruments in Saudi Arabia (32). Quaternary 
ammonium compounds are also commonly used for cleaning and disinfection in health care 
settings in other industrialised countries, including USA and Europe (34–36).  
Products that are used for cleaning medical instruments prior to disinfection such as 
enzymatic cleaners and chlorine-based bleach products were used for the longest duration 
compared to the high-level disinfectants. This finding is consistent with workplace 
observations conducted during the exposure assessment evaluation in that HWs spent more 
time cleaning medical instruments to remove gross biological contaminants than handling or 
working with high-level disinfectants. 
In this study, chlorine-based bleach was the most common product, which also had the 
longest average duration of use for fixed surface cleaning and disinfection in both hospitals. 
In the SAH, HWs used both the liquid bleach and the granules (which were dissolved in 
water before use). Liquid bleach and sodium dichloroisocyanurate (Troclosene sodium) 
effervescent tablets were used in the TAH. Bleach is commonly used for cleaning and 
disinfection in both the domestic and hospital settings (33,37). Interestingly, bleach was not 
used in 6 hospitals studied in a US-based study among HWs responsible for cleaning and 
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disinfection demonstrating the feasibility of substituting bleach with other cleaning products 
(6).  
In this study, alcohols were commonly used for several cleaning tasks such as medical 
instruments cleaning and disinfection, fixed surfaces cleaning and disinfection, specimen 
preparation, patients‘ skin / wound cleaning and disinfection and hand washing / sanitising. 
These findings corroborate results of previous studies conducted globally that reported 
alcohols as one of the most common  ingredients of cleaning products used in hospital 
settings (6,34,36). 
Workplace controls for reducing exposure to cleaning agents were either lacking or present 
in only a few areas of both hospitals. Notably, there were no local exhaust ventilation (LEV) 
systems in any of the work areas. Whilst extractor fans were present in a few areas, their 
effectiveness/efficiency was not assessed. Furthermore, use of appropriate personal 
protective equipment was very low, and none of the workers used appropriate respirators 
nor was appropriate protective clothing to prevent dermal exposure. It was also noted that 
there was no medical surveillance program specific for HWs exposed to cleaning agents. 
Control of workplace exposures to cleaning agents has posed challenges not only in lower 
income health care settings but also in the industrialised world (38). A study of 5 hospitals in 
Canada reported lack of LEV in all the locations that glutaraldehyde was used (38). It may 
be a challenge to establish engineering controls (e.g. LEV) for some cleaning tasks that are 
conducted in numerous hospital locations such as fixed surfaces cleaning. However, it is 
possible to install LEV systems in areas where specific tasks are performed such as medical 
instrument cleaning and disinfection, decanting or dilution of cleaning products. A Saudi 
Arabian study among nurses responsible for medical instrument cleaning and disinfection 
reported promising findings as most nurses (96.4%) worked in areas with negative 
ventilation (32). 
In this study, OPA levels (GM = 0.010 ppm) were, on average, 10-fold higher than in similar 
settings elsewhere (11,18,21,23,39,40). The highest OPA concentration measured in this 
study was 0.027 ppm. The mean OPA concentration reported in a previous Italian study 
among HWs in endoscopy units was 0.0015 ppm (39). A Japanese study that conducted air 
measurements for OPA in an endoscopy unit reported OPA concentrations in the range of 
0.0006 – 0.002 ppm (40). The highest concentration (0.002 ppm) was found when a bucket 
containing OPA was left open without a lid while an endoscope washing machine was 
operating (40). A later Japanese study conducted air measurements for OPA in 9 manual 
disinfection rooms and in 8 rooms using automatic endoscope washers (21). The TWA 
concentration of OPA in this Japanese study was higher in the manual group (median = 
0.0007 ppm) than in the automatic endoscopic washer group (median = 0.0003 ppm) (21). A 
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more recent US study conducted among 8 health facilities, confirmed that the average OPA 
concentrations were higher (GM = 0.00006 ppm) in the group of workers from the 
departments using OPA than in the comparison group (GM = 0.00003 ppm) where OPA was 
not used, although these levels were lower than the OPA exposures reported in the current 
study (23). 
There are several reasons that could explain the higher OPA concentrations reported in the 
current study. The first possible reason is the lack of adequate engineering methods for 
controlling airborne exposures to OPA. In comparison to the US study (23), which  reported 
use of LEV in some departments of the five facilities that were studied, none of the two 
hospitals in our study had LEV for cleaning and disinfecting tasks. It should be noted that the  
higher concentrations of OPA in the current study (compared to the US study) cannot be 
explained by the variability in frequency and duration of OPA use since the proportion of 
study participants that used OPA for one hour of less per day in this study (69%) was similar 
to the US study (71%) (23). Further comparisons with other studies that conducted 
environmental sampling for OPA could not be done since information about the frequency of 
OPA use was not included. Secondly, the higher levels of OPA observed in the current study 
could be explained by different work practices employed in these hospitals while conducting 
cleaning/disinfecting tasks, which probably resulted in HWs in this study being more 
exposed. It is well known that exposures associated with cleaning agents are a function of 
the manner in which tasks are performed as well as the chemical ingredients present in the 
cleaning products that are used (6). Finally, the use of manual versus automatic methods of 
OPA disinfection cannot explain the higher concentrations of OPA observed in the current 
study since manual methods were also used in the other studies reported. While only one 
department in this current study conducted automatic OPA disinfection, HWs in this 
department also performed manual OPA disinfection procedures. 
Environmental sampling for formaldehyde has been conducted previously in US hospitals (a 
pathology and a histology laboratory in two different locations) using both active and passive 
methods (26). The median formaldehyde concentration reported ranged from 0.04 ppm 
using the active method to 0.05 ppm for the passive method. In contrast, formaldehyde 
levels (GM = 0.005 ppm) recorded in the current study were, on average, 10-fold lower 
(26)(26). The most likely reason for the observed differences is that the current study 
population did not include laboratory workers, who are well known for their higher usage of 
formaldehyde for specimen preparation compared to other categories of hospital workers. 
Furthermore, the formaldehyde levels in the current study are more comparable to average 
levels in US general buildings (41). Since only a small proportion of the variability in the 
formaldehyde levels obtained in the current study was explained by the departments, it is 
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probable that the most likely source of exposure is the widespread use of formaldehyde 
(10%) solution used for specimen preparation in most departments, residue evaporation 
from formaldehyde contaminated surfaces and other general indoor sources.  
The highest glutaraldehyde concentration measured during the pilot sampling conducted in 
the TAH was 0.028 ppm. This particular measurement was collected from a nurse working in 
an endoscopy unit with the highest duration (60 minutes) of glutaraldehyde usage for high-
level disinfection of endoscopes. The average glutaraldehyde levels (GM = 0.006 ppm) in 
this study were similar to those reported by the Italian study of Marena and colleagues 
(mean = 0.005 ppm), slightly higher than the US study (range: not detected – 0.005 ppm), 
but lower than levels measured by the Canadian study (GM = 0.025 ppm) of five hospitals 
(23,38,39). Although glutaraldehyde levels in this study were below the ACGIH‘s TLV-Ceiling 
Limit, HWs reported work-related symptoms due to glutaraldehyde (Figure 4.1), 
underscoring the need to lower the regulatory exposure standards for this chemical. 
In embarking on a sampling strategy for chlorhexidine, only few studies were identified, all 
reporting different methods for the determination of chlorhexidine and its metabolites (PCA 
and 1-chloro-4-nitrobenzene) in biological fluids (27). A number of challenges have been 
reported, including some being less sensitive, less specific, less accurate or some of them 
requiring a lengthy extraction process (27). This points to the lack of standardised, validated 
and sensitive methods for exposure assessment of chlorhexidine. An intensive literature 
search was unable to identify any study that has reported concentrations of chlorhexidine 
metabolites such as PCA in urine rendering comparisons with other studies impossible. 
While Wainwright and Cooke have described a method for detecting PCA in urine, it was not 
able to provide quantitative measures of exposure (28). Nevertheless, the findings of this 
study could be useful for future studies focussing on measuring PCA in urine. 
To the best of our knowledge, this is the first study in Africa to conduct quantitative exposure 
assessment for aldehydes (OPA, glutaraldehyde and formaldehyde) in hospital settings. This 
study is also the first African study to have conducted biological monitoring for chlorhexidine 
exposures in HWs. The current study is also unique in that it was conducted in two different 
African hospital settings (SAH and TAH) using similar qualitative and quasi-quantitative 
exposure assessment methods for exposures to cleaning agents. Notably, the study has 
described the most common cleaning agents used for specific cleaning tasks in these 
settings and the typical durations of exposure to cleaning agents in different hospital 
departments in two geographical contexts. 
There are some important limitations that need to be considered. The study initially sought to 
determine quantitative exposure to chlorhexidine and its metabolites (PCA and 1-chloro-4-
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nitrobenzene) in urine. Due to logistical and methodological considerations, it was not 
possible to develop a multiplex assay for all these compounds except for PCA. Furthermore, 
although a robust assay for PCA was developed in the current study, it was not possible to 
compare with other studies because of lack of information in the literature. In this study, 
passive sampling was used for environmental exposure assessment of aldehydes. While 
environmental conditions such as temperature, relative humidity, ozone and air movements 
are well known factors that could affect the performance of passive samplers in measuring 
airborne aldehyde concentrations, these factors are less likely to have affected the study 
findings since most workers worked indoors, with insignificant air movements and 
temperatures that ranged between 22 to 30 degrees Celsius and relative humidity ranging 
between 40 – 68%. While ozone measurements have also been conducted in some studies, 
there were not done due to resource constraints. Additionally, due to logistical reasons, air 
measurements for some common cleaning agents such as bleach were not conducted in this 
study.  
4.5. CONCLUSION 
This study set out to characterise exposure of HWs to cleaning agents in two hospitals in 
sub-Saharan Africa. This study demonstrated a wide variety of chemicals used for cleaning 
and disinfection in these hospital settings, some of which are known to cause or aggravate 
respiratory and skin diseases such as asthma and contact dermatitis. Although the 
frequency and duration of use differed in these settings, the cleaning agents commonly used 
in this study were similar to those used in health care settings beyond sub-Saharan Africa. 
The study also confirmed that workplace controls for reducing exposure to cleaning agents 
were deficient. The study concluded that mean detectable exposures to OPA are higher and 
more isolated to certain departments and are dependent on the personal use of OPA, 
duration of use and job title in contrast to the more widespread low-level formaldehyde 
exposures present throughout the hospitals. There is a need for more standardized, 
sensitive and validated assays for the determination of chlorhexidine and its metabolites 
(PCA and 1-chloro-4-nitrobenzene) in biological fluids. 
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CHAPTER 5 
Prevalence of symptoms, allergic sensitisation and lung function abnormalities among health 
workers in the two large tertiary hospitals 
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ABSTRACT 
Background: Health workers (HWs) are exposed to relatively higher concentrations of a 
wide range of chemicals used for cleaning and disinfection in health care facilities compared 
to domestic settings. This has been largely attributed to the ever-increasing demand for 
effective cleaning and disinfection in hospital settings in an effort to prevent healthcare 
associated infections, particularly due to the multi-drug resistant organisms. In recent years, 
there has been growing evidence linking cleaning agents to adverse health effects such as 
rhinitis, asthma and contact dermatitis. Most cleaning agents are irritants, however some 
have both irritant and sensitising properties. Some of the major sensitisers in hospital 
settings include aldehydes (glutaraldehyde and ortho-phthalaldehyde - OPA), quaternary 
ammonium compounds and natural rubber latex (NRL). The aim of this study was to 
determine the prevalence of work-related respiratory and skin symptoms, allergic 
sensitisation and lung function abnormalities among HWs in two large tertiary academic 
hospitals in sub-Saharan Africa. 
Methods: A cross-sectional study of 699 HWs was conducted in two large tertiary hospitals. 
A total of 697 participants (n=344 - South Africa hospital, n=353 - Tanzanian hospital) 
underwent interviews using a modified version of the ECRHS questionnaire adapted for local 
conditions. Sera was collected from 682 participants and analysed for specific 
immunoglobulin E (sIgE) antibody reactivity to common aero-allergens (Phadiatop) and 
specific occupational allergens (NRL - Hevea brasiliensis (Hev b5, Hev b6.02), chlorhexidine 
and OPA). Methacholine challenge tests (MCT) were performed on all South African HWs 
(n=318), based on standard inclusion criteria. Spirometry, accompanied by a post-
bronchodilator (post-BD) test was conducted on all Tanzanian HWs (n=329) and a small 
proportion (n=25) of South African HWs (SAHWs) where MCT was contraindicated. All HWs 
from both hospitals (n= 654) underwent Fractional Exhaled Nitric Oxide (FeNO) testing 
during the working day prior to spirometry. 
Results: More than two thirds of the participants were women (78%), having a median age 
of 42 years (interquartile range - IQR: 32 – 51 years). Among the HWs investigated, 76% 
were registered, enrolled or assistant nurses, 12% cleaners and 5% administrative workers. 
Current smokers only formed 12% of the entire population surveyed, most being employed 
in the South African hospital (12% vs 1%). While 43% were atopic, a much lower prevalence 
of doctor-diagnosed asthma (7%) was found. The prevalence of specific sensitisation was 
highest to OPA (4%) compared to NRL (2%) and chlorhexidine (1%). The prevalence of 
work-related ocular-nasal symptoms in the past 12 months (16%) was higher than work-
related skin (12%) and chest (7%) symptoms. Overall, the prevalence of skin symptoms 
(work-related and non-work-related) was significantly higher (p < 0.001) among HWs in the 
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South African hospital (SAH) compared to the Tanzanian hospital (TAH). However, 
Tanzanian HWs (TAHWs) had significantly lower lung volumes (adjusted) and a significantly 
(p < 0.001) higher degree of airflow obstruction compared to their counterparts. Among the 
SAHWs, 12% had non-specific bronchial hyperresponsiveness (NSBH), 10% positive on 
MCT and 2% positive on the post-BD test (an increase in FEV1 of ≥12% and ≥200 milliliters 
post bronchodilator). Among the TAHWs, 6% demonstrated a positive post-BD test. Overall, 
77% of all HWs had normal FeNO (<25 ppb) levels, 17% elevated (25–50 ppb) and 6% high 
(>50 ppb) levels suggestive of eosinophillic airway inflammation. 
Conclusion: South African HWs experienced a higher prevalence of work-related skin 
symptoms compared to their Tanzanian counterparts, while THWs have comparatively lower 
lung volumes and higher degree of airflow obstruction. The findings from this study also 
suggest that the prevalence of NRL sensitisation is declining in South Africa most likely due 
to the NRL preventive measures implemented. 
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5.1. INTRODUCTION 
There has been a growing demand for effective cleaning and disinfection in hospital settings 
in order to prevent healthcare associated infections, particularly due to the multi-drug 
resistant organisms (1). These efforts have resulted in extensive use of different types of 
cleaning chemicals in hospital settings. Consequently, health workers (HWs) in particular are 
exposed to higher concentrations of a wide range of chemicals. Several studies have 
demonstrated an association between exposure to cleaning agents and adverse health 
effects, commonly in the form rhinitis, asthma and contact dermatitis (2). HWs have 
therefore been identified as one of the occupational groups at high risk developing work-
related asthma, due to their exposure to various products with irritative or allergenic 
properties such cleaning agents, natural rubber latex (NRL), methacrylates in dental and 
surgical cements, aerosolised medications (e.g. pentamidine), micro-organisms and mildew 
in certain contexts (3,4).  
Health workers are exposed to various cleaning agents including high-level disinfectants 
used for heat-sensitive medical equipment such as endoscopes. Of particular importance 
are the two aldehydes, glutaraldehyde and ortho-phthalaldehyde (OPA). Glutaraldehyde has 
been used for over 40 years in health care settings and has been linked to various health 
effects such as occupational asthma and allergic contact dermatitis (5,6). Due to these 
health effects, OPA was introduced as a safer alternative to glutaraldehdye in some health 
care settings. However, OPA has also been recently reported to cause occupational asthma 
and anaphylaxis in various case reports, including patients undergoing instrument 
procedures (7). Despite this, only a few studies have been conducted to assess the 
immunological mechanisms in individuals suspected to have OPA allergy and none of those 
studies have been conducted in Africa (7). In addition, most of these studies have been case 
reports involving a small number of participants (7). In a Japanese study among 70 HWs 
responsible for endoscope disinfection, 24% had work-related skin, respiratory or eye 
symptoms due to OPA (8). Work-related symptoms due to OPA were also reported in 
another Japanese study among 80 female HWs from endoscopy units, with respiratory 
symptoms being the majority (16%), followed by skin (10%) and eye (9%) symptoms (9). 
However, both of these two studies did not perform specific immunological test for OPA 
(8,9). Recently, a team of National Institute for Occupational Safety and Health (NIOSH) 
conducted skin prick tests (SPT) and specific immunoglobulin E (sIgE) and IgG assessment 
for OPA among 129 US health workers (10). In this US study, 5 (4%) HWs had positive skin 
responses to SPTs with OPA solution but none had detectable sIgE and IgG antibodies in 
any of the blood samples tested (10).  
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Exposure to chemicals contained in hand hygiene products is also quite common in hospital 
settings since HWs are required to wash and disinfect their hands several times per day in 
order to comply with infection control standards. Chorhexidine is one of the most commonly 
encountered chemical used in hand hygiene products. It is also used for disinfection of 
wounds and patients‘ skin before various medical procedures. Chlorhexidine is a known 
sensitiser and irritant to both the skin and airways (11). There have been a few published 
reports of asthma and dermatitis due to chlorhexidine, mostly among patients and a few 
reported in HWs (12–16). Nagendran et al. identified 4 cases of occupational IgE-mediated 
allergy to chlorhexidine among 53 HWs in the United Kingdom (UK) hospital (14). Urticaria 
was reported in all 4 cases identified, with one also having rhinitis and another with contact 
dermatitis (14). Furthermore, in this study 3 cases had positive reactions to SPT and 2 had 
positive sIgE to chlorhexidine (14). Wittczak et al. have also described 3 cases of 
occupational allergy among HWs confirmed by placebo-controlled specific bronchial 
challenge testing (15). One case was diagnosed with occupational asthma, the second with 
both occupational asthma and rhinitis, while  the third case had an anaphylactic reaction to 
chlorhexidine (15). Serum sIgE to chlorhexidine was positive in all the 3 identified cases but 
only 2 had positive SPT (15). To the knowledge of the investigators, no studies have been 
conducted on the immunological assessment for chlorhexidine in Africa. 
Although the incidence of sensitization to NRL allergens has decreased to 1% in the 
countries that have promoted latex avoidance, HWs in the least developed countries 
continue to use significant amounts of powdered NRL gloves (17). The prevalence of NRL 
allergy among HWs has been reported to range between 3% and 31% in different studies 
globally (17–19). In South Africa, the prevalence of NRL sensitisation has ranged between 
5% and 21% among HWs (20–25). The prevalence of NRL sensitization and allergy is 
unknown in Tanzania. The most common NRL allergens associated with latex allergy in 
health workers are Hev b 5, Hev b 6.01 and Hev b 6.02 (26,27). The changeover to latex 
free gloves in South Africa has been sporadic and inconsistent especially in resource 
constrained settings. These NRL allergens (Hev b 5 and Hev b 6.02) were found to be 
elevated in gloves being used in public sector academic dental teaching hospitals in South 
Africa (28).   
Studies that have conducted exhaled nitric oxide (FeNO) tests in HWs exposed to cleaning 
agents are limited. An Italian study (29) did not find any difference in FeNO between hospital 
cleaners and a control group of students as well as other hospital employees not exposed to 
cleaning agents. Similarly, a Spanish study of professional cleaners (including hospital 
cleaners) did not observe any difference in FeNO between asthma cases and controls (30). 
However, higher FeNO levels were associated with work-related use of multi-use products, 
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glass cleaners and polishes (30). Furthermore, a French study among domestic cleaners 
reported higher FeNO levels among non-asthmatics who used sprays, especially glass 
cleaning sprays and acids (31). 
The aim of this study was to determine the prevalence of work-related respiratory and skin 
symptoms, allergic sensitisation and lung function abnormalities among HWs in two large 
tertiary academic hospitals in sub-Saharan Africa. 
 
5.2. METHODS 
5.2.1. Study design, Population and Sampling 
A cross-sectional study of 699 HWs was conducted in two large tertiary academic hospitals 
(346 from a South Africa hospital – SAH and 353 from Tanzanian hospital - TAH). Following 
meetings with several key stakeholders and walk-through inspections by the investigators of 
both hospitals, specific departments were identified as potentially high-risk exposure settings 
for cleaning agents. Health workers in these high-risk departments used significant amounts 
of cleaning agents at a frequency much higher than other departments. The departments 
identified in the SAH included out-patient clinics, intensive care units (ICUs), operating 
theaters, emergency units, ENT ward, vascular radiology and the haemodialysis unit. The 
out-patient clinics, ICUs, operating theaters, emergency unit, Central Sterile Services 
Department (CSSD) and haemodialysis unit were identified in the TAH. 
All permanently employed HWs in the high-risk departments constituted the sampling frame 
of the study. Doctors were excluded from the sampling frame as they were more likely to 
work in multiple different exposure settings across the hospital. A list of all permanently 
employed HWs in the high-risk departments was obtained from their respective managers. 
Study participants were selected from these departments through stratified random sampling 
according to job title, choosing up to five HWs from each high-risk department. For 
departments having more than five HWs with the same job title, a random sample of five 
workers was selected. For departments having less than five workers, all workers were 
selected to participate in the study. Ethics approval was obtained from the Human Research 
Ethics Committee (HREC) of the University of Cape Town (HREC Ref: 212/2013), Muhimbili 
University of Health and Allied Sciences (MUHAS) Institutional Review Board and University 
of Michigan Medical School Institutional Review Board (HUM00083115). 
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5.2.2. Questionnaire 
A total of 697 participants completed the questionnaire interviews (344 from SAH and 353 
from TAH). Each participant answered a modified questionnaire for the investigation of 
asthma as contained in the Protocol for the European Community Respiratory Health Survey 
(32). The study questionnaire also included validated questions from the NIOSH specific 
questionnaire for cleaning agents in the health care setting (33). The questionnaire was 
administered by trained interviewers in English language for South African health workers 
(SAHWs) and in Swahili language for Tanzanian health workers (TAHWs). The translated 
Swahili questionnaire was back-translated to ensure validity and repeatability. 
5.2.3. Immunological assessment  
Blood samples were collected from 682 participants (339 SAHWs and 343 TAHWs). Specific 
IgE antibody reactivity to common aero-allergens (Phadiatop) and specific occupational 
allergens was evaluated. The quantification of specific IgE antibodies to specific 
occupational allergens: NRL (Hevea brasiliensis - Hev b5, Hev b6.02), chlorhexidine and 
OPA was performed using the UniCAP system (Phadia, Uppsala, Sweden). Immunological 
assessment for chlorhexidine was only done on sera of SAHWs since chlorhexidine 
containing chemicals were not used in the TAH.  
Commercial ImmunoCAPs containing Phadiatop (Phad), Chlorhexidine (C8), rHev b5 (K218) 
and rHev b6.02 (K220) allergens were obtained from Thermo Scientific. Serum samples 
were tested at the National Institute for Occupational Health (NIOH) Immunology laboratory 
using the UNICAP 250 machine supplied by Thermo Scientific according to the manufacturer 
manual. This instrument uses the fluorescent enzyme immunoassay (FEIA) technique in an 
automated process. Briefly, serum is added to allergen of interest that is covalently coupled 
to ImmunoCAP. If specific IgE is present in the serum being tested, it will bind to the antigen 
and form an antigen–antibody complex. After washing away non-specific IgE, a fluorescent 
labelled anti human immunoglobulin is added that binds to the unwashed antigen–antibody 
complex. The fluorescent colour is converted into specific IgE concentrations by the machine 
software. 
Since the OPA test was not readily available commercially, it required further development. 
Ortho-phthalaldehyde (OPA) was coupled to albumin using a modification of the ELISA 
method by Suzukawa et al., 2007, Anderson et al., 2010 and Johnson et al., 2011 (34–36).  
A 4% (40mg in 1ml) solution of bovine serum albumin (BSA) (GE healthcare life sciences, 
cat no: SH30574.02) was prepared in phosphate buffered saline (PBS) (Roche, cat no: 
11 418 165 001) and a 2.2 % (22mg in 1ml) solution of OPA (Sigma, cat no: P1378-5G) was 
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prepared in sterile water. Equal amounts (500μl) of BSA and OPA solutions were mixed 
resulting in a final concentration of 2 % BSA and 1.1 % OPA.  
This mixture was labelled with Biotin and separated on a Sephadex G-25 column using the 
Biotin labelling kit from Roche according to the manufacturer‘s instructions (Roche, cat no: 
11 418 165 001). Briefly 6.7µl of Biotin-7-NHS was added to the BSA/OPA mix and 
incubated for 2 hours at 15-250C while stirring. The Sephadex G-25 column was prepared by 
adding 5 ml of blocking solution to the column and allowed to flow through. Thereafter, the 
column was rinsed 6 times with 5ml of PBS. The biotin labelled protein mixture was added to 
the column. This was then eluted with 3.5ml of PBS and 40 drops of labelled protein was 
collected and used as the allergen. 
The ImmunoCAPs were then washed and placed in a 2ml Eppendorf with a pipette tip. 
These were then centrifuged to get rid of the glycerol for 2 min 1450g. ImmunoCAPs were 
washed and centrifuged 4 times with 50 μl ImmunoCAP Washing solution. Washed 
ImmunoCAPs were placed in a microtiter plate and 50 µl of biotinylated allergen was added 
into each ImmunoCAP. After 30 minutes the ImmunoCAPs were put into a carrier and 
loaded into the Phadia250 machine. Specific IgE antibodies to prepared OPA allergens were 
then measured using the UNICAP 250 machine according to manufacturer‘s procedure.  
Individuals with atopy were defined as those having a positive Phadiatop test. Individuals 
with sensitization to specific occupational allergens were identified based on sIgE ≥ 0.35 
KU/L. 
 5.2.4. Spirometry (pre and post-bronchodilator) 
There were 328 participants from the TAH and 25 participants from the SAH who performed 
spirometry (pre- and post-bronchodilator). The latter group did not proceed to methacholine 
challenge testing (see below) due to contra-indications (e.g. FEV1 below 1.5 litres or 70% 
predicted, pregnant and breastfeeding women). Spirometry was conducted according to 
guidelines of the American Thoracic Society/European Respiratory Society (ATS/ERS) (37) 
using EasyOne World spirometer (ndd Medical Technologies, Zurich, Switzerland) at the 
TAH and Jaeger Aerosol Provocation System (APS) Pro apparatus at the SAH according to 
the manufacturer‘s instructions. Special instructions were given to health workers to abstain 
from smoking tobacco (at least 2 hours before) taking any anti-asthmatic inhalers (12 hours 
before) or oral asthma medications (48 hours before) prior to the test. The Global Lung 
Function Initiative (GLI) 2012 reference values using ―other‖ ethnic group were used for 
grading degree of impairment of spirometry (38). A change in FEV1 of ≥200 milliliters and 
≥12% 10 minutes after the administration of bronchodilator (400 µg of salbutamol) was 
considered to be significant bronchial reversibility. To achieve additional quality control for 
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the Tanzanian group that did not perform methacholine challenge tests (due to logistical 
considerations), each spirometric test was evaluated for the quality according to the ATS 
standards (39) as outlined in Table 5.1, which compares grading between the Easyone 
spirometer output and the ATS grading. All spirometric tests with ATS quality grade F were 
not included in the analysis. Data from 182 participants were available after excluding those 
with ATS grade D, E and F on pre-bronchodilator (pre-BD) tests.  
 
Table 5.1: Spirometry quality grades of health workers in the Tanzanian hospital 
 Pre-BD Easyone grade 
n (%) 
Pre-BD ATS grade  
n (%) 
Post-BD Easyone grade 
n (%) 
Post-BD ATS grade 
n (%) 
A 86 (26) 129 (39) 132 (41) 175 (54) 
B 43 (13) 69 (21) 43 (13) 40 (12) 
C 102 (31) 34 (10) 57 (18) 18 (6) 
D 97 (29) 9 (3) 75 (23) 13 (4) 
E  87 (26)  61 (19) 
F 3 (1) 3 (1) 18 (6) 18 (6) 
Total 331 331 325 325 
Note: Those with ≥2 acceptable tests with repeatability of > 0.250 L were assigned ATS grade E 
 
5.2.5. Methacholine challenge tests 
Methacholine challenge testing (MCT) was only performed in the South African study site 
due to logistical considerations. The tests were conducted in a pulmonary function laboratory 
that was well equipped with appropriate resuscitation facilities. Among 318 participants who 
underwent spirometry, 239 performed interpretable PD20 methacholine results while 52 
participants had ≥10% decrease in FEV1 after administration of saline diluent and were 
therefore not considered for MCT. MCT was discontinued in two participants who requested 
the test to be stopped. As explained above, 25 participants underwent post-bronchodilator 
spirometry, since MCT was contraindicated. MCT was conducted under the supervision of 
an experienced technologist according to an abbreviated protocol used in epidemiological 
surveys. The Medic Aid Pro Nebulizer dosimeter method involved a protocol of increasing 
numbers of breaths to achieve pre-defined cumulative doses of methacholine (40). The 
doses were delivered by the Jaeger APS MedicAid Side Stream APS-Nebulizer according to 
the manufacturer‘s instructions, commencing with the lowest dose of 0.026 mg. The dose 
was increased to a maximum of 2.048 mg methacholine if a positive endpoint (fall in FEV1 of 
20% or more) was not obtained. The results of the MCT were interpreted as follows: 
borderline defined as 0.4mg <PD20M<1.0 mg; mild = 0.08 mg < PD20M <0.4mg; 
moderate/severe = PD20M< 0.08mg. Borderline values for PD20M were considered negative 
in the definition of non-specific bronchial hyper responsiveness (NSBH). These cut-offs for 
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the APS system are based on the results from a validation study performed on 40 hyper-
responsive bakery workers that confirmed a satisfactory correlation between the APS 
cumulative PD20M method and the standard VMAX (Sensormedics) method (34). A urine 
pregnancy test was offered to women prior to the administration of methacholine, while 
pregnant women and nursing mothers were automatically excluded from testing.  
5.2.6. Fractional exhaled nitric oxide (FeNO) 
A total of 654 participants performed FeNO tests (334 from SAH and 320 from TAH). A 
hand-held portable exhaled nitric oxide sampling device (NIOX MINO® Airway Inflammation 
Monitor (NIOX MINO); Aerocrine AB, Solna, Sweden) was used. Under guidance of clinical 
personnel, all HWs inhaled NO-free air close to total lung capacity and exhale for 10 
seconds at a flow rate of 50 ml/sec according to the manufacturer‘s instructions. Two 
technically adequate measurements were performed in line with the current American 
Thoracic Society /European Respiratory Society recommendations (41). A third maneuver 
was performed if the difference between the first two measurements was more than 10 ppb. 
The FeNO test was done during the work shift before spirometry / MCT. Special instructions 
were provided to workers to ensure that tested individuals did not smoke tobacco, eat or 
drink (at least 1 hour before) prior to the test. Ambient NO and temperature were also 
recorded. FeNO results were interpreted as follows: low < 25ppb; elevated for values 25 - 
50ppb; and high for values > 50ppb (42). 
5.2.7. Statistical analysis 
All data analysis was performed using statistical package STATA version 14. Frequencies of 
categorical variables were compared between the two hospitals using Chi-squared test or 
Fisher‘s exact test where appropriate. Numerical variables were summarised using median 
and interquartile range, since not all variables followed a normal distribution. Numerical 
variables were compared between the two hospitals using Wilcoxon sum rank test.  
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5.3. RESULTS 
5.3.1. Study population 
Demographic characteristics of the study population are summarised in Table 5.2. The 
majority of study participants were women (78%), having a median age of 42 years 
(interquartile range - IQR: 32 – 51 years) and had worked in the healthcare industry for 14 
years (median: 14 years; IQR: 6 – 28 years). A significant number of study participants 
(76%) were nursing professionals (registered nurses, enrolled nurses and nurse assistants 
or health attendants). Cleaners (12%) and other health workers including administrative 
workers (5%) were also included in the study. South African HWs were significantly older, 
with higher BMI (although comparable to their respective general populations), and a higher 
prevalence of current smoking, atopy and past history of tuberculosis compared to their 
counterparts. However, a history of repeated childhood chest infections was significantly 
higher among Tanzanian HWs (p-value = 0.001). 
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Table 5.2: Demographic characteristics of health workers in the two tertiary hospitals 
Demographic characteristics Overall SAH  
n (%) 
TAH  
n (%) 
p-value 
(Chi-squared 
test) 
Participants (n) 697 344 353  
Age (years) [median (IQR)] 42 (32 – 51) 46 (33 – 51) 39 (31 – 51) 0.009* 
Gender (%F:M) 77:23 84:16 71:29 <0.001 
BMI [median (IQR)] 29 (26 – 34) 31 (27 – 37) 28 (25 – 32) <0.001* 
Smoking status: n (%)   
<0.001 Current smokers 42 (6) 40 (12) 2 (1) 
Ex-smokers 48 (7) 48 (14) 0 (0) 
Never smokers 607 (87) 256 (74) 351 (99) 
Job title: n (%)   
 
 
<0.001 
Registered nurse 283 (41) 132 (38) 151 (43) 
Nurse assistant / Health attendant 168 (24) 59 (17) 109 (31) 
Enrolled nurse 75 (11) 48 (14) 27 (8) 
Cleaner 85 (12) 45 (13) 40 (11) 
Clerk 38 (5) 13 (4) 25 (7) 
Technician 34 (5) 33 (10) 1 (0) 
Porter 14 (2) 14 (4) 0 (0) 
Total years in healthcare industry [median (IQR)] 14 (6 – 28) 20 (8 – 28) 11 (4 – 27) <0.001* 
Total years in the current job [median (IQR)] 4 (2 – 9) 4 (1 – 11) 4 (2 – 8) 0.862* 
Past history of lung disease (self-reported)  
Previous treatment for chronic bronchitis 44 (6) 42 (12) 2 (1) <0.001 
Repeated childhood chest infections 76 (11) 24 (7) 52 (15) 0.001 
Previous treatment for tuberculosis 32 (5) 22 (6) 10 (3) 0.025 
Family history of allergy 353 (51) 219 (64) 134 (38) <0.001 
Cleaning activities at home in the last 12 months 660 (95) 342 (99) 318 (90) <0.001 
Less than 1 day per week 96 (14) 17 (5) 79 (22) <0.001 
1 or more days per week 601 (86) 327 (95) 274 (78) 
SAH: South African hospital; TAH: Tanzanian hospital; F: female; M: male; IQR: interquartile range; *: Wilcoxon sum rank test 
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5.3.2. Immunological characteristics 
The prevalence of atopy (positive Phadiatop test) was higher (47%) in South African HWs (p 
= 0.047) (Table 5.3). The prevalence of OPA sensitisation was relatively low, although 
relatively higher (4%) than for natural rubber latex (Hev b5 or Hev b6.02) (2%), but with no 
significant difference observed between the two hospitals. The prevalence of chlorhexidine 
sensitisation was only 1% among SAHWs. As explained earlier, immunological assessment 
for chlorhexidine was not conducted for THWs. 
 
Table 5.3: Allergic sensitisation profiles of health workers in the two tertiary hospitals 
Allergic sensitisation profiles Overall SAH  
n (%) 
TAH 
n (%) 
p-value 
(Chi-squared 
test) 
Participants (n) 682 339 343  
Atopy (Positive Phadiatop test) 296 (43) 160 (47) 136 (40) 0.047 
OPA 26 (4) 12 (4) 14 (4) 0.712 
Chlorhexidine NA 3 (1) ND NA 
Latex (Hev b5 or Hev b6.02) 11 (2) 7 (2) 4 (1) 0.352 
Latex Hev b5 3 (0) 3 (1) 0 (0) 0.122# 
Latex Hev b6.02 8 (1) 4 (1) 4 (1) 1.000# 
Sensitisation to at least one occupational 
allergen (OPA, Chlorhexidine or Latex)* 
34 (5) 19 (6) 15 (4) 0.460 
Peroxidase: 19 (6); SAH: South African hospital; TAH: Tanzanian hospital; OPA: ortho-phthalaldehyde; *: Sensitisation to at 
least one occupational allergen (OPA, Chlorhexidine or Latex) and peroxidase negative (in relation to latex) ;#: Fisher‘s exact 
test; NA: Not applicable; ND: Not done 
 
 
 
 
 
 
 
 
 
 
 
 
 
118 
 
 
5.3.3. Symptoms 
Although the prevalence of doctor-diagnosed asthma was 7%, with no significant difference 
between the two hospitals (Table 5.4), the majority (60%) of these individuals reported adult-
onset asthma. A higher prevalence of SAHWs (17%) had an asthma symptom score ≥2 
compared to their Tanzanian counterparts (9%). Overall, the prevalence of work-related 
ocular-nasal symptoms in the past 12 months (16%) was higher than work-related skin 
(12%) and asthma (7%) symptoms (Table 5.6). The prevalence of skin symptoms (work-
related and non-work-related) was significantly higher among HWs in the SAH compared to 
the TAH (p < 0.001) (Table 5.5 and 5.6). Skin symptoms commonly affected the hands or 
forearms (12%), compared to the whole body (5%). There were 16 (2%) workers from both 
hospitals who reported job changes due to work-related chest symptoms. The major agents 
attributed for these work-related chest symptoms by respondents included the general dust, 
NRL and OPA / glutaraldehyde.    
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Table 5.4: Asthma history and respiratory symptoms reported by health workers in 
the two tertiary hospitals 
Symptoms Overall SAH  
n (%) 
TAH 
n (%) 
p-value 
(Chi-
squared 
test) 
Participants (n) 697 344 353  
Asthma history  
Ever attacks of breathlessness at rest with wheezing 33 (5) 13 (4) 20 (6) 0.241 
Ever asthma 52 (8) 28 (8) 24 (7) 0.501 
Ever asthma attack 55 (8) 26 (8) 29 (8) 0.748 
Doctor-diagnosed asthma 48 (7) 29 (8) 19 (5) 0.112 
≤16 years 19 (3) 9 (2) 10 (3) 0.135 
>16 years 29 (4) 20 (6) 9 (2) 
Current use of asthma medication 39 (6) 21 (6) 18 (5) 0.564 
Asthma attack in the past 12 months 31 (5) 16 (5) 15 (4) 0.797 
Current use of asthma medication OR 
Asthma attack in the past 12 months 
44 (6) 24 (7) 20 (6) 0.477 
Asthma-like symptoms 219 (31) 154 (45) 65 (18) <0.001 
Short of breath while wheezing in the last 12 months 67 (10) 38 (11) 29 (8) 0.214 
Woken up with chest tightness in the last 12 months 85 (12) 51 (15) 34 (10) 0.039 
Attack of shortness of breath at rest during daytime 
in the last 12 months 
51 (7) 18 (5) 33 (9) 0.035 
Attack of shortness of breath following running or 
exercise in the last 12 months 
154 (22) 128 (37) 26 (7) <0.001 
Woken up by an attack of shortness of breath in the 
last 12 months 
48 (7) 26 (8) 22 (6) 0.503 
More symptomatic (≥ 2 asthma-like symptoms) 91 (13) 58 (17) 33 (9) 0.003 
Less symptomatic (0 – 1 asthma-like symptom) 606 (87) 286 (83) 320 (91) 
Asthma symptom score     
 
<0.001 
  0 478 (69) 190 (55) 288 (82) 
  1 128 (18) 96 (28) 32 (9) 
  2 42 (6) 31 (9) 11 (3) 
  3 17 (2) 11 (3) 6 (2) 
  4 18 (3) 10 (3) 8 (2) 
  5 14 (2) 6 (2) 8 (2) 
Upper airway symptoms  
Presence of ocular–nasal symptoms ever 306 (44) 167 (49) 139 (39) 0.015 
SAH: South African hospital; TAH: Tanzanian hospital 
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Table 5.5: Skin symptoms reported by health workers in the two tertiary hospitals 
Symptoms Overall SAH  
n (%) 
TAH 
n (%) 
p-value 
(Chi-
squared 
test) 
Participants (n) 697 344 353  
Presence of skin symptoms ever 215 (31) 148 (43) 67 (19) <0.001 
Two or more episodes of skin symptoms in 
the last 12 months 
125 (18) 82 (24) 43 (12) <0.001 
Symptoms affecting hands or forearms# 86 (12) 50 (15) 36 (10) 0.082 
Itchy/scratchy skin 72 (10) 40 (12) 32 (9) 0.266 
Redness of the skin 45 (7) 34 (10) 11 (3) <0.001 
Burning skin 24 (3) 22 (6) 2 (1) <0.001 
Hives 15 (2) 9 (3) 6 (2) 0.404 
Dry/scaly skin 7 (1) 0 (0) 7 (2) 0.015* 
Blisters/weeping skin 10 (1) 6 (2) 4 (1) 0.541* 
Rash within an hour of contact with a 
rubber latex product 
8 (1) 7 (2) 1 (0) 0.036* 
Symptoms affecting the whole body# 36 (5) 22 (6) 14 (4) 0.147 
Itchy/scratchy skin 34 (5) 20 (6) 14 (4) 0.257 
Redness of the skin 21 (3) 15 (4) 6 (2) 0.040 
Burning skin 11 (2) 11 (3) 0 (0) 0.001 
Hives 6 (1) 3 (1) 3 (1) 1.000* 
Dry/scaly skin 9 (1) 9 (3) 0 (0) 0.002* 
Blisters/weeping skin 2 (0) 1 (0) 1 (0) 1.000* 
Rash within an hour of contact with a 
rubber latex product 
1 (0) 1 (0) 0 (0) 0.494* 
SAH: South African hospital; TAH: Tanzanian hospital; *: Fisher‘s exact test;  
#: presence of itchy/scratchy skin, hives, dry/scaly skin, redness of the skin, blisters/weeping skin or burning skin 
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Table 5.6: Work-related symptoms reported by health workers in the two tertiary 
hospitals 
Symptoms Overall SAH  
n (%) 
TAH 
n (%) 
p-value 
(Chi-
squared 
test) 
Participants (n) 697 344 353  
Work-related asthma symptoms  
Episode of high exposure at work causing tight chest, 
shortness of breath, wheeze or cough 
3 (0) 2 (1) 1 (0) 0.043 
Work-related asthma symptoms (ever) 83 (12) 38 (11) 45 (13) 0.488 
Work-related asthma symptoms in the past 12 months a 65 (9) 28 (8) 37 (11) 0.288 
Work-related asthma symptoms in the past 12 months b 48 (7) 20 (6) 28 (8) 0.270 
Doctor-diagnosed work-related asthma (ever) 15 (2) 8 (2) 7 (2) 0.755 
Job change due to work-related chest symptoms 16 (2) 10 (3) 6 (2) 0.287 
Work-related upper airway symptoms  
Work-related ocular–nasal symptoms (ever) 163 (23) 80 (23) 83 (24) 0.936 
Work-related ocular–nasal symptoms in the past 12 months a 146 (21) 70 (20) 76 (22) 0.702 
Work-related ocular–nasal symptoms in the past 12 months b 109 (16) 48 (14) 61 (17) 0.227 
Doctor-diagnosed work-related ocular–nasal symptoms 
(ever) 
19 (3) 9 (3) 10 (3) 0.861 
Work-related skin symptoms  
Work-related skin symptoms (ever) 130 (19) 95 (28) 35 (10) <0.001 
Work-related skin symptoms in the past 12 months a 103 (15) 76 (22) 27 (8) <0.001 
Work-related skin symptoms in the past 12 months b 80 (12) 61 (18) 19 (5) <0.001 
Doctor-diagnosed work-related skin condition(ever) 20 (3) 16 (5) 4 (1) 0.005 
SAH: South African hospital; TAH: Tanzanian hospital;  
a: Symptoms (asthma / ocular-nasal / skin) experienced at work in the last 12 months;  
b: Symptoms (asthma / ocular-nasal / skin) experienced at work in the last 12 months that gets better when away from work OR 
worsen on return to work 
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5.3.4. Pulmonary function tests (spirometry, MCT and FeNO) 
The results of the pulmonary function tests are summarised in Table 5.7. Overall, TAHWs 
had significantly lower lung volumes and a higher prevalence of airflow obstruction than their 
counterparts (p < 0.001). While 29% of workers had an FEV1 of less than lower limit of 
normal (LLN), 11% had evidence of airflow obstruction (pre-bronchodilator FEV1/FVC ratio 
less than LLN). In the South African group, 12% of workers had evidence of NSBH (10% 
positive on methacholine challenge test - PD20 methacholine < 0.4 mg, and 2% with 
significant bronchial reversibility). In the Tanzanian group, 6% of HWs had evidence of 
NSBH on the basis of significant bronchial reversibility. Overall, combining results from both 
hospitals, 9% of the study population had evidence of NSBH.  
The median FeNO levels (interquartile range: 11 – 24) were slightly higher among SAHWs 
compared to the Tanzanian counterparts. Overall across all hospitals, 77% had low FeNO 
(<25 ppb), 17% elevated (25–50 ppb) levels and 6% high (>50 ppb) levels. The proportion of 
HWs with high FeNO, was slightly higher in the South African group. 
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Table 5.7: Pulmonary function indices of health workers in the two tertiary hospitals 
Pulmonary function indices 
# ǂ
 Overall SAH  
n (%) 
TAH 
n (%) 
p-value 
(Chi-
squared 
test) 
Participants (n) 646 318 328  
FVC L [median (IQR)] 3.02 (2.47 – 3.53) 3.23 (2.80 – 3.68) 2.68 (2.21 – 3.35) <0.001* 
FEV1 L [median (IQR)] 2.42 (1.96 – 2.88) 2.66 (2.30 – 3.07) 2.16 (1.78 – 2.65) <0.001* 
FEV1 /FVC, % [median (IQR)] 82 (77 – 86) 83 (80 – 87) 81 (76 – 85) <0.001* 
FVC % pred. [median (IQR)] 91 (79 – 103) 99 (90 – 108) 82 (73 – 94) <0.001* 
FEV1 % pred. [median (IQR)] 89 (76 – 101) 99 (89 – 108) 79 (70 – 90) <0.001* 
FVC < 80% pred. 168 (26) 24 (8) 144 (44) <0.001 
FVC < LLN (n,%) 172 (27) 24 (8) 148 (45) <0.001 
FEV1< 80% pred. (n,%) 205 (32) 33 (10) 172 (52) <0.001 
FEV1< LLN (n,%) 185 (29) 26 (8) 159 (49) <0.001 
FEV1 /FVC < LLN (n,%) 73 (11) 20 (6) 53 (16) <0.001 
FEV1 /FVC < 70% (n,%) 50 (8) 14 (4) 36 (11) 0.002 
Bronchial hyperresponsiveness 
≥12% and ≥200 ml FEV1 increase post-
bronchodilator 
n = 207 n = 25 n = 182 NA 
26 (13) 7 (28) 19 (10) 
≥10% FEV1 decrease post-saline 
diluent (n = 291) 
 52 (18) ND NA 
Methacholine challenge test: PD20 
methacholine < 0.4 mg (n = 239) 
 31 (13) ND NA 
NSBH## (n = 264)  38 (14) ND NA 
Fractional exhaled nitric oxide (FeNO) n = 654 n = 334 n = 320  
FeNO (ppb) [median (IQR)] 17 (11 – 24) 17 (12 – 25) 15 (10 – 22) 0.003* 
Low <25 ppb 504 (77) 251 (75) 253 (79)  
0.487 Elevated 25 – 50 ppb 111 (17) 61 (18) 50 (16) 
High >50 ppb 39 (6) 22 (7) 17 (5) 
SAH: South African hospital; TAH: Tanzanian hospital; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity; 
L: litres; LLN: Lower limit of normal;IQR: interquartile range; % pred: % predicted; PD20 methacholine: provocative dose of 
methacholine causing a ≥ 20% fall in FEV1; NSBH: nonspecific bronchial hyperresponsiveness; ND: Not done; NA: Not 
applicable; #: pre-bronchodilator values, unless stated otherwise; ǂ:Global lung function initiative (GLI) reference values used; 
##: NSBH defined as any of the following two criteria: PD20methacholine <0.4 mg OR≥12% and ≥ 200 ml increase in FEV1 after 
administration of a bronchodilator; *: Wilcoxon sum rank test; 
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5.4. DISCUSSION 
The findings of this study has demonstrated that HWs in two tertiary academic hospitals in 
sub-Saharan Africa experience an appreciable proportion of work-related airway and skin 
symptoms as their counterparts in other regions of the world. While South African HWs 
reported a higher prevalence of work-related skin symptoms, Tanzanian HWs had 
comparatively higher proportion of individuals with decreased lung volumes and airflow 
obstruction. The study has also confirmed that the prevalence of NRL sensitisation has 
declined in South Africa over the past decade.  
As has been reported in most studies of work-related rhinitis and asthma (43), the 
prevalence of work-related ocular-nasal symptoms was twice as common as asthma 
symptoms in this study. Furthermore, in this current study, lifetime prevalence of work-
related ocular-nasal (23%) and asthma symptoms (12%) was higher than that reported in 
South African dental HWs (14% and 4% respectively) (25). Moreover, in this current study, 
the prevalence of work-related asthma symptoms (WRAS) in the past 12 months (7%) was 
higher than a US study of HWs (3.3%) and on the upper end of the range compared to the 
Saudi Arabian study of HWs (5.7%), both using a similar definition of WRAS (44,45). 
Although the authors did not comment on the available workplace controls in the two studies 
(44,45), the inadequate workplace controls observed in the current study could partly explain 
the relatively higher prevalence of WRAS. In addition, 16 (2%) workers with WRAS in the 
current study had to change their jobs due to these symptoms, underscoring the negative 
consequences associated with work-related asthma (46). 
Unlike upper and lower airway symptoms that were similar across both study groups, a 
higher prevalence of skin symptoms (work-related and non-work-related) was reported 
among SAHWs in this study, although there was no correlation between the presence of 
respiratory and skin symptoms. This could partially be explained by the significantly 
(p<0.001) higher frequency of hand washing at work among South African HWs (58 times 
per day), compared to Tanzanian HWs (20 times per day). Another possible explanation 
could be the different hand hygiene products used, with SAHWs using mostly chlorhexidine 
containing products and alcohols compared to the TAHWs who used mainly a diluted all-
purpose cleaner and alcohols. Chlorhexidine is a well known skin irritant and allergen 
capable of causing both IgE-mediated (e.g. urticaria) and delayed type (e.g. contact 
dermatitis) hypersensitivity skin reactions (11,47). The predominance of skin symptoms 
affecting the hand/forearms rather than the whole body, suggests a clinical picture of a 
contact dermatitis, although contact urticaria cannot be ruled out completely. However, since 
skin patch testing was not performed in this study it was not possible to characterise this 
further as to whether they were allergic or irritant in nature. The prevalence of work-related 
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skin symptoms (lifetime = 19% and in the past 12 months = 12%) in the current study is 
consistent with results from previous studies (11% - 28%) among workers exposed to 
cleaning agents in other parts of the world (48–51). 
In this study, the prevalence of atopy (positive Phadiatop test) was higher (47%) in the 
SAHWs compared to the TAHWs (40%) and on upper end of other workplace-based South 
African studies (36 – 46%) (25,52–54). However, the overall atopy prevalence (43%) in this 
study was similar to that observed (45%) in a US study of HWs (10). In the latter study, 
among the 129 participants evaluated for sensitisation to OPA, 5 (4%) had positive skin 
responses to SPTs with OPA solution (10). While the reported prevalence of OPA 
sensitisation in the US study is similar to that observed in the current study, interestingly, 
sIgE and IgG antibodies were not detected in any of the blood samples tested. Since the 
current study only used sIgE to OPA in the immunological assessment, it is probable that a 
higher prevalence of OPA sensitisation could have been obtained had SPT been used, since 
sIgE determination is a measure of circulating antibodies and fails to detect locally bound 
IgE. Interestingly, in the current study, prevalence of work-related symptoms due to OPA 
(4%) was similar to the prevalence of OPA sensitisation (4%), with HWs experiencing more 
ocular-nasal symptoms (3%) compared to chest (2%) and skin (1%) symptoms. As 
expected, prevalence of work-related symptoms due to OPA was much higher (9% - 24%) in 
the two Japanese studies that only investigated HWs exposed to OPA in the endoscopy 
units (8,9). 
Despite 20% of SAHWs reporting work-related symptoms due to chlorhexidine in this study, 
only three (1%) HWs had evidence of chlorhexidine sensitisation. Since Tanzanian HWs did 
not use chlorhexidine containing products, immunological assessment for chlorhexidine was 
not evaluated. The low prevalence of chlorhexidine sensitisation in this study is similar to the 
findings by Garvey et al that did not identify any HW with sensitisation to chlorhexidine using 
a series of immunological skin tests (skin prick, intradermal and patch tests) (12). Four cases 
of occupational IgE-mediated allergy to chlorhexidine were diagnosed among 53 HWs in the 
UK hospital (14). Among the 4 cases of occupational chlorhexidine allergy identified, 3 HWs 
had positive SPT responses while two had a positive (≥ 0.35 KU/L) sIgE test (14). Wittczak 
et al. have also described 3 cases of among HWs in Poland with all 3 identified cases having 
positive sIgE tests and only 2 with positive SPT (15). Interestingly, only one was atopic 
(positive SPT to common aeroallergens) while another case had concurrent NRL allergy 
confirmed by sIgE and a positive specific bronchial challenge test. In contrast, several cases 
of chlorhexidine allergy have been frequently reported among patients (16) and coexistence 
of chlorhexidine and NRL allergy has also been observed in other studies (14,55).  
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In this current study, the prevalence of NRL sensitisation was 2% compared to a previous 
study (22) conducted more than a decade ago in the same SAH, which reported a 9% 
prevalence of NRL sensitisation. The decline in prevalence of NRL sensitisation is most 
likely related to the latex avoidance measures implemented in the hospital, and more 
specifically the substitution of powdered latex gloves with less-powdered/powder-free low 
protein gloves. Other previous (20,21) and recent (23–25) South African studies conducted 
among HWs reported prevalence of NRL sensitisation to range between 5% and 20.8%. 
Despite the lower frequency of NRL sensitisation in this study, 12% of HWs reported a 
history of NRL-related symptoms, but no significant differences were observed between the 
two hospitals. However, SAHWs (4%) were significantly (p=0.003) more likely to be 
diagnosed with NRL allergy, compared to their Tanzanian counterparts (1%). 
In this current study, pulmonary function tests revealed significantly lower lung volumes 
among Tanzanian HWs compared to their South African counterparts even after poor quality 
spirograms were excluded. Furthermore, there was no correlation between the poor quality 
of spirometry and the presence of respiratory symptoms. One possible explanation for this 
finding is the high frequency of repeated childhood chest infections reported in the 
Tanzanian HWs. Repeated childhood chest infections has been reported to be a risk factor 
for the lower adult FEV1 (56). Another possible explanation for the observed difference is the 
exposure to biomass fuel. Biomass fuel was used for cooking by most individuals (99.5%) in 
a recent Tanzanian study (57).  
Furthermore, a higher prevalence of airway obstruction was also found in this group of 
TAHWs. A vigorous literature search was unable to identify any study that has reported on 
airway obstruction among HWs in Tanzania and hence limiting comparisons with the study 
findings. However, compared to other Tanzanian workplaces, the prevalence of airways 
obstruction in this study was similar or lower (58–62). The higher frequency of repeated 
childhood chest infections reported in the Tanzanian HWs and potential biomass fuel 
exposure could also explain the higher prevalence of airways obstruction among TAHWs. 
The higher prevalence of significant bronchial reversibility observed (Table 5.7) among 
SAHWs (28%) compared to TAHWs (10%) is mainly because of the selective nature of the 
SAHWs who performed pre- and post-BD spirometry. This was evidenced by the fact that a 
significantly higher proportion of SAHWs who performed pre- and post-BD spirometry (24%) 
reported history of asthma compared to those who conducted MCT (7%) (p=0.009). 
Moreover, SAHWs who performed pre- and post-BD spirometry had significantly lower FEV1 
compared to those who conducted MCT (p<0.001) and hence more likely to obtain 
significant bronchial reversibility. On the other hand, the higher prevalence of non-specific 
bronchial hyper-responsiveness (NSBH) observed among the SAHWs could be explained by 
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the use of a more sensitive test (MCT), compared to the pre- and post-BD spirometry used 
in the TAH. 
In the current study, FeNO levels were comparable to the other workplace-based studies in 
Tanzania and South Africa in non-health care settings (54,61,63–65). While, the median 
FeNO levels in the current study (17 ppb) were similar to supermarket bakery workers 
(median = 15 ppb), cement factory workers (median = 15 ppb) and coffee factory workers 
(geometric mean = 17.4 ppb) (61,63,64), the prevalence of high FeNO (>50 ppb) in the 
current study (6%) indicative of allergic airway inflammation, was much lower than previous 
South African studies of workers exposed to predominantly high molecular weight protein 
agents (poultry farm: 7%, spice mill: 8%, supermarket bakeries: 11%) (54,63,65). This 
suggest that the work-related asthma reported in this current group of workers to have both 
allergic and non-allergic components, requiring further investigation (2,66).  
To the best of our knowledge, this is the first study in southern Africa of HWs exposed to 
cleaning agents and the first globally to have undertaken an extensive epidemiological study 
on the immunological assessment of HWs to OPA and chlorhexidine. Previous studies by 
Fujita et al. (8) and Miyajima et al. (9), reported only on work-related symptoms and did not 
provide more objective measures of work-related allergy and asthma as the current study. 
To the knowledge of investigators, this is the first epidemiological study in southern Africa to 
have conducted FeNO measurements in HWs. Furthermore, this is also the first 
epidemiological study on the immunological assessment of HWs sensitized to NRL in 
Tanzania. Despite these strengths, there are some limitations in obtaining a detailed 
immunological assessment of the Tanzanian group. Immunological assessment of 
sensitisation to glutaraldehyde was not done due to the lack of commercially available 
immunoCAP for glutaraldehyde. This is important since glutaraldehyde continue to be used 
as a high-level disinfectant in the TAH. Furthermore, methacholine challenge tests could not 
be conducted in the TAH due to logistical reasons. Hence, a more composite picture of HWs 
in this hospital could not be obtained compared to their South African counterparts. 
Nevertheless, the study has provided important insight into work-related asthma in sub-
Saharan HWs exposed to OPA and NRL. Furthermore, while some of the factors that could 
potentially explain the differences in outcome prevalence between the two hospitals such as 
socio-economic status were not assessed, other factors such as age, gender, smoking 
status and body mass index were not able to explain the differences observed in the 
outcome prevalence. Additionally, since health outcome status of non-respondents was not 
known, the possibility of sampling bias affecting the results cannot be ruled out given the 
response rate (average: 53%) obtained in this study.  
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5.5. CONCLUSION 
This study has demonstrated that HWs in these two hospitals experience an appreciable 
proportion of work-related airway and skin symptoms. However, South African HWs 
experienced higher prevalence of work-related skin symptoms as compared to the 
Tanzanian HWs, possibly due to their higher frequency of hand washing. Tanzanian HWs 
had comparatively higher proportion of individuals with decreased lung volumes and airflow 
obstruction. The study has also shown that the prevalence of NRL sensitisation is declining 
in South Africa most likely due to the NRL preventive measures implemented, particularly 
the substitution of powdered latex gloves with less-powdered/powder-free gloves.  
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Chapter 6 
Asthma phenotypes and host risk factors associated with various asthma-related outcomes 
among health workers  
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ABSTRACT 
Background: Asthma is a heterogeneous disease with diverse clinical, physiological and 
inflammatory characteristics. A few studies have characterised occupational asthma 
phenotypes mainly based on its aetiology, be it high molecular weight (HMW) and low 
molecular weight (LMW) agents. However, little is known about the pattern of asthma 
phenotypes in health workers (HWs) exposed to cleaning agents. Differentiating between 
various asthma phenotypes in the workplace is important in understanding the 
heterogeneous nature of the disease in order to develop appropriate management and 
preventive strategies. This study was conducted to describe various asthma phenotypes in 
HWs exposed to cleaning agents and to identify important host risk factors associated with 
various asthma phenotypes based on symptoms, presence of non-specific bronchial 
hyperresponsiveness and allergic airway inflammation. 
Methods: A cross-sectional study of 699 HWs was conducted in two large tertiary hospitals. 
A total of 697 participants completed questionnaire interviews. Sera was collected from 682 
HWs and analysed for specific immunoglobulin E (sIgE) antibody reactivity to common aero-
allergens (Phadiatop) and specific occupational allergens (NRL - Hevea brasiliensis (Hev b5, 
Hev b6.02), chlorhexidine and OPA). Methacholine challenge tests (MCT) were performed 
on all South African HWs (n=318), based on standard inclusion criteria. Spirometry, 
accompanied by a post-bronchodilator (post-BD) test was conducted on all Tanzanian HWs 
(n=329) and a small proportion (n=25) of South African HWs (SAHWs) where MCT was 
contraindicated. All HWs from both hospitals (n= 654) underwent fractional exhaled nitric 
oxide (FeNO) testing during the working day prior to spirometry. An asthma symptom score 
was computed based on the sum of answers to five questions on asthma-related symptoms 
in the past 12 months. Current asthma was defined as either having an asthma attack in the 
past 12 months, current use of asthma medication or woken up by an attack of shortness of 
breath in the past 12 months. Nonspecific bronchial hyperresponsiveness (NSBH) was 
defined as either positive MCT (PD20 methacholine < 0.4 mg) or presence of a significant 
bronchodilator response - BDR (≥12% and ≥ 200 ml increase in FEV1 after administration of 
a bronchodilator). Two continuous indices of NSBH (continuous index of responsiveness 
(CIR) and dose-response slope (DRS)) were also calculated. 
Results: The prevalence of current asthma was 10% with atopic asthma (6%) more 
prevalent than non-atopic asthma (4%). Overall, there were 2% of subjects with work-related 
asthma. There was a weak positive correlation between NSBH (CIR: Beta coefficient (β) = 
0.12; 95% Confidence Interval (CI): 0.03 – 0.22 and DRS: β = 0.07; 95% CI: 0.03 – 0.12) 
and FeNO. Combining FeNO ≥ 50 ppb with post-BD spirometry test (mean ratio (MR) = 
5.89; 95% CI: 1.02 – 34.14) or with NSBH (MR = 4.62; 95% CI: 1.16 – 18.46) correlated 
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better with asthma symptom score than either of them individually (FeNO ≥ 50 ppb: MR = 
2.23; 95% CI: 1.30 – 3.85). Participants with current asthma were more likely to be atopic 
(odds ratio (OR) = 2.04; 95% CI: 1.23 – 3.39), have a family history of allergy (OR = 2.25; 
95% CI: 1.32 – 3.82) and a history of hay fever (OR = 2.30; 95% CI: 1.38 – 3.83). 
Furthermore, FeNO ≥ 50 ppb was positively associated with atopy (OR = 3.19; 95% CI: 1.59 
– 6.39) and a history of hay fever (OR = 2.05; 95% CI: 1.08 – 3.93). The majority of HWs 
who were sensitised to occupational allergens (OPA, chlorhexidine and NRL) were atopic. 
Conclusion: This study has demonstrated that atopic asthma was more prevalent than non-
atopic asthma. Furthermore, most asthma-related outcomes and work-related symptoms 
were positively associated with allergic predictors suggesting a more dominant role of 
allergic mechanisms in asthma and work-related symptoms experienced by these HWs. 
Stronger associations observed for asthma symptoms when high FeNO (≥ 50 ppb) was 
combined with NSBH (BDR + MCT), together with the finding that atopic individuals 
displayed an increased risk of sensitisation to OPA and chlorhexidine, further suggests an 
IgE mediated mechanism for the asthma reported in this group of HWs. 
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6.1. INTRODUCTION 
Asthma is a heterogeneous disease with diverse clinical, physiological and inflammatory 
characteristics (1–3). A number of studies have reported various phenotypes for non-work-
related asthma, with significant efforts directed towards characterising the severe asthma 
phenotypes (2,3). However, studies that have investigated occupational asthma phenotypes 
are quite limited and most of them have only characterised occupational asthma based on its 
aetiological agent, viz., high molecular weight and low molecular weight agents (1,4,5). The 
published literature on asthma phenotypes in health workers (HWs) exposed to cleaning 
agents is even more scant (6). Differentiating between various asthma phenotypes in the 
workplace is important in understanding the heterogeneous nature of the disease so as to 
develop appropriate management and preventive strategies (1,5). 
Few epidemiological studies have investigated the magnitude of asthma among HWs. In an 
international prospective population-based study [European Community Respiratory Health 
Survey-II (ECRHS-II)], the prevalence of new-onset asthma (asthma attack or taking asthma 
medication in the past 12 months) among nurses was reported to be 4.8% (7). A more 
detailed analysis of HWs from this study (8) reported a slightly higher prevalence of new-
onset asthma (currently taking asthma medication, asthma attack or woken up by an attack 
of shortness of breath in last 12 months) of 6%, most likely due to the different asthma 
definitions used. These findings are similar to a US study of HWs (n=3650) with active 
professional licenses (9), which demonstrated an overall prevalence of doctor-diagnosed 
asthma with onset after entry into the healthcare profession of 6.6%. In this study (9), the 
highest prevalence was among nurses (7.3%) followed by respiratory therapists (5.6%), 
occupational therapists (4.5%) and doctors (4.2%). However, a study published 2 years later 
from the same US population of HWs reported a much higher prevalence (9.8%) of doctor 
diagnosed asthma with onset after entry into the healthcare profession among nurses based 
on their longest job held (10).  
In a South African population-based study of adults (11), the prevalence of recent wheeze 
was higher (16.3%) than actual asthma diagnosis (3.8%) and asthma medication usage 
(8.6%). Little is known about the magnitude of asthma specifically in HWs of general health 
facilities in South Africa. However, a recent study of dental HWs (12) reported a 6.9% 
prevalence of atopic asthma, while a slightly lower proportion (5.9%) had non-atopic asthma. 
In this occupational group, work-exacerbated asthma was reported in 4% of the study 
population. In contrast, previous studies of the general population in Tanzania reported a 
much lower prevalence of asthma between 3.3% and 3.5% (13,14). However, the 
prevalence of asthma specifically among HWs in Tanzania is unknown.  
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Various studies have investigated the host-associated risk factors in adult asthma. Common 
host risk factors that have been associated with asthma include age, gender, seniority, 
smoking status and atopy (9,10). A previous study by Kogevinas et al. (7) of workers across 
different industries, demonstrated that atopic individuals had a significantly higher risk for 
new-onset asthma than non-atopics. The study also demonstrated an increased risk of new-
onset asthma in those with a parental history of asthma and among non-smokers compared 
to current smokers. More recently, risk factors for non work-related adult-onset asthma and 
occupational asthma have also been reviewed in a comparative manner (1). This review 
found that while host associated factors (e.g age, gender, genetics, atopy and obesity) did 
not differ for these two broad asthma phenotypes, environmental factors appeared to play a 
very important role in occupational asthma. Rava et al. have also (15) identified novel genes 
involved in adult asthma related to occupational exposure to LMW agents / irritants in three 
large European cohorts of general population. 
Among HWs, women appear to be more affected than men. The US study (16) of HWs by 
Arif et al., demonstrated women to have a higher prevalence of all asthma phenotypes, 
including WRA symptoms (3.6% vs 1.8%), work-exacerbated asthma (1.3% vs 0.3%) and 
occupational asthma (1.0% vs 0.1%) than men. Similar findings were reported in a large 
population European study (7) that found a slightly higher relative risk of new-onset asthma 
among women compared to men. It is likely that the gendered distribution of work plays an 
important role.  
The aim of this study was to describe various asthma phenotypes and to determine host risk 
factors associated with these phenotypes in a group of HWs from two large tertiary 
academic hospitals in sub-Saharan Africa. 
 
6.2. METHODS 
6.2.1. Study design, Population and Sampling 
      A cross-sectional study of 699 HWs was conducted in two large tertiary academic 
hospitals (346 from a South Africa hospital – SAH and 353 from Tanzanian hospital - TAH). 
All permanently employed HWs in the high-risk departments, as previously described 
(Chapter 3), constituted the sampling frame of the study. Doctors were excluded from the 
sampling frame as they were more likely to work in multiple different exposure settings 
across the hospital. A list of all permanently employed HWs in the high-risk departments of 
both hospitals was obtained from their respective managers. Study participants were 
selected from these departments through stratified random sampling according to job title, 
choosing up to five HWs from each high-risk department. For departments having more than 
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five HWs with the same job title, a random sample of five workers was selected. For 
departments having less than five workers, all workers were selected to participate in the 
study. Ethics approval was obtained from the Human Research Ethics Committee (HREC) of 
the University of Cape Town (HREC Ref: 212/2013), Muhimbili University of Health and 
Allied Sciences (MUHAS) Institutional Review Board and University of Michigan Medical 
School Institutional Review Board (HUM00083115). 
6.2.2. Questionnaire 
A total of 697 participants completed the questionnaire interviews (344 from SAH and 353 
from TAH). Each participant answered a modified questionnaire for the investigation of 
asthma as contained in the Protocol for the European Community Respiratory Health Survey 
(17). The study questionnaire also included validated questions from the NIOSH specific 
questionnaire for cleaning agents in the health care setting (18). The questionnaire was 
administered by trained interviewers in English language for South African health workers 
(SAHWs) and in Swahili language for Tanzanian health workers (TAHWs). The translated 
Swahili questionnaire was back-translated to ensure validity and repeatability. 
6.2.3. Immunological assessment  
Blood samples were collected from 682 participants (339 SAHWs and 343 TAHWs). Specific 
IgE antibody reactivity to common aero-allergens (Phadiatop) and specific occupational 
allergens was evaluated. The quantification of specific IgE antibodies to specific 
occupational allergens: NRL (Hevea brasiliensis - Hev b5, Hev b6.02), chlorhexidine and 
OPA was performed using the UniCAP system (Phadia, Uppsala, Sweden). Immunological 
assessment for chlorhexidine was only done on sera of SAHWs since chlorhexidine 
containing chemicals were not used in the TAH.  
Commercial ImmunoCAPs containing Phadiatop (Phad), Chlorhexidine (C8), rHev b5 (K218) 
and rHev b6.02 (K220) allergens were obtained from Thermo Scientific. Since the OPA test 
was not readily available commercially, it required further development as previously 
described (Chapter 3). Serum samples were tested at the National Institute for Occupational 
Health (NIOH) Immunology laboratory using the UNICAP 250 machine supplied by Thermo 
Scientific according to the manufacturer‘s manual.  
6.2.4. Spirometry (pre and post-bronchodilator) 
There were 328 participants from the TAH and 25 participants from the SAH who performed 
spirometry (pre- and post-bronchodilator). The latter group did not proceed to methacholine 
challenge testing (see below) due to contra-indications (e.g. FEV1 below 1.5 litres or 70% 
predicted, pregnant and breastfeeding women). Spirometry was conducted according to 
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guidelines of the American Thoracic Society/European Respiratory Society (ATS/ERS) (19) 
using EasyOne World spirometer (ndd Medical Technologies, Zurich, Switzerland) at the 
TAH and Jaeger Aerosol Provocation System (APS) Pro apparatus at the SAH according to 
the manufacturer‘s instructions as previously described.  
6.2.5. Methacholine challenge tests 
Methacholine challenge testing (MCT) was only performed in the South African study site 
due to logistical considerations. The tests were conducted in a pulmonary function laboratory 
that was well equipped with appropriate resuscitation facilities. Among 318 participants who 
underwent spirometry, 239 performed interpretable PD20 methacholine results while 52 
participants had ≥10% decrease in FEV1 after administration of saline diluent and were 
therefore not considered for MCT. MCT was discontinued in two participants who requested 
the test to be stopped. As explained above, 25 participants underwent post-bronchodilator 
spirometry, since MCT was contraindicated. MCT was conducted under the supervision of 
an experienced technologist according to an abbreviated protocol used in epidemiological 
surveys. The Medic Aid Pro Nebulizer dosimeter method involved a protocol of increasing 
numbers of breaths to achieve pre-defined cumulative doses of methacholine (20). The 
doses were delivered by the Jaeger APS MedicAid Side Stream APS-Nebulizer according to 
the manufacturer‘s instructions, commencing with the lowest dose of 0.026 mg. The dose 
was increased to a maximum of 2.048 mg methacholine if a positive endpoint (fall in FEV1 of 
20% or more) was not obtained. The results of the MCT were interpreted as follows: 
borderline defined as 0.4mg <PD20M<1.0 mg; mild = 0.08 mg < PD20M <0.4mg; 
moderate/severe = PD20M< 0.08mg. Borderline values for PD20M were considered negative 
in the definition of non-specific bronchial hyper responsiveness (NSBH) as previously 
described.  
6.2.6. Fractional exhaled nitric oxide (FeNO) 
A total of 654 participants performed FeNO tests (334 from SAH and 320 from TAH). A 
hand-held portable exhaled nitric oxide sampling device (NIOX MINO® Airway Inflammation 
Monitor (NIOX MINO); Aerocrine AB, Solna, Sweden) was used according to the 
manufacturer‘s instructions. Two technically adequate measurements were performed in line 
with the current American Thoracic Society /European Respiratory Society 
recommendations (21). A third maneuver was performed if the difference between the first 
two measurements was more than 10 ppb. The FeNO test was done during the work shift 
before spirometry / MCT.  
 
 
140 
 
6.2.7. Operational definitions of asthma phenotypes and host-associated risk factors 
Information on which the asthma phenotypes were based was obtained from the modified 
ECRHS questionnaire, immunological tests, spirometry (pre- and post-bronchodilator), 
methacholine challenge tests and FeNO levels.  
An asthma symptom score was computed based on the sum of answers (0=no, 1=yes) to 
five questions reported in the past 12 months. These included the presence of shortness of 
breath while wheezing; being woken up with chest tightness; an attack of shortness of breath 
at rest; an attack of shortness of breath after exercise; and being woken up by an attack of 
shortness of breath, as has been described in previous studies (22–25). A binary variable 
was created from these five asthma-related symptoms (≥ 2 symptoms vs 0-1 symptom). 
Having ≥ 2 asthma-related symptoms was considered ‗more symptomatic‘ and 0-1 symptom 
as ‗less symptomatic‘. 
Individuals with sensitization to specific occupational allergens were identified based on sIgE 
≥ 0.35 KU/L. A variable was created for sensitisation to at least one occupational allergen 
(OPA, Chlorhexidine or NRL).  
A categorical variable for NSBH was defined as any of the following two criteria: positive 
methacholine challenge test (PD20 methacholine < 0.4 mg) or significant bronchodilator 
response (≥12% and ≥ 200 ml increase in FEV1 after administration of a bronchodilator).  
Two continuous indices of MCT (continuous index of responsiveness (CIR) and dose-
response slope (DRS)) were also calculated (26). CIR = (Post-diluent FEV1 – FEV1 at the 
last dose of methacholine) ÷ Post-diluent FEV1 and DRS = (Post-diluent FEV1 – FEV1 at the 
last dose of methacholine) ÷ (Post-diluent FEV1 x Last methacholine dose). CIR and DRS 
were all multiplied by 100 to convert them into percentages.  
FeNO results were interpreted as follows: low < 25ppb; elevated for values 25 - 50ppb; and 
high for values > 50ppb, the last mentioned is generally considered to signify the presence 
of allergic airway inflammation (27). In addition to FeNO being analysed as a continuous 
variable, two categorical variables (FeNO ≥ 25 ppb and FeNO ≥ 50 ppb) were also 
computed to gain more specificity in the analysis. 
In order to further characterise the asthma phenotypes, various definitions were employed in 
the analysis. Current asthma was defined as either having an asthma attack in the past 12 
months, current use of asthma medication or woken up by an attack of shortness of breath in 
the past 12 months (8,24,28). Atopic asthma was defined as either having an asthma attack 
in the past 12 months, current use of asthma medication or woken up by an attack of 
shortness of breath in the past 12 months; and presence of atopy. Nonatopic asthma was 
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defined as either having an asthma attack in the past 12 months, current use of asthma 
medication or woken up by an attack of shortness of breath in the past 12 months; and being 
nonatopic. Work-related asthma was defined as either having an asthma attack in the past 
12 months, current use of asthma medication or woken up by an attack of shortness of 
breath in the past 12 months; and work-related chest symptoms in the past 12 months that 
gets better when away from work or worsen on return to work. 
Further information on the host-associated risk factors was based on information obtained 
from the questionnaire and immunological tests (for atopy). Body mass index (BMI) was 
calculated as weight in kilograms divided by height in metres squared. Two categorical 
variables were created for smoking history. One was a binary variable: ever smokers 
(current smokers and ex-smokers) vs never smokers. The second smoking variable was a 
nominal variable with three categories (current smokers, ex-smokers and never smokers). A 
family history of allergy was defined as a positive answer to the question ―do or did any 
member of your family (blood relatives) ever have any kind of allergies?‖. Individuals with 
atopy were defined as those subjects having a positive Phadiatop test. Hay-fever was 
defined as a positive response to the question ―have you ever had any nose or eye problems 
or allergies such as hay fever?‖. Childhood-onset asthma was defined as doctor-diagnosed 
asthma at the age of 16 years or younger. Adult-onset asthma was defined as doctor-
diagnosed asthma at the age of 17 years or older. Frequency of domestic cleaning was 
categorised as ≥1 day/week vs <1 day/week. All these items were obtained from the 
questionnaire responses. 
6.2.8. Statistical analysis 
All data analysis was performed using statistical software STATA version 14 (StataCorp, 
College Station, Texas, USA). Frequencies of categorical variables were compared between 
the two hospitals using chi-squared test. Numerical variables were summarised using 
median and interquartile range, since not all variables followed a normal distribution. 
Numerical variables were compared between the two hospitals using Wilcoxon sum rank 
test. Scatter plots, Spearman rank correlational analysis (for non-normally distributed) and 
unadjusted linear regression models were used to assess association between numerical 
variables (CIR, DRS and FeNO). Continuous indices of MCT (CIR and DRS) and FeNO 
were log transformed (natural log) before linear regression analysis was conducted.  
After conducting univariate and bivariate analyses, unadjusted logistic and linear regression 
models were run to test the association between health outcomes (e.g. asthma-related 
symptoms, NSBH, FeNO, current asthma, atopic asthma, non-atopic asthma, work-related 
asthma) and host-related risk factors (e.g. age, gender, BMI, atopy).  A negative binomial 
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regression analysis was used for the association between asthma symptom score (a count 
outcome variable) and host-related risk factors. The results of negative binomial regression 
models were reported as mean ratios with 95% confidence intervals. 
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6.3. RESULTS 
6.3.1. Asthma phenotypes 
The overall prevalence of current asthma was 10% with atopic asthma (6%) being slightly 
more prevalent than non-atopic asthma (4%) (Table 6.1). Overall, there were 2% of subjects 
with work-related asthma. While the prevalence of atopic asthma was slightly higher in the 
SAH, the prevalence of non-atopic asthma was similar in both settings. Similarly, the 
prevalence of work-related asthma was higher in the Tanzanian (3%) than the South African 
(2%) academic hospital, but these were also not statistically significant different. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
144 
 
Table 6.1: Prevalence of asthma-related outcomes among health workers in the 
tertiary hospitals  
 Overall Tertiary Hospital - 
South Africa  
N (%) 
Tertiary Hospital - 
Tanzania  
N (%) 
p-value 
(Chi-
squared 
test) 
Participants (n) 697 344 353  
Asthma symptom score     
 
<0.001 
  0 478 (69) 190 (55) 288 (82) 
  1 128 (18) 96 (28) 32 (9) 
  2 42 (6) 31 (9) 11 (3) 
  3 17 (2) 11 (3) 6 (2) 
  4 18 (3) 10 (3) 8 (2) 
  5 14 (2) 6 (2) 8 (2) 
Asthma history     
Doctor-diagnosed asthma 48 (7) 29 (8) 19 (5) 0.112 
Current use of asthma medication 39 (6) 21 (6) 18 (5) 0.564 
Asthma attack in the past 12 months 31 (5) 16 (5) 15 (4) 0.797 
Woken up by an attack of shortness of breath in the 
last 12 months 
48 (7) 26 (8) 22 (6) 0.503 
Current use of asthma medication OR 
asthma attack in the past 12 months 
44 (6) 24 (7) 20 (6) 0.477 
Work-related symptoms     
Work-related chest symptoms in the past 12 months 48 (7) 20 (6) 28 (8) 0.270 
Work-related ocular–nasal symptoms in the past 12 
months 
109 (16) 48 (14) 61 (17) 0.227 
Atopy 296 (43) 160 (47) 136 (40) 0.047 
Bronchial hyperresponsiveness     
Positive Bronchodilator response (BDR): ≥12% and 
≥200 ml FEV1 increase post-bronchodilator 
n = 207 n = 25 n = 182 NA 
26 (13) 7 (28) 19 (10) 
Methacholine challenge test: PD20 methacholine  
< 0.4 mg (n = 239) 
NA 31 (13) ND NA 
NSBH# n = 446 n = 264 n = 182 NA 
57 (13) 38 (14) 19 (10) 
Fractional exhaled nitric oxide (FeNO) n = 654 n = 334 n = 320  
FeNO (ppb) [median (IQR)] 17 (11 – 24) 17 (12 – 25) 15 (10 – 22) 0.003* 
≥25 ppb 150 (23) 83 (25) 67 (21) 0.234 
≥50 ppb 41 (6) 23 (7) 18 (6) 0.506 
Asthma phenotypes     
Current asthma 69 (10) 37 (11) 32 (9) 0.455 
Atopic asthma 41 (6) 22 (6) 19 (5) 0.583 
Non-atopic asthma 28 (4) 15 (4) 13 (4) 0.660 
Work-related asthma 17 (2) 8 (2) 9 (3) 0.848 
FEV1: forced expiratory volume in 1 second; PD20 methacholine: provocative dose of methacholine causing a ≥ 
20% fall in FEV1; NSBH: nonspecific bronchial hyperresponsiveness; #: NSBH defined as any of the following two 
criteria: PD20 methacholine < 0.4 mg OR a positive BDR defined as ≥12% and ≥ 200 ml increase in FEV1 after 
administration of a bronchodilator; *: Wilcoxon sum rank test; ND: Not done; NA: Not applicable; IQR: 
interquartile range 
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6.3.2. Association between FeNO and/or NSBH and asthma symptoms 
There was a statistically significant weak positive correlation between continuous indices of 
bronchial hyperresponsiveness (CIR: Beta coefficient (β) = 0.12; 95% Confidence Interval 
(CI): 0.03 – 0.22 and DRS: β = 0.07; 95% CI: 0.03 – 0.12) and FeNO (Table 6.2). A similar 
pattern was observed between bronchial hyperresponsiveness (CIR: Odds ratio (OR) = 1.65; 
95% CI: 1.10 – 2.47 and DRS: OR = 1.25; 95% CI: 1.06 – 1.47) and FeNO ≥25 ppb. 
However, only 3-5% of the variability in bronchial hyperresponsiveness could explain the 
FeNO levels. Further analysis found that levels of FeNO ≥ 50 ppb coupled with either a 
positive BDR (mean ratio (MR) = 5.89; 95% CI: 1.02 – 34.14) or increased  NSBH (MR = 
4.62; 95% CI: 1.16 – 18.46) was more strongly associated with asthma symptoms than 
FeNO on its own (FeNO ≥ 50 ppb: MR = 2.23; 95% CI: 1.30 – 3.85) (Table 6.3). 
Furthermore, an asthma symptom score ≥2 appeared to be a better discriminator of asthma 
symptoms than the presence of any asthma symptom. This formed the basis for further 
investigation of these outcomes with the host risk factors of interest. 
 
 
Table 6.2: Association between continuous indices of bronchial hyperresponsiveness 
and FeNO in South African health workers 
 FeNO 
 FeNO, ppb
 #
 FeNO ≥25 ppb FeNO ≥50 ppb 
 Beta coefficient (95% CI) R
2
 Odds ratio (95% CI) 
Continuous index of 
responsiveness (CIR)
#
 
 
0.12 (0.03 – 0.22)* 0.03 1.65 (1.10 – 2.47)* 1.69 (0.88 – 3.27) 
Dose-response slope (DRS)
#
 
 
0.07 (0.03 – 0.12)** 0.05 1.25 (1.06 – 1.47)** 1.18 (0.93 – 1.50) 
Each odds ratio/Beta coefficient represents a separate unadjusted regression model; CI: Confidence Interval; #: 
natural log-transformed values;*: p-value < 0.05; **: p-value < 0.01 
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Figure 6.1: Scatter plot demonstrating the association between continuous index of 
responsiveness (CIR) and FeNO in South African health workers 
 
Spearman rank correlation coefficient = 0.20 (p-value = 0.003)  
 
 
 
 
Figure 6.2: Scatter plot demonstrating the association between dose-response slope 
(DRS) and FeNO in South African health workers 
 
Spearman rank correlation coefficient = 0.20 (p-value = 0.004)  
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Table 6.3: Association between FeNO and/or bronchial hyperresponsiveness and 
asthma symptoms among health workers in the tertiary hospitals 
 Prevalence: 
n (%) 
Asthma symptoms 
Asthma symptom 
score 
Asthma symptom score 
(≥2 vs 0-1  ) 
MR (95% CI) OR (95% CI) 
Prevalence:  n (%)   91 (13) 
FeNO ≥ 25 ppb (n = 654) 150 (23) 1.53 (1.09 – 2.16)* 1.61 (0.97 – 2.66) 
FeNO ≥ 50 ppb (n = 654) 39 (6) 2.23 (1.30 – 3.85)** 3.10 (1.51 – 6.34)** 
Positive BDR (n = 207) ¶ 26 (13) 0.87 (0.27 – 2.78) 0.55 (0.12 – 2.46) 
PD20M < 0.4 mg (n = 239) # 31 (13) 1.26 (0.76 – 2.08) 1.54 (0.62 – 3.82) 
NSBH (n = 446) 57 (13) 1.17 (0.71 – 1.94) 1.16 (0.54 – 2.50) 
FeNO and/or positive BDR (n=662)    
FeNO ≥ 25 ppb OR positive BDR 168 (25) 1.31 (0.94 – 1.83) 1.32 (0.80 – 2.17) 
FeNO ≥ 25 ppb AND positive BDR 8 (1) 2.42 (0.74 – 7.90) 2.25 (0.45 – 11.35) 
FeNO ≥ 50 ppb OR positive BDR 62 (9) 1.45 (0.89 – 2.36) 1.70 (0.87 – 3.34) 
FeNO ≥ 50 ppb AND positive BDR 3 (1) 5.89 (1.02 – 34.14)* 13.64 (1.22 – 152.11)* 
FeNO and/or PD20M < 0.4 mg
#(n = 337)    
FeNO ≥ 25 ppb OR PD20M < 0.4 mg 103 (31) 1.25 (0.90 – 1.75) 1.31 (0.72 – 2.40) 
FeNO ≥ 25 ppb AND PD20M < 0.4 mg 11 (3) 1.47 (0.66 – 3.29) 1.92 (0.49 – 7.47) 
FeNO ≥ 50 ppb OR PD20M < 0.4 mg 51 (15) 1.52 (1.01 – 2.28)* 2.18 (1.09 – 4.38)* 
FeNO ≥ 50 ppb AND PD20M < 0.4 mg 2 (1) 2.01 (0.36 – 11.20) 5.06 (0.31 – 82.04) 
FeNO and/or NSBH (n=665)    
FeNO ≥ 25 ppb OR NSBH  188 (28) 1.38 (1.00 – 1.90) 1.42 (0.88 – 2.30) 
FeNO ≥ 25 ppb AND NSBH 19 (3) 2.17 (0.99 – 4.75) 2.48 (0.87 – 7.08) 
FeNO ≥ 50 ppb OR NSBH  91 (14) 1.56 (1.04 – 2.34)* 1.83 (1.03 – 3.25)* 
FeNO ≥ 50 ppb AND NSBH 5 (1) 4.62 (1.16 – 18.46)* 10.39 (1.71 – 63.11)* 
#: South African HCWs only; ¶: ≥12% and ≥200 ml FEV1 increase post-bronchodilator; MR: mean ratio; OR: odds ratio; CI: 
confidence interval; FEV1: forced expiratory volume in 1 second; PD20M: provocative dose of methacholine causing a ≥ 20% fall 
in FEV1; NSBH: nonspecific bronchial hyperresponsiveness; NSBH defined as any of the following two criteria: PD20M < 0.4 mg 
OR positive BDR: ≥12% and ≥ 200 ml increase in FEV1 after administration of a bronchodilator; *: p-value < 0.05; **: p-value < 
0.01; Each OR represents a separate unadjusted regression model 
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6.3.3. Host risk factors associated with respiratory symptoms 
In the exploration of demographic host risk factors (Table 6.4), higher mean asthma 
symptom scores were more likely to be observed in females (mean ratio (MR) = 2.03; 95% 
CI: 1.37 – 3.00), those with a higher BMI (MR = 1.04; 95% CI: 1.02 – 1.06), atopic 
individuals (MR = 1.74; 95% CI: 1.30 – 2.33), with family history of allergy (MR = 2.11; 95% 
CI: 1.58 – 2.82) and a past history of hay fever (MR = 2.61; 95% CI: 1.97 – 3.47) and they 
were more likely to have suffered from chronic bronchitis (MR = 2.79; 95% CI: 1.69 – 4.60) 
and pulmonary tuberculosis (PTB) (MR = 2.21; 95% CI: 1.21 - 4.06). In addition, participants 
who were more symptomatic (≥ 2 asthma-related symptoms) were more likely to have ever 
smoked (OR = 1.99; 95% CI: 1.13 – 3.49), when compared to those who were less 
symptomatic (0 – 1 asthma-related symptom).  
Workers with work-related ocular-nasal symptoms (WRONS) in the past 12 months had an 
8-fold increased odds (OR = 8.16; 95% CI: 4.84 – 13.76) of past history of hay fever. 
Participants with work-related asthma symptoms (WRAS) in the past 12 months were also 
more likely to be females (OR = 3.25; 95% CI: 1.15 – 9.19), have a previous history of hay 
fever (OR = 3.03; 95% CI: 1.61 – 5.69) or PTB (OR = 4.26; 95% CI: 1.74 – 10.44) and were 
also more likely to have had adult-onset asthma (OR = 10.42; 95% CI: 4.59 – 23.67).  
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Table 6.4: Host risk factors associated with respiratory symptoms among health workers in the tertiary hospitals  
 Prevalence: 
n (%) 
Asthma symptom 
score
##
 
Asthma symptom score 
(≥2 vs 0-1) 
WRONS WRAS 
Prevalence: n (%) (n = 697)   91 (13) 109 (16) 48 (7) 
Demographic characteristics      
Age  1.01 (1.00 – 1.03) 1.02 (1.00 – 1.04)* 0.99 (0.97- 1.01) 1.00 (0.97 – 1.03) 
Gender (Females vs Males):   2.03 (1.37 – 3.00)*** 1.98 (1.05 - 3.74)* 1.12 (0.68– 1.86) 3.25 (1.15 – 9.19)* 
BMI  1.04 (1.02 – 1.06)** 1.04 (1.01 – 1.08)** 0.99 (0.96– 1.02) 1.00 (0.96 – 1.04) 
Smoking history      
Smoking (ever) ǂǂ 90 (13) 1.48 (0.99 – 2.23) 1.99 (1.13 – 3.49)* 1.30 (0.74– 2.31) 0.60 (0.21– 1.70) 
Current smoking 42 (6) 1.48 (0.83 – 2.63) 1.75 (0.78 – 3.92) 1.75 (0.83 – 3.68) 0.31 (0.04 – 2.32) 
Allergy history      
Family history of allergy 353 (51) 2.11 (1.58 – 2.82)*** 2.60 (1.61 – 4.19)*** 1.13 (0.75 – 1.70) 1.16 (0.65– 2.10) 
Atopy (positive Phadiatop) 296 (43) 1.74 (1.30 – 2.33)*** 2.40 (1.52 – 3.79)*** 1.33 (0.88 – 2.02) 1.67 (0.92– 3.02) 
Medical history      
Hay fever 306 (44) 2.61 (1.97 – 3.47)*** 4.03 (2.47 – 6.56)*** 8.16 (4.84 - 13.76)*** 3.03 (1.61 – 5.69)** 
Childhood-onset (≤16 yrs) asthma 19 (3) 4.35 (2.17 - 8.74)*** 13.00 (4.97 – 33.99)*** 0.63 (0.14 – 2.76) 2.64 (0.74 – 9.39) 
Adult-onset (>16 yrs) asthma 29 (4) 4.57 (2.63 – 7.93)*** 9.73 (4.51 – 21.02)*** 1.77 (0.74– 4.24) 10.42 (4.59 – 23.67)*** 
Repeated childhood chest infections 76 (11) 1.53 (0.99 – 2.37) 1.76 (0.96 – 3.26) 1.66 (0.93– 2.97) 1.71 (0.77– 3.80) 
Chronic bronchitis 44 (6) 2.79 (1.69 – 4.60)*** 3.49 (1.77 – 6.87)*** 1.89 (0.92 – 3.86) 2.30 (0.92– 5.74) 
Pulmonary tuberculosis 32 (5) 2.21 (1.21 - 4.06)* 4.45 (2.10 – 9.45)*** 1.26 (0.51– 3.14) 4.26 (1.74 – 10.44)** 
Domestic chemical exposures      
Home cleaning in the past 12 months (≥1 day vs <1 day/week) 601 (86) 1.54 (0.98 – 2.44) 1.76 (0.82 – 3.77) 0.92 (0.51 – 1.64) 1.40 (0.54 – 3.64) 
Use of sprays for home cleaning in the past 12 months  
(≥1 day vs <1 day/week) 
218 (31) 1.47 (1.08 – 1.99)* 1.37 (0.87 – 2.16) 0.90 (0.57 – 1.41) 0.81 (0.42 – 1.55) 
Data are presented as OR (95% CI), unless otherwise indicated. ##: MR (95% CI); OR: odds ratio; CI: confidence interval; MR: mean ratio; *: p-value < 0.05; **: p-value < 0.01; ***: p-value < 0.001; ǂǂ: current & ex-smokers vs 
never smokers; WRONS: Work-related ocular–nasal symptoms (ocular–nasal symptoms experienced at work in the past 12 months that gets better when away from work OR worsen on return to work; WRAS: Work-related 
asthma symptoms (asthma symptoms experienced at work in the past 12 months that gets better when away from work OR worsen on return to work; Each OR represents a separate unadjusted regression model 
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6.3.4. Host risk factors associated with allergic sensitisation to occupational allergens 
All (except one) of the study participants who were sensitised to either one of the 
occupational allergens (OPA, chlorhexidine and NRL) were atopic. Individuals sensitised to 
OPA were more likely to have lower BMI (OR = 0.92; 95% CI: 0.86 – 0.99) (Table 6.5). 
Participants who were sensitised to at least one occupational allergen (OPA, NRL or 
chlorhexidine) had a 2-fold increased odds (OR = 2.09; 95% CI: 1.03 – 4.24) of having 
medical history of hay fever.  
 
Table 6.5: Host risk factors associated with allergic sensitisation to occupational 
allergens among health workers in the tertiary hospitals  
 Prevalence: 
n (%) 
Sensitisation to OPA   
 
Sensitisation to at least one 
occupational allergen 
Prevalence: n (%) (n = 682)  26 (4) 34 (5) 
Demographic characteristics    
Age  0.98 (0.94 – 1.01) 0.98 (0.95 – 1.02) 
Gender (Females vs Males)  1.53 (0.52– 4.52) 1.06 (0.45 – 2.49) 
BMI  0.92 (0.86 – 0.99)* 0.95 (0.89 – 1.00) 
Smoking history    
Smoking (ever) ǂǂ 90 (13) 0.26 (0.04– 1.98) 0.90 (0.31 – 2.63) 
Current smoking 42 (6) 0.57 (0.08– 4.30) 1.48 (0.43 – 5.08) 
Allergy history    
Family history of allergy 353 (51) 1.36 (0.61 –3.00) 1.26 (0.63– 2.52) 
Atopy (positive Phadiatop) 296 (43) 35.52 (4.78 – 263.70)*** 48.31 (6.57 – 355.39)*** 
Medical history    
Hay fever 306 (44) 2.05 (0.92– 4.58) 2.09 (1.03 – 4.24)* 
Childhood-onset (≤16 yrs) asthma 19 (3) NC NC 
Adult-onset (>16 yrs) asthma 29 (4) 3.15 (0.89 – 11.17) 2.31 (0.66 – 8.04) 
Repeated childhood chest infections 76 (11) 1.05 (0.31– 3.60) 0.77 (0.23 – 2.59) 
Chronic bronchitis 44 (6) NC 0.90 (0.21– 3.88) 
Pulmonary tuberculosis 32 (5) 0.80 (0.11– 6.13) 1.28 (0.29 – 5.61) 
Domestic chemical exposures    
Home cleaning in the past 12 months  
(≥1 day vs < 1 day/week) 
601 (86) 0.89 (0.30– 2.64) 0.94 (0.35 – 2.49) 
Use of sprays for home cleaning in the past 12 months 
(≥1 day vs <1 day/week) 
218 (31) 0.80 (0.33 – 1.92) 1.04 (0.50 – 2.18) 
Data presented as OR (95% CI); OR: odds ratio; CI: confidence interval; *: p-value < 0.05; **: p-value < 0.01; ***: p-value < 0.001; ǂǂ: current & 
ex-smokers vs never smokers; NC: not calculable; Each OR represents a separate unadjusted logistic regression model 
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6.3.5. Host risk factors associated with bronchial hyperresponsiveness and FeNO 
Bronchial hyperresponsiveness (increased DRS) was associated with being female 
(Geometric mean ratio (GM ratio) = 3.40; 95% CI: 1.72 – 6.73), atopic (GM ratio = 1.83; 95% 
CI: 1.08 – 3.10), history of hay fever (GM ratio = 2.01; 95% CI: 1.19 – 3.39), childhood-onset 
asthma (GM ratio = 9.01; 95% CI: 1.59 – 50.93) and chronic bronchitis (GM ratio = 2.61; 
95% CI: 1.20 – 5.67) (Table 6.6). Participants with NSBH were twice as likely (OR = 2.41; 
95% CI: 1.07 – 5.42) to have history of chronic bronchitis as those without NSBH. Atopy (GM 
ratio = 1.38; 95% CI: 1.25 – 1.52), history of hay fever (GM ratio = 1.16; 95% CI: 1.05 – 1.28) 
and childhood-onset asthma (GM ratio = 1.49; 95% CI: (1.11 – 1.99) were associated with 
increased FeNO. On the other hand, current smoking (GM ratio = 0.76; 95% CI: 0.62 – 0.94) 
and being female (GM ratio = 0.87; 95% CI: 0.77 – 0.98) was associated with lower FeNO. 
Participants with FeNO ≥ 50 ppb were more likely to be atopic (OR = 3.19; 95% CI: 1.59 – 
6.39) and have a history of hay fever (OR = 2.05; 95% CI: 1.08 – 3.93). 
 
Table 6.6: Host risk factors associated with bronchial hyperresponsiveness and FeNO 
among health workers in the tertiary hospitals 
 Prevalence: 
n (%) 
Dose-response 
slope (DRS)
ǂ
 
(n = 239) 
NSBH 
 
(n = 446) 
FeNO, ppb
ǂ
 
 
(n = 654) 
FeNO≥ 50 ppb 
 
(n = 654) 
Prevalence: n (%)   57 (13)  41 (6) 
Demographic characteristics      
Age  1.00 (0.98 – 1.03) 1.02 (0.99 – 1.05) 1.00 (1.00 – 1.01) 0.99 (0.96 – 1.02) 
Gender (Females vs Males)  3.40 (1.72 – 6.73)*** 2.08 (0.91 – 4.75) 0.87 (0.77 – 0.98)* 0.84 (0.40 – 1.76) 
BMI  0.98 (0.96 – 1.01) 1.00 (0.97 – 1.03) 1.00 (1.00 – 1.01) 1.01 (0.98– 1.04) 
Smoking history      
Smoking (ever) ǂǂ 90 (13) 0.88 (0.48 - 1.61) 1.07 (0.50 – 2.29) 0.88 (0.76 – 1.02) 0.16 (0.02 – 1.16) 
Current smoking 42 (6) 1.02 (0.46 - 2.26) 0.98 (0.33 – 2.92) 0.76 (0.62 – 0.94)** 0.34 (0.05 – 2.52) 
Allergy history      
Family history of allergy 353 (51) 1.25 (0.72 – 2.18) 1.01 (0.58 - 1.77) 1.04 (0.94 - 1.15) 1.21 (0.64 – 2.29) 
Atopy (positive Phadiatop) 296 (43) 1.83 (1.08 – 3.10)* 1.22 (0.70– 2.12) 1.38 (1.25 – 1.52)*** 3.19 (1.59 – 6.39)** 
Medical history      
Hay fever 306 (44) 2.01 (1.19 – 3.39)** 1.16 (0.67 - 2.03) 1.16 (1.05 – 1.28)** 2.05 (1.08 – 3.93)* 
Childhood-onset (≤16 yrs) asthma 19 (3) 9.01 (1.59 – 50.93)* 1.74 (0.48 – 6.37) 1.49 (1.11 - 1.99)** 2.94 (0.82– 10.52) 
Adult-onset (>16 yrs) asthma 29 (4) 2.91 (0.88 – 9.61) 0.71 (0.16 - 3.12) 1.22 (0.95 - 1.57) 1.93 (0.56 – 6.70) 
Repeated childhood chest 
infections 
76 (11) 1.31 (0.49 – 3.49) 0.56 (0.19 – 1.62) 1.03 (0.87 – 1.20) 1.17 (0.44 – 3.08) 
Chronic bronchitis 44 (6) 2.61 (1.20 – 5.67)* 2.41 (1.07 – 5.42)* 1.19 (0.98 – 1.46) 1.13 (0.33 – 3.81) 
Pulmonary tuberculosis 32 (5) 0.46 (0.14 – 1.44) 0.35 (0.05 – 2.64) 1.10 (0.87 – 1.39) 1.03 (0.24– 4.47) 
Domestic chemical exposures      
Home cleaning in the past 12 
months (≥1 day vs < 1 day/week) 
601 (86) 3.12 (0.84 – 11.62) 1.83 (0.63 – 5.28) 0.95 (0.82 – 1.09) 1.16 (0.44 – 3.05) 
Use of sprays for home cleaning in 
the past 12 months  
(≥1 day vs <1 day/week) 
218 (31) 1.28 (0.74 – 2.21) 1.71 (0.98 – 2.99) 1.13 (1.01 – 1.25)* 1.09 (0.56 – 2.12) 
Data presented as OR (95% CI), unless otherwise indicated; OR: odds ratio; CI: confidence interval; ǂ: Geometric mean ratio (95% CI); *: p-value 
< 0.05; **: p-value < 0.01; ***: p-value < 0.001; ǂǂ: current & ex-smokers vs never smokers; NSBH: nonspecific bronchial hyperresponsiveness; 
NSBH defined as any of the following two criteria: PD20 methacholine < 0.4 mg OR positive BDR: ≥12% and ≥ 200 ml increase in FEV1 after 
administration of a bronchodilator; Each OR represents a separate unadjusted regression model 
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6.3.6. Host risk factors associated with asthma phenotypes 
Participants with current asthma were more likely to be atopic (OR = 2.04; 95% CI: 1.23 – 
3.39), with family history of allergy (OR = 2.25; 95% CI: 1.32 – 3.82), history of hay fever 
(OR = 2.30; 95% CI: 1.38 – 3.83), repeated childhood chest infections (OR = 2.08; 95% CI: 
1.08 – 4.02), chronic bronchitis (OR = 3.42; 95% CI: 1.64 – 7.12) and PTB (OR = 3.95; 95% 
CI: 1.75 – 8.91) (Table 6.7). Atopic asthma was positively associated with family history of 
allergy (OR = 2.48; 95% CI: 1.24 – 4.94), history of hay fever (OR = 2.93; 95% CI: 1.49 – 
5.76), repeated childhood chest infections (OR = 2.47; 95% CI: 1.13 – 5.40), chronic 
bronchitis (OR = 3.44; 95% CI: 1.43 – 8.29) and skin symptoms (OR = 2.25; 95% CI: 1.19 – 
4.25). Participants with non-atopic asthma were more likely to be smoking (OR = 3.77; 95% 
CI: 1.35 – 10.57) and have had PTB (OR = 6.75; 95% CI: 2.52 – 18.05). Work-related 
asthma was positively associated with atopy (OR = 3.20; 95% CI: 1.12 – 9.19), history of hay 
fever (OR = 3.15; 95% CI: 1.10 – 9.04) and PTB (OR = 10.08; 95% CI: 3.31 – 30.64). 
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Table 6.7: Host risk factors associated with asthma phenotypes among health workers in the tertiary hospitals 
 Prevalence: 
n (%) 
Current asthma Atopic Asthma Non-atopic Asthma Work-related Asthma 
Prevalence: n (%) (n = 697)  69 (10) 41 (6) 28 (4) 17 (2) 
Demographic characteristics      
Age  1.03 (1.01 – 1.06)* 1.02 (0.99 – 1.05) 1.04 (1.00 - 1.08)* 1.01 (0.97– 1.06) 
Gender (females vs males)  1.72 (0.86 – 3.46) 2.68 (0.94 – 7.65) 1.02 (0.41– 2.56) NC 
BMI   1.02 (1.00 – 1.05) 1.03 (1.00– 1.06) 1.01 (0.96 – 1.05) 1.03 (0.99 – 1.06) 
Smoking history      
Smoking (ever) ǂǂ 90 (13) 1.32 (0.66 – 2.62) 0.72 (0.25– 2.06) 2.35 (0.97 – 5.71) 0.42 (0.05 – 3.17) 
Current smoking 42 (6) 1.89 (0.81 – 4.45) 0.77 (0.18– 3.31) 3.77 (1.35 – 10.57)* 0.90 (0.12– 6.96) 
Allergy history      
Family history of allergy 353 (51) 2.25 (1.32 – 3.82)** 2.48 (1.24 – 4.94)* 1.80 (0.82– 3.95) 1.40 (0.53– 3.73) 
Atopy (positive Phadiatop) 296 (43) 2.04 (1.23 – 3.39)** NA NA 3.20 (1.12 – 9.19)* 
Medical history      
Hay fever 306 (44) 2.30 (1.38 – 3.83)** 2.93 (1.49 – 5.76)** 1.50 (0.70 – 3.20) 3.15 (1.10 – 9.04)* 
Childhood-onset (≤16 yrs) asthma 19 (3) 31.72 (11.01 – 91.33)*** 29.70 (11.13 – 79.26)*** 4.90 (1.34 – 17.90)* 8.89 (2.32 – 34.03)** 
Adult-onset (>16 yrs) asthma 29 (4) 51.83 (20.11 – 133.63)*** 15.55 (6.80 – 35.58)*** 23.40 (9.60 – 57.06)*** 37.13 (12.98 – 106.21)*** 
Repeated childhood chest infections 76 (11) 2.08 (1.08 – 4.02)* 2.47 (1.13 – 5.40)* 1.38 (0.47– 4.10) 1.78 (0.50 - 6.35) 
Chronic bronchitis 44 (6) 3.42 (1.64 – 7.12)** 3.44 (1.43 – 8.29)** 2.62 (0.87– 7.92) 2.03 (0.45– 9.15) 
Pulmonary tuberculosis 32 (5) 3.95 (1.75 – 8.91)** 1.71 (0.50– 5.86) 6.75 (2.52 – 18.05)*** 10.08 (3.31 – 30.64)*** 
Skin symptoms      
Skin symptoms (ever) 215 (31) 1.51 (0.90 – 2.51) 2.25 (1.19 – 4.25)* 0.74 (0.31– 1.77) 0.93 (0.32 – 2.68) 
Two or more episodes of skin symptoms in the last 12 months 125 (18) 1.31 (0.71 – 2.40) 1.52 (0.72 – 3.18) 1.00 (0.37 – 2.67) 1.42 (0.46– 4.44) 
Symptoms affecting hands or forearms# 86 (12) 1.40 (0.70 – 2.78) 1.50 (0.65– 3.51) 1.19 (0.40 – 3.53) 1.54 (0.43 – 5.48) 
Symptoms affecting the whole body# 36 (5) 0.82 (0.25– 2.75) 1.49 (0.44– 5.08) NC 2.53 (0.56 – 11.53) 
Work-related skin symptoms (ever) 130 (19) 1.49 (0.83 – 2.67) 1.89 (0.94– 3.81) 0.95 (0.35 – 2.54) 0.93 (0.26 – 3.30) 
Work-related skin symptoms in the past 12 months 80 (12) 1.18 (0.56– 2.47) 1.35 (0.55– 3.31) 0.92 (0.27 – 3.13) 0.48 (0.06 – 3.63) 
Doctor-diagnosed work-related skin symptoms (ever) 20 (3) 1.63 (0.47– 5.72) 2.97 (0.83 – 10.57) NC 2.17 (0.27 – 17.25) 
Domestic chemical exposures      
Home cleaning in the past 12 months (≥1 day vs <1 day/week) 601 (86) 0.94 (0.46 – 1.90) 1.51 (0.53– 4.33) 0.57 (0.23– 1.44) 1.20 (0.27 - 5.35) 
Use of sprays for home cleaning in the past 12 months  
(≥1 day vs <1 day/week) 
218 (31) 1.11 (0.66 – 1.88) 1.44 (0.75 – 2.75) 0.72 (0.30 – 1.73) 0.91 (0.32 – 2.63) 
Data presented as OR (95% CI); OR: odds ratio; CI: confidence interval; *: p-value < 0.05; **: p-value < 0.01; ***: p-value < 0.001; ǂǂ: current & ex-smokers vs never smokers; #: presence of itchy/scratchy skin, hives, dry/scaly 
skin, redness of the skin, blisters/weeping skin or burning skin; NC: not calculable; NA: not applicable; Each OR represents a separate unadjusted logistic regression model 
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6.4. DISCUSSION 
In this study of health workers employed in two tertiary academic hospitals in sub-Saharan 
Africa, the prevalence of atopic asthma was found to be more prevalent than non-atopic 
asthma. Furthermore, most asthma-related outcomes and work-related symptoms were 
positively associated with host attributes of allergic disease further suggesting a more 
dominant role of allergic mechanisms in asthma and work-related symptoms experienced by 
these HWs. The weak, but positive association between NSBH and FeNO suggests that 
these two outcomes detect different underlying pathophysiological mechanisms that produce 
different asthma phenotypes. The stronger associations were also observed for asthma 
symptoms when FeNO ≥ 50 ppb (a marker of allergic airway inflammation) was combined 
with NSBH (BDR or MCT positive). Furthermore, atopic individuals were also more likely to 
be sensitised to LMW agents such as OPA and chlorhexidine, an association commonly 
observed with HMW agents. 
The prevalence of current asthma (10%) observed in this study was similar to the Spanish 
study (11%) of professional cleaners (including hospital cleaners) (24) but higher than that 
reported among nurses (6%) in a general population study of 13 European countries (8). The 
definition of current asthma used in the current study was similar to the two European 
studies (8,24). The reported prevalence of asthma among HWs has varied as has been 
reported for other occupational groups probably due to the different asthma definitions used 
in these studies (29). However, in this current study, the prevalence of atopic asthma (6%) 
was similar to that reported in South African dental HWs (6.9%) (30). On the other hand, the  
prevalence of non-atopic asthma in this current study (4%) was slightly lower than that 
reported in the South African dental HWs (5.9%). (30). Furthermore, the prevalence of work-
related asthma (2%) in this study was on the lower end of the spectrum of prevalence (3 – 
13%) reported from recent workplace based studies in South Africa (12,31,32). 
It is interesting to note that, in this study, atopic asthma (6%) was more prevalent than non-
atopic asthma (4%). In addition, most asthma-related outcomes (DRS, asthma symptom 
score and current asthma) and work-related outcomes (WRONS, WRAS and work-related 
asthma) were positively associated with allergic disease attributes (atopy, history of hay 
fever, family history of allergy and FeNO). In this study, there was also a weak positive 
association between bronchial hyperresponsiveness (MCT+BDR) and FeNO. Similar 
findings have been observed in corticosteroid-naive patients with normal FEV1 on baseline 
spirometry (33). These findings suggest different underlying pathophysiological mechanisms 
that co-exist. However, it would appear that allergic mechanisms may be playing a more 
dominant role in work-related asthma in these HWs. The pathophysiological mechanisms 
involved in asthma related to cleaning agents are still not yet clear for most of the cleaning 
155 
 
chemicals. Previous studies have suggested involvement of both allergic and irritant 
mechanisms although the latter has been generally thought to be the dominant mechanism 
(6,34). Furthermore, it is probable that both these mechanisms may enhance each other, 
such that airway epithelial damage due to irritant exposures can also activate an allergic T 
helper type 2 (Th2) response and increase the risk of sensitisation (6,34).  
In this current study, stronger associations were observed for asthma symptoms when FeNO 
≥ 50 ppb (a marker of allergic airway inflammation) was combined with NSBH (BDR or MCT 
positive). Furthermore, stronger associations were also observed between sensitisation to 
occupational allergens and atopy. With exception of one non-atopic participant who was 
sensitised to OPA, all the remaining participants who were sensitised to occupational 
allergens (OPA, chlorhexidine and NRL) were atopic (data not shown). While several studies 
have observed a higher likelihood of atopic individuals developing sensitisation to high 
molecular weight occupational allergens such as natural rubber latex (30–32,35), this 
association has not been observed with low molecular weight occupational allergens such as 
OPA and chlorhexidine, although, serum specific IgE antibodies to OPA and chlorhexidine 
have been detected in a few studies of individuals exposed to these agents (36–39). 
Furthermore, animal studies have suggested that OPA is a respiratory and dermal sensitiser 
as was evidenced by a predominant expression of Th2 cytokines (IL-4, IL-5 and IL-13) in 
mice that were exposed to OPA (40,41). In addition, the clinical history in the case reports of 
asthma due to OPA also demonstrated a latency period between first exposure to OPA and 
development of symptoms implying immunologic response caused by OPA (42,43). 
Interestingly, animal studies have also suggested that OPA is more irritant than GTA using 
both in-vitro EpiDerm Skin Irritation Test and in-vivo tests (40). In addition to being 
consistent with an immunological mechanism, this further suggests that the mechanism is 
probably IgE-mediated. Future studies should investigate this further so as to have a better 
understanding of the underlying pathophysiological mechanisms associated with asthma to 
these agents. 
As to be expected, FeNO (a non-invasive marker of eosinophilic airway inflammation) was 
positively associated with allergic predictors (atopy and history of hay fever) and a history of 
childhood-onset asthma. Even stronger associations were observed with high FeNO (≥50 
ppb) levels. A positive association between FeNO and atopy is well-known and has also 
been reported in recent South African studies in other occupational exposure contexts 
(30,44,32), while the few studies that have conducted FeNO studies in Tanzania did not 
assess the role of atopy (45,46). Furthermore, a strong positive association (ORunadj = 3.59, 
CI: 1.63 – 7.93; ORadj (atopy + smoking) = 1.93, CI: 0.85 – 4.37) was also observed between 
elevated FeNO (≥25 ppb) and allergic sensitisation to OPA / chlorhexidine (data not shown). 
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Much stronger relationships have been demonstrated in workplace-based studies among 
South African workers exposed to predominantly high molecular weight agents (30,44).  
In this current study, a positive association was observed between female gender and 
asthma-related outcomes (asthma symptom score, WRAS and DRS). New-onset asthma in 
adulthood has been shown to be more prevalent amongst women with female sex hormones 
implicated in the pathogenesis (1). Furthermore, this could also be explained by the 
gendered distribution of the workforce, since a large proportion (78%) of study participants 
were women. This is consistent with other studies of asthma and occupational exposures to 
cleaning agents that have reported an increased risk amongst women as they are more 
likely to be exposed to cleaning agents than men (16,47,48).  
Interestingly, in the current study, a past history of pulmonary tuberculosis (TB) was strongly 
associated with asthma symptoms, current asthma as well as work-related asthma. This 
association persisted even after adjusting for age, gender, smoking, atopy and body mass 
index. Similar findings have also been reported in South African population-based and 
workplace-based studies (49). In a recent study among adults exposed to a sulphur stockpile 
fire incident, a past history of TB (more than one year prior to the fire) was an important 
predictor for chronicity of asthma-related symptoms (50). Due to the cross-sectional nature 
of this current study, it was not possible to establish a temporal relationship between TB and 
asthma-related outcomes. However, since all of the asthma-related outcomes were based 
on recent symptoms (past 12 months), it is probable that the TB preceded the symptoms. 
This observation needs further exploration in a larger longitudinal study of these health 
workers. 
In this study, smoking was positively associated with asthma symptom score (≥2 vs 0-1) as 
well as with non-atopic asthma. However, smoking was not associated with allergic 
sensitisation to occupational allergens, NSBH, current asthma, work-related ocular-nasal 
symptoms nor with work-related asthma. This is consistent with the current body of evidence 
of asthma on the association between smoking and occupational asthma (1,6,51). While 
some studies have demonstrated that smoking at baseline increased the risk of incident 
asthma in adulthood, no significant association was reported in a follow-up cross-sectional 
analysis (52). Overall, various studies have reported inconsistent findings of the association 
between smoking and asthma in general and with occupational asthma in particular (1,51). 
Furthermore, very limited specific information is available on the risk of smoking in relation to 
asthma among HWs exposed to cleaning agents (51,53). The study by Zock et al. in 
cleaning workers did not demonstrate any association between smoking and asthma (53). 
Additional longitudinal studies are needed to better understand this relationship between 
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smoking, occupational allergic sensitisation and asthma risk among health workers exposed 
to cleaning agents. 
Despite the major strengths of this study in using additional objective markers for asthma, 
there were some limitations of the methodology. Some of the asthma phenotypes such as 
current asthma, asthma symptom score and work-related asthma were based on self-
reported information from the questionnaire. This could have resulted in misclassification of 
asthma status. Self-reported symptom information is usually characterised by high sensitivity 
but low specificity in identifying individuals with asthma. However, in this study, self-reported 
asthma information obtained from a standardised questionnaire correlated relatively well with 
NSBH and FeNO, suggesting that this did not impact significantly on the results obtained. 
 
6.5. CONCLUSION 
This study has demonstrated that atopic asthma was more prevalent than non-atopic 
asthma. Furthermore, most asthma-related outcomes and work-related symptoms were 
positively associated with allergic attributes suggesting a more dominant role of allergic 
mechanisms in asthma and work-related symptoms experienced by these HWs. The 
stronger associations observed for asthma symptoms when high FeNO (≥ 50 ppb) was 
combined with NSBH (BDR + MCT), together with the finding that atopic individuals were 
more likely to be sensitised to LMW occupational allergens such as OPA and chlorhexidine, 
further suggests an IgE mediated mechanism underlying the asthma reported in this group 
of HWs. 
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Chapter 7 
Environmental risk factors for asthma among health workers exposed to specific cleaning 
agents in two large tertiary hospitals in South Africa and Tanzania 
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ABSTRACT 
Background: Previous studies have demonstrated an association between asthma-related 
outcomes and broad categories of cleaning-related exposures in health care settings. 
However, there is little information on the specific cleaning agents and tasks associated with 
various asthma-related outcomes. Furthermore, very limited information exists regarding 
exposure-response relationships between the frequency of exposure to specific cleaning 
agents and asthma-related outcomes. This study investigated the environmental risk factors 
and exposure response relationships for various asthma-related outcomes among HWs 
exposed to diverse cleaning agents in two academic tertiary hospitals in South Africa and 
Tanzania. 
Methods: A cross-sectional study of 699 HWs was conducted in two large tertiary hospitals. 
A total of 697 participants completed questionnaire interviews, which contained information 
on asthma, based on the ECRHS study, as well as detailed information on tasks and 
chemicals used during the course of their work. Sera was collected from 682 HWs and 
analysed for specific immunoglobulin E (sIgE) antibody reactivity to common aero-allergens 
(Phadiatop) and specific occupational allergens (NRL - Hevea brasiliensis (Hev b5, Hev 
b6.02), chlorhexidine and OPA). Methacholine challenge tests (MCT) were performed on all 
South African HWs (n=318), based on standard inclusion criteria. Spirometry, accompanied 
by a post-bronchodilator (post-BD) test was conducted on all Tanzanian HWs (n=329) and a 
small proportion (n=25) of South African HWs (SAHWs) where MCT was contraindicated. All 
HWs from both hospitals (n=654) underwent fractional exhaled nitric oxide (FeNO) testing 
during the working day prior to spirometry. An asthma symptom score was computed based 
on the sum of answers to five questions on asthma-related symptoms in the past 12 months. 
Nonspecific bronchial hyperresponsiveness (NSBH) was defined as either positive MCT 
(PD20 methacholine < 0.4 mg) or presence of a significant bronchodilator response - BDR 
(≥12% and ≥ 200 ml increase in FEV1 after administration of a bronchodilator). A continuous 
index of NSBH (dose-response slope - DRS) was calculated from MCT results. For 
exposure-response analyses, cleaning-related predictor variables were categorised into 3 
levels (cleaning product not used; use of a cleaning product for up to 99 minutes per week 
and use of a cleaning product for ≥ 100 minutes per week). 
Results: Asthma-related outcomes (increasing asthma symptom score and FeNO) 
demonstrated consistent positive associations with certain medical instrument cleaning 
agents (OPA, QACs and enzymatic cleaners) and tasks (pre-cleaning of medical 
instruments, changing sterilisation solutions and manual disinfection of medical instruments) 
as well as certain patient care activities (disinfection prior to procedures, 
cleaning/disinfecting wounds, application of wound dressing, usage of adhesives and 
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adhesive removing solvents). A particularly pronounced dose-response relationship was 
observed between work-related ocular-nasal symptoms and medical instrument cleaning 
agents (OPA, glutaraldehdye, QACs, enzymatic cleaners, alcohols and bleach; OR range: 
2.50 – 12.08) and tasks (OR range: 2.58 – 3.97). Furthermore, a strong association was 
observed between higher asthma symptom scores and use of more sprays than wipes for 
fixed surface cleaning activities (mean ratio = 3.00; 95% CI: 1.50 – 5.98).  
Conclusion: Specific cleaning agents such as OPA, quaternary ammonium compounds and 
enzymatic cleaners associated with medical instrument cleaning/disinfection as well as 
patient care activities and the use of sprays for fixed surface cleaning are important 
environmental risk factors, for various asthma-related outcomes among health workers in 
health care settings. 
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7.1. INTRODUCTION 
Previous studies have demonstrated an association between asthma or respiratory 
symptoms and broad categories of cleaning-related exposures in health care settings 
involved with medical instrument cleaning and disinfection, fixed surfaces cleaning and 
disinfection, floor finishing tasks (stripping, waxing and buffing), patients‘ skin/wound 
cleaning and disinfection and hand washing/sanitising activities (1–4). However, only a few 
epidemiological studies and case reports have identified the specific cleaning agents related 
to asthma and other health outcomes (5–7).  
Products used for medical instrument cleaning and disinfection such as glutaraldehyde, 
ortho-phthalaldehyde (OPA) and quaternary ammonium compounds (QACs) have been 
implicated in the causation and exacerbation of work-related asthma and upper airway 
outcomes such as rhinitis (7–10). Little is known regarding exposure-response relationships 
between exposure to specific cleaning agents and asthma-related outcomes. A few studies 
have only reported exposure-response relationships for broad categories of cleaning-related 
exposures with very limited information on specific cleaning agents (e.g. OPA) used for 
medical instrument cleaning and disinfection (6). Arif et al. demonstrated exposure-response 
relationships for work-exacerbated asthma in HWs who used disinfectants for medical 
instrument disinfection (6). In recent years, there has been an increase in the use of 
enzymatic cleaners for pre-cleaning of medical instruments prior to high-level disinfection in 
various health care settings (11,12). Two studies have reported cases of occupational 
asthma and rhinitis among HWs using enzymatic cleaners (12,13). Hydrogen peroxide and a 
mixture of hydrogen peroxide, peracetic acid and acetic used for high-level disinfection of 
medical instruments have also been linked to respiratory and ocular symptoms (14,15).  
Several studies have reported an association between asthma and fixed surface cleaning 
products such as ammonia and bleach (5–7,10,16–18). A Spanish study among cleaning 
workers employed in various settings including hospitals, reported an increased risk of 
asthma symptoms in workers using hydrochloric acid (mean ratio [MR] = 1.7; 95% CI: 1.1 to 
2.6), degreasers (MR = 1.6; 95% CI: 1.0 to 2.4), air fresheners (MR = 1.5; 95% CI: 1.0 to 
2.4) or ammonia (MR = 1.6; 95% CI: 1.0 to 2.5) in the last year (16). Recently, Dumas et al. 
(7) demonstrated an association between poor asthma control and exposure to hypochlorite 
bleach among US nurses. A previous US study demonstrated exposure-response 
relationships between use of cleaning agents for fixed surfaces cleaning/disinfection and 
work-related asthma symptoms (6). Medina-Ramon et al. demonstrated dose-response 
relationship between use of bleach and asthma among domestic cleaners in Spain (19). 
Similarly, Zock et al. demonstrated dose-response relationships for asthma with the 
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frequency of use of cleaning sprays as well as with increasing number of the types of sprays 
used (20). 
In order to adhere to strict infection prevention standards in health care settings, HWs wash 
and sanitise their hands quite frequently, using products such as alcohols, chlorhexidine and 
povidone iodine (21–23). Alcohols, chlorhexidine and povidone iodine are the most 
commonly reported agents used for hand hygiene (21–23). Chlorhexidine is well known for 
its sensitising and irritating properties to both the skin and airways (21–23). Previous studies 
have reported cases of occupational asthma and dermatitis due to chlorhexidine (21–23). 
Alcohols are potential respiratory and skin irritants. Povidone iodine is a well-known skin 
irritant but its sensitising properties have not been well characterised (24). There is little 
information from epidemiological studies regarding the potential respiratory risks associated 
with hand hygiene practices among HWs, with very limited focus on exposure-response 
relationships (23). In a recent study by Dumas et al., poor asthma control was positively 
associated with increased frequency of hand hygiene practices among US nurses, with clear 
dose-response relationship demonstrated for surgical hand/arm hygiene (23). 
Patient care activities performed by nurses often includes the use of adhesives and adhesive 
removers, particularly in surgical and intensive care units (8,11). A US study (8) found an 
almost 2-fold increased odds of asthma among nursing professionals who were exposed to 
adhesives, adhesive removers and / or solvents. Alcohols, chlorhexidine and povidone 
iodine are also commonly used in hospital settings for disinfection of wounds and patients‘ 
skin before various medical procedures (24).  
There is little information on the specific cleaning agents and tasks associated with various 
asthma-related outcomes. Furthermore, very limited information exists regarding exposure-
response relationships between the frequency of exposure to specific cleaning agents (e.g. 
OPA) and asthma-related outcomes. This specific information is needed to guide the 
development of appropriate preventive strategies in health care settings. The aim of this 
study was to determine the association between exposure to specific cleaning agents (e.g. 
OPA, glutaraldehyde and enzymatic cleaners), associated tasks and duration of use, and 
their relationship with various asthma-related outcomes in health workers. . 
 
7.2. METHODS 
7.2.1. Study design, Population and Sampling 
A cross-sectional study of 699 HWs was conducted in two large tertiary academic hospitals 
(346 from a South Africa hospital – SAH and 353 from Tanzanian hospital - TAH). All 
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permanently employed HWs in the high-risk departments, as previously described (Chapter 
3), constituted the sampling frame of the study. Doctors were excluded from the sampling 
frame as they were more likely to work in multiple different exposure settings across the 
hospital. A list of all permanently employed HWs in the high-risk departments of both 
hospitals was obtained from their respective managers. Study participants were selected 
from these departments through stratified random sampling according to job title, choosing 
up to five HWs from each high-risk department. For departments having more than five HWs 
with the same job title, a random sample of five workers was selected. For departments 
having less than five workers, all workers were selected to participate in the study. Ethics 
approval was obtained from the Human Research Ethics Committee (HREC) of the 
University of Cape Town (HREC Ref: 212/2013), Muhimbili University of Health and Allied 
Sciences (MUHAS) Institutional Review Board and University of Michigan Medical School 
Institutional Review Board (HUM00083115). 
7.2.2. Questionnaire 
A total of 697 participants completed the questionnaire interviews (344 from SAH and 353 
from TAH). Each participant answered a modified questionnaire for the investigation of 
asthma as contained in the Protocol for the European Community Respiratory Health Survey 
(25). The study questionnaire also included validated questions from the NIOSH specific 
questionnaire for cleaning agents in the health care setting (26). The questionnaire was 
administered by trained interviewers in English language for South African health workers 
(SAHWs) and in Swahili language for Tanzanian health workers (TAHWs). The translated 
Swahili questionnaire was back-translated to ensure validity and repeatability. 
7.2.3. Immunological assessment  
Blood samples were collected from 682 participants (339 SAHWs and 343 TAHWs). Specific 
IgE antibody reactivity to common aero-allergens (Phadiatop) and specific occupational 
allergens was evaluated. The quantification of specific IgE antibodies to specific 
occupational allergens: NRL (Hevea brasiliensis - Hev b5, Hev b6.02), chlorhexidine and 
OPA was performed using the UniCAP system (Phadia, Uppsala, Sweden). Immunological 
assessment for chlorhexidine was only done on sera of SAHWs since chlorhexidine 
containing chemicals were not used in the TAH.  
Commercial ImmunoCAPs containing Phadiatop (Phad), Chlorhexidine (C8), rHev b5 (K218) 
and rHev b6.02 (K220) allergens were obtained from Thermo Scientific. Since the OPA test 
was not readily available commercially, it required further development as previously 
described (Chapter 3). Serum samples were tested at the National Institute for Occupational 
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Health (NIOH) Immunology laboratory using the UNICAP 250 machine supplied by Thermo 
Scientific according to the manufacturer‘s manual.  
7.2.4. Spirometry (pre and post-bronchodilator) 
There were 328 participants from the TAH and 25 participants from the SAH who performed 
spirometry (pre- and post-bronchodilator). The latter group did not proceed to methacholine 
challenge testing (see below) due to contra-indications (e.g. FEV1 below 1.5 litres or 70% 
predicted, pregnant and breastfeeding women). Spirometry was conducted according to 
guidelines of the American Thoracic Society/European Respiratory Society (ATS/ERS) (27) 
using EasyOne World spirometer (ndd Medical Technologies, Zurich, Switzerland) at the 
TAH and Jaeger Aerosol Provocation System (APS) Pro apparatus at the SAH according to 
the manufacturer‘s instructions as previously described. 
7.2.5. Methacholine challenge tests 
Methacholine challenge testing (MCT) was only performed in the South African study site 
due to logistical considerations. The tests were conducted in a pulmonary function laboratory 
that was well equipped with appropriate resuscitation facilities. Among 318 participants who 
underwent spirometry, 239 performed interpretable PD20 methacholine results while 52 
participants had ≥10% decrease in FEV1 after administration of saline diluent and were 
therefore not considered for MCT. MCT was discontinued in two participants who requested 
the test to be stopped. As explained above, 25 participants underwent post-bronchodilator 
spirometry, since MCT was contraindicated. MCT was conducted under the supervision of 
an experienced technologist according to an abbreviated protocol used in epidemiological 
surveys. The Medic Aid Pro Nebulizer dosimeter method involved a protocol of increasing 
numbers of breaths to achieve pre-defined cumulative doses of methacholine (28). The 
doses were delivered by the Jaeger APS MedicAid Side Stream APS-Nebulizer according to 
the manufacturer‘s instructions, commencing with the lowest dose of 0.026 mg. The dose 
was increased to a maximum of 2.048 mg methacholine if a positive endpoint (fall in FEV1 of 
20% or more) was not obtained. The results of the MCT were interpreted as follows: 
borderline defined as 0.4mg <PD20M<1.0 mg; mild = 0.08 mg < PD20M <0.4mg; 
moderate/severe = PD20M< 0.08mg. Borderline values for PD20M were considered negative 
in the definition of non-specific bronchial hyper responsiveness (NSBH) as previously 
described. 
7.2.6. Fractional exhaled nitric oxide (FeNO) 
A total of 654 participants performed FeNO tests (334 from SAH and 320 from TAH). A 
hand-held portable exhaled nitric oxide sampling device (NIOX MINO® Airway Inflammation 
Monitor (NIOX MINO); Aerocrine AB, Solna, Sweden) was used according to the 
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manufacturer‘s instructions. Two technically adequate measurements were performed in line 
with the current American Thoracic Society /European Respiratory Society 
recommendations (29). A third maneuver was performed if the difference between the first 
two measurements was more than 10 ppb. The FeNO test was done during the work shift 
before spirometry / MCT. 
7.2.7. Operational definitions of asthma-related outcomes and environmental risk 
factors 
Information on which the asthma phenotypes were based was obtained from the modified 
ECRHS questionnaire, immunological tests, spirometry (pre- and post-bronchodilator), 
methacholine challenge tests and FeNO levels.  
An asthma symptom score was computed based on the sum of answers (0=no, 1=yes) to 
five questions reported in the past 12 months. These included the presence of shortness of 
breath while wheezing; being woken up with chest tightness; an attack of shortness of breath 
at rest; an attack of shortness of breath after exercise; and being woken up by an attack of 
shortness of breath, as has been described in previous studies (30,31,16,32). A binary 
variable was created from these five asthma-related symptoms (≥ 2 symptoms vs 0-1 
symptom). Having ≥ 2 asthma-related symptoms was considered ‗more symptomatic‘ and 0-
1 symptom as ‗less symptomatic‘. 
A categorical variable for NSBH was defined as any of the following two criteria: positive 
methacholine challenge test (PD20 methacholine < 0.4 mg) or significant bronchodilator 
response (≥12% and ≥ 200 ml increase in FEV1 after administration of a bronchodilator).  
Two continuous indices of MCT (continuous index of responsiveness (CIR) and dose-
response slope (DRS)) were also calculated (33). CIR = (Post-diluent FEV1 – FEV1 at the 
last dose of methacholine) ÷ Post-diluent FEV1 and DRS = (Post-diluent FEV1 – FEV1 at the 
last dose of methacholine) ÷ (Post-diluent FEV1 x Last methacholine dose) (33). CIR and 
DRS were all multiplied by 100 to convert them into percentages.  
FeNO results were interpreted as follows: low < 25ppb; elevated for values 25 - 50ppb; and 
high for values > 50ppb, the last mentioned is generally considered to signify the presence 
of allergic airway inflammation (34). In addition to FeNO being analysed as a continuous 
variable, two categorical variables (FeNO ≥ 25 ppb and FeNO ≥ 50 ppb) were also 
computed to gain more specificity in the analysis. Individuals with atopy were defined as 
those subjects having a positive Phadiatop test. 
Further information on the environmental risk factors was based on information obtained 
from the questionnaire, which had detailed information on use of cleaning agents and related 
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tasks in the past 12 months. This included information on the duration of use per day for 
each cleaning agent and number of days used per week (26). For cleaning tasks, the 
questionnaire included information on the typical duration of each individual task, number of 
times per day that the task was performed and the number of days per week an individual 
HW performed the task in question (26). Furthermore, for each cleaning agent, frequency of 
use per week was calculated by multiplying duration of use per day and number of days 
used per week. Similarly, for each cleaning task, frequency of task performance per week 
was calculated by multiplying duration of the task, number of times the task was performed 
per day and number of days the task was performed per week. For exposure-response 
analyses, cleaning-related predictor variables were categorised into 3 levels (cleaning 
product not used; use of a cleaning product for up to 99 minutes per week and use of a 
cleaning product for ≥ 100 minutes per week). These cut-off numbers were chosen after 
studying the distribution of the data based on duration and frequency of exposure. These 
cut-offs were considered the best fit and appropriate to use across all cleaning agents used 
and tasks performed.  
7.2.8. Statistical analysis 
All data analyses were performed using statistical software STATA version 14 (StataCorp, 
College Station, Texas, USA). Univariate and bivariate analyses were conducted. 
Multivariate logistic and linear saturated regression models adjusted for atopy, gender and 
smoking were used to evaluate the association between asthma-related outcomes (and 
other relevant clinical endpoints) and cleaning-related risk factors (specific cleaning agents 
and tasks). The three covariates (atopy, gender and smoking) were selected a priori but they 
also had consistent associations with asthma-related outcomes. Age was also initially 
selected a priori although no consistent associations were observed with asthma-related 
outcomes. Furthermore, since effect estimates did not change significantly when age was 
added into the regression models it was therefore not included in the final models. For linear 
regression analyses, log transformed values of DRS and FeNO were used, with geometric 
mean ratios and 95% confidence intervals. A negative binomial regression analysis was 
used for the association between asthma symptom score (a count outcome variable) and 
cleaning-related risk factors. The results of the negative binomial regression models were 
reported as mean ratios with 95% confidence intervals. 
 
 
 
 
171 
 
7.3. RESULTS 
7.3.1. Asthma-related outcomes associated with medical instrument cleaning and 
disinfection 
Presence of work-related ocular-nasal symptoms (WRONS) in the past 12 months was 
positively associated with increased duration (≥100 minutes/week) of use of OPA (OR = 
3.22; 95% CI: 1.43 – 7.25), glutaraldehyde (OR = 4.47; 95% CI: 1.61 – 12.45), enzymatic 
cleaners (OR = 2.59; 95% CI: 1.29 – 5.20), quaternary ammonium compounds (QACs) (OR 
= 12.08; 95% CI: 1.05 – 138.76), alcohols (OR = 4.40; 95% CI: 1.58 – 12.26) and bleach 
(OR = 2.50; 95% CI: 1.41 – 4.43) (Table 7.1.1). Furthermore, increased duration (≥100 
minutes/week) of tasks such as manual disinfection of instruments (OR = 2.58; 95% CI: 1.20 
– 5.55) and changing sterilisation solutions (OR = 3.97; 95% CI: 1.55 – 10.15) were also 
significantly associated with WRONS. An increased odds of work-related asthma symptoms 
(WRAS) in the past 12 months was also observed with hydrogen peroxide (OR = 3.14; 95% 
CI: 1.29 – 7.66) use for medical instrument disinfection. Furthermore, increasing asthma 
symptom score was also associated with pre-cleaning of instruments to remove gross 
contaminants (mean ratio = 1.41; 95% CI: 1.04 – 1.92), changing sterilisation solutions 
(mean ratio = 1.40; 95% CI: 1.00 – 1.94) and manual disinfection of medical instruments 
using immersion containers (mean ratio = 1.45; 95% CI: 1.03 – 2.03) (Table 7.1.2).  
While no significant associations were observed with markers of bronchial 
hyperresponsiveness, increasing FeNO levels were weakly associated with OPA (Geometric 
mean (GM) ratio = 1.19; 95% CI: 1.01 – 1.40) and chlorhexidine (GM ratio = 1.38; 95% CI: 
1.14 – 1.66) use (Table 7.2.1). However, stronger associations were observed for FeNO ≥ 
50 ppb among HWs who used QACs (OR = 5.31; 95% CI: 1.32 – 21.28), enzymatic cleaners 
(OR = 3.90; 95% CI: 1.53 – 9.98), OPA (OR = 3.73; 95% CI: 1.60 – 8.73) and chlorhexidine 
(OR = 2.91; 95% CI: 1.02 – 8.35) between 1-99 minutes per week. Furthermore, increasing 
FeNO was also associated with HWs that were involved with pre-cleaning of medical 
instruments to remove gross contaminants (GM ratio = 1.18; 95% CI: 1.05 – 1.34) and 
manually disinfected medical instruments (GM ratio = 1.16; 95% CI: 1.01 – 1.32) between 1- 
99 minutes per week (Table 7.2.2).  
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Table 7.1.1: Respiratory symptoms associated with specific chemicals in medical instrument cleaning and disinfection among health workers in 
the tertiary hospitals 
 Prevalence 
(%) 
Asthma symptom 
score
##
 
Asthma symptom score 
(≥2 vs 0-1) 
WRONS WRAS 
Prevalence (%) (n = 697)   91 (13) 109 (16) 48 (7) 
Medical instruments cleaning and disinfection 301 (43) 1.14 (0.85 – 1.52) 1.06 (0.67 – 1.68) 1.26 (0.83 – 1.92) 0.75 (0.41 – 1.40) 
Agents      
Ortho-phthalaldehyde      
Yes vs No 113 (16) 1.09 (0.75 – 1.60) 0.84 (0.45 – 1.58) 1.55 (0.92 – 2.60) 0.73 (0.30 – 1.77) 
0 minutes / week 584 (86) 1 1 1 1 
1 – 99 minutes / week 64 (10) 1.28 (0.80 – 2.05) 1.10 (0.52 – 2.32) 1.05 (0.51 – 2.16) 0.62 (0.18 – 2.07) 
≥ 100 minutes / week 30 (4) 1.15 (0.58 – 2.26) 0.72 (0.21 – 2.47) 3.22 (1.43 – 7.25)** 1.47 (0.42 – 5.16) 
Glutaraldehyde      
Yes vs No 49 (7) 1.03 (0.59 – 1.81) 1.17 (0.50 – 2.75) 1.42 (0.68 – 2.96) 1.14 (0.39 – 3.37) 
0 minutes / week 648 (94) 1 1 1 1 
1 – 99 minutes / week 28 (4) 1.14 (0.56 – 2.30) 1.18 (0.39 – 3.57) 0.66 (0.20– 2.24) 1.00 (0.23 – 4.40) 
≥ 100 minutes / week 16 (2) 0.79 (0.27 – 2.34) 1.07 (0.23 – 4.93) 4.47 (1.61 – 12.45)** 2.02 (0.43 – 9.47) 
Enzymatic cleaners      
Yes vs No 113 (16) 1.16 (0.80– 1.70) 1.17 (0.65 – 2.10) 1.20 (0.70– 2.06) 1.39 (0.66 – 2.91) 
0 minutes / week 584 (87) 1 1 1 1 
1 – 99 minutes / week 46 (7) 1.52 (0.89 – 2.59) 1.72 (0.78 – 3.80) 0.66 (0.25– 1.74) 1.64 (0.60 – 4.47) 
≥ 100 minutes / week 43 (6) 1.15 (0.64 – 2.09) 0.95 (0.36 – 2.54) 2.59 (1.29 – 5.20)** 1.18 (0.34 – 4.05) 
Chlorhexidine      
Yes vs No 84 (12) 1.26 (0.83 – 1.92) 0.85 (0.43 – 1.71) 0.66 (0.33 – 1.34) 0.61 (0.21 – 1.76) 
0 minutes / week 613 (91) 1 1 1 1 
1 – 99 minutes / week 44 (7) 1.41 (0.81 – 2.45) 0.64 (0.22 – 1.87) 0.64 (0.25 – 1.69) NC 
≥ 100 minutes / week 13 (2) 1.54 (0.60 – 3.95) 0.94 (0.20 – 4.41) 1.52 (0.41 – 5.71) 0.96 (0.12 – 7.78) 
Data are presented as OR (95% CI), unless otherwise indicated. ##: mean ratio (95% CI); OR: odds ratio; CI: confidence interval; *: p-value < 0.05; **: p-value < 0.01; ***: p-value < 0.001;  
Each OR represents a separate model adjusted for atopy, gender and smoking; WRONS: Work-related ocular–nasal symptoms (ocular–nasal symptoms experienced at work in the past 12 months that gets better when away 
from work OR worsen on return to work; WRAS: Work-related asthma symptoms (asthma symptoms experienced at work in the past 12 months that gets better when away from work OR worsen on return to work; NC: not 
calculable 
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Table 7.1.1 (contd.): Respiratory symptoms associated with specific chemicals in medical instrument cleaning and disinfection among health 
workers in the tertiary hospitals 
 Prevalence 
(%) 
Asthma symptom 
score
## 
Asthma symptom score 
(≥2 vs 0-1) 
WRONS WRAS 
Prevalence (%) (n = 697)   91 (13) 109 (16) 48 (7) 
Medical instruments cleaning and disinfection 301 (43)     
Agents      
Quaternary ammonium compounds      
Yes vs No 26 (4) 1.02 (0.49 – 2.13) 1.41 (0.49 – 4.02) 0.91 (0.30 – 2.74) 2.09 (0.59 – 7.44) 
0 minutes / week 671 (97) 1 1 1 1 
1 – 99 minutes / week 15 (2) 0.84 (0.29 – 2.42) 0.99 (0.21 – 4.75) 0.34 (0.04 – 2.69) NC 
≥ 100 minutes / week 3 (1) 1.83 (0.29 – 11.57) 2.94 (0.25 – 34.30) 12.08 (1.05 – 138.76)* 8.34 (0.62 – 111.58) 
Hydrogen peroxide      
Yes vs No 40 (6) 1.44 (0.81 – 2.56) 1.48 (0.62 – 3.53) 1.66 (0.76– 3.61) 3.14 (1.29 – 7.66)* 
0 minutes / week 657 (95) 1 1 1 1 
1 – 99 minutes / week 27 (4) 1.71 (0.87 – 3.36) 1.91 (0.73 – 5.03) 2.01 (0.82– 4.95) 2.99 (1.06 – 8.45)* 
≥ 100 minutes / week 7 (1) 0.97 (0.21 – 4.48) NC 1.05 (0.12– 8.91) NC 
Alcohols      
Yes vs No 104 (15) 0.93 (0.62 – 1.39) 0.81 (0.42 – 1.57) 1.07 (0.60 – 1.90) 0.75 (0.31 – 1.82) 
0 minutes / week 593 (88) 1 1 1 1 
1 – 99 minutes / week 64 (10) 1.03 (0.63 – 1.69) 1.02 (0.48 – 2.18) 0.56 (0.23– 1.35) 0.78 (0.27 – 2.29) 
≥ 100 minutes / week 16 (2) 1.12 (0.45 – 2.80) 0.93 (0.20 – 4.26) 4.40 (1.58 – 12.26)** 0.85 (0.11 – 6.75) 
Bleach      
Yes vs No 204 (29) 0.91 (0.66 – 1.26) 0.86 (0.51 – 1.44) 1.21 (0.77– 1.90) 0.74 (0.37 – 1.47) 
0 minutes / week 493 (75) 1 1 1 1 
1 – 99 minutes / week 89 (14) 0.96 (0.63 – 1.48) 0.82 (0.40 – 1.69) 0.72 (0.35– 1.47) 0.26 (0.06 – 1.11) 
≥ 100 minutes / week 75 (11) 0.88 (0.55 – 1.43) 0.80 (0.36 – 1.78) 2.50 (1.41 – 4.43)** 1.36 (0.60 – 3.09) 
Data are presented as OR (95% CI), unless otherwise indicated. ##: mean ratio (95% CI); OR: odds ratio; CI: confidence interval; *: p-value < 0.05; **: p-value < 0.01; ***: p-value < 0.001; WRONS: Work-related ocular–nasal 
symptoms (ocular–nasal symptoms experienced at work in the past 12 months that gets better when away from work OR worsen on return to work; WRAS: Work-related asthma symptoms (asthma symptoms experienced at 
work in the past 12 months that gets better when away from work OR worsen on return to work; Adjusted for atopy, gender and smoking; NC: not calculable 
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Table 7.1.2: Respiratory symptoms associated with specific tasks in medical instrument cleaning and disinfection among health workers in the 
tertiary hospitals 
 Prevale
nce (%) 
Asthma symptom 
score
## 
Asthma symptom 
score 
(≥2 vs 0-1) 
WRONS WRAS 
Prevalence (%) (n = 697)   91 (13) 109 (16) 48 (7) 
Medical instruments cleaning and disinfection 301 (43)     
Tasks      
Medical instruments cleaning and disinfecting tasksǂ 331 (48) 1.31 (0.97 – 1.75) 1.28 (0.81 – 2.03) 1.07 (0.70 – 1.64) 0.90 (0.49 – 1.65) 
Manually disassembling instruments, removing/flushing gross contaminants      
Yes vs No 201 (29) 1.41 (1.04 – 1.92)* 1.31 (0.81 – 2.12) 1.08 (0.69– 1.70) 1.14 (0.60 – 2.17) 
0 minutes / week 496 (71) 1 1 1 1 
1 – 99 minutes / week 133 (19) 1.44 (1.01 – 2.07)* 1.42 (0.82 – 2.46) 0.78 (0.44– 1.39) 1.17 (0.55 – 2.47) 
≥ 100 minutes / week 68 (10) 1.34 (0.84 – 2.14) 1.10 (0.51 – 2.37) 1.77 (0.95 – 3.29) 1.09 (0.40 – 2.92) 
Diluting or mixing cleaning products      
Yes vs No 251 (36) 1.20 (0.89 – 1.61) 1.09 (0.68 – 1.74) 1.24 (0.81 – 1.90) 0.96 (0.51 – 1.78) 
0 minutes / week 446 (64) 1 1 1 1 
1 – 99 minutes / week 213 (31) 1.19 (0.87 – 1.63) 1.12 (0.69 – 1.82) 1.22 (0.78 – 1.91) 0.99 (0.52 – 1.90) 
≥ 100 minutes / week 38 (5) 1.20 (0.65 – 2.23) 0.94 (0.34 – 2.57) 1.35 (0.56 – 3.24) 0.74 (0.17 – 3.26) 
Changing sterilisation solutions      
Yes vs No 157 (23) 1.40 (1.00 – 1.94)* 1.36 (0.81 – 2.29) 1.49 (0.93 – 2.38) 0.79 (0.37 – 1.70) 
0 minutes / week 540 (78) 1 1 1 1 
1 – 99 minutes / week 135 (19) 1.48 (1.04 – 2.08)* 1.56 (0.92 – 2.68) 1.21 (0.72 – 2.04) 0.80 (0.36 – 1.78) 
≥ 100 minutes / week 22 (3) 0.89 (0.37– 2.15) 0.34 (0.04 – 2.59) 3.97 (1.55 – 10.15)** 0.75 (0.10 – 5.83) 
Manually sterilise/disinfection of medical instruments      
Yes vs No 143 (21) 1.45 (1.03 – 2.03)* 1.36 (0.80 – 2.31) 1.18 (0.71 – 1.96) 0.90 (0.42 – 1.94) 
0 minutes / week 554 (80) 1 1 1 1 
1 – 99 minutes / week 106 (15) 1.52 (1.04 – 2.21)* 1.45 (0.81 – 2.60) 0.82 (0.44 – 1.53) 0.80 (0.33 – 1.97) 
≥ 100 minutes / week 37 (5) 1.25 (0.68– 2.33) 1.11 (0.41 – 3.01) 2.58 (1.20 – 5.55)* 1.22 (0.35 – 4.25) 
Sterilise medical instruments using automated systems      
Yes vs No 15 (2) 1.84 (0.77 – 4.40) 2.39 (0.72 – 7.91) 1.38 (0.38 – 5.01) 2.41 (0.51 – 11.43) 
0 minutes / week 682 (98) 1 1 1 1 
1 – 99 minutes / week 8 (1) 1.78 (0.53 – 6.02) 2.21 (0.42 – 11.50) NC 2.76 (0.31 – 24.29) 
≥ 100 minutes / week 7 (1) 1.90 (0.55 – 6.57) 2.62 (0.48 – 14.39) 4.29 (0.94 – 19.62) 2.13 (0.24 – 18.76) 
Data are presented as OR (95% CI), unless otherwise indicated. ##: mean ratio (95% CI); OR: odds ratio; CI: confidence interval; *: p-value < 0.05; **: p-value < 0.01; ***: p-value < 0.001; WRONS: Work-related ocular–nasal 
symptoms (ocular–nasal symptoms experienced at work in the past 12 months that gets better when away from work OR worsen on return to work; WRAS: Work-related asthma symptoms (asthma symptoms experienced at 
work in the past 12 months that gets better when away from work OR worsen on return to work; ǂ: A combined variable consisting of 5 tasks involved in medical instruments cleaning and disinfection i.e. pre-cleaning of 
instruments by removing/flushing gross contaminants, diluting/mixing cleaning products, changing sterilization solutions, manually sterilize/disinfection of medical instruments and sterilize medical instruments using automated 
systems; Adjusted for atopy, gender and smoking; NC: not calculable 
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Table 7.2.1: Bronchial hyperresponsiveness and airway inflammation associated with specific chemicals in medical instrument cleaning and 
disinfection among health workers in the tertiary hospitals 
 Prevalence 
(%) 
Dose-response slope 
(DRS)
ǂ
 
(n = 239) 
NSBH 
 
(n = 446) 
FeNO, ppb
ǂ
 
 
(n = 654) 
FeNO≥ 50 ppb 
 
(n = 654) 
Prevalence (%)   57 (13)  41 (6) 
Medical instruments cleaning and disinfection 301 (43) 1.02 (0.61 – 1.72) 0.77 (0.43 – 1.37) 1.06 (0.96 – 1.17) 1.34 (0.70 – 2.59) 
Agents      
Ortho-phthalaldehyde      
Yes vs No 113 (16) 1.02 (0.56 – 1.86) 0.79 (0.37 – 1.70) 1.10 (0.96 – 1.25) 2.81 (1.32 – 5.94)** 
0 minutes / week 584 (86) 1 1 1 1 
1 – 99 minutes / week 64 (10) 1.00 (0.46 – 2.16) 1.01 (0.40 – 2.57) 1.19 (1.01 – 1.40)* 3.73 (1.60 – 8.73)** 
≥ 100 minutes / week 30 (4) 1.83 (0.56 – 6.05) 0.29 (0.04 – 2.21) 0.98 (0.78 – 1.23) 0.77 (0.10 – 6.02) 
Glutaraldehyde      
Yes vs No 49 (7) 0.45 (0.03 – 6.65) 0.43 (0.10 – 1.86) 0.89 (0.73 – 1.07) 0.88 (0.26 – 3.02) 
0 minutes / week 648 (94) 1 1 1 1 
1 – 99 minutes / week 28 (4) 0.45 (0.03 – 6.65) 0.40 (0.05 – 3.08) 0.93 (0.73 – 1.18) 1.18 (0.26 – 5.30) 
≥ 100 minutes / week 16 (2) NC NC 0.88 (0.64 – 1.23) 0.79 (0.10 – 6.35) 
Enzymatic cleaners      
Yes vs No 113 (16) 1.03 (0.54 – 1.97) 0.73 (0.33 – 1.62) 1.12 (0.99 – 1.28) 2.20 (1.04 – 4.65)* 
0 minutes / week 584 (87) 1 1 1 1 
1 – 99 minutes / week 46 (7) 1.37 (0.51 – 3.70) 1.54 (0.55 – 4.33) 1.18 (0.97 – 1.43) 3.90 (1.53 – 9.98)** 
≥ 100 minutes / week 43 (6) 1.14 (0.39 – 3.28) 0.21 (0.03 – 1.61) 1.00 (0.82 – 1.22) 0.98 (0.22– 4.37) 
Chlorhexidine      
Yes vs No 84 (12) 1.13 (0.63 – 2.03) 1.31 (0.63 – 2.70) 1.31 (1.13 – 1.51)*** 2.13 (0.91 – 4.99) 
0 minutes / week 613 (91) 1 1 1 1 
1 – 99 minutes / week 44 (7) 0.75 (0.33 – 1.68) 1.05 (0.35 – 3.18) 1.38 (1.14 – 1.66)** 2.91 (1.02 – 8.35)* 
≥ 100 minutes / week 13 (2) 2.09 (0.71 – 6.20) 1.90 (0.50 – 7.27) 1.11 (0.79 – 1.55) NC 
Quaternary ammonium compounds      
Yes vs No 26 (4) 0.42 (0.15 – 1.13) 0.34 (0.04 – 2.62) 1.20 (0.94 – 1.53) 2.77 (0.75 – 10.21) 
0 minutes / week 671 (97) 1 1 1 1 
1 – 99 minutes / week 15 (2) 0.30 (0.08 – 1.08) NC 1.26 (0.92 – 1.74) 5.31 (1.32 – 21.28)* 
≥ 100 minutes / week 3 (0) 1.39 (0.16 – 12.36) 2.93 (0.26 – 33.44) 1.50 (0.74 – 3.04) NC 
Data are presented as OR (95% CI), unless otherwise indicated. OR: odds ratio; CI: confidence interval; ǂ: Geometric mean ratio (95% Confidence Interval); *: p-value < 0.05; **: p-value < 0.01; ***: p-value < 0.001;NSBH: 
nonspecific bronchial hyperresponsiveness; NSBH defined as any of the following two criteria: PD20 methacholine < 0.4 mg OR ≥12% and ≥ 200 ml increase in FEV1 after administration of a bronchodilator; Adjusted for atopy, 
gender and smoking; NC: not calculable 
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Table 7.2.1 (contd.): Bronchial hyperresponsiveness and airway inflammation associated with specific chemicals in medical instrument cleaning 
and disinfection among health workers in the tertiary hospitals 
 Prevalence 
(%) 
Dose-response slope 
(DRS)
ǂ
 
(n = 239) 
NSBH 
 
(n = 446) 
FeNO, ppb
ǂ
 
 
(n = 654) 
FeNO≥ 50 ppb 
 
(n = 654) 
Prevalence (%)   57 (13)  41 (6) 
Medical instruments cleaning and disinfection 301 (43)     
Agents      
Hydrogen peroxide      
Yes vs No 40 (6) 2.03 (0.72 – 5.74) 1.28 (0.42 – 3.89) 1.11 (0.91 – 1.37) 2.51 (0.90 – 7.04) 
0 minutes / week 657 (95) 1 1 1 1 
1 – 99 minutes / week 27 (4) 2.71 (0.80 – 9.20) 2.22 (0.68 – 7.23) 1.14 (0.88 – 1.46) 1.96 (0.54 – 7.06) 
≥ 100 minutes / week 7 (1) 1.51 (0.17 – 13.42) NC 0.97 (0.61 – 1.55) 4.29 (0.46 – 40.10) 
Alcohols       
Yes vs No 104 (15) 0.89 (0.45 – 1.75) 0.60 (0.25 – 1.47) 1.01 (0.89 – 1.16) 1.42 (0.62 – 3.24) 
0 minutes / week 593 (88) 1 1 1 1 
1 – 99 minutes / week 64 (10) 0.96 (0.34 – 2.74) 0.39 (0.09 – 1.70) 1.01 (0.85 – 1.19) 1.75 (0.68 – 4.49) 
≥ 100 minutes / week 16 (2) 1.76 (0.41 – 7.54) 1.93 (0.51 – 7.38) 1.21 (0.89 – 1.65) 1.25 (0.15 – 10.17) 
Bleach      
Yes vs No 204 (29) 0.97 (0.51 – 1.85) 0.78 (0.41 – 1.50) 0.90 (0.81 – 1.00) 0.71 (0.34 – 1.50) 
0 minutes / week 493 (75) 1 1 1 1 
1 – 99 minutes / week 89 (14) 0.96 (0.41 – 2.29) 0.55 (0.19 – 1.61) 0.94 (0.81– 1.08) 0.67 (0.23 – 1.98) 
≥ 100 minutes / week 75 (11) 1.28 (0.32 – 5.11) 1.05 (0.43 – 2.52) 0.87 (0.75– 1.02) 0.72 (0.24 – 2.13) 
Data are presented as OR (95% CI), unless otherwise indicated. OR: odds ratio; CI: confidence interval; ǂ: Geometric mean ratio (95% Confidence Interval); *: p-value < 0.05; **: p-value < 0.01; ***: p-value < 0.001;NSBH: 
nonspecific bronchial hyperresponsiveness;NSBH defined as any of the following two criteria: PD20 methacholine < 0.4 mg OR ≥12% and ≥ 200 ml increase in FEV1 after administration of a bronchodilator; Adjusted for atopy, 
gender and smoking; NC: not calculable 
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Table 7.2.2: Bronchial hyperresponsiveness and airway inflammation associated with specific tasks in medical instrument cleaning and 
disinfection among health workers in the tertiary hospitals 
 Prevalence 
(%) 
Dose-response 
slope (DRS)
ǂ
 
(n = 239) 
NSBH 
 
(n = 446) 
FeNO, ppb
ǂ
 
 
(n = 654) 
FeNO≥ 50 ppb 
 
(n = 654) 
Prevalence (%)   57 (13)  41 (6) 
Medical instruments cleaning and disinfection 301 (43)     
Tasks      
Medical instruments cleaning and disinfecting tasks# 331 (48) 0.89 (0.51 – 1.54) 1.31 (0.73 – 2.32) 1.13 (1.03 – 1.25)* 1.55 (0.80 – 3.02) 
Manually disassembling instruments, removing/flushing gross contaminants      
Yes vs No 201 (29) 1.01 (0.59 – 1.72) 1.01 (0.55 – 1.85) 1.14 (1.03 – 1.27)* 1.69 (0.85 – 3.37) 
0 minutes / week 496 (71) 1 1 1 1 
1 – 99 minutes / week 133 (19) 0.95 (0.52 – 1.71) 1.09 (0.55 – 2.16) 1.18 (1.05 – 1.34)** 2.02 (0.94 – 4.37) 
≥ 100 minutes / week 68 (10) 1.20 (0.49 – 2.96) 0.85 (0.32 – 2.30) 1.06 (0.90 – 1.26) 1.18 (0.39 – 3.57) 
Diluting or mixing cleaning products      
Yes vs No 251 (36) 0.95 (0.57 – 1.59) 1.12 (0.64 – 1.98) 1.06 (0.96 – 1.17) 1.32 (0.68 – 2.56) 
0 minutes / week 446 (64) 1 1 1 1 
1 – 99 minutes / week 213 (31) 1.03 (0.60 – 1.75) 1.14 (0.63 – 2.05) 1.03 (0.93 – 1.14) 1.26 (0.63 – 2.54) 
≥ 100 minutes / week 38 (5) 0.61 (0.22 – 1.69) 0.99 (0.28 – 3.54) 1.23 (0.99 – 1.53) 1.70 (0.47 – 6.18) 
Changing sterilisation solutions      
Yes vs No 157 (23) 0.96 (0.53 – 1.75) 0.73 (0.36 – 1.47) 1.05 (0.93 – 1.17) 1.24 (0.58 – 2.64) 
0 minutes / week 540 (78) 1 1 1 1 
1 – 99 minutes / week 135 (19) 0.85 (0.45 – 1.60) 0.76 (0.36 – 1.58) 1.02 (0.91 – 1.16) 1.30 (0.59 – 2.86) 
≥ 100 minutes / week 22 (3) 1.91 (0.49 – 7.46) 0.51 (0.07 – 4.04) 1.19 (0.90 – 1.57) 0.89 (0.11 – 7.08) 
Manually sterilise/disinfection of medical instruments      
Yes vs No 143 (21) 0.71 (0.42 – 1.21) 1.03 (0.54 – 1.97) 1.16 (1.03 – 1.31)* 1.60 (0.74 – 3.46) 
0 minutes / week 554 (80) 1 1 1 1 
1 – 99 minutes / week 106 (15) 0.56 (0.32 – 1.00) 0.98 (0.47 – 2.02) 1.16 (1.01 – 1.32)* 1.92 (0.86 – 4.32) 
≥ 100 minutes / week 37 (5) 1.98 (0.69 – 5.68) 1.19 (0.39 – 3.67) 1.18 (0.95– 1.48) 0.64 (0.08 – 4.95) 
Sterilise medical instruments using automated systems      
Yes vs No 15 (2) 1.26 (0.41 – 3.84) 1.17 (0.25 – 5.44) 1.33 (0.97 – 1.83) 2.60 (0.53 – 12.77) 
0 minutes / week 682 (98) 1 1 1 1 
1 – 99 minutes / week 8 (1) 0.49 (0.12 – 2.09) NC 1.18 (0.76 – 1.82) 2.54 (0.27 – 24.08) 
≥ 100 minutes / week 7 (1) 4.59 (0.85 – 24.97) 2.63 (0.49 – 14.08) 1.53 (0.97 – 2.43) 2.66 (0.29 – 24.39) 
Data are presented as OR (95% CI), unless otherwise indicated. OR: odds ratio; CI: confidence interval; ǂ: Geometric mean ratio (95% Confidence Interval); *: p-value < 0.05; **: p-value < 0.01; ***: p-value < 0.001;NSBH: 
nonspecific bronchial hyperresponsiveness; NSBH defined as any of the following two criteria: PD20 methacholine < 0.4 mg OR ≥12% and ≥ 200 ml increase in FEV1 after administration of a bronchodilator; #: A combined 
variable consisting of 5 tasks involved in medical instruments cleaning and disinfectioni.e. pre-cleaning of instruments by removing/flushing gross contaminants, diluting/mixing cleaning products, changing sterilization solutions, 
manually sterilize/disinfection of medical instruments and sterilize medical instruments using automated systems; Adjusted for atopy, gender and smoking; NC: not calculable 
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7.3.2. Asthma-related outcomes associated with fixed surfaces cleaning and 
disinfection 
A higher mean asthma symptom score (mean ratio = 1.52; 95% CI: 1.04 – 2.22) was 
observed for HWs who used bleach for fixed surface cleaning and disinfection between 1-99 
minutes per week (Table 7.3.1). The use of chemical products containing ammonia was 
strongly associated more symptomatic HWs (≥ 2 asthma-related symptoms) (OR= 2.76; 
95% CI: 1.11 – 6.90) compared to those that were less or not symptomatic. Furthermore, 
these symptomatic HWs were also more likely to use sprays rather than wipes (OR = 5.58; 
95% CI: 2.04 – 15.24) for fixed surfaces cleaning and disinfection (Table 7.3.2). Finally, 
while no significant associations were observed between specific chemicals used in fixed 
surface cleaning, an increased odds of having bronchial hyperresponsiveness (higher DRS) 
was observed among HWs that performed terminal cleaning of patient rooms (GM ratio = 
1.70; 95% CI: 1.01 – 2.88) (Table 7.4.2), and increasing FeNO levels were positively 
associated with spraying of deodorants/disinfectants (GM ratio = 1.20; 95% CI: 1.08 – 1.33). 
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Table 7.3.1: Respiratory symptoms associated with specific chemicals used in fixed surface cleaning and disinfection among health workers in the 
tertiary hospitals  
 Prevalence 
(%) 
Asthma symptom 
score
##
 
Asthma symptom 
score 
(≥2 vs 0-1) 
WRONS WRAS 
Prevalence (%) (n = 697)   91 (13) 109 (16) 48 (7) 
Fixed surfaces cleaning and disinfection 572 (82) 1.40 (0.92 – 2.13) 1.56 (0.77 – 3.15) 0.83 (0.48 – 1.42) 0.90 (0.40 – 2.02) 
Agents      
Ammonia      
Yes vs No 73 (11) 0.96 (0.61 – 1.52) 1.06 (0.53 – 2.11) 0.87 (0.44 – 1.75) 0.15 (0.02 – 1.14) 
0 minutes / week 624 (95) 1 1 1 1 
1 – 99 minutes / week 24 (4) 1.60 (0.81 – 3.17) 2.76 (1.11 – 6.90)* 1.29 (0.47 – 3.58) NC 
≥ 100 minutes / week 9 (1) 0.34 (0.06 – 1.85) NC 0.62 (0.08 – 5.20) NC 
Bleach      
Yes vs No 474 (68) 1.10 (0.80– 1.52) 1.02 (0.62 – 1.69) 0.94 (0.60 – 1.47) 1.09 (0.56 – 2.14) 
0 minutes / week 223 (40) 1 1 1 1 
1 – 99 minutes / week 154 (27) 1.52 (1.04 – 2.22)* 1.52 (0.84 – 2.75) 0.77 (0.42 – 1.40) 0.66 (0.25 – 1.71) 
≥ 100 minutes / week 189 (33) 0.95 (0.65– 1.40) 0.89 (0.48 – 1.66) 1.35 (0.80 – 2.26) 1.58 (0.75 – 3.32) 
Data are presented as OR (95% CI), unless otherwise indicated. ##: mean ratio (95% CI); OR: odds ratio; CI: confidence interval; *: p-value < 0.05; **: p-value < 0.01; ***: p-value < 0.001; WRONS: Work-related ocular–nasal 
symptoms (ocular–nasal symptoms experienced at work in the past 12 months that gets better when away from work OR worsen on return to work; WRAS: Work-related asthma symptoms (asthma symptoms experienced at 
work in the past 12 months that gets better when away from work OR worsen on return to work; Adjusted for atopy, gender and smoking; NC: not calculable 
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Table 7.3.2: Respiratory symptoms associated with specific tasks used in fixed surface cleaning and disinfection among health workers in the 
tertiary hospitals 
 Prevalence 
(%) 
Asthma symptom 
score
## 
Asthma symptom score 
(≥2 vs 0-1) 
WRONS WRAS 
Prevalence (%) (n = 697)   91 (13) 109 (16) 48 (7) 
Fixed surfaces cleaning and disinfection 572 (82)     
Tasks      
Use more sprays vs more wipes 18 (3) 3.00 (1.50 – 5.98)** 5.58 (2.04 – 15.24)** 0.59 (0.13 – 2.66) 1.65 (0.35 – 7.81) 
Manually mix, refill, or empty cleaning/disinfecting products      
Yes vs No 354 (51) 1.20 (0.89 – 1.61) 0.98 (0.62 – 1.55) 1.37 (0.89 – 2.11) 1.09 (0.59 – 2.00) 
0 minutes / week 343 (59) 1 1 1 1 
1 – 99 minutes / week 221 (38) 1.34 (0.96 – 1.87) 1.01 (0.60 – 1.69) 1.41 (0.88 – 2.27) 1.05 (0.52 – 2.10) 
≥ 100 minutes / week 19 (3) 1.64 (0.71– 3.79) 1.13 (0.31 – 4.14) 2.24 (0.77 – 6.56) NC 
Spray deodorant/ disinfectant      
Yes vs No 208 (30) 1.46 (1.08 – 1.99)* 1.54 (0.95 – 2.47) 1.06 (0.67 – 1.68) 0.87 (0.44 – 1.70) 
0 minutes / week 489 (78) 1 1 1 1 
1 – 99 minutes / week 128 (20) 1.76 (1.23 – 2.52)** 2.00 (1.17– 3.44)* 1.24 (0.73 – 2.09) 0.88 (0.39 – 1.99) 
≥ 100 minutes / week 12 (2) 0.92 (0.29– 2.89) 0.66 (0.08 – 5.45) 0.48 (0.06 – 3.76) NC 
Clean instruments or equipment      
Yes vs No 404 (58) 1.22 (0.91 – 1.64) 1.12 (0.70 – 1.78) 1.01 (0.66 – 1.55) 0.83 (0.45 – 1.51) 
0 minutes / week 293 (51) 1 1 1 1 
1 – 99 minutes / week 170 (29) 1.30 (0.90 – 1.88) 0.97 (0.53 – 1.78) 1.02 (0.60 – 1.73) 0.73 (0.32 – 1.64) 
≥ 100 minutes / week 114 (20) 1.17 (0.77 – 1.78) 1.40 (0.74 – 2.62) 1.40 (0.80 – 2.46) 0.87 (0.37 – 2.05) 
Terminal cleaning of patient rooms      
Yes vs No 159 (23) 1.05 (0.74 – 1.47) 1.05 (0.62 – 1.79) 0.64 (0.37 – 1.11) 0.88 (0.42 – 1.83) 
0 minutes / week 538 (87) 1 1 1 1 
1 – 99 minutes / week 59 (10) 1.24 (0.76 – 2.04) 1.26 (0.59 – 2.69) 0.90 (0.42 – 1.92) 0.91 (0.31 – 2.70) 
≥ 100 minutes / week 21 (3) 1.29 (0.58 – 2.88) 1.51 (0.47 – 4.87) 0.53 (0.12 – 2.34) 0.64 (0.08 – 4.94) 
Data are presented as OR (95% CI), unless otherwise indicated. ##: mean ratio (95% CI); OR: odds ratio; CI: confidence interval; *: p-value < 0.05; **: p-value < 0.01; ***: p-value < 0.001; WRONS: Work-related ocular–nasal 
symptoms (ocular–nasal symptoms experienced at work in the past 12 months that gets better when away from work OR worsen on return to work; WRAS: Work-related asthma symptoms (asthma symptoms experienced at 
work in the past 12 months that gets better when away from work OR worsen on return to work; Adjusted for atopy, gender and smoking; NC: not calculable 
  
 
 
181 
 
Table 7.4.1: Bronchial hyperresponsiveness and airway inflammation associated with specific chemicals used in fixed surface cleaning and 
disinfection among health workers in the tertiary hospitals 
 Prevalence 
(%) 
Dose-response slope 
(DRS)
ǂ
 
(n = 239) 
NSBH 
 
(n = 446) 
FeNO, ppb
ǂ
 
 
(n = 654) 
FeNO≥ 50 ppb 
 
(n = 654) 
Prevalence (%)   57 (13)  41 (6) 
Fixed surfaces cleaning and disinfection 572 (82) 1.06 (0.42 – 2.69) 0.68 (0.33 – 1.43) 1.12 (0.98 – 1.28) 1.05 (0.44 – 2.54) 
Agents      
Ammonia      
Yes vs No 73 (11) 0.82 (0.43 – 1.56) 0.59 (0.22 – 1.56) 1.00 (0.86 – 1.17) 1.30 (0.47 – 3.54) 
0 minutes / week 624 (95) 1 1 1 1 
1 – 99 minutes / week 24 (4) 0.60 (0.21 – 1.72) 0.32 (0.04 – 2.50) 1.12 (0.87 – 1.45) 0.65 (0.08 – 5.07) 
≥ 100 minutes / week 9 (1) 0.41 (0.07 – 2.26) NC 0.97 (0.62 – 1.50) 3.17 (0.32 – 31.04) 
Bleach      
Yes vs No 474 (68) 0.99 (0.54 – 1.79) 0.95 (0.51 – 1.76) 1.05 (0.95 – 1.17) 1.12 (0.54 – 2.34) 
0 minutes / week 223 (40) 1 1 1 1 
1 – 99 minutes / week 154 (27) 0.73 (0.38 – 1.41) 0.73 (0.31 – 1.68) 1.14 (0.99 – 1.30) 1.48 (0.62 – 3.52) 
≥ 100 minutes / week 189 (33) 0.80 (0.38 – 1.67) 0.65 (0.29 – 1.46) 1.03 (0.91 – 1.17) 1.32 (0.58 – 3.04) 
Data are presented as OR (95% CI), unless otherwise indicated. OR: odds ratio; CI: confidence interval; ǂ: Geometric mean ratio (95% Confidence Interval); *: p-value < 0.05; **: p-value < 0.01; ***: p-value < 0.001;NSBH: 
nonspecific bronchial hyperresponsiveness;NSBH defined as any of the following two criteria: PD20 methacholine < 0.4 mg OR ≥12% and ≥ 200 ml increase in FEV1 after administration of a bronchodilator; Adjusted for atopy, 
gender and smoking; NC: not calculable 
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Table 7.4.2: Bronchial hyperresponsiveness and airway inflammation associated with specific tasks used in fixed surface cleaning and 
disinfection among health workers in the tertiary hospitals 
 Prevalence 
(%) 
Dose-response 
slope (DRS)
ǂ
 
(n = 239) 
NSBH 
 
(n = 446) 
FeNO, ppb
ǂ
 
 
(n = 654) 
FeNO≥ 50 ppb 
 
(n = 654) 
Prevalence (%)   57 (13)  41 (6) 
Fixed surfaces cleaning and disinfection 572 (82)     
Tasks      
Use more sprays vs more wipes 18 (3) 1.04 (0.27 – 4.08) NC 0.97 (0.72 – 1.30) 0.70 (0.09 – 5.63) 
Manually mix, refill, or empty cleaning/disinfecting products      
Yes vs No 354 (51) 0.93 (0.52 – 1.66) 1.14 (0.64 – 2.04) 1.09 (0.98 – 1.20) 1.31 (0.67 – 2.57) 
0 minutes / week 343 (59) 1 1 1 1 
1 – 99 minutes / week 221 (38) 0.86 (0.48 – 1.55) 0.98 (0.50 – 1.91) 1.08 (0.97 – 1.21) 1.06 (0.49 – 2.32) 
≥ 100 minutes / week 19 (3) 0.83 (0.26 – 2.72) 0.47 (0.06 – 3.85) 1.18 (0.88 – 1.59) 3.18 (0.80 – 12.62) 
Spray deodorant/ disinfectant      
Yes vs No 208 (30) 0.79 (0.47 – 1.32) 1.01 (0.55 – 1.82) 1.20 (1.08 – 1.33)** 1.76 (0.89 – 3.45) 
0 minutes / week 489 (78) 1 1 1 1 
1 – 99 minutes / week 128 (20) 0.77 (0.45 – 1.34) 0.80 (0.39 – 1.67) 1.23 (1.09– 1.39)** 1.81 (0.82 – 3.98) 
≥ 100 minutes / week 12 (2) 0.15 (0.03 – 0.77)* 0.90 (0.11 – 7.62) 1.05 (0.74– 1.49) 1.70 (0.20 – 14.24) 
Clean instruments or equipment      
Yes vs No 404 (58) 0.93 (0.50 – 1.73) 0.98 (0.55 – 1.74) 1.08 (0.98 – 1.19) 1.56 (0.78 – 3.12) 
0 minutes / week 293 (51) 1 1 1 1 
1 – 99 minutes / week 170 (29) 0.83 (0.41 – 1.65) 0.82 (0.39 – 1.74) 1.09 (0.97 – 1.24) 1.45 (0.61 – 3.44) 
≥ 100 minutes / week 114 (20) 0.99 (0.44 – 2.24) 1.01 (0.46 – 2.22) 1.13 (0.99 – 1.30) 2.23 (0.95 – 5.26) 
Terminal cleaning of patient rooms      
Yes vs No 159 (23) 1.70 (1.01 – 2.88)* 1.20 (0.65 – 2.24) 1.10 (0.98 – 1.24) 1.32 (0.61 – 2.84) 
0 minutes / week 538 (87) 1 1 1 1 
1 – 99 minutes / week 59 (10) 1.10 (0.53 – 2.30) 1.00 (0.36 – 2.77) 1.08 (0.90 – 1.28) 1.41 (0.46 – 4.29) 
≥ 100 minutes / week 21 (3) 2.42 (0.70 – 8.30) 0.43 (0.05 – 3.35) 1.08 (0.82 – 1.42) 0.93 (0.12 – 7.41) 
Data are presented as OR (95% CI), unless otherwise indicated. OR: odds ratio; CI: confidence interval; ǂ: Geometric mean ratio (95% Confidence Interval); *: p-value < 0.05; **: p-value < 0.01; ***: p-value < 0.001; NSBH: 
nonspecific bronchial hyperresponsiveness; NSBH defined as any of the following two criteria: PD20 methacholine < 0.4 mg OR ≥12% and ≥ 200 ml increase in FEV1 after administration of a bronchodilator; Adjusted for atopy, 
gender and smoking 
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7.3.3. Asthma-related outcomes associated with specimen preparation products 
A higher mean asthma symptom score (mean ratio = 1.55; 95% CI: 1.07 – 2.26) was 
observed for HWs that used formalin (10%) solution to prepare specimens for up to 99 
minutes per week (Table 7.5). Furthermore, HWs with increasing FeNO levels were also 
more likely to use formalin (10%) solution (GM ratio = 1.19; 95% CI: 1.06 – 1.34) for tissue 
fixation and alcohol-based cytological fixative spray (GM ratio = 1.33; 95% CI: 1.04 – 1.71) 
for similar durations of time (Table 7.6). 
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Table 7.5: Respiratory symptoms associated with specific chemicals used in specimen preparation among health workers in the tertiary hospitals  
 Prevalence 
(%) 
Asthma symptom 
score
##
 
Asthma symptom score   
(≥2 vs 0-1) 
WRONS WRAS 
Prevalence (%) (n = 697)   91 (13) 109 (16) 48 (7) 
Specimen preparation products 157 (23) 1.36 (0.98 – 1.90) 1.21 (0.72 – 2.04) 1.43 (0.89 – 2.29) 1.27 (0.65 – 2.48) 
Formalin 10% in normal saline      
Yes vs No 146 (21) 1.34 (0.96 – 1.88) 1.17 (0.68 – 1.99) 1.39 (0.86 – 2.24) 1.21 (0.61 – 2.42) 
0 minutes / week 549 (82) 1 1 1 1 
1 – 99 minutes / week 110 (17) 1.55 (1.07 – 2.26)* 1.26 (0.70 – 2.27) 1.56 (0.93 – 2.64) 1.22 (0.56 – 2.64) 
≥ 100 minutes / week 5 (1) 0.67 (0.10 – 4.29) NC 1.51 (0.17 – 13.77) NC 
Alcohol-based cytological fixative spray      
Yes vs No 25 (4) 1.34 (0.66 – 2.73) 1.67 (0.63 – 4.43) 2.10 (0.84 – 5.24) 1.67 (0.47 – 5.92) 
0 minutes / week 672 (98) 1 1 1 1 
1 – 99 minutes / week 17 (2) 1.56 (0.67 – 3.66) 1.28 (0.71 – 2.30) 2.30 (0.78 – 6.73) 1.67 (0.36 – 7.78) 
≥ 100 minutes / week 0 (0) NC NC NC NC 
Solvents      
Yes vs No 2 (0) 3.27 (0.41 – 25.87) 4.64 (0.28 – 77.99) NC NC 
0 minutes / week 695 (100) 1 1 1 1 
1 – 99 minutes / week 2 (0) 3.27 (0.41 – 25.87) 4.64 (0.28 – 77.99) NC NC 
≥ 100 minutes / week 0 (0) NC NC NC NC 
Data are presented as OR (95% CI), unless otherwise indicated. ##: mean ratio (95% CI); OR: odds ratio; CI: confidence interval; *: p-value < 0.05; **: p-value < 0.01; ***: p-value < 0.001; WRONS: Work-related ocular–nasal 
symptoms (ocular–nasal symptoms experienced at work in the past 12 months that gets better when away from work OR worsen on return to work; WRAS: Work-related asthma symptoms (asthma symptoms experienced at 
work in the past 12 months that gets better when away from work OR worsen on return to work; Adjusted for atopy, gender and smoking; NC: not calculable 
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Table 7.6: Bronchial hyperresponsiveness and airway inflammation associated with specific chemicals used in specimen preparation among 
health workers in the tertiary hospitals 
 Prevalence 
(%) 
Dose-response slope 
(DRS)
ǂ
 
(n = 239) 
NSBH 
 
(n = 446) 
FeNO, ppb
ǂ
 
 
(n = 654) 
FeNO≥ 50 ppb 
 
(n = 654) 
Prevalence (%)   57 (13)  41 (6) 
Specimen preparation products 157 (23) 1.08 (0.61 – 1.91) 1.77 (0.97 – 3.22) 1.20 (1.07 – 1.35)** 1.25 (0.58 – 2.67) 
Formalin 10% in normal saline      
Yes vs No 146 (21) 1.06 (0.59 – 1.91) 1.76 (0.96 – 3.23) 1.19 (1.06 – 1.34)** 1.15 (0.52 – 2.52) 
0 minutes / week 549 (83) 1 1 1 1 
1 – 99 minutes / week 110 (16) 0.99 (0.51 – 1.92) 1.86 (0.96 – 3.61) 1.20 (1.05 – 1.38)** 1.32 (0.58 –3.00) 
≥ 100 minutes / week 5 (1) 0.97 (0.07 – 14.01) NC 1.18 (0.68– 2.04) NC 
Alcohol-based cytological fixative spray      
Yes vs No 25 (4) 0.72 (0.26 – 1.97) 0.34 (0.04 – 2.60) 1.33 (1.04 – 1.71)* 2.27 (0.62 – 8.35) 
0 minutes / week 672 (98) 1 1 1 1 
1 – 99 minutes / week 17 (2) 0.83 (0.28 – 2.45) 0.41 (0.05 – 3.18) 1.55 (1.15 – 2.09)** 3.62 (0.93 – 14.17) 
≥ 100 minutes / week 0 (0) NC NC NC NC 
Solvents      
Yes vs No 2 (0) 6.36 (0.43 – 93.39) NC 0.85 (0.36 – 2.02) NC 
0 minutes / week 695 (100) 1 1 1 1 
1 – 99 minutes / week 2 (0) 6.36 (0.43 – 93.39) NC 0.85 (0.36 – 2.02) NC 
≥ 100 minutes / week 0 (0) NC NC NC NC 
Data are presented as OR (95% CI), unless otherwise indicated. OR: odds ratio; CI: confidence interval; ǂ: Geometric mean ratio (95% Confidence Interval); *: p-value < 0.05; **: p-value < 0.01; ***: p-value < 0.001;NSBH: 
nonspecific bronchial hyperresponsiveness;NSBH defined as any of the following two criteria: PD20 methacholine < 0.4 mg OR ≥12% and ≥ 200 ml increase in FEV1 after administration of a bronchodilator; Adjusted for atopy, 
gender and smoking; NC: not calculable 
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7.3.4. Asthma-related outcomes associated with patients’ skin/wound cleaning and 
disinfection 
Health workers that were more symptomatic (≥ 2 asthma-related symptoms) were more 
likely to perform patient care activities such as disinfecting skin areas on patients prior to 
procedure (OR = 2.36; 95% CI: 1.15 – 4.81), cleaning and disinfecting wounds (OR = 3.21; 
95% CI: 1.21 – 8.50) and removing adhesives from patients skin using solvents (OR = 3.47; 
95% CI: 1.06 – 11.36) (Table 7.7). This relationship showed a clear dose-response trend 
with those who performed patient care activities for ≥ 100 minutes per week having higher 
odds of being more symptomatic. A strong association was also observed between the 
presence of WRONS among HWs involved in disinfecting skin areas on patients prior to a 
procedure (OR = 2.30; 95% CI: 1.20 – 4.41) as well as between WRAS and applying wound 
dressings (OR = 3.60; 95% CI: 1.08 – 11.94).  
While no associations were observed for bronchial hyperresponsiveness, weak exposure-
response relationships were observed between increasing FeNO levels and most tasks  
including disinfecting skin areas on patients prior to procedure (GM ratio = 1.23; 95% CI: 
1.03 – 1.47), cleaning and disinfecting wounds (GM ratio = 1.41; 95% CI: 1.09 – 1.82), 
applying wound dressings (GM ratio = 1.22; 95% CI: 1.00 – 1.49), using adhesives (GM ratio 
= 1.16; 95% CI: 1.03 – 1.30) as well as removing adhesives from patient‘s skin using 
solvents (GM ratio = 1.24; 95% CI: 1.09 – 1.42), mostly for durations up to 99 minutes per 
week (Table 7.8). 
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Table 7.7: Respiratory symptoms associated with specific chemicals and tasks used in patients’ skin/wound cleaning and disinfection among 
health workers in the tertiary hospitals  
 Prevalence 
(%) 
Asthma symptoms 
score
##
 
Asthma symptoms   
(≥2 vs 0-1) 
WRONS WRAS 
Prevalence (%) (n = 697)   91 (13) 109 (16) 48 (7) 
Patients’ skin/wound cleaning and disinfection 327 (47) 1.23 (0.92 – 1.64) 1.17 (0.74 – 1.85) 1.03 (0.68 – 1.57) 0.71 (0.39 – 1.31) 
Disinfect skin areas on patients prior to procedure      
Yes vs No 253 (36) 1.37 (1.02 – 1.83)* 1.46 (0.92 – 2.31) 1.53 (1.00 – 2.34)* 0.79 (0.42 – 1.50) 
0 minutes / week 444 (74) 1 1 1 1 
1 – 99 minutes / week 96 (16) 1.33 (0.87 – 2.02) 1.26 (0.65 – 2.45) 1.39 (0.76 – 2.54) 1.00 (0.42 – 2.39) 
≥ 100 minutes / week 58 (10) 1.55 (0.94 – 2.57) 2.36 (1.15 – 4.81)* 2.30 (1.20 – 4.41)* 0.47 (0.11 – 2.03) 
Clean and disinfect wounds      
Yes vs No 162 (23) 1.17 (0.84 – 1.63) 1.19 (0.72– 1.99) 1.02 (0.63– 1.66) 1.03 (0.51 – 2.05) 
0 minutes / week 535 (90) 1 1 1 1 
1 – 99 minutes / week 39 (6) 0.98 (0.52 – 1.88) 0.88 (0.32– 2.44) 0.31 (0.07 – 1.30) 0.36 (0.05 – 2.72) 
≥ 100 minutes / week 22 (4) 1.81 (0.84 – 3.88) 3.21 (1.21 – 8.50)* 2.42 (0.95 – 6.15) 2.55 (0.80 – 8.08) 
Apply wound dressing      
Yes vs No 143 (21) 1.19 (0.84 – 1.68) 1.10 (0.64 – 1.88) 1.29 (0.79 – 2.11) 1.08 (0.53– 2.19) 
0 minutes / week 554 (90) 1 1 1 1 
1 – 99 minutes / week 44 (7) 1.14 (0.63 – 2.06) 0.85 (0.32– 2.30) 0.76 (0.29 – 2.00) 0.63 (0.15 – 2.74) 
≥ 100 minutes / week 18 (3) 1.34 (0.57 – 3.15) 2.55 (0.88 – 7.37) 2.15 (0.74 – 6.26) 3.60 (1.08 – 11.94)* 
Use adhesives      
Yes vs No 279 (40) 1.36 (1.02 – 1.83)* 1.42 (0.90 – 2.25) 1.13 (0.74 – 1.73) 0.89 (0.48 – 1.65) 
0 minutes / week 418 (69) 1 1 1 1 
1 – 99 minutes / week 154 (26) 1.55 (1.10 – 2.18)* 1.44 (0.83– 2.51) 1.17 (0.71 – 1.95) 0.53 (0.21 – 1.31) 
≥ 100 minutes / week 30 (5) 1.16 (0.59 – 2.30) 1.89 (0.72– 5.02) 2.04 (0.86 – 4.83) 2.47 (0.86 – 7.09) 
Use adhesive removing solvents      
Yes vs No 197 (28) 1.50 (1.10 – 2.04)* 1.43 (0.88 – 2.31) 0.91 (0.57 – 1.46) 0.62 (0.30– 1.29) 
0 minutes / week 500 (81) 1 1 1 1 
1 – 99 minutes / week 105 (17) 1.74 (1.19 – 2.54)** 1.38 (0.75 – 2.53) 0.88 (0.48 – 1.61) 0.23 (0.05 – 0.98)* 
≥ 100 minutes / week 14 (2) 1.63 (0.66 – 4.04) 3.47 (1.06 – 11.36)* 2.06 (0.62 – 6.84) 2.24 (0.45 – 11.11) 
Data are presented as OR (95% CI), unless otherwise indicated. ##: mean ratio (95% CI); OR: odds ratio; CI: confidence interval; *: p-value < 0.05; **: p-value < 0.01; ***: p-value < 0.001; WRONS: Work-related ocular–nasal 
symptoms (ocular–nasal symptoms experienced at work in the past 12 months that gets better when away from work OR worsen on return to work; WRAS: Work-related asthma symptoms (asthma symptoms experienced at 
work in the past 12 months that gets better when away from work OR worsen on return to work; Adjusted for atopy, gender and smoking 
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Table 7.8: Bronchial hyperresponsiveness and airway inflammation associated with specific chemicals and tasks used in patients’ skin/wound 
cleaning and disinfection among health workers in the tertiary hospitals 
 Prevalence 
(%) 
Dose-response slope 
(DRS)
ǂ
 
(n = 239) 
NSBH 
 
(n = 446) 
FeNO, ppb
ǂ
 
 
(n = 654) 
FeNO≥ 50 ppb 
 
(n = 654) 
Prevalence (%)   57 (13)  41 (6) 
Patients’ skin/wound cleaning and disinfection 327 (47) 0.74 (0.42 – 1.28) 1.28 (0.72 – 2.26) 1.16 (1.06 – 1.28)** 1.55 (0.80 – 3.00) 
Disinfect skin areas on patients prior to procedure      
Yes vs No 253 (36) 0.83 (0.50 – 1.40) 1.40 (0.79 – 2.47) 1.08 (0.98– 1.19) 0.94 (0.47 – 1.86) 
0 minutes / week 444 (74) 1 1 1 1 
1 – 99 minutes / week 96 (16) 0.80 (0.42 – 1.53) 1.61 (0.77 – 3.40) 1.11 (0.96– 1.28) 0.50 (0.15 – 1.70) 
≥ 100 minutes / week 58 (10) 0.46 (0.15 – 1.39) 0.93 (0.30 – 2.83) 1.23 (1.03 – 1.47)* 1.95 (0.75 – 5.08) 
Clean and disinfect wounds      
Yes vs No 162 (23) 0.95 (0.56 – 1.60) 1.65 (0.92 – 2.97) 1.14 (1.02 – 1.28)* 2.36 (1.19 – 4.68)* 
0 minutes / week 535 (90) 1 1 1 1 
1 – 99 minutes / week 39 (6) 0.44 (0.16 – 1.18) 1.33 (0.43 – 4.14) 1.15 (0.94– 1.40) 0.59 (0.08– 4.56) 
≥ 100 minutes / week 22 (4) 0.91 (0.27 – 3.08) 2.27 (0.69 – 7.47) 1.41 (1.09 – 1.82)** 7.36 (2.51 – 21.58)*** 
Apply wound dressing      
Yes vs No 143 (21) 0.76 (0.44 – 1.30) 0.91 (0.47 – 1.76) 1.04 (0.92 – 1.17) 0.91 (0.40 – 2.07) 
0 minutes / week 554 (90) 1 1 1 1 
1 – 99 minutes / week 44 (7) 0.77 (0.31 – 1.90) 1.23 (0.44 – 3.41) 1.22 (1.00 – 1.49)* 1.81 (0.58 – 5.61) 
≥ 100 minutes / week 18 (3) 0.47 (0.13 – 1.68) NC 0.99 (0.74 – 1.33) NC 
Use adhesives      
Yes vs No 279 (40) 0.76 (0.44 – 1.30) 1.25 (0.71 – 2.20) 1.10 (1.00 – 1.21) 1.51 (0.79 – 2.91) 
0 minutes / week 418 (69) 1 1 1 1 
1 – 99 minutes / week 154 (26) 0.72 (0.40 – 1.30) 1.08 (0.54 – 2.16) 1.16 (1.03 – 1.30)* 1.82 (0.86 – 3.81) 
≥ 100 minutes / week 30 (5) 1.01 (0.30 – 3.36) 2.68 (0.87 – 8.23) 1.09 (0.87– 1.38) 0.64 (0.08 – 4.99) 
Use adhesive removing solvents      
Yes vs No 197 (28) 0.89 (0.53 – 1.50) 1.09 (0.61 – 1.97) 1.15 (1.04 – 1.28)** 1.45 (0.72 – 2.91) 
0 minutes / week 500 (81) 1 1 1 1 
1 – 99 minutes / week 105 (17) 0.88 (0.49 – 1.58) 1.01 (0.48 – 2.11) 1.24 (1.09 – 1.42)** 2.03 (0.92 – 4.49) 
≥ 100 minutes / week 14 (2) 1.03 (0.25 – 4.32) 1.30 (0.27 – 6.28) 1.04 (0.75 – 1.459) NC 
Data are presented as OR (95% CI), unless otherwise indicated. OR: odds ratio; CI: confidence interval; ǂ: Geometric mean ratio (95% Confidence Interval); *: p-value < 0.05; **: p-value < 0.01; ***: p-value < 0.001;NSBH: 
nonspecific bronchial hyperresponsiveness;NSBH defined as any of the following two criteria: PD20 methacholine < 0.4 mg OR ≥12% and ≥ 200 ml increase in FEV1 after administration of a bronchodilator; Adjusted for atopy, 
gender and smoking; NC: not calculable 
 
 
 
7.4. DISCUSSION 
This study has identified a number of cleaning agents and tasks that are positively 
associated with asthma-related outcomes (asthma symptoms, bronchial 
hyperresponsiveness and FeNO) and work-related ocular-nasal symptoms. This consistent 
association with multiple asthma parameters suggests overall consistency and confidence in 
this relationship. Furthermore, there was also some specificity in these relationships in that 
consistent associations were more prominent for certain medical instrument cleaning agents 
(OPA, QACs and enzymatic cleaners) and tasks (pre-cleaning of medical instruments, 
changing sterilisation solutions and manual disinfection of medical instruments) as well as 
certain patient care activities (disinfecting patients‘ skin before procedure, 
cleaning/disinfecting wounds, applying wound dressing, using adhesives and adhesive 
removing solvents). A particularly pronounced dose-response relationship was observed 
between WRONS and medical instrument cleaning agents associated with asthma and 
tasks. Furthermore, a strong association was observed between higher asthma symptom 
scores and use of more sprays than wipes for fixed surface cleaning activities. 
In this study, positive dose-response relationships (based on frequency duration measure) 
were observed between WRONS and specific agents (OPA, glutaraldehdye, QACs, 
enzymatic cleaners, alcohols and bleach) used for cleaning and disinfection of medical 
instruments. Similar relationships were observed between WRONS and specific cleaning 
and disinfecting tasks for medical instruments (changing sterilisation solutions and manual 
disinfection). Furthermore, cleaning and disinfecting tasks for medical instruments were also 
positively associated asthma symptom score and airway inflammation (FeNO). This finding 
is consistent with previous studies that have demonstrated an association between agents 
used for medical instrument cleaning and disinfection (glutaraldehyde, formaldehyde, 
hydrogen peroxide, quaternary ammonium compounds and enzymatic cleaners) and asthma 
or rhinitis (7–10). Arif et al (8) reported significantly increased odds of reported asthma 
among HWs exposed to medical instrument cleaning agents (OR = 1.67; 95% CI: 1.06 to 
2.62). Lack of consistent associations between WRAS and cleaning-related exposures could 
be due to healthy worker survival bias in that HWs who developed symptoms due to 
cleaning agents may have self-selected themselves out of their jobs, redeployed to other 
jobs/areas with less exposure or left the workforce completely. In this study, 2% of study 
participants had to change their jobs due to WRAS. The major agents responsible for the 
WRAS included the general dust, natural rubber latex and OPA / glutaraldehyde. Healthy 
worker survival bias has been reported in other studies of HWs exposed to cleaning agents 
(6,7,16). 
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Glutaraldehyde was widely used in the past as a high-level disinfectant for medical 
instruments in health care settings, its use has declined since exposure to glutaraldehyde 
has been linked to various adverse health effects including ocular-nasal symptoms and 
asthma (9,10,35–38). Although some health facilities have switched to other high-level 
disinfectants such as OPA and QACs, glutaraldehyde was still the most common high-level 
disinfectant used in the Tanzanian hospital compared to the South African hospital that 
commonly used OPA in the past decade.  
Although initially considered a safer replacement for glutaraldehyde, OPA has increasingly 
been reported to cause occupational asthma, contact dermatitis and anaphylaxis in health 
workers as well as patients undergoing instrument procedures during this period (39–45). A 
more recent study (45) reported a case of occupational asthma in a HW caused by OPA that 
was confirmed by a specific bronchial challenge test (45). In the study by Miyajima et al. (46) 
of Japanese HWs that performed endoscope disinfection with OPA, 16% reported 
respiratory symptoms and 9% ocular symptoms related to OPA. Similarly, another Japanese 
study that only investigated HWs exposed to OPA in endoscopy units reported higher 
prevalence (24%) of OPA-related symptoms (respiratory, ocular, skin symptoms or 
headache) (47). In the current study, 13% of HWs who used OPA had OPA-related 
symptoms (ocular-nasal: 11%, skin: 4% or chest: 3%), consistent with results from the two 
Japanese studies. In contrast to the two Japanese studies, this current study also used more 
objective measures by conducting quantitative exposure measurements as well as 
immunological assessment for OPA. In the current study, OPA detectable levels (GM = 
0.010 ppm) were higher than the newly proposed ACGIH‘s TLV-Ceiling Limit of 0.0001 ppm. 
The results of this current study are consistent with previous studies that have demonstrated 
an association between exposure to QACs and asthma or rhinitis, not only in HWs but also 
in domestic cleaners (3,4,9,10,48). During the period of the present study, reports of 
anaphylaxis in cancer patients undergoing repeated cystoscopies that were sterilised with 
OPA prompted a switch to a product containing QACs (alkyl dimethyl benzyl ammonium 
chloride) for disinfection of urologic instruments in the South African hospital. However, due 
to concerns regarding its effectiveness in infection prevention and HWs reporting work-
related symptoms, the disinfectant containing QACs was replaced by another product 
containing a mixture of acetic acid, peracetic acid and hydrogen peroxide. In the current 
study a more than 3-fold increased odds of WRAS was observed for HWs that used 
hydrogen peroxide for medical instrument disinfection. This is consistent with a previous 
French study (14) that reported two cases of asthma among HWs that was attributed to a 
peracetic acid-hydrogen peroxide disinfectant used for high-level disinfection of medical 
instruments. Furthermore, a recent US study (15) also demonstrated positive association 
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between acute nasal and eye irritation with exposure to a mixture containing hydrogen 
peroxide and peracetic acid and also to hydrogen peroxide, peracetic acid and acetic acid. 
In this study, enzymatic cleaners were used in both hospitals for pre-cleaning of medical 
instruments to remove gross contaminants before disinfecting them with high-level 
disinfectants. In recent years, there has been an increase in the use of proteolytic enzymes 
for medical instrument cleaning in the health care settings (11,12). Subsequently, few 
studies have reported cases of occupational asthma and rhinitis among HWs using 
enzymatic cleaners (12,13). Immunological assessment of sensitisation to proteolytic 
enzymes among HWs has proved to be a challenge mainly due to the lack of specific 
information from manufacturers and suppliers regarding the types of enzymes present in the 
cleaning products (12). Furthermore, commercially available immunological tests have failed 
to identify specific IgE antibodies to these enzymes in symptomatic HWs probably due to the 
lack of specificity of the tests as they were developed for an earlier generation of enzymes, 
which are thought to have a slightly different molecular structure compared to the newer 
generation (12). Exposure to proteolytic enzymes is a recognised cause of allergic 
respiratory and skin symptoms in other occupational groups, particularly among detergent 
manufacturing workers (11,12).  
The findings of this study demonstrated widespread use of chlorine-based bleach that was 
used commonly for fixed surface cleaning and disinfection but also for medical instrument 
cleaning and disinfection in both hospitals. After adjusting for known confounders, chlorine-
based bleach was positively associated with both asthma symptom score (MR = 1.52; 95% 
CI: 1.04 – 2.22) and WRONS (OR = 2.50; 95% CI: 1.41 – 4.43). These results are consistent 
with previous studies that have demonstrated an association between exposure to bleach 
and asthma-related outcomes (4–7,10,17). In a cross-sectional analysis of a population-
based European cohort, domestic use of hypochlorite bleach was associated with lower 
rates of atopy, hay fever and allergic symptoms but higher rates of lower respiratory 
symptoms and NSBH (49). The lack of association between bleach and eosinophilic airway 
inflammation (FeNO) could be due to the irritant nature of bleach-related pathophysiological 
changes. However, the lack of association between bleach and NSBH could be due to the 
lack of statistical power due to the small number of participants who performed interpretable 
methacholine challenge test. Similarly, more symptomatic HWs (≥ 2 asthma-related 
symptoms) had a two-fold increased odds of using ammonia-based products for fixed 
surfaces cleaning and disinfection. Previous studies have also reported an association 
between exposure to cleaning products containing ammonia and asthma-related outcomes 
(5,6,16,50,51). As in the health setting, both chlorine and ammonia are known to be 
associated with irritant induced asthma in other occupational settings (4,6,16).  
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In this study, predominant use of sprays rather than wipes for fixed surface 
cleaning/disinfection was associated with a 3-fold higher odds of increasing asthma 
symptom score. This relationship was more pronounced for more symptomatic HWs as 
evidenced by the 5-fold increased odds of reporting 2 or more asthma-associated symptoms 
among those who used more sprays than wipes. It is well known that the use of sprays 
generates more aerosols and hence facilitates inhalational exposure. The results of the 
current study are therefore consistent with other studies that have demonstrated a positive 
association between use of cleaning sprays and asthma (and other respiratory symptoms) 
(7,20,32,50–53). Non-specific bronchial hyperresponsiveness (higher DRS) and FeNO were 
also positively associated with terminal cleaning of patient rooms and spraying of 
deodorants/disinfectants respectively. Previous studies have also demonstrated similar 
associations between fixed surfaces cleaning and asthma (4,8,11,16).  
Increased odds of high FeNO were consistently observed among HWs that performed 
patient care activities in this study. In addition, consistent positive dose-response 
relationships were observed between specific asthma-related outcomes (FeNO and 
presence of ≥ 2 asthma-associated symptoms) and either disinfection of patients‘ skin before 
procedures or cleaning/disinfection of wounds. These results are consistent with a previous 
study by Delclos et al, which also demonstrated an association between bronchial 
hyperresponsiveness–related symptoms and the use of adhesives on patients (11). The 
products used for patient care activities are mostly irritants (such as alcohols, ethers and 
acetone), but some such as chlorhexidine are also known sensitisers (11,21,22,54,55). 
The present study also demonstrated a positive association between use of formalin solution 
and increasing FeNO and asthma symptom score in keeping with the findings of previous 
studies (6,7,56). Formaldehyde is known asthmagen with both irritant and sensitising 
properties (57,58). Formalin (10%) solution was commonly used in both hospitals for 
specimen preparation (tissue fixation). The exposure assessment study conducted in the 
South African hospital identified detectable levels of formaldehyde (GM = 0.005 ppm) in a 
greater proportion (38%) of the 269 collected samples (Chapter 4). Three (1%) samples had 
formaldehyde levels higher than the NIOSH recommended exposure limit (REL) of 0.016 
ppm TWA, but none greater than the ACGIH TLV-TWA (0.1 ppm). 
One of the overall findings of this study showed that FeNO, a non-invasive marker of 
eosinophilic airway inflammation, was positively associated with the use of OPA, QACs, 
enzymatic cleaners, chlorhexidine, formalin solution and spraying of 
deodorants/disinfectants. All of these agents are known sensitisers capable of causing 
allergic respiratory and skin symptoms in exposed individuals. Deodorants usually contain 
limonene and pinene, which have both sensitizing and irritant properties and known to be 
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associated with adverse respiratory health effects (1,16,20). Increased FeNO was also 
commonly observed among HWs who performed patient care activities. This may be due to 
exposure to sensitising agents such as chlorhexidine commonly used in patient care 
activities. Alternatively, this could be due to exposure to irritants such as alcohols and ethers 
used in these tasks. There have been few studies that have reported high FeNO levels in 
individuals exposed to irritants (59,60), although this is not a common finding. Since irritant 
exposures are known to enhance allergic inflammation (4,3), increased FeNO levels could 
also be explained by co-exposure to irritants and sensitisers during the course of their work. 
This is suggested by the findings of a Spanish study (61) that demonstrated an association 
between FeNO and usage of multi-use cleaning products, glass cleaners and polishes 
among professional cleaners. 
In a study of this nature, the impact of potential biases need to be considered. There is a 
possibility of recall bias since self-reported information of chemical usage by HWs in relation 
to asthma symptoms was used in the study. However, this is unlikely to have had a major 
influence on the results since consistent associations were also observed with more 
objective tests such as FeNO. The inability to demonstrate statistically significant 
associations between NSBH (particularly the categorical variable) and some cleaning agents 
and tasks could be attributable to the lack of statistical power due to the small number of 
participants using certain agents. In addition, due to the small number of study participants in 
the last category (≥100 minutes per week) for some cleaning agents and tasks and some 
missing information for the duration and frequency data, the results of this study should be 
interpreted with caution due to the unstable nature of some of these estimates. Since 
multiple statistical tests were used in this study to investigate the associations between a 
number of chemicals, spurious associations could have been observed so the results should 
be interpreted in conjunction with the relevant contextual information. This could also be a 
possible reason for the inverse association observed between adhesive removing solvents 
and work-related asthma symptoms, although selection effects in the form of the healthy 
worker effect may have played a role since symptomatic individuals may choose alternative 
tasks or jobs associated with less continuous irritant exposures. Furthermore, due to the 
cross-sectional nature of this study, temporal relationships between exposure to these 
cleaning agents and asthma-related outcomes could not be determined with certainty. 
Finally, the lack of objective exposure data also hampered the ability to move beyond 
duration and frequency of use to more specific exposure metrics such as exposure 
concentrations to further quantify the dose response relationships. 
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7.5. CONCLUSION 
A number of medical instrument cleaning agents (including OPA, QACs and enzymatic 
cleaners) and tasks (pre-cleaning of medical instruments, changing sterilisation solutions 
and manual disinfection of medical instruments) as well as patient care activities were 
associated with an increased risk of having asthma-related outcomes in health workers of 
two tertiary hospitals located in sub-Saharan Africa. Furthermore, a positive dose-response 
relationship was found between work-related ocular-nasal symptoms and medical instrument 
cleaning agents and tasks. Asthma symptom score was also positively associated with the 
use of sprays for fixed surface cleaning, confirming the findings of studies in other 
professional cleaning contexts. 
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8.1. SUMMARY OF STUDY FINDINGS 
This study was initiated as a result of an increasing trend of work-related asthma (WRA) 
associated with cleaning agents among health workers (HWs) being referred to the 
Occupational Medicine Clinic at Groote Schuur Hospital. The thesis examines the magnitude 
and risk factors for WRA in HWs exposed to cleaning agents in two academic tertiary public 
hospitals, one in South Africa and the other in Tanzania. It has demonstrated that asthma 
and work-related symptoms are common in these HWs and that cleaning agents have 
replaced natural rubber latex (NRL) as an important cause of WRA in health care settings in 
southern Africa. The novel contribution is in the exposure assessment to cleaning agents 
using quantitative environmental sampling, immunological assessment of sensitisation to 
ortho-phthlaldehyde (a high-level disinfectant for medical instrument) and chlorhexidine 
(used for patient care activities and hand hygiene), and using markers of allergic airway 
inflammation (FeNO) and bronchial hyperresponsiveness. It further describes various 
asthma phenotypes in these HWs and investigates host and environmental risk factors 
associated with work-related asthma outcomes.  
 
8.1.1. CHARACTERISATION OF EXPOSURE TO CLEANING AGENTS AND 
DETERMINANTS 
Most studies investigating the relationship between cleaning agents and asthma have lacked 
systematic exposure assessment, with only a few reports of quantitative measurements in 
the health setting (1,2). This is largely due to the challenges associated with exposure 
assessment of cleaning agents, since many cleaning agents are usually used 
simultaneously resulting in complex airborne exposures that require multiple sampling 
techniques (3). The current study has addressed some of these challenges by conducting 
detailed exposure assessment through environmental measurements of aldehydes (ortho-
phthalaldehyde - OPA, glutaraldehyde and formaldehyde) and biomonitoring for exposure to 
chlorhexidine. The current study has demonstrated that a wide variety of agents are used for 
cleaning and disinfection in hospital settings located in southern Africa (Chapter 4). 
Although, cleaning agents used in this study were similar to those used in other health care 
settings, the frequency and duration of use differed from these contexts. 
The most common high-level disinfectant used in the South African hospital (SAH) was OPA 
followed by hydrogen peroxide. However, in the Tanzanian hospital (TAH), glutaraldehyde 
was more commonly used, followed by OPA. Products that are used for cleaning medical 
instruments prior to disinfection such as enzymatic cleaners and chlorine-based bleach 
products were used for the longest duration compared to the high-level disinfectants. For 
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fixed surfaces cleaning and disinfection, chlorine-based bleach was the most common 
product, which also had the longest average duration of use in both hospitals. In the SAH, 
HWs used both the hypochlorite liquid bleach and the granules (which were dissolved in 
water before use). Hypochlorite liquid bleach and troclosene sodium effervescent tablets 
were used in the TAH.  
While floor finishing tasks were not performed by HWs in the TAH, floor strippers and waxes 
were used once a year in each department in the SAH as well as buff sprays (diluted floor 
waxes) which were used more frequently. Formalin (10%) solution was commonly used in 
both hospitals for specimen preparation (tissue fixation), mostly in areas where procedures 
were performed such as operating theatres. However, HWs in the SAH reported a higher 
duration of formalin use than their Tanzanian counterparts. Alcohols and povidone iodine 
were used commonly in both hospitals for disinfection of patients‘ surfaces before a surgical 
or instrument procedure or for wound care, with the longest duration of use recorded in 
emergency units as well as in operating theatres and intensive care units. On the other 
hand, chlorhexidine containing products were commonly used in the SAH for patients‘ 
surfaces disinfection and wound care but not in Tanzania. Liquid products for hand hygiene 
were used quite commonly by HWs in all the departments studied in both hospitals although 
SAHWs reported much higher frequency of use. Chlorhexidine containing products, liquid 
hand soap and alcohol sanitisers were the most common hand hygiene products used in the 
SAH while in the TAH, a diluted all-purpose cleaner was the most commonly used, followed 
by an alcohol sanitiser. 
In this study, OPA was detectable in 6 (2%) of all samples analysed. These detectable 
samples (GM = 0.010 ppm) were all collected in the gastrointestinal unit of the SAH and all 
had OPA levels higher than the newly proposed ACGIH‘s TLV-Ceiling Limit of 0.0001 ppm 
(4). Furthermore, OPA levels were, on average, 10-fold higher than in similar settings 
elsewhere and were dependent on the type of department, job title, personal use of OPA 
and duration of use. Formaldehyde, on the other hand was detectable in a greater proportion 
(38%) of the 269 collected samples (GM = 0.005 ppm), with three (1%) samples recording 
formaldehyde levels higher than the NIOSH recommended exposure limit (REL) of 0.016 
ppm TWA, but none greater than the ACGIH TLV-TWA (0.1 ppm). Formaldehyde levels 
recorded in the current study were, on average, 10-fold lower compared to studies among 
laboratory workers in hospital settings (5). Laboratory workers are well known for their higher 
usage of formaldehyde for specimen preparation compared to other categories of hospital 
workers. Furthermore, the formaldehyde levels in the current study were more comparable 
to average levels in US general buildings (6). Since only a small proportion of the variability 
in the formaldehyde levels measured in the current study was explained by the type of 
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department, it is probable that the most likely source of exposure is the widespread use of 
formaldehyde (10%) solution used for specimen preparation in most departments, residue 
evaporation from formaldehyde contaminated surfaces and other general indoor sources. 
While the study was initially set up to determine the concentration of chlorhexidine and its 
metabolites (p-chloroaniline (PCA) and 1-chloro-4-nitrobenzene), the development of an 
assay only for PCA proved feasible. PCA was detectable in 13 (4%) of all 336 urine samples 
that were analysed (GM = 2.41 ng/ml), which did not appear to differ by department or job 
type. It was not possible to compare the measured PCA levels in this study with other 
studies due to the lack of exposure measurements obtained using standardised, validated 
and sensitive methods for chlorhexidine. Nevertheless, the findings of this study could be a 
useful comparison for future studies focussing on measuring PCA in urine. 
The study also highlighted that workplace controls for reducing exposure to cleaning agents 
were inadequate. Notably, there were no local exhaust ventilation (LEV) systems in any of 
the work areas evaluated. Whilst extractor fans were present in a few areas, their 
effectiveness/efficiency was not assessed. Furthermore, use of appropriate personal 
protective equipment was very low and none of the workers used appropriate respirators nor 
was appropriate protective clothing made available to prevent dermal exposure. Moreover, a 
low proportion of HWs (44% in SAH and 23% in TAH) had received training on adverse 
health effects caused by cleaning agents, while none had undergone medical surveillance. 
 
8.1.2. PREVALENCE OF SYMPTOMS, ALLERGIC SENSITISATION AND LUNG 
FUNCTION ABNORMALITIES 
The findings of this study have demonstrated that HWs in the two tertiary academic hospitals 
experienced an appreciable proportion of work-related airway and skin symptoms similar to 
their counterparts in other regions of the world. As has been reported in most studies of 
work-related rhinitis and asthma (7), the prevalence of work-related ocular-nasal symptoms 
(WRONS) was twice as common as asthma symptoms in this study. Furthermore, in this 
current study, the prevalence of WRONS (23%) and asthma symptoms (12%) was higher 
than that reported in South African dental HWs (14% and 4% respectively) (8) (Chapter 5). 
Moreover, in this current study, the prevalence of work-related asthma symptoms (WRAS) in 
the past 12 months (7%) was higher than a US study of HWs (3.3%) and on the upper end 
of the range compared to a Saudi Arabian study of HWs (5.7%), both of which used a similar 
definition of WRAS (9,10). This is most likely due to inadequate workplace controls observed 
in the current study. In addition, 16 (2%) workers with WRAS in the current study had to 
change their jobs due to these symptoms, underscoring the negative consequences 
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associated with WRA. Unlike upper and lower airway symptoms that were similar across 
both hospitals studied, a higher prevalence of skin symptoms (work-related and non-work-
related) was reported among South African HWs (SAHWs), which is most likely due to the 
significantly (p<0.001) higher frequency of hand washing at work among SAHWs (58 times 
per day), compared to Tanzanian HWs (20 times per day).  
In this study, the prevalence of atopy (positive Phadiatop test) was higher (47%) in the 
SAHWs compared to the Tanzanian HWs (40%) and on upper end of other workplace-based 
South African studies (36 – 46%) (8,11–13). Furthermore, in the current study, 8% of HWs 
had OPA allergic sensitisation or work-related symptoms due to OPA, with HWs 
experiencing more ocular-nasal symptoms (3%) compared to chest (2%) and skin (1%) 
symptoms.  
Despite 20% of SAHWs reporting work-related symptoms due to chlorhexidine in this study, 
only three (1%) HWs had evidence of chlorhexidine sensitisation. Since Tanzanian HWs 
(TAHWs) did not use chlorhexidine containing products, immunological assessment for 
chlorhexidine was not evaluated in the latter group. The low prevalence of chlorhexidine 
sensitisation in this study is similar to the findings by Garvey et al. that did not identify any 
HW with sensitisation to chlorhexidine using a different series of immunological skin tests 
(skin prick, intradermal and patch tests) (14). In contrast, several cases of chlorhexidine 
allergy have been frequently reported among patients, which may be related to direct 
mucosal contact during operative procedures (15). 
In this current study, the prevalence of NRL sensitisation was 2% compared to a previous 
study (16) conducted more than a decade ago in the same SAH, which reported a 9% 
prevalence of NRL sensitisation. The decline in prevalence of NRL sensitisation is most 
likely related to the latex avoidance measures implemented in the hospital following the 
initial study, more specifically the substitution of powdered latex gloves with less-
powdered/powder-free low protein gloves in accordance with the hospital‘s latex policy.  
In this current study, pulmonary function tests revealed significantly lower lung volumes 
among TAHWs compared to their South African counterparts. One possible explanation for 
this finding is the high frequency of repeated childhood chest infections reported in the 
TAHWs. Repeated childhood chest infections has been reported to be a risk factor for the 
lower adult FEV1 (17). Another possible explanation for the observed difference is the 
exposure to biomass fuel, which is commonly used for cooking by most individuals (99.5%) 
(18). Furthermore, a higher prevalence of airway obstruction was also found in this group of 
TAHWs, which could be related to the higher prevalence of repeated childhood chest 
infections and biomass fuel exposure reported by TAHWs. 
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The median FeNO levels (17 ppb) obtained for HWs in the current study were comparable to 
the findings reported in other workplace-based studies in Tanzania and South Africa in non-
health care settings (13,19–22). However, the prevalence of high FeNO (>50 ppb)  indicative 
of allergic airway inflammation in the current study (6%), was much lower than previous 
South African study of workers exposed to predominantly high molecular weight protein 
agents (11%) (19). This suggests that WRA observed in this current group of workers had 
both allergic and non-allergic components, that required further investigation (2,23).  
 
8.1.3. ASTHMA PHENOTYPES AND HOST-RELATED RISK FACTORS 
In previous studies, the reported prevalence of asthma among HWs has varied quite widely 
most likely due to the different asthma definitions used. Therefore, the standardized ECRHS 
definition of current asthma was used in this study. The prevalence of current asthma was 
10%, with atopic asthma (6%) more prevalent than non-atopic asthma (4%). Overall, there 
were 2% of subjects with WRA (Chapter 6). In addition, most asthma-related outcomes 
(DRS, asthma symptom score and current asthma) and work-related outcomes (WRONS, 
WRAS and work-related asthma) were positively associated with allergic disease attributes 
(atopy, history of hay fever, family history of allergy and FeNO). In this study, there was also 
a weak positive association between bronchial hyperresponsiveness and FeNO. These 
findings suggest different underlying pathophysiological mechanisms that co-exist. However, 
it would appear that allergic mechanisms may be playing a more dominant role in work-
related asthma in these HWs. The pathophysiological mechanisms involved in asthma 
related to cleaning agents are still not yet clear for most of the cleaning chemicals. Previous 
studies have suggested involvement of both allergic and irritant mechanisms although the 
latter has been generally thought to be the dominant mechanism. Furthermore, it is probable 
that both these mechanisms may enhance each other, such that airway epithelial damage 
due to irritant exposures can also activate an allergic T helper type 2 (Th2) response and 
increase the risk of sensitisation (2,23). 
In this study, stronger associations were observed for asthma symptoms when FeNO ≥ 50 
ppb (a marker of allergic airway inflammation) was combined with NSBH (BDR or MCT 
positive). Furthermore, stronger associations were also observed between sensitisation to 
occupational allergens and atopy. With the exception of one non-atopic participant who was 
sensitised to OPA, all the remaining HWs that were sensitised to occupational allergens 
(OPA, chlorhexidine and NRL) were atopic. Most studies have reported a greater likelihood 
of atopic individuals developing sensitisation to high molecular weight occupational allergens 
(12,13,22,24). The findings of the current study that atopic individuals are also more likely to 
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be sensitised to low molecular weight occupational allergens such as OPA and 
chlorhexidine, add to the small number of agents in other exposure contexts demonstrating a 
similar finding. Serum specific IgE antibodies to OPA and chlorhexidine have also been 
detected in a few studies of individuals exposed to these agents (15,25–27). Furthermore, 
animal studies have suggested that OPA is a respiratory and dermal sensitiser as was 
evidenced by a predominant expression of Th2 cytokines (IL-4, IL-5 and IL-13) in mice that 
were exposed to OPA (28,29). In addition, the clinical history in the case reports of asthma 
due to OPA also demonstrated a latency period between first exposure to OPA and 
development of symptoms implying immunologic response caused by OPA (30,31). 
Interestingly, animal studies have also suggested that OPA is more irritant than GTA using 
both in-vitro EpiDerm Skin Irritation Test and in-vivo tests (28). In addition to being 
consistent with an immunological mechanism, this further suggests that the mechanism is 
probably IgE-mediated. Future studies should investigate this further so as to have a better 
understanding of the underlying pathophysiological mechanisms associated with asthma to 
these agents. 
As to be expected, FeNO (a non-invasive marker of eosinophilic airway inflammation) was 
positively associated with allergic predictors (atopy and history of hay fever) and a history of 
childhood-onset asthma. Even stronger associations were observed with high FeNO (≥50 
ppb) levels. A positive association between FeNO and atopy is well-known and has also 
been reported in recent South African studies in other occupational exposure contexts 
(13,19,22), while the few studies that have conducted FeNO studies in Tanzania did not 
assess the role of atopy (20,21). Furthermore, a strong positive association (ORunadj = 3.59, 
CI: 1.63 – 7.93; ORadj (atopy + smoking) = 1.93, CI: 0.85 – 4.37) was also observed between 
elevated FeNO (≥25 ppb) and allergic sensitisation to OPA / chlorhexidine. Much stronger 
relationships have been demonstrated in workplace-based studies among South African 
workers exposed to predominantly high molecular weight agents (13,19).  
In this current study, a positive association was observed between female gender and 
asthma-related outcomes consistent with other studies of asthma and occupational 
exposures to cleaning agents. This could be explained by the gendered distribution of the 
workforce, since a large proportion (78%) of study participants were women. However, new-
onset asthma in adulthood has been shown to be more prevalent amongst women with 
female sex hormones implicated in the pathogenesis (32).  
Interestingly, in the current study, a past history of pulmonary tuberculosis (TB) was strongly 
associated with asthma-related outcomes. This association persisted even after adjusting for 
age, gender, smoking, atopy and body mass index. Similar findings have also been reported 
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in South African population-based and workplace-based studies (33,34). This observation 
needs further exploration in a larger longitudinal study of these HWs. 
In this study, smoking was positively associated with only certain asthma-related outcomes 
(asthma symptom score and with non-atopic asthma). This is consistent with the current 
body of evidence with studies reporting inconsistent findings of the association between 
smoking and asthma in general and with occupational asthma in particular (32,35). 
Furthermore, very limited specific information is available on the risk of smoking in relation to 
asthma among HWs exposed to cleaning agents (35,36). The study by Zock et al. in 
cleaning workers did not demonstrate any association between smoking and asthma (36). 
Additional longitudinal studies are needed to better understand this relationship between 
smoking, occupational allergic sensitisation and asthma risk among HWs exposed to 
cleaning agents. 
 
8.1.4. EXPOSURE-RESPONSE RELATIONSHIPS 
This study has identified a number of cleaning agents and tasks that are positively 
associated with asthma-related outcomes (asthma symptoms, bronchial 
hyperresponsiveness and FeNO) and WRONS. This consistent association with multiple 
asthma parameters suggests overall consistency and confidence in this relationship. 
Furthermore, there was also some specificity in these relationships in that consistent 
associations were more prominent for certain medical instrument cleaning agents (OPA, 
QACs and enzymatic cleaners) and tasks (pre-cleaning of medical instruments, changing 
sterilisation solutions and manual disinfection of medical instruments) as well as certain 
patient care activities (disinfecting patients‘ skin before procedure, cleaning/disinfecting 
wounds, applying wound dressing, using adhesives and adhesive removing solvents). A 
particularly pronounced dose-response relationship was observed between WRONS and 
medical instrument cleaning agents associated with asthma and tasks (Chapter 7). 
In this study, predominant use of sprays rather than wipes for fixed surface 
cleaning/disinfection was associated with a 3-fold increased odds of having a higher asthma 
symptom score. This relationship was more pronounced for more symptomatic HWs as 
evidenced by the 5-fold increased odds of reporting 2 or more asthma-associated symptoms 
among those who used more sprays than wipes. It is well known that the use of sprays 
generates more aerosols and hence facilitates inhalational exposure. The results of the 
current study are therefore consistent with other studies that have demonstrated a positive 
association between use of cleaning sprays and asthma (and other respiratory symptoms) 
(37–43). Non-specific bronchial hyperresponsiveness and FeNO were also positively 
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associated with terminal cleaning of patient rooms and spraying of deodorants/disinfectants 
respectively, consistent with previous studies that have demonstrated similar associations 
between fixed surfaces cleaning and asthma (23,44–46). 
Increased odds of high FeNO were consistently observed among HWs that performed 
patient care activities in this study. In addition, consistent positive dose-response 
relationships were observed between specific asthma-related outcomes (FeNO and 
presence of ≥ 2 asthma-associated symptoms) and either disinfection of patients‘ skin before 
procedures or cleaning/disinfection of wounds. These results are consistent with a previous 
study by Delclos et al., which also demonstrated an association between bronchial 
hyperresponsiveness–related symptoms and the use of adhesives on patients (45). The 
products used for patient care activities are mostly irritants (such as alcohols, ethers and 
acetone), but some such as chlorhexidine are also known sensitisers (45,25,27,47,15). 
One of the overall findings of this study showed that FeNO, a non-invasive marker of 
eosinophilic airway inflammation, was positively associated with the use of OPA, QACs, 
enzymatic cleaners, chlorhexidine, formalin solution and spraying of 
deodorants/disinfectants. All of these agents are known sensitisers capable of causing 
allergic respiratory and skin symptoms in exposed individuals. Deodorants usually contain 
limonene and pinene, which have both sensitising and irritant properties and known to be 
associated with adverse respiratory health effects (48,46,38). Increased FeNO was also 
commonly observed among HWs who performed patient care activities. This may be due to 
exposure to sensitising agents such as chlorhexidine commonly used in patient care 
activities. Alternatively, this could be due to exposure to irritants such as alcohols and ethers 
used in these tasks. There have been few studies that have reported high FeNO levels in 
individuals exposed to irritants (49,50), although this is not a common finding. Since irritant 
exposures are known to enhance allergic inflammation (23,2), increased FeNO levels could 
also be explained by co-exposure to irritants and sensitisers during the course of their work. 
This is suggested by the findings of a Spanish study (51) that demonstrated an association 
between FeNO and usage of multi-use cleaning products, glass cleaners and polishes 
among professional cleaners. 
 
8.2. STRENGTHS AND LIMITATIONS 
8.2.1. STRENGTHS 
To the knowledge of investigators, this is the first study in Africa to have conducted 
quantitative exposure assessment for aldehydes (OPA, glutaraldehyde and formaldehyde) in 
hospital settings. This study is also the first African study to have conducted biological 
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monitoring for evaluation of chlorhexidine exposures in HWs. The study is also unique in that 
it was conducted in two different southern African hospital settings (SAH and TAH) using 
similar qualitative and quasi-quantitative exposure assessment methods for exposures to 
cleaning agents. Notably, the study has described the most common cleaning agents used 
for specific cleaning tasks in these settings and the typical frequency and durations of 
exposure to cleaning agents in different hospital departments in two different contexts in 
southern Africa.  
This is also the first study in southern Africa of HWs exposed to cleaning agents and the first 
globally to have undertaken an extensive epidemiological study, using multiple clinical 
endpoints of asthma, including the immunological assessment of HWs to OPA and 
chlorhexidine and assessing the presence of airway inflammation using exhaled nitric oxide. 
Previous studies reported only on the presence of work-related symptoms and did not 
provide more objective measures of work-related allergy and asthma as was done in the 
current study. Furthermore, this is also the first epidemiological study on the immunological 
assessment of HWs sensitized to NRL in Tanzania. 
8.2.2. LIMITATIONS 
Selection bias due to healthy worker effect (healthy worker selection bias and healthy worker 
survival bias) is one of major challenges of workplace-based cross-sectional epidemiological 
studies. Healthy worker selection bias could have underestimated the effect of cleaning 
agents on asthma if individuals without respiratory symptoms/disorders such as asthma 
were more likely to select themselves or be screened into jobs with exposure to cleaning 
agents in the hospitals. However, since this practice was non-existent in the hospitals 
studied, this type of selection bias was unlikely to have affected the results of this study. On 
the other hand, HWs who developed symptoms due to cleaning agents may self-select 
themselves out of their jobs, redeployed to other jobs/areas with less exposure or leave the 
workforce completely and hence cause another type of selection bias (healthy worker 
survival bias). This may have impacted on the overall prevalence of work-related asthma 
reported in this study. While only 2% of study participants changed their jobs due to WRAS 
in this study, selection bias may have influenced the direction of the bias towards the null 
resulting in less power to demonstrate some of the associations. This could have been 
further compounded by the 53% overall response rate and lack of information on health 
workers who may have left their job due to their asthma symptoms. 
Some of the asthma phenotypes such as current asthma, asthma symptom score and work-
related asthma were based on self-reported information from the questionnaire. This could 
have resulted in misclassification of asthma status. Self-reported symptom information is 
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usually characterised by high sensitivity but low specificity in identifying individuals with 
asthma. However, in this study, self-reported asthma information correlated relatively well 
with NSBH and FeNO (Chapter 6). Furthermore, there is also a possibility of differential 
misclassification of the exposure to cleaning agents since self-reported information of 
chemical usage was used. This would be possible if HWs with asthma symptoms recalled 
better their use of cleaning products and hence the direction of the bias would be away from 
the null. However, this bias is unlikely to have had major influence on the results since 
consistent associations were also observed with objective tests such as FeNO (Chapter 7).  
In the current study, there were some limitations in obtaining a comprehensive 
immunological evaluation of the Tanzanian group. Immunological assessment of 
sensitisation to glutaraldehyde was not done due to the lack of commercially available 
immunoCAP for glutaraldehyde. This is important since glutaraldehyde continues to be used 
as a high-level disinfectant in the TAH. Similarly, it was not possible to conduct 
immunological assessment of sensitisation to enzymatic cleaners in this study due to the 
lack of specific information from manufacturers and suppliers regarding the types of 
enzymes present in the cleaning products. Furthermore, commercially available 
immunological tests have failed to identify specific IgE antibodies to these enzymes in 
symptomatic HWs probably due to the lack of specificity of the tests as they were developed 
for an earlier generation of enzymes, which are thought to have a slightly different molecular 
structure compared to the newer generation. Additionally, methacholine challenge tests 
could not be conducted in the TAH due to logistical reasons. Hence, a slightly less 
composite picture of HWs in this hospital was obtained compared to their South African 
counterparts. Nevertheless, the study has provided important insights into work-related 
asthma in southern African HWs exposed to OPA and NRL. 
The inability to demonstrate statistically significant associations between NSBH (particularly 
the categorical variable) and some cleaning agents and tasks could be attributable to the 
lack of statistical power due to the small number of participants using certain agents. 
Moreover, the lack of objective exposure data (e.g. only 2% of the samples analysed had 
detectable OPA levels) also hampered the ability to move beyond duration and frequency of 
use to more specific exposure metrics such as exposure concentrations to further quantify 
the dose response relationships. 
The study initially sought to determine quantitative exposure to chlorhexidine and its 
metabolites (PCA and 1-chloro-4-nitrobenzene) in urine. Due to logistical and 
methodological considerations, it was not possible to develop a multiplex assay for all these 
compounds except for PCA. Furthermore, although a robust assay for PCA was developed 
in the current study, it was not possible to compare with other studies because of lack of 
211 
 
information in the literature. In this study, passive sampling was used for environmental 
exposure assessment of aldehydes. While environmental conditions such as temperature, 
relative humidity, ozone and air movements are well known factors that could affect the 
performance of passive samplers in measuring airborne aldehyde concentrations, these 
factors are less likely to have affected the study findings since most workers worked indoors, 
with insignificant air movements and temperatures that ranged between 22 to 30 degrees 
Celsius and relative humidity ranging between 40 – 68%. While ozone measurements have 
also been conducted in some studies, there were not done due to resource constraints. 
While the results of this study may be generalisable to tertiary and secondary level hospitals 
in Southern Africa, they may not be relevant to primary health care settings where some of 
cleaning-related tasks are not performed and certain chemicals are not used.  
 
8.3. RECOMMENDATIONS 
8.3.1. An oversight committee of occupational health and infection prevention 
personnel 
In recent years, infection prevention and control (IPC) in health care settings has become 
increasingly important due to the risk of healthcare associated infections, particularly those 
caused by multi-drug resistant organisms. However, these efforts need to be balanced with 
the protection of HWs from harmful exposure to a wide variety of cleaning agents that are 
used for IPC. The best way to accomplish this is to establish a team of both IPC and 
occupational health and safety (OHS) professionals to steward both considerations in order 
to achieve optimal outcomes.  
One of the impacts of this study has been the establishment of a working group of OHS and 
IPC staff as well as other stakeholders (e.g. procurement of chemicals) at the SAH that 
regularly reviews new cleaning agents to be introduced into various departments in the 
hospital. The working group assesses the new cleaning agents with regard to their 
effectiveness in IPC as well as the potential adverse health effects to HWs. The 
establishment of the group was proposed as a result of regular meetings between the study 
investigators and various stakeholders in the SAH during the planning and fieldwork periods. 
At the time, it was not possible to have the same working group at the TAH as there were no 
OHS services provided for the hospital workers. However, the study investigators will 
recommend the development of an OHS service to the TAH management and also assist 
them in establishing this oversight committee involving IPC, OHS and other stakeholders 
(e.g. procurement of chemicals, waste disposal). The aim is to have an integrated approach 
towards prevention of both work-related diseases and healthcare associated infections in the 
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hospital. This approach has also been recently proposed by a multidisciplinary group in the 
US (52). Apart from identifying the least hazardous cleaning agents for use in the hospital, 
the committee should also be responsible for assessment of the ongoing cleaning activities 
and recommend the best work practices to be pursued during cleaning and disinfection as 
well as other appropriate exposure control measures. This committee should also be 
responsible for assessing the compliance of staff to the proposed work practices and 
address any other issues related to IPC and the management of workers experiencing 
adverse health effects due to cleaning agents.  
 
8.3.2. Workplace control measures 
Elimination and Substitution 
Substitution of hazardous agents with less hazardous or non-hazardous agents is usually 
the preferred method of prevention for work-related diseases since it is a more effective 
approach than other methods. In the current study, some of the cleaning agents such as 
OPA, QACs and enzymatic cleaners were consistently identified to be associated with 
asthma and skin symptoms. Furthermore, during the period of the present study, reports of 
anaphylaxis in cancer patients undergoing repeated cystoscopies that were sterilised with 
OPA prompted a switch to a product containing QACs (alkyl dimethyl benzyl ammonium 
chloride) for disinfection of urologic instruments in the SAH. However, due to concerns 
regarding its effectiveness in IPC and work-related symptoms among exposed HWs, the 
disinfectant containing QACs was replaced by another product containing a mixture of acetic 
acid, peracetic acid and hydrogen peroxide. While glutaraldehyde had already been 
replaced with OPA at the SAH a few years prior to the commencement of the study, it 
continued to be used at the TAH. However, the current study findings have now also 
confirmed an association between exposure to OPA and adverse health outcomes, 
consistent with other studies recently being reported. Substituting OPA also pose a 
challenge since other alternatives such as hydrogen peroxide or a mixture of acetic acid, 
peracetic acid and hydrogen peroxide have also been recently reported to produce adverse 
health effects. Similar challenges exist regarding substitution of enzymatic cleaners, more so 
since exact enzymes that are being used in these products are being withheld from 
producers of these agents. When considering substitution, care should be exercised not to 
replace an agent with known hazards with an agent that has similar potential, as was seen 
when glutaraldehyde was replaced by OPA. Quantitative structure-activity software that can 
predict sensitisation potential of chemicals may be very useful for decisions regarding new 
cleaning agents to be introduced in the workplaces (53–55). The use of ―green‖ cleaning 
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agents is promising but more studies are needed regarding their potential health effects to 
workers and patients as well as their effectiveness in IPC (56). Moreover, there are no 
universally accepted criteria for green cleaners and there may be some challenges in 
accessing these cleaning agents in resource constrained health care settings. As a result of 
these challenges associated with substitution, other control measures such as engineering 
methods and administrative controls should also be considered in an effort towards 
prevention of WRA associated with cleaning agents in the health care setting. 
Engineering controls 
In the study, medical instrument cleaning and disinfection tasks (e.g. pre-cleaning of medical 
instruments, changing sterilisation solutions and manual disinfection of medical instruments) 
were consistently associated with work-related asthma outcomes. These tasks are usually 
performed in certain dedicated areas enabling the use of engineering control methods such 
as local exhaust ventilation (LEV) systems. The areas where these tasks are performed in 
both hospitals should have LEV systems located at the source of exposure, which should 
undergo regular preventive maintenance. A recent study (57) has proposed specific 
ventilation standards for areas where OPA is used for high-level disinfection of medical 
instruments. Since detectable OPA levels were all higher than the newly proposed ACGIH‘s 
TLV-Ceiling Limit of 0.0001 ppm, engineering controls should be seriously considered in 
these hospitals. In addition, further occupational hygiene monitoring need be conducted in 
order to evaluate the effectiveness of the implemented exposure control measures. In 
addition, general ventilation should be improved in all hospital areas so as to reduce 
exposure of HWs to ubiquitous cleaning agents such as those used for fixed surfaces 
cleaning. 
Administrative controls 
There should be written policies and codes of practise for the use of different cleaning 
agents for various cleaning tasks in the hospital. Several administrative controls should be 
considered in the light of the specific findings of this study. Since a higher asthma symptom 
score was observed in HWs that used sprays more frequently than wipes, the use of sprays 
should be replaced with wipes where possible. Entry into certain dedicated areas such as 
those used for medical instrument cleaning and disinfection should be restricted to properly 
trained workers. Health workers should be trained in the proper use, storage and disposal of 
cleaning agents; use of appropriate personal protective equipment (PPE) and potential 
health effects associated with exposure to cleaning agents. In this study, a low proportion of 
HWs (44% in South Africa and 23% in Tanzania) had received training on adverse health 
effects due to cleaning agents. Mixing of different cleaning products (such as bleach and 
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ammonia) should be avoided. There should also be regular supervision and monitoring of 
cleaning-related work practices among workers. 
Personal protective equipment (PPE) 
Use of PPE is the least effective method for the control of exposure to work-related hazards. 
Since inadequate engineering and administrative methods were demonstrated in both 
hospitals, in the interim, HWs should use appropriate PPE until more effective control 
measures are in place. For most cleaning tasks, HWs should use appropriate gloves, fluid 
repellent clothing (gowns/aprons) and protective shoes. For certain tasks such as those 
involved in medical instrument cleaning and disinfection, proper eye protection (e.g. goggles 
/ face shields) and respirators with vapour cartridges should be used in addition to gloves, 
fluid repellent clothing and shoes. Hospital management should provide PPE to HWs after 
appropriate consultation with workers in order to ensure the most appropriate PPE is chosen 
and achieve worker compliance as to their use.  
8.3.3. Medical surveillance programmes 
Secondary prevention through instituting appropriate medical surveillance programmes is 
advised for HWs exposed to cleaning agents. This will enable identification of affected HWs 
relatively early in their employment and inform redeployment strategies and removal from 
further exposure of affected workers in order to reduce progression and disability due to 
occupational asthma. Medical surveillance, together with occupational hygiene surveillance 
will also be useful to determine effectiveness of the workplace control measures that are 
implemented in the hospital. There should be pre-placement as well as annual periodic 
medical assessment of these workers, preferably using a symptom questionnaire. More 
frequent surveillance (e.g. every 6 months) is recommended in the first two years of 
employment due to increased risk in those exposed to respiratory sensitisers. Further testing 
(e.g. spirometry) can be done to HWs with suspected work-related upper and/or lower 
airway symptoms associated with exposure to respiratory sensitisers/irritants. For HWs 
exposed to known sensitisers such as OPA, immunological assessment through detection of 
specific IgE to OPA could be useful, if commercially available, in those health workers that 
report work-related symptoms. 
8.3.4. Future research 
Most of the cleaning agents that have been reported in literature do not have specific 
regulatory exposure standards or need to be reviewed in the light of new evidence. Improved 
dose-response studies using quantitative exposure assessment strategies are needed in 
order to develop regulatory exposure standards for these cleaning agents and to assess 
whether the current exposure standards are protective. More reliable and valid data can be 
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obtained through a combination of methods including self-reported information from 
questionnaires, job-exposure matrices, expert judgments and quantitative measurements. 
There is a need for more studies on the exposure characterisation using biomonitoring 
approaches to chlorhexidine and its metabolites (PCA and 1-chloro-4-nitrobenzene) in 
biological fluids, with particular efforts towards the development of standardized, sensitive 
and validated assays for this agent due to its widespread use in most settings. Future 
studies in this group should also explore the possibility of conducting both skin prick tests 
and specific IgE to common sensitisers (e.g. enzymatic cleaners and glutaraldehyde) in 
order to obtain a more comprehensive immunological assessment of symptomatic workers. 
Furthermore, the current study findings need to be replicated in future studies among HWs 
exposed to cleaning agents. There is a need for larger prospective studies in HWs exposed 
to cleaning agents using various clinical, physiological and inflammatory markers including 
sputum eosinophils and serum periostin in order to further characterise the asthma 
phenotypes in HWs exposed cleaning agents. This will inform improved clinical management 
and preventive strategies for these HWs. More studies are needed to study health effects of 
―green‖ cleaning agents that are increasingly been proposed and newly introduced into the 
health care setting.  
 
8.4. CONCLUSION 
This study has demonstrated that detectable exposures to OPA are higher and more 
isolated to certain departments than the more widespread low-level formaldehyde exposures 
present throughout the hospitals. Furthermore, cleaning agents have replaced NRL as 
important causes for WRA in health settings. Finally, specific cleaning agents such as OPA, 
quaternary ammonium compounds and enzymatic cleaners associated with medical 
instrument cleaning/disinfection as well as patient care activities and the use of sprays for 
fixed surface cleaning are important environmental risk factors, for various asthma-related 
outcomes among HWs in health care settings. 
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CONSENT FORM  
 
1. Title of research project 
 
Risk factors for work-related asthma in health care workers with exposure to diverse cleaning agents 
in two African health care settings – Groote Schuur Hospital and Muhimbili National Hospital 
 
2. Purpose of the research 
 
The University of Cape Town is conducting this important study of work related asthma in health 
care workers. This study is going to be done by researchers who are independent of the hospital. 
We will be studying health care workers working in the different departments of the hospital. It is 
hoped that this study will provide greater insight into the risk factors for work related asthma among 
health care workers and identify appropriate preventative strategies to be implemented in order to 
reduce the incidence of asthma among health care workers. 
 
3. Description of the research project 
  
 If you agree to participate you will be asked to complete the following tests during working time: 
  
a) Complete a questionnaire.  A member of our study team will interview you in privacy to complete 
the questionnaire. You will be asked questions about any breathing or chest problems; current and 
previous employment history; and working with different products at the hospital. 
 
b) Blood test 
You will also be asked to undergo a blood test to check for allergies to specific allergens. Ten ml 
(about two teaspoons) of blood will be drawn once by a nurse. 
 
c) Breathing tests 
- You will be asked to blow several times into a machine which measures how well your lungs are 
working.  
- You will be asked to repeat the breathing test after you first breathe in a small amount of a 
chemical substance (methacholine). Methacholine is a chemical that can cause the airways to 
become narrow. This test helps us to find out if you may have a breathing problem like asthma. You 
may be asked to breathe in this substance and then blow into the machine several times.  
This test will not be done if you are pregnant or breastfeeding.   
- You will also be asked to blow two times into a NIOX MINO machine, which measures nitric oxide 
produced by the airways. This machine is used to detect if a person has allergic airway inflammation 
which is present in asthma or rhinitis. 
 
d) Urine test 
- We will collect a urine sample to test for chlorhexidine and its products. 
- Should you be uncertain of your menstrual pattern you will be offered a urine pregnancy test before 
we conduct the breathing test with methacholine.  
 
4. Confidentiality of information collected 
 
Your name will not appear on any reports or data collection forms. The records of blood tests, 
questionnaires and breathing tests will be kept completely confidential and will be seen only by 
members of the study team. 
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5. Risks and discomforts of the research 
 
a) From the questionnaire: Some of the research questions may make you uncomfortable; 
however, we have trained our interviewer to be as sensitive when asking these questions. You 
may be concerned about confidentiality of the information that you provide; however, we have 
taken precautions to minimize this risk.  
 
b) From the blood tests. You will feel a single needle stick when the blood is taken. Sometimes a 
small bruise may occur from the needle stick. The total amount of blood taken is quite small and 
your body will quickly replace it.  
 
c) From breathing tests: There is a small chance that the initial breathing test could cause you to 
become light-headed or faint. Having you complete the test in a seated position under the 
observation of trained personnel greatly reduces the chance of your having such a problem. You 
will be given medicine (salbutamol) to breathe in that works to open your lungs. Although very 
rare, this medication can briefly cause a fast heartbeat, tremor, nervousness or chest pain. Part 
of the breathing test uses a chemical substance (methacholine) that can cause headache, 
cough, shortness of breath, chest tightness, wheezing, hoarse voice or a sore throat for a short 
time in some people. Very rarely it can cause severe breathing problems. Such breathing 
problems almost always can be treated successfully immediately with a different medication 
(salbutamol), which you breathe in. You will only be given the chemical substance 
(methacholine) if your simple breathing test is normal. This greatly reduces the chance of having 
a serious problem. These tests will be carried out in a lung function laboratory with medical 
personnel knowledgeable in the treatment of such problems being immediately available. In a 
very rare instance the test resulted in a fatality (the individual had a number of methacholine 
challenge tests over a period of 2 weeks). You will have this test only once. 
 
6. Expected benefits to you and to others 
  
You may not receive any personal or direct benefit from participating in this research study. 
However, you will be given a written copy of all your test results along with an explanation of what 
they mean, unless you tell us that you do not wish to receive this. You may wish to show these to 
your doctor if you are having any problems. These tests will help determine if you have asthma or 
allergy to several substances used in the allergy test. What we learn from this study will help to 
protect you, and those working with different products in the hospitals in South Africa and other parts 
of the world. We will learn how best to monitor workers’ health and how to reduce workers’ exposure 
to different products. 
 
7. Costs to you resulting from participation in the study 
 
The study is offered at no cost to you.  In the event a problem is discovered and you wish to be seen 
by a doctor for it, we can recommend to you who to see. However, the study cannot pay for these 
additional medical visits or treatments. 
 
8. Contact person   
 
You may contact one of the following persons for answers to further questions about the research, 
your rights, or any injury you may feel is related to the study.   
 
University of Cape Town Researchers: 
Prof. Mohamed Jeebhay, Telephone No. (021) 406-6309 
Dr Hussein Mwanga, Telephone No. 079 034 1280 / 084 331 2222 / 021 404 5428 
 
University of Cape Town Human Research Ethics Committee (HREC): 
Prof. Marc Blockman (021) 406-6492 
 
University of Michigan Medical School Institutional Review Board (IRBMED) 
Telephone No. 001-734-763-4768; E-mail: irbmed@umich.edu 
2800 Plymouth Road, Building 520, Room 3214, Ann Arbor, Michigan 48105 (USA) 
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RISK FACTORS FOR WORK-RELATED ASTHMA IN HEALTH CARE 
WORKERS WITH EXPOSURE TO DIVERSE CLEANING AGENTS – 2014 
HREC REF: 212/2013 
 
CONSENT FORM  
 
 
STUDY NO. ______________ 
 
 
 
9. Consent of the participant 
  
I have read the information given above, or it has been read to me. I understand the meaning of this 
information, Dr./Mr./Ms. ________________________________________________________ 
has offered to answer any questions concerning the study. By signing this form, I hereby consent to 
participate in the study. I also understand that I am free to withdraw from the study at any time 
without penalty. 
 
10. Documentation of the consent 
  
One copy of this signed document will be kept together with our research records for this study. A 
copy of the information sheet about the study will be given to you to keep. 
 
 
 __________________________________  _____________________________ 
 Printed name of participant    Signature, Mark, or Thumb Print  
 
 
__________________________________  ______________________________ 
 Interviewer’s name (Print)    Signature 
 
 
 DATE: ____________________ 
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SABABU ZINAZOHUSIANA NA UGONJWA WA PUMU UNAOHUSIANA NA 
KAZI KWA WATUMISHI WA AFYA WAFANYAO KAZI NA KEMIKALI 
MBALIMBALI ZA KUFANYIA USAFI KATIKA SEKTA YA AFYA YA NCHI 
MBILI ZA AFRICA – 2017 
 
FOMU YA RIDHAA 
 
1. Jina la mradi wa utafiti 
 
Sababu zinazohusiana na ugonjwa wa pumu unaohusiana na kazi kwa watumishi wa afya wafanyao 
kazi na kemikali mbalimbali za kufanyia usafi katika sekta ya afya ya nchi mbili za Africa – Hospitali 
ya Taifa Muhimbili na Hospitali ya Groote Schuur. 
 
2. Madhumuni ya utafiti 
 
Chuo kikuu cha afya na sayansi shirikishi Muhimbili (MUHAS) kinafanya utafiti huu muhimu wa 
ugonjwa wa pumu unaohusiana na kazi kwa watumishi wa afya. Utafiti huu utafanywa na watafiti 
ambao hawako chini ya utawala wa hospitali ya taifa ya Muhimbili (MNH). Tutafanya utafiti huu kwa 
watumishi wa afya katika idara tofauti za MNH. Ni matumaini yetu kwamba utafiti huu utatoa 
ufahamu zaidi kuhusu sababu zinazohusiana na ugonjwa wa pumu kwa watumishi ya afya ili kuweza 
kupanga mikakati ya kupunguza kasi ya kupata ugonjwa wa pumu kwa watumishi wa afya. 
 
3. Maelezo kuhusu utafiti 
  
Kama ukikubali kushiriki katika utafiti huu, utaombwa kufanya mambo yafuatayo wakati wa muda 
wako wa kazi: 
 
a) Kujaza dodoso.  
Mmoja wa watafiti wetu atafanya mahojiano na wewe katika sehemu ya faragha. Utaulizwa maswali 
kuhusu matatizo yoyote ya kupumua au ya kifua; ajira yako ya sasa na ya zamani; na maswali 
kuhusu kufanya kwako kazi na kemikali mbalimbali katika hospitali hii. 
 
b) Kipimo cha damu.  
Utaombwa kufanya kipimo cha damu kupima kama una “allergy” na vitu fulani. Muuguzi atatoa 
mililita 10 (kama vijiko viwili vidogo vya chai) za damu kutoka kwenye mwili wako. 
 
c) Vipimo vya upumuaji.  
 Utaombwa kupuliza mara kadhaa kwenye mashine ambayo inapima jinsi gani mapafu yako 
yanafanya kazi. 
 Utaombwa vilevile kupuliza mara mbili kwenye mashine ya NIOX MINO ambayo inapima gesi ya 
nitric oxide inayotolewa na njia ya hewa. Hii mashine inatumika kupima kama mtu ana 
mabadiliko yatokanayo na “”allergy” kwenye njia yake ya hewa, ambayo huwepo kwa watu 
wenye ugonjwa wa pumu na “allergy” za pua.  
  
4. Usiri wa taarifa zinazokusanywa 
 
Jina lako halitaonekana kwenye ripoti zozote au fomu za kukusanyia taarifa za utafiti huu. 
Kumbukumbu za majibu ya vipimo vya damu, dodoso na vipimo vya kupumua zitatunzwa kwa usiri 
wa hali ya juu na ni watafiti tu watakaoweza kuziona. 
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5. Madhara na usumbufu wa utafiti 
 
a) Kutokana na kipimo cha damu: Utahisi kuchomwa na sindano mara moja wakati damu yako 
ikitolewa. Mara nyingine damu inaweza kuvilia kidogo kwenye ngozi kwasababu ya sindano hiyo. 
Jumla ya kiwango cha damu kinachotolewa ni kidogo sana, mwili wako utatengeza damu kurudisha 
hiyo iliyotelewa haraka.  
 
b) Kutokana na dodoso: Unaweza usifurahie baadhi ya maswali utakayoulizwa, hivyo basi, 
tumemfundisha mtafiti atakaekuhoji kuwa makini wakati wa kuuliza maswali hayo. Unaweza kuwa na 
wasiwasi kuhusu usiri wa taarifa unazotupa, hivyo basi, tumechukua tahadhari za kutosha 
kuepukana na hili. 
 
c) Kutokana na vipimo vya upumuaji: Kuna uwezekano japo kidogo wa kupata kizunguzungu au 
kuzirai. Kufanya kwako vipimo hivi ukiwa umekaa kitako, chini ya uangalizi wa wataalam itapunguza 
sana uwezekano wa kupata tatizo hilo. Utapewa dawa (salbutamol) ambayo utaivuta ambayo 
inasaidia kufungua mapafu yako. Ingawa ni nadra sana, dawa hii inaweza kusababisha kwa muda 
mfupi mapigo ya moyo kwenda mbio, kutetemeka, wasiwasi au maumivu ya kifua. Vipimo hivi 
vitafanywa katika maabara ya kupima ufanyajikazi wa mapafu na wataalam wa afya wenye ujuzi wa 
kutibu matatizo hayo watakuwa wanapatikana mara moja. 
 
6. Faida utakazopata wewe na wengineo  
  
Unaweza usipate faida yoyote binafsi au ya moja kwa moja kwako kwa kushiriki katika utafiti huu. 
Hata hivyo, utapewa nakala ya majibu yako ya vipimo pamoja na maelezo yake, au la utuambie 
hupendelei hivyo. Unaweza kumuonyesha daktari wako hayo majibu ya vipimo kama una matatizo 
yoyote. Vipimo hivi vitasaidia kugundua kama una ugonjwa wa pumu au “allergy” na vitu mbali mbali. 
Tutakachojifunza kutokana na utafiti huu itasaidia kukulinda wewe na wale wafanyao kazi na 
kemikali mbali mbali kwenye mahosipitali ya hapa nchini na sehemu nyingine duniani. Tutajifunza 
namna bora ya kufatilia afya za wafanyakazi na namna ya kupunguza “exposure” ya kemikali mbali 
mbali kwa wafanyakazi.  
 
7. Gharama zitokanazo na kushiriki kwenye utafiti 
 
Unafanyiwa uchunguzi huu bila gharama yoyote kutoka kwako. Kama tatizo likigunduliwa na 
unahitaji kuonwa na daktari kwa ajili hiyo, tunaweza kupendekeza daktari gani wa kumuona. Hata 
hivyo, utafiti huu hauwezi kulipia hizo gharama za ziada za kuonwa na daktari au matibabu. 
 
8. Mawasiliano   
 
Unaweza kuwasiliana na mmoja wa watu wafuatao kwa majibu ya maswali zaidi kuhusu utafiti huu 
au haki zako au tatizo lolote unalofikiri limetokana na utafitti huu. 
 
Watafiti wa chuo kikuu cha afya na sayansi shirikishi Muhimbili (MUHAS) 
Prof. Ferdinand Mugusi, namba ya simu: +255 784 613 354 
Dr Simon Mamuya, namba ya simu: +255 787 721 377 
Dr Hussein Mwanga, namba ya simu: +255 673 341 280 
 
Kamati ya maadili ya utafiti ya chuo kikuu cha afya na sayansi shirikishi Muhimbili (MUHAS) 
Namba ya simu: +255-022-2152489; E-mail: drp@muhas.ac.tz  
 
Kamati ya maadili ya utafiti ya chuo kikuu cha Cape Town 
Namba ya simu. +27 21 406 6492; E-mail: Shuretta.Thomas@uct.ac.za 
 
Kamati ya maadili ya utafiti ya chuo kikuu cha Michigan 
Namba ya simu. 001-734-763-4768; E-mail: irbmed@umich.edu 
2800 Plymouth Road, Building 520, Room 3214, Ann Arbor, Michigan 48105 (USA) 
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SABABU ZINAZOHUSIANA NA UGONJWA WA PUMU UNAOHUSIANA NA 
KAZI KWA WATUMISHI WA AFYA WAFANYAO KAZI NA KEMIKALI 
MBALIMBALI ZA KUFANYIA USAFI KATIKA SEKTA YA AFYA YA NCHI 
MBILI ZA AFRICA – 2017 
 
FOMU YA RIDHAA 
 
 
Namba ya mshiriki. ______________ 
 
 
 
9. Ridhaa ya mshiriki 
  
Nimesoma maelezo yaliyotolewa hapo juu, au nimesomewa. Ninaelewa maana ya maelezo hayo, 
Dr./Bwana/Bi.                                                                               amejitolea kujibu maswali yoyote 
yanayohusiana na utafiti huu. Kwa kusaini fomu hii, naridhia kushiriki kwenye utafiti huu. Naelewa 
vile vile kwamba niko huru kujitoa kwenye utafiti huu muda wowote ule bila kupata adhabu yoyote.            
 
 
10. Uwekaji kumbukumbu wa ridhaa 
  
Nakala moja ya fomu hii iliyosainiwa itawekwa pamoja na kumbukumbu za utafiti huu. Utapewa 
nakala ya maelezo kuhusu utafiti huu. 
 
 
 
 __________________________________  _____________________________ 
 Jina la mshiriki                Sahihi au alama ya kidole  
 
 
__________________________________  ______________________________ 
 Jina la anaehoji                           Sahihi 
 
 
 TAREHE: ____________________ 
      UNIVERSITY OF CAPE TOWN
RISK FACTORS FOR WORK-RELATED ASTHMA IN HEALTH CARE WORKERS
WITH EXPOSURE TO DIVERSE CLEANING AGENTS - 2014
ENGLISH QUESTIONNAIRE
Card 1
Survey Number  ________________ 1-3
A. IDENTIFICATION DATA
1.Surname ____________________________________
2. First name/s ____________________________________
3. Address ________________________________________________
________________________________________________
________________________________________________
4. Staff number: ____________________________________ 4-11
5. Date of birth:    Day_____Month______Year________ 12-17
6. Gender:          ___ Male (1)          ___ Female (2) 18
7. Home Language: ____ English (1) 19-20
____ Afrikaans (2)
____ Xhosa (3)
____ Other (4)   ________________________
8. Contact telephone No's: Home     _______________________
Work     _______________________
Cell     _______________________
9. E-mail address:          _________________________________________
10. Interviewer's initials   ______________________ 21-22
11. Date of interview:         Day_______Month_________Year_________ 23-28
12. Health facility: ____________________________ 29
13. Department / Section / Area: ______________________________ 30-31
14.1 Date of last shift?               Day____Month_________Year______ 32-37
14.2. Did you work today?               ___ Yes (1)      ___No (2) 38
If YES, go on to Question 14.3
If NO, skip to next section (Health problems)
14.3 Which shift did you work today?
From ___________ to ___________ 39
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B. HEALTH PROBLEMS
Wheeze and tightness in the chest
1. Have you ever  had wheezing or whistling in your chest in the past?
  ___ Yes (1)      ___No (2) 40
If YES, go on to Question 1.1
If NO, skip to Question 2
1.1 If yes, when was the first time you had these symptoms.
Date: Month ______  Year _____ 41-44
1.2 Have you had wheezing or whistling in your chest at any time in the 
      last 12 months?   ___ Yes (1)      ___No (2) 45
If YES, go on to Question 1.2.1
If NO, skip to Question 2
1.2.1 Have you been short of breath when the wheezing noise was present?
   ___ Yes (1)      ___No (2) 46
1.2.2 Have you had this wheezing or whistling when you did not have 
          a cold or flu?   ___ Yes (1)      ___No (2) 47
2. Have you been woken up with a feeling of tightness in your chest at any time 
    in the last 12 months?   ___ Yes (1)      ___No (2) 48
Shortness of breath
3. Have you had an attack of shortness of breath at any time in the 
    last 12 months?   ___ Yes (1)      ___No (2) 49
4. Have you had an attack of shortness of breath that came on during the daytime
    when you were at rest at any time in the last 12 months?
  ___ Yes (1)      ___No (2) 50
5. Have you had an attack of shortness of breath that came on following running
    or exercise at any time in the last 12 months?
  ___ Yes (1)      ___No (2) 51
6. Have you been woken up by an attack of shortness of breath at any time in the
    last 12 months?   ___ Yes (1)      ___No (2) 52
Cough and phlegm from the chest
7. Have you been woken up by an attack of coughing at any time in the 
    last 12 months?   ___ Yes (1)      ___No (2) 53
8. Do you usually cough first thing in the morning?
  ___ Yes (1)      ___No (2) 54
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9. Do you usually cough during the rest of the day, or at night?
  ___ Yes (1)      ___No (2) 55
If YES, go on to Question 9.1
If NO, skip to Question 10
9.1 Do you cough like this on most days/nights for as much as 3 or more months
 in each of the last two years?
  ___ Yes (1)      ___No (2) 56
10. Do you usually bring up any phlegm from your chest first thing in the 
       morning?   ___ Yes (1)      ___No (2) 57
11. Do you usually bring up any phlegm from your chest during the day, or 
       at night?   ___ Yes (1)      ___No (2) 58
If YES, go on to Question 11.1
If NO, skip to Question 12
11.1. Do you bring up phlegm like this on most days/nights for as much as 3 or 
         more months in each of the last two years?
  ___ Yes (1)      ___No (2) 59
Breathing
12. Do you ever  have trouble with your breathing?
  ___ Yes (1)      ___No (2) 60
If YES, go on to Question 12.1
If NO, skip to Question 13
12.1 Do you have this trouble:
Give all options at once (3)
Insert a cross (X) next to the most correct answer
61
a) Continuously so that your breathing is never quite right? ____
b) Repeatedly, but it goes away completely between the times when it 
    troubles you? ____
c) Only rarely? ____
13. Are you disabled from walking by a condition other than heart or lung 
      disease?   ___ Yes (1)      ___No (2) 62
If YES, state the condition ______________________________________ 63
              and go on to the next section (Asthma)
If NO, go to Question 13.1
13.1 Are you troubled by shortness of breath when hurrying on level ground
or walking up a slight hill? 
  ___ Yes (1)      ___No (2) 64
If YES, go on to Question 13.1.1
If NO, skip to the next section (Asthma)
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13.1.1 Do you notice being short of breath when walking with other people
of your own age on level ground?
  ___ Yes (1)      ___No (2) 65
13.1.2 Do you have to stop for breath when walking at your own pace
on level ground?
  ___ Yes (1)      ___No (2) 66
Asthma
1. Have you ever  had attacks of breathlessness at rest with wheezing in 
       your chest?   ___ Yes (1)      ___No (2) 67
2. Have you ever  had asthma?   ___ Yes (1)      ___No (2) 68
3. Have you ever  had an asthma attack?          ___ Yes (1)      ___No (2) 69
An "asthma attack" is when your asthma symptoms (wheezing, shortness of 
breath, chest tightness or cough) are worse than usual
If YES to either of questions 1, 2, or 3, go on to Question 4
If NO to questions 1, 2 and 3, skip to the next section (Medical history)
4. Has your asthma been confirmed by a doctor?          ___ Yes (1)      ___No (2) 70
5. How old were you when you were told by the doctor that you have asthma?
Give all options at once (3)
Insert a cross (X) next to one answer only
71
a)  Only before you were 17 years old     ____
b)  Only at the age of 17 years or older   ____
c)  Both                                                        ____
6. Have you had an attack of asthma in the last 12 months?
  ___ Yes (1)      ___No (2) 72
If YES, go on to Question 6.1
If NO, skip to Question 7
6.1. How many attacks of asthma have you had in the last 12 months?
Enter approximate number: ________     attacks 73-74
6.2. How many attacks of asthma have you had in the last 3 months?
Enter approximate number: ________     attacks 75-76
7. How old were you when you had your first attack of asthma? Card 2
Enter approximate age: _______   years old 1-2
OR
Enter approximate year: Year     ___________ 3-6
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8. How old were you when you had your most recent attack of asthma?
Enter approximate age: _______   years old 7-8
OR
Enter approximate year: Year     ___________ 9-12
9. Were you employed when you had your first attack of asthma? 
  ___ Yes (1)      ___No (2) 13
If YES, go on to Question 9.1
If NO, skip to Question 10
When you had your first attack of asthma:
9.1 What type of job did you have?
Job title:  ____________________________________________________________ 14-15
9.2. What did you do in this job?
Tasks: _______________________________________________________________ 16-17
9.3 What type of company did you work for?
Industry: ____________________________________________________________ 18-19
10. After onset of asthma, did you ever  have a period when you did not have
       asthma symptoms?
   ___ Yes (1)      ___No (2) 20
DO NOT record if a participant was using asthma medicines during that period
If YES, go on to Question 10.1
If NO, skip to Question 11
10.1 At what age did your asthma symptoms disappear?     
Enter approximate age: _______   years old 21-22
OR
Enter approximate year: Year     ___________ 23-26
10.2 Did your asthma symptoms reappear?      ___ Yes (1)      ___No (2) 27
If YES, go on to Question 10.2.1
If NO, skip to Question 11
10.2.1 At what age did your asthma symptoms reappear?  
Enter approximate age: _______   years old 28-29
OR
Enter approximate year: Year     ___________ 30-33
10.2.2 Were you employed when your asthma symptoms reappeared?  
  ___ Yes (1)      ___No (2) 34
If YES, go on to Question 10.2.2.1
If NO, skip to Question 11
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When your symptoms reappeared:
10.2.2.1  What type of job did you have?
Job title:  ____________________________________________ 35-36
10.2.2.2  What did you do in this job?
Tasks: ____________________________________________________ 37-38
10.2.2.3  What type of company did you work for?
Industry: _____________________________________________________________ 39-40
11. Which season(s) of the year do you usually have attacks of asthma?
11.1. Winter ___ Yes (1)      ___No (2)      ___Don't know (3) 41
11.2. Spring ___ Yes (1)      ___No (2)      ___Don't know (3) 42
11.3. Summer ___ Yes (1)      ___No (2)      ___Don't know (3) 43
11.4. Autumn ___ Yes (1)      ___No (2)      ___Don't know (3) 44
12. Are your chest symptoms caused by, or made worse by any of the following:
Answer all questions
12.1. Contact with animals/pets   ___ Yes (1)      ___No (2) 45
12.2. Grass or flowers   ___ Yes (1)      ___No (2) 46
12.3. Heavy exercise   ___ Yes (1)      ___No (2) 47
12.4. Breathing cold air   ___ Yes (1)      ___No (2) 48
12.5. Tobacco smoke   ___ Yes (1)      ___No (2) 49
12.6. Change in the weather   ___ Yes (1)      ___No (2) 50
12.7. Cleaning agents at home   ___ Yes (1)      ___No (2) 51
12.8. Perfumes   ___ Yes (1)      ___No (2) 52
13. Have you had to miss any days of work due to asthma in the last 12 months?
  ___ Yes (1)      ___No (2) 53
If YES, go on to Question 13.1 
If NO, skip to Question 14
13.1. How many days of work did you have to miss due to asthma in the
         last 12 months?
Enter approximate number.    __ __ __ days 54-56
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14. Did you ever go to work in the last 12 months even though your asthma 
symptoms were especially bad?
  ___ Yes (1)      ___No (2) 57
If YES, go on to Question 14.1
If NO, skip to Question 15
14.1 On how many days in the last 12 months  did you go to work even though
         your asthma symptoms were especially bad?
Enter approximate number.    __ __ __ days 58-60
15. Have you ever  been hospitalized overnight for asthma?  
  ___ Yes (1)      ___No (2) 61
If YES, go on to Question 15.1
If NO, skip to Question 16
15.1 In the last 12 months,  were you hospitalized overnight for asthma?  
  ___ Yes (1)      ___No (2) 62
16. In the last 12 months,  did you get urgent treatment for an asthma attack at a
 doctor's office, urgent care facility, or emergency casualty department?
  ___ Yes (1)      ___No (2) 63
Do not count routine planned appointments. 
If YES, go on to Question 16.1
If NO, skip to Question 17
16.1. In the last 12 months,  how many times did you get urgent treatment for
         an asthma attack at a doctor’s office, urgent care facility, or emergency 
         casualty department? 
 Do not count routine planned appointments          __ __ times 64-65
17. Are you using any medicines, including inhalers/pumps, nebulizers, syrups or
tablets, for asthma or breathing problems?
  ___ Yes (1)      ___No (2) 66
If YES, go on to Question 17.1, showing examples of each
If NO, skip to Question 18
17.1. Which medicines? 
______________________________________________________________ 67
______________________________________________________________ 68
______________________________________________________________ 69
17.2. Do you take these medicines every day even when you do not have any 
          trouble breathing?
  ___ Yes (1)      ___No (2) 70
17.3. In the last 12 months,  did you use fast-acting or rescue bronchodilators, for
           example Asthavent or Ventolin, for asthma?
  ___ Yes (1)      ___No (2) 71
If YES, go on to Question 17.3.1
If NO, skip to Question 18
17.3.1. In the last 12 months,  were there times when you increased your usage of
              fast-acting or rescue bronchodilators on a short-term basis, over a period
              from 2 days to 2 weeks?
  ___ Yes (1)      ___No (2) 72
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17.4. In the last 12 months,  did you use inhaled steroids, for example Budeflam,
           Inflammide or Flixotide, for asthma?
  ___ Yes (1)      ___No (2) 73
If YES, go on to Question 17.4.1
If NO, skip to Question 17.5
17.4.1. In the last 12 months,  were there times when you increased your usage of
          inhaled steroids on a short-term basis, over a period from 2 days to 2 weeks?
  ___ Yes (1)      ___No (2) 74
17.5. In the last 12 months,  did you use oral steroids, for example Prednisone,
           for asthma?
  ___ Yes (1)      ___No (2) 75
If YES, go on to Question 17.5.1
If NO, skip to Question 18
17.5.1. In the last 12 months,  were there times when you increased your usage of
              oral steroids on a short-term basis, over a period from 2 days to 2 weeks?
  ___ Yes (1)      ___No (2) 76
Current asthma control test
Now I'm going to ask you about your asthma control in the past 4 weeks:
18. In the past 4 weeks , how much of the time did your asthma keep you from 
       getting as much done at work or at home? 77
______ All of the time (1)
______ Most of the time (2)
______ Some of the time (3)
______ A little of the time (4)
______ None of the time (5)
19. During the past 4 weeks , how often have you had shortness of breath? 78
______ More than once a day (1)
______ Once a day (2)
______ 3 to 6 times a week (3)
______ Once or twice a week (4)
______ Not at all (5)
20. During the past 4 weeks,  how often did your asthma symptoms (wheezing, 
       coughing, shortness of breath, chest tightness or pain) wake you up at night
       or earlier than usual in the morning? 79
______ 4 or more nights a week (1)
______ 2 to 3 nights a week (2)
______ Once a week (3)
______ Once or twice (4)
______ Not at all (5)
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21. During the past 4 weeks,  how often have you used your rescue inhaler or 
       nebulizer medication (such as Asthavent or Ventolin)? 80
______ 3 or more times per day (1)
______ 1 or 2 times per day (2)
______ 2 or 3 times per week (3)
______ Once a week or less (4)
______ Not at all (5)
Card 3
23. How would you rate your asthma control during the past 4 weeks? 1
______ Not controlled at all (1)
______ Poorly controlled (2)
______ Somewhat controlled (3)
______ Well controlled (4)
______ Completely controlled (5)
Medical History
1. Have you ever been treated for any of the following:
Answer all questions
1.1. Chronic bronchitis ___ Yes (1)      ___No (2)      ___Don't know (3) 2
1.2. Tuberculosis (TB) ___ Yes (1)      ___No (2)      ___Don't know (3) 3
1.3. Repeated  chest infections as a child 
___ Yes (1)      ___No (2)      ___Don't know (3) 4
Nose and eye symptoms
1. Have you ever  had any nose or eye problems or allergies such as hay fever?
  ___ Yes (1)      ___No (2) 5
If YES, go on to Question 1.1.   Answer all questions
If NO, skip to Question 1.4
1.1. How old were you when you first noticed these symptoms? 
Enter approximate age: _______   years old 6-7
OR
Enter approximate year: Year     ___________ 8-11
1.2 During the past 12 months  have you had two or more  episodes of:
1.2.1 sneezy, itchy or runny nose when you did not have a cold or flu?
  ___ Yes (1)      ___No (2) 12
1.2.2 red, itchy or watery eyes   ___ Yes (1)      ___No (2) 13
1.2.3 Do you usually have the nose or eye symptoms at any particular time 
of the year?   ___ Yes (1)      ___No (2) 14
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1.2.3.1. If YES, which is the worst season?
Give all options at once (6)
Insert a cross (X) next to one answer only
1.2.3.1.1. Winter ___ Yes (1)      ___No (2)      ___Don't know (3) 15
1.2.3.1.2. Spring ___ Yes (1)      ___No (2)      ___Don't know (3) 16
1.2.3.1.3. Summer ___ Yes (1)      ___No (2)      ___Don't know (3) 17
1.2.3.1.4. Autumn ___ Yes (1)      ___No (2)      ___Don't know (3) 18
1.3. Are you using any medicines, including nose sprays, drops, tablets or 
injections, for your nose or eye symptoms at present?
  ___ Yes (1)      ___No (2) 19
If YES, go on to Question 1.3.1
If NO, go on to Question 1.4
Present a chart with different samples of allergy medicines 
(N.B. a health care worker might show you his/her medicines). 
1.3.1. Which medicines? 
______________________________________________________________ 20
______________________________________________________________ 21
______________________________________________________________ 22
1.4. Did you have hay fever (itchy or watery eyes/nose) as a child?
___ Yes (1)      ___No (2)      ___Don't know (3) 23
Skin symptoms
1. Have you ever  had any kind of skin problem either at home or at work?
  ___ Yes (1)      ___No (2) 24
If YES, go on to Question 1.1 
If NO, skip to Question 1.6
1.1. If Yes, what was it?
______________________________________________________________ 25-26
______________________________________________________________
1.2. How old were you when you first noticed this skin problem?
Enter approximate age: _______   years old 27-28
OR
Enter approximate year: Year     ___________ 29-32
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1.3. During the past 12 months  have you had any skin problems that occurred 
2 or more times?
  ___ Yes (1)      ___No (2) 33
If Yes, which of the following problems did you have?
Go through each option in the table below and circle the appropriate response.
Forearms / Hands Whole body
1.3.1.
Itchy or scratchy skin ___Yes (1) ___No (2) ___Yes (1) ___No (2) 34
35
1.3.2.
Hives (“bommels”) ___Yes (1) ___No (2) ___Yes (1) ___No (2) 36
37
1.3.3.
Dry, scaly skin ___Yes (1) ___No (2) ___Yes (1) ___No (2) 38
39
1.3.4
redness of the skin ___Yes (1) ___No (2) ___Yes (1) ___No (2) 40
41
1.3.5.
Blisters or weeping skin ___Yes (1) ___No (2) ___Yes (1) ___No (2) 42
43
1.3.6.
Burning skin ___Yes (1) ___No (2) ___Yes (1) ___No (2) 44
45
1.3.7.
Rash within an hour of ___Yes (1) ___No (2) ___Yes (1) ___No (2) 46
contact with a rubber 47
latex product
1.3.8. ___Yes (1) ___No (2) ___Yes (1) ___No (2) 48
Other, specify:_________________________________________________________ 49
______________________________________________________________________
______________________________________________________________________ 50
1.4. Did you develop chest symptoms after experiencing these skin symptoms?
  ___ Yes (1)      ___No (2) 51
1.5. Are you using any medicines, including any creams or ointments, for your
         skin problems at present?
  ___ Yes (1)      ___No (2) 52
If YES, go on to Question 1.5.1
If NO, skip to question 1.6
1.5.1. Which medicines? 
_______________________________________________________________ 53
_______________________________________________________________ 54
_______________________________________________________________ 55
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1.6. Have you ever bruised or injured your fingers or hands while working
        in the hospital?
  ___ Yes (1)      ___No (2) 56
1.7. How many times do you wash your hands in the course of a day?
Enter approximate number.           __ __  times/day 57-58
1.8. Did you have eczema as a child?
___ Yes (1)      ___No (2)      ___Don't know (3) 59
Other allergic conditions
1. Are you allergic to insect stings or bites?
___ Yes (1)      ___No (2)      ___Don't know (3) 60
If YES, go on to Question 1.1
If NO, skip to Question 2
1.1 What kind of reactions do you have?
1.1.1. Breathing difficulty, feeling faint, fever?
  ___ Yes (1)      ___No (2) 61
1.1.2 Redness, itching or swelling at the sting site?
  ___ Yes (1)      ___No (2) 62
1.1.3 Other: _______________________________ 63
2. Have you ever had any difficulty with your breathing after taking medications
      or injections that you did not have before?
  ___ Yes (1)      ___No (2) 64
If YES, go on to Question 2.1
If NO, skip to 3
2.1. Which medicines? 
______________________________________________________________________ 65
______________________________________________________________________ 66
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3. Have you ever  had any symptoms related to latex products such as gloves, 
catheters, etc.?   ___ Yes (1)      ___No (2) 67
If YES, go on to Question 3.1
If NO, skip to question 4
3.1. If Yes, which symptoms did you experience?
3.1.1. Itchy or scratchy skin   ___ Yes (1)      ___No (2) 68
3.1.2. Hives ("bommels")   ___ Yes (1)      ___No (2) 69
3.1.3. Blistering or weeping skin   ___ Yes (1)      ___No (2) 70
3.1.4. Breathlessness/tight chest/wheeze   ___ Yes (1)      ___No (2) 71
3.1.5. Sneezing, itchy, stuffy or runny nose   ___ Yes (1)      ___No (2) 72
3.1.6. Red, itchy or watery eyes   ___ Yes (1)      ___No (2) 73
3.1.7. "Collapsed" / fainted   ___ Yes (1)      ___No (2) 74
3.2. Have you ever being diagnosed with latex allergy?
  ___ Yes (1)      ___No (2) 75
If YES, go on to Question 3.2.1
If NO, skip to question 4
3.2.1. If Yes, when was it? Card 4
Enter approximate age: _______   years old 1-2
OR
Enter approximate year: Year     ___________ 3-6
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4. Have you ever had an illness, health problem or allergy caused by eating a 
   particular type of food /fruit?
___ Yes (1)      ___No (2)      ___Don't know (3) 7
If YES, go on to Question 4.1
If NO, skip to question 5
4.1 What type of food/fruit was this? 
_________________________________________________________ 8-9
4.1. Did this illness or health problem include:
4.1.1 Itchy skin or rash   ___ Yes (1)      ___No (2) 10
4.1.2 Diarhoea or vomiting   ___ Yes (1)      ___No (2) 11
4.1.3 Runny or stuffy nose   ___ Yes (1)      ___No (2) 12
4.1.4 Severe headaches   ___ Yes (1)      ___No (2) 13
4.1.5 Breathlessness/tight chest/wheeze   ___ Yes (1)      ___No (2) 14
4.1.6 Other:________________________________________ 15
4.2 Was the food canned or preserved?   ___ Yes (1)      ___No (2) 16
4.3 Do you experience these problems when you drink fizzy drinks also?
  ___ Yes (1)      ___No (2) 17
5. Have you ever had a surgical or dental operation that required you to be 
     in theatre?   ___ Yes (1)      ___No (2) 18
6. When you are near animals (such as cats, dogs or horses), 
      OR  near trees, grass or flowers or when there is a lot of pollen around,
      OR  near pillows, quilts or duvets, or in a dusty part of the house, do you ever:
6.1 Start to cough?   ___ Yes (1)      ___No (2) 19
6.2 Start to wheeze?   ___ Yes (1)      ___No (2) 20
6.3 Get a tight chest?   ___ Yes (1)      ___No (2) 21
6.4 Start to feel short of breath?   ___ Yes (1)      ___No (2) 22
6.5 Get a runny/stuffy nose or sneeze?   ___ Yes (1)      ___No (2) 23
6.6 Get itchy or watery eyes?   ___ Yes (1)      ___No (2) 24
6.7 Get itchy skin/rash?   ___ Yes (1)      ___No (2) 25
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C. FAMILY HISTORY
1. Do or did any members of your family (blood relatives) ever have 
    any kind of allergies?
 Do not include relatives by marriage
 If family history is completely unknown (subject is adopted, etc.),
 mark 'Unknown' and do not complete table. Move to next section
___ Yes (1)      ___No (2)      ___Unknown (3) 26
If YES, complete table below. Insert a cross (X) in the appropriate 
block for each option
If NO, skip to the next section (Smoking history)
Type of allergy:
Parent Sibling Child
1.1 Hay fever 1 2 3 27-29
1.2 Eczema 1 2 3 30-32
1.3 Asthma 1 2 3 33-35
1.4 Food related (e.g. 1 2 3 36-38
fruit, shellfish, spices)
1.5 Other allergy, 1 2 3 39-41
Specify: ______________________________
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D. SMOKING HISTORY
1. Have you ever  smoked tobacco (cigarettes or pipe) for as long as a year?
‘YES’ means at least 20 packs of cigarettes or 360 grams of tobacco
 in a lifetime  or at least one cigarette per day for one year
  ___ Yes (1)      ___No (2) 42
If YES, go on to Question 1.1
If NO, skip to Question 2
1.1. How old were you when you started smoking regularly?
Enter approximate age: _______   years old 43-44
OR
Enter approximate year: Year     ___________ 45-48
1.2 Do you smoke at present?
‘YES’ means smoking tobacco in the  last month or more
  ___ Yes (1)      ___No (2) 49
If YES, go on to Question 1.2.1
If NO, skip to Question 1.3
1.2 How much do you now smoke on average?
1.2.1 Number of cigarettes per day ____ ____ 50-51
1.2.2 Pipe tobacco in grams/week ___ ___ ___ 52-54
1.3. Have you ever  stopped smoking completely?          ___ Yes (1)      ___No (2) 55
If YES, go on to Question 1.3.1
If NO, skip to Question 1.4
1.3.1. How old were you when you stopped smoking completely?
Enter approximate age: _______   years old 56-57
OR
Enter approximate year: Year     ___________ 58-61
1.3.1.1 How many years in total did you smoke cigarettes?
(Do not include the years the participant stopped before they started again.)
____ ____ years 62-63
1.3.2 On average of the entire time you smoked, how much did you smoke?
1.3.2.1 Number of cigarettes per day ___ ___ 64-65
1.3.2.2 Pipe tobacco in grams/week  ___ ___ ___ 66-68
1.4. Do you or did you inhale the smoke?          ___ Yes (1)      ___No (2) 69
2. Have you been regularly  exposed to tobacco smoke from other people smoking
    cigarettes or pipe in the last 12 months?
  ___ Yes (1)      ___No (2) 70
‘Regularly’ means on most days or nights
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E. HEALTH AND SAFETY EDUCATION AND TRAINING
1. Are you aware of any health problems caused by the chemicals that you 
work with? ___ Yes (1)      ___No (2)      ___Don't know (3) 71
If YES, go on to Question 1.1
If NO, skip to Question 2
1.1. If Yes, what are these problems? ____________________________________ 72-73
____________________________________________________________________
____________________________________________________________________
2. Are you aware of any protective measures to protect your health and the health
of others at work? ___ Yes (1)      ___No (2)      ___Don't know (3) 74
If YES, go on to Question 2.1
If NO, skip to Question 3
2.1. If Yes, what are these measures? ____________________________________ 75-76
____________________________________________________________________ 77-78
____________________________________________________________________
3. Are there any protective measures currently in place in this hospital?
___ Yes (1)      ___No (2)      ___Don't know (3) 79
If Yes, go on to Question 3.1
If NO, continue to 4 Card 5
3.1. If Yes, what are these measures? ____________________________________ 1-2
_____________________________________________________________________ 3-4
_____________________________________________________________________
3.2. How would you rate these protective measures that are in place, on a 
        scale of 1-5? 5
_____ 3.2.1. Very poor (1)
_____ 3.2.2. Poor (2)
_____ 3.2.3. Adequate (3)
_____ 3.2.4. Good (4)
_____ 3.2.5. Very good (5)
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4. Have you had any health and safety training on working with chemicals
    in the hospital?
___ Yes (1)      ___No (2)      ___Don't know (3) 6
If YES, go on to Question 4.1
If NO, skip to the next section (Home environment)
4.1. Did you receive this training on induction?
___ Yes (1)      ___No (2)      ___Don't know (3) 7
4.2. How often do you receive health and safety training on working with 
chemicals? 8
_____ 4.2.1. Less than once a year
_____ 4.2.2. Once a year
_____ 4.2.3. More than once a year
4.3. How would rate the health and safety training you received, on a scale of 1-5? 9
_____ 4.3.1. Very poor (1)
_____ 4.3.2. Poor (2)
_____ 4.3.3. Adequate (3)
_____ 4.3.4. Good (4)
_____ 4.3.5. Very good (5)
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F. HOME ENVIRONMENT
The following questions are about the house or apartment where you 
currently live.
1. In the last 12 months, have you observed any of the following at home?
 
1.1. Water leakage or water damage indoors on walls, floors, or ceilings?
___ Yes (1)      ___No (2)      ___Don't know (3) 10
1.2. Visible mold growth indoors on walls, floors, or ceilings (not on food)?
___ Yes (1)      ___No (2)      ___Don't know (3) 11
1.3. Smell of mold or mildew (not from food)?
___ Yes (1)      ___No (2)      ___Don't know (3) 12
2. In the last 12 months, have there been any renovations or construction
    at home?   ___ Yes (1)      ___No (2) 13
3. In the last 12 months,  how often have you personally cleaned your own home?
Never < 1 day 1-2 days 3-4 days 5-7 days
/week /week / week / week
(a) (b) (c) (d) (e) 14
If ‘NEVER’:  Go to the next section (Accidental chemical spill or gas release)
If any answer other than ‘NEVER’:  Go to Questions 4
4. In the last 12 months,  on how many days a week have you used the following
cleaning products in your own home?
Mark the single best answer for each cleaning product.
Never < 1 day 1-2 days 3-4 days 5-7 days
/week /week / week / week
4.1. Bleach, like Domestos, Jik 1 2 3 4 5 15
4.2. Ammonia products, like 1 2 3 4 5 16
        Handy Andy
4.3. Window cleaners, like 1 2 3 4 5 17
        Windolene
4.4. Air freshening sprays, 1 2 3 4 5 18
        like Glade
4.5. Any spray cleaning 1 2 3 4 5 19
       product
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G. ACCIDENTAL CHEMICAL SPILL OR RELEASE
1. Were you ever involved in or near  an accidental chemical spill or release at
    home, work, or elsewhere that required you to receive medical care?
___ Yes (1)      ___No (2)      ___Don't know (3) 20
If YES, go on to Question 1.1
If NO, skip to the next section (Employment history)
1.1. In what year did the most recent accidental chemical spill or release occur?
       __  __  __  __ Year  21-24
1.2. Where did this most recent accidental chemical spill or release occur?
Please mark one location
____Home (1) ____Work (2) ____Elsewhere (3) 25
1.3. What were you exposed to?   
Specify the name/s of the chemical
_____________________________________________________________________ 26-27
1.4. In the first 24 hours following the most recent accidental exposure, did
       you experience any respiratory symptoms such as shortness of breath, 
       wheezing, cough, or tightness in your chest?
___ Yes (1)      ___No (2)      ___Don't know (3) 28
If YES, go on to Question 1.5
If NO, skip to the next section (Employment history)
1.5. When you experienced respiratory symptoms in the first 24 hours following
       the most recent accidental chemical spill or release, how long did these 
      symptoms last? 29
Don't know < 1 week 1 week to >1 month 3 months
1 month but or longer
<3 months
1 2 3 4 5
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H. EMPLOYMENT HISTORY
History of Healthcare Work
1. Please tell me the age  when you started working in the healthcare industry OR
     the age you began as a healthcare student, whichever was earlier.
Enter approximate age: _______   years old 30-31
OR
Enter approximate year: Year     ___________ 32-35
2. How many total years  have you worked in healthcare? Include years you
    were a healthcare student.
_______  total years 36-37
Current Employment
3. What is your current job title? 38-39
_____ 3.1. Registered nurse
_____ 3.2. Enrolled nurse
_____ 3.3. Nurse assistant
_____ 3.4. Cleaner
_____ 3.5. Clerk
_____ 3.6. Porter
_____ 3.7. Technician, specify: ______________________________________
4. Which department/ unit/ section are you working in? 
40-41
OUT-PATIENT CLINICS
_____ 1. Respiratory (E16)
_____ 2. Cardiac (E17)
_____ 3. GIT (E23)
_____ 4. Urology (E26)
_____ 5. ENT
_____ 6. Eye
_____ 7. Surgery
_____ 8. Oral & Maxillofacial
_____ 9. Gynae colposcopy
WARDS
_____ 10. ENT ward (F8)
_____ 11. Hemodialysis Lab/ward (E13)
TRAUMA & EMERGENCY
_____ 12. Trauma (C14)
_____ 13. Emergency (C15)
_____ 14. Gynae. Emergency (C24)
OTHER:
_____ 15. ICU, specify __________________________________________
_____ 16. Theatre, specify _______________________________________
_____ 17. Vascular radiology (C8)
_____ 18. Other, specify: _________________________________________
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5. How long  have you been working in this department/section/area?
Years ______ 42-43
Months _____ 44-45
6. How many hours per week  do you work in your current  job?
__ __ hours per week 46-47
7. In this job, do you experience regular  exposure to any  of the following: vapours,
     gases, dust, or fumes? ___ Yes (1)      ___No (2)      ___Don't know (3) 48
‘Regularly’ means on most working days
If YES, go on to Question 7.1
If NO, skip to Question 8
7.1. To what vapours, gases, dusts, or fumes are you exposed regularly?
_____________________________________________________________ 49-50
_____________________________________________________________ 51-52
8. In the last 12 months,  did you observe any of the following in the area(s) 
     where you work?
8.1 Water leakage or water damage indoors on walls, floors, or ceilings?                  
___ Yes (1)      ___No (2)      ___Don't know (3) 53
8.2 Visible mold growth (not on food) indoors on walls, floors, or ceilings? 
___ Yes (1)      ___No (2)      ___Don't know (3) 54
8.3 Smell of mold or mildew (not from food)? 
___ Yes (1)      ___No (2)      ___Don't know (3) 55
9. In the last 12 months, did you observe any of the following renovations or
    construction in, or next  to, the area(s) where you work?   
9.1. Painting walls and fixtures?  
___ Yes (1)      ___No (2)      ___Don't know (3) 56
9.2. Ripping out and replacing walls, woodwork, and partitions?   
___ Yes (1)      ___No (2)      ___Don't know (3) 57
9.3. Ripping out and replacing floors, carpets, and fixed furniture?  
___ Yes (1)      ___No (2)      ___Don't know (3) 58
9.4. Other, specify: __________________________________________________
____________________________________________________________ 59
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Use of Liquid Hand Soaps / Sanitizers
Thinking about your current job and what you have done in this job in the last  
12 months :
10. Do you use liquid  hand soaps/sanitisers to wash or disinfect your hands?
___ Yes (1)      ___No (2) 60
If YES, go on to Question 10.1
If NO, skip to Question 11
10.1. Which products do you use at work?
10.1.1. Chlorhexidine containing products such as Bioscrub, Steriscrub, D-germ, 
               or Biotane in alcohol ___ Yes (1)      ___No (2) 61
10.1.2. FRESH liquid hand soap ___ Yes (1)      ___No (2) 62
10.1.3. SPARKEM hand soap liquid ___ Yes (1)      ___No (2) 63
10.1.4. Other products _________________________________________________ 64
                    __________________________________________________________________________________________________________________________________
10.1.1. How many times on a typical day,  do you use these products at work?
10.1.1.1. Chlorhexidine containing products such as Bioscrub,
              Steriscrub, D-germ, or Biotane in alcohol _____   times/day 65-66
10.1.1.2. FRESH Liquid hand soap _____   times/day 67-68
10.1.1.3. SPARKEM hand soap liquid _____   times/day 69-70
10.1.1.4. Other products ______________________________ _____   times/day 71-72
               ____________________________________________ _____   times/day 73-74
10.2. Which products do you use at home?
__________________________________________________________________ 75-76
__________________________________________________________________ 77-78
10.2.1. How many times on a typical day,  do you use these products at home? Card 6
________________________________________________ _____   times/day 1-2
________________________________________________ _____   times/day 3-4
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Cleaning / Sterilizing Medical Instruments
Thinking about your current job and what you have done in this job in the last  
12 months :
11. At work, do you clean,  sterilise or conduct high-level disinfection  of medical 
     instruments such as bronchoscopes, laryngoscopes, endoscposes, cystoscopes, 
    OR  metal  instruments (needle holder, forceps, etc.),
   OR  plastic  instruments such as ear specula for ear examination?
___ Yes (1)      ___No (2) 5
IF RESPONDENT DOESN’T KNOW, PROBE: To the best of their knowledge.
If YES: go on to Question 11.1
If NO, skip to Question 11.2
11.1. At work, which of the following products  do you use to sterilize or high-level
disinfect medical instruments?
Chemical name or product
11.1.1. Ortho-phthalaldehydes such as Cidex OPA
®
, or Cidex OPA® C
___ Yes (1)      ___No (2)      ___Don't know (3) 6
11.1.2. Glutaraldehydes such as Cidex®
___ Yes (1)      ___No (2)      ___Don't know (3) 7
11.1.3. Enzymatic cleaners, such as Endozime®, or Biozyme®
___ Yes (1)      ___No (2)      ___Don't know (3) 8
11.1.4. Chlorhexidine containing products such as Bioscrub, D-germ,
               Biotane in alcohol, or Steriscrub
___ Yes (1)      ___No (2)      ___Don't know (3) 9
11.1.5. Quaternary ammonium compounds such as MEDDIS®
___ Yes (1)      ___No (2)      ___Don't know (3) 10
11.1.6. Peracetic acid
___ Yes (1)      ___No (2)      ___Don't know (3) 11
11.1.6. Acetic acid
___ Yes (1)      ___No (2)      ___Don't know (3) 12
11.1.7. Hydrogen peroxide
___ Yes (1)      ___No (2)      ___Don't know (3) 13
11.1.8. Surgislip®
___ Yes (1)      ___No (2)      ___Don't know (3) 14
11.1.9. Surgistain®
___ Yes (1)      ___No (2)      ___Don't know (3) 15
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11.1.10. Alcohol, such as ethyl alcohol 96% (ethanol), isopropanol, methylated
    spirits, alcohol 50%, or 70%
___ Yes (1)      ___No (2)      ___Don't know (3) 16
11.1.11. Bleach or chlorine, such as Domestos®, Medisure®, Biocide D®, or Clorox® 
___ Yes (1)      ___No (2)      ___Don't know (3) 17
11.1.12. Bicarbonate concentrate 8.4%
___ Yes (1)      ___No (2)      ___Don't know (3) 18
11.1.13. Citric acid 50%
___ Yes (1)      ___No (2)      ___Don't know (3) 19
11.1.14. Citrosteril
___ Yes (1)      ___No (2)      ___Don't know (3) 20
11.1.15. Renalin 100
___ Yes (1)      ___No (2)      ___Don't know (3) 21
11.1.16. Tiutol KF
___ Yes (1)      ___No (2)      ___Don't know (3) 22
11.1.17. Do you use any other products to sterilize or high level-disinfect
                medical instruments?  
___ Yes (1)      ___No (2) 23
IF ‘NO’: GO TO QUESTION 11.2
IF ‘YES’: CONTINUE WITH QUESTION 11.1.17.1
11.1.17.1. What other products do you use?
(i) ______________________________________________________ 24-25
(ii) _____________________________________________________ 26-27
11.1.18. If Yes to any  of the above in question 11.1, complete a separate sheet 
                 of paper for each product
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Tasks
11.2. In the last 12 months,  have you ever prepared medical instruments for
sterilization by manually disassembling instruments, removing gross
contaminants, or flushing gross contaminants and waste?  
___ Yes (1)      ___No (2)      ___Don't know (3) 28
IF ‘NO’: GO TO QUESTION 11.3
IF ‘YES’: CONTINUE WITH QUESTION 11.2.1
11.2.1. When you remove gross contaminants and waste from scopes and
instruments, please indicate how many days per week, times per day, and the
duration when you perform this task.  
11.2.1.1
.
How many days per week  do you perform this task? __________
29
11.2.1.2
. 
How many times per day  do you perform this task? __________
30-31
11.2.1.3
.
What is the duration  of this task? __________ (hours)
32-33
11.2.1.4
.
Gloves used? Yes (1) No (2) 
34
11.2.1.4
.1.
Type?
Latex 
(1)
Nitrile (2) Vinyl (3) Yellow domestic (4)
35
11.2.1.5
.
Respirator used? Yes (1) No (2) 
36
11.2.1.5
.1. What type of a respirator? 37
Surgical mask 1
Particulate respirator such as an N95 2
Air purifying half mask 3
Air purifying full face piece 4
Powered air purifying 5
11.2.1.6
.
What type of ventilation  exist in the work area when you do this task?
11.2.1.6
.1.
Local exhaust ventilation with hood and duct
___ Yes (1)      ___No (2)      ___Don't know (3) 38
11.2.1.6
.2.
Extractor fans in the ceiling
___ Yes (1)      ___No (2)      ___Don't know (3) 39
11.2.1.6
.3.
Fan pushing contaminated air away from worker/s
___ Yes (1)      ___No (2)      ___Don't know (3) 40
11.2.1.6
.4.
Natural ventilation (open doors/windows)
___ Yes (1)      ___No (2)      ___Don't know (3) 41
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11.3. In the last 12 months,  have you ever prepared  cleaning solutions for e.g. 
           by diluting or mixing cleaning products? 
___ Yes (1)      ___No (2)      ___Don't know (3) 42
IF ‘NO’: GO TO QUESTION 11.4
IF ‘YES’: CONTINUE WITH QUESTION 11.3.1
11.3.1  When you prepare cleaning solutions , please indicate how many days per
week, times per day, and the duration when you perform this task.
11.3.1.1
.
How many days per week  do you perform this task? __________
43
11.3.1.2
. 
How many times per day  do you perform this task? __________
44-45
11.3.1.3
.
What is the duration  of this task? __________ (hours)
46-47
11.3.1.4
.
Gloves used? Yes (1) No (2) 
48
11.3.1.4
.1.
Type?
Latex 
(1)
Nitrile (2) Vinyl (3) Yellow domestic (4)
49
11.3.1.5
.
Respirator used? Yes (1) No (2) 
50
11.3.1.5
.1. What type of a respirator? 51
Surgical mask 1
Particulate respirator such as an N95 2
Air purifying half mask 3
Air purifying full face piece 4
Powered air purifying 5
11.3.1.6
.
What type of ventilation  exist in the work area when you do this task?
11.3.1.6
.1.
Local exhaust ventilation with hood and duct
___ Yes (1)      ___No (2)      ___Don't know (3) 52
11.3.1.6
.2.
Extractor fans in the ceiling
___ Yes (1)      ___No (2)      ___Don't know (3) 53
11.3.1.6
.3.
Fan pushing contaminated air away from worker/s
___ Yes (1)      ___No (2)      ___Don't know (3) 54
11.3.1.6
.4.
Natural ventilation (open doors/windows)
___ Yes (1)      ___No (2)      ___Don't know (3) 55
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11.4. In the last 12 months,  have you ever prepared medical instruments for 
sterilization by changing sterilization solutions?
___ Don't know (3) ___ No (2) ___Yes (1) 56
IF ‘NO’: GO TO QUESTION 11.5
IF ‘YES’: CONTINUE WITH QUESTION 11.4.1
11.4.1  When you change sterilization solutions,  please indicate how many days
per week, times per day, and the duration when you perform this task.
11.4.1.1
.
How many days per week  do you perform this task? __________
57
11.4.1.2
. 
How many times per day  do you perform this task? __________
58-59
11.4.1.3
.
What is the duration  of this task? __________ (hours)
60-61
11.4.1.4
.
Gloves used? Yes (1) No (2) 
62
11.4.1.4
.1.
Type?
Latex 
(1)
Nitrile (2) Vinyl (3) Yellow domestic (4)
63
11.4.1.5
.
Respirator used? Yes (1) No (2) 
64
11.4.1.5
.1. What type of a respirator? 65
Surgical mask 1
Particulate respirator such as an N95 2
Air purifying half mask 3
Air purifying full face piece 4
Powered air purifying 5
11.4.1.6
.
What type of ventilation  exist in the work area when you do this task?
11.4.1.6
.1.
Local exhaust ventilation with hood and duct
___ Yes (1)      ___No (2)      ___Don't know (3) 66
11.4.1.6
.2.
Extractor fans in the ceiling
___ Yes (1)      ___No (2)      ___Don't know (3) 67
11.4.1.6
.3.
Fan pushing contaminated air away from worker/s
___ Yes (1)      ___No (2)      ___Don't know (3) 68
11.4.1.6
.4.
Natural ventilation (open doors/windows)
___ Yes (1)      ___No (2)      ___Don't know (3) 69
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11.5. In the last 12 months,  have you ever used a sterilants immersion container
to manually sterilize or high-level disinfect medical instruments ?  
___ Don't know (3) ___ No (2) ___Yes (1) 70
IF ‘NO’: GO TO QUESTION 11.6
IF ‘YES’: CONTINUE WITH QUESTION 11.5.1
11.5.1 When you use a sterilants immersion container to manually sterilize or 
high-level disinfect  medical instruments, please indicate how many days per week,
times per day, and the duration when you perform this task.
11.5.1.1
.
How many days per week  do you perform this task? __________
71
11.5.1.2
. 
How many times per day  do you perform this task? __________
72-73
11.5.1.3
.
What is the duration  of this task? __________ (hours)
74-75
11.5.1.4
.
Gloves used? Yes (1) No (2) 
76
11.5.1.4
.1.
Type?
Latex 
(1)
Nitrile (2) Vinyl (3) Yellow domestic (4)
77
11.5.1.5
.
Respirator used? Yes (1) No (2) 
78
11.5.1.5
.1. What type of a respirator? 79
Surgical mask 1
Particulate respirator such as an N95 2
Air purifying half mask 3
Air purifying full face piece 4
Powered air purifying 5
11.5.1.6
.
What type of ventilation  exist in the work area when you do this task?
11.5.1.6
.1.
Local exhaust ventilation with hood and duct
Card 7
___ Yes (1)      ___No (2)      ___Don't know (3) 1
11.5.1.6
.2.
Extractor fans in the ceiling
___ Yes (1)      ___No (2)      ___Don't know (3) 2
11.5.1.6
.3.
Fan pushing contaminated air away from worker/s
___ Yes (1)      ___No (2)      ___Don't know (3) 3
11.5.1.6
.4.
Natural ventilation (open doors/windows)
___ Yes (1)      ___No (2)      ___Don't know (3) 4
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11.6. In the last 12 months , have you ever sterilized medical instruments using
automated systems ?
___ Yes (1)      ___No (2)      ___Don't know (3) 5
IF ‘NO’: GO TO QUESTION 12
IF ‘YES’: CONTINUE WITH QUESTION 11.6.1
11.6.1. Which tasks do you perform to sterilize medical instruments using
automated systems?
Do you perform this task?
11.6.1.1. Operate Cidex OPA® system
___ Yes (1)      ___No (2)      ___Don't know (3) 6
11.6.1.2. Operate other system 
___ Yes (1)      ___No (2)      ___Don't know (3) 7
Specify: _____________________________________________________ 8
11.6.2. Do you conduct maintenance on the automated system, such as cleaning or
 replacing screens and filters?
___ Yes (1)      ___No (2)      ___Don't know (3) 9
Please indicate how many days per week, times per day, duration of task,  
and if there is a device that captures and removes gases and vapours from the
automated system.
11.6.3. Operate Cidex OPA® system 10
11.6.3.1
.
How many days per week  do you perform this task? __________
11
11.6.3.2
. 
How many times per day  do you perform this task? __________
12-13
11.6.3.3
.
What is the duration  of this task? __________ (hours)
14-15
11.6.3.4
.
Gloves used? Yes (1) No (2) 
16
11.6.3.4
.1.
Type?
Latex 
(1)
Nitrile (2) Vinyl (3) Yellow domestic (4)
17
11.6.3.5
.
Respirator used? Yes (1) No (2) 
18
11.6.3.5
.1. What type of a respirator? 19
Surgical mask 1
Particulate respirator such as an N95 2
Air purifying half mask 3
Air purifying full face piece 4
Powered air purifying 5
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11.6.3.6
.
What type of ventilation  exist in the work area when you do this task?
11.6.3.6
.1.
Local exhaust ventilation with hood and duct
___ Yes (1)      ___No (2)      ___Don't know (3) 20
11.6.3.6
.2.
Extractor fans in the ceiling
___ Yes (1)      ___No (2)      ___Don't know (3) 21
11.6.3.6
.3.
Fan pushing contaminated air away from worker/s
___ Yes (1)      ___No (2)      ___Don't know (3) 22
11.6.3.6
.4.
Natural ventilation (open doors/windows)
___ Yes (1)      ___No (2)      ___Don't know (3) 23
11.6.4. Operate other system: ______________________ 24
11.6.4.1
.
How many days per week  do you perform this task? __________
25
11.6.4.2
. 
How many times per day  do you perform this task? __________
26-27
11.6.4.3
.
What is the duration  of this task? __________ (hours)
28-29
11.6.4.4
.
Gloves used? Yes (1) No (2) 
30
11.6.4.4
.1.
Type?
Latex 
(1)
Nitrile (2) Vinyl (3) Yellow domestic (4)
31
11.6.4.5
.
Respirator used? Yes (1) No (2) 
32
11.6.4.5
.1. What type of a respirator? 33
Surgical mask 1
Particulate respirator such as an N95 2
Air purifying half mask 3
Air purifying full face piece 4
Powered air purifying 5
11.6.4.6
.
What type of ventilation  exist in the work area when you do this task?
11.6.4.6
.1.
Local exhaust ventilation with hood and duct
___ Yes (1)      ___No (2)      ___Don't know (3) 34
11.6.4.6
.2.
Extractor fans in the ceiling
___ Yes (1)      ___No (2)      ___Don't know (3) 35
11.6.4.6
.3.
Fan pushing contaminated air away from worker/s
___ Yes (1)      ___No (2)      ___Don't know (3) 36
11.6.4.6
.4.
Natural ventilation (open doors/windows)
___ Yes (1)      ___No (2)      ___Don't know (3) 37
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Cleaning Fixed Surfaces, Equipment or Instruments
Thinking about your current job and what you have done in this job in the  last  
12 months :
12. At work, do you clean or disinfect fixed surfaces, equipment, or instruments?
     Examples of fixed surfaces are: countertops, floors, beds and bathrooms
     Examples of equipment are: IV poles, monitors, trolleys and computers
     Examples of instruments are: blood pressure cuffs and stethoscopes
___ Yes (1)      ___No (2) 38
IF RESPONDENT DOESN’T KNOW, PROBE: To the best of their knowledge.
If YES: go on to Question 12.1
If NO, skip to Question 15
12.1. At work, which products do you use to clean and disinfect fixed surfaces,
          equipment, or instruments?  
Chemical name or product
12.1.1. Alcohol, such as ethyl alcohol 96% (ethanol), isopropanol, methylated
    spirits, alcohol 50%, or 70%
___ Yes (1)      ___No (2)      ___Don't know (3) 39
12.1.2. Ammonia, such as Handysan, or Ammonia cleaner (cleaner all purpose)
___ Yes (1)      ___No (2)      ___Don't know (3) 40
12.1.3. Bleach or chlorine, such as Domestos®, Medisure®, Biocide D, or Clorox® 
___ Yes (1)      ___No (2)      ___Don't know (3) 41
12.1.4. Utensils cleaning products such as SPARKLE dishwashing liquid, or
      Liquid soap ___ Yes (1)      ___No (2)      ___Don't know (3) 42
12.1.5. Phenolics, such as MEDIFEN Phenolic disinfectant
___ Yes (1)      ___No (2)      ___Don't know (3) 43
12.1.6. Enzymatic cleaners such as Endozime®, or Biozyme®
___ Yes (1)      ___No (2)      ___Don't know (3) 44
12.1.7. Floor wax strippers, such as Multistrip®, or RADICAL Non-ammoniated
              floor stripper ___ Yes (1)      ___No (2)      ___Don't know (3) 45
12.1.8. Floor sealer/wax, such as buff spray (diluted floor sealer/wax), Vision gold®,
              or Claro-cote® ___ Yes (1)      ___No (2)      ___Don't know (3) 46
12.1.9. Glass cleaning products such as Liquid soap, or Windex®
___ Yes (1)      ___No (2)      ___Don't know (3) 47
12.1.10. SPARKEM Scouring paste
___ Yes (1)      ___No (2)      ___Don't know (3) 48
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12.1.11. Air freshener, such as Biocidol disinfectant (Ocean Cherry), air freshener
without disinfectant, or DUX ___ Yes (1)      ___No (2)      ___Don't know (3) 49
12.1.12. Carpet shampoo
___ Yes (1)      ___No (2)      ___Don't know (3) 50
12.1.13. Furniture polish
___ Yes (1)      ___No (2)      ___Don't know (3) 51
12.1.14. M4 paste
___ Yes (1)      ___No (2)      ___Don't know (3) 52
12.1.15. Stainless steel cleaner
___ Yes (1)      ___No (2)      ___Don't know (3) 53
12.1.16. Sumasan
___ Yes (1)      ___No (2)      ___Don't know (3) 54
12.1.17. Terrazzo cleaner
___ Yes (1)      ___No (2)      ___Don't know (3) 55
12.1.18. Wall cleaner
___ Yes (1)      ___No (2)      ___Don't know (3) 56
12.1.19. Washing powder for cleaning floor mops
___ Yes (1)      ___No (2)      ___Don't know (3) 57
12.1.20. Do you use any other products for cleaning fixed surfaces, equipment, or
 instruments?
Yes (1) No (2) 58
If YES, go on to Question 12.1.20.1
If NO, skip to Question 13
12.1.20.1. What other products do you use?
1. ______________________________________________________ 59-60
2. ______________________________________________________ 61-62
12.1.21. If Yes to any  of the above in question 12.1, complete a separate sheet 
           of paper for each product
Tasks
I'm now going to ask you about certain tasks  you perform at work.
13. Do you use more sprays  or more wipes,  or do you use both equally often in
       your work?
 Select the ONE best answer.
13.1 Use more sprays than wipes 1 63
Use more wipes than sprays 2
Use sprays and wipes about equally 3
Not sure which I use more 4
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14. At work, which tasks do you perform when cleaning or disinfecting fixed
surfaces, equipment, or instruments?  
14.1. Wipe down beds, furniture, counters, walls, etc.
___ Yes (1)      ___No (2)      ___Don't know (3) 64
14.2. Cleanup blood or cleanup other spills
___ Yes (1)      ___No (2)      ___Don't know (3) 65
14.3. Manually mix, refill, or empty cleaning or disinfecting products
___ Yes (1)      ___No (2)      ___Don't know (3) 66
14.4. Clean bathrooms including toilet, sink, shower
___ Yes (1)      ___No (2)      ___Don't know (3) 67
14.5. Spray then wipe glass, windows, mirrors
___ Yes (1)      ___No (2)      ___Don't know (3) 68
14.6. Polish wood furniture
___ Yes (1)      ___No (2)      ___Don't know (3) 69
14.7. Polish stainless steel surfaces
___ Yes (1)      ___No (2)      ___Don't know (3) 70
14.8. Spray deodorant/ disinfectant
___ Yes (1)      ___No (2)      ___Don't know (3) 71
14.9. Sweep floors
___ Yes (1)      ___No (2)      ___Don't know (3) 72
14.10. Hovering
___ Yes (1)      ___No (2)      ___Don't know (3) 73
14.11. Rug beating
___ Yes (1)      ___No (2)      ___Don't know (3) 74
14.12. Mop floors
___ Yes (1)      ___No (2)      ___Don't know (3) 75
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14.13. Clean instruments such as scissors, stethoscopes, and thermometers, or
             equipment such as IV poles, trolleys, monitors, and computers
___ Yes (1)      ___No (2)      ___Don't know (3) 76
14.14. Conduct terminal cleaning of patient rooms
___ Yes (1)      ___No (2)      ___Don't know (3) 77
14.15. Use fogging equipment with hydrogen peroxide or peracetic acid vapors to
conduct terminal cleaning of patient rooms
___ Yes (1)      ___No (2)      ___Don't know (3) 78
14.16. Clean or disinfect for methicillin-resistant staphylococcus aureus, 
vancomycin-resistant enterococci or other drug resistant bacteria in patient rooms
___ Yes (1)      ___No (2)      ___Don't know (3) 79
14.17. Conduct end of shift cleaning of operating rooms, dialysis units or other
patient care areas
___ Yes (1)      ___No (2)      ___Don't know (3) 80
14.18. If Yes to any  of the above in question 14, complete a separate sheet of 
             paper for each task
15. In the last 12 months,  have you cleaned and waxed  floors using strippers Card 8
       and buffers?
___ Yes (1)      ___No (2)      ___Don't know (3) 1
If YES, go on to Question 15.1
If NO, skip to Question 16
15.1. Which tasks do you perform when cleaning and waxing floors using
         strippers and buffers?
15.1.1. Strip floors
___ Yes (1)      ___No (2)      ___Don't know (3) 2
15.1.2. Scrape floors
___ Yes (1)      ___No (2)      ___Don't know (3) 3
15.1.3. Buff floors
___ Yes (1)      ___No (2)      ___Don't know (3) 4
15.1.4. Wax floors
___ Yes (1)      ___No (2)      ___Don't know (3) 5
15.1.5. If Yes to any  of the above in question 15.1, complete a separate sheet 
              of paper for each task
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Exposure to chemicals used for specimen preparation
16. Do you ever prepare specimes  for histology or cytology?
___ Yes (1)      ___No (2)      ___Don't know (3) 6
If YES, go on to Question 16.1
If NO, skip to Question 17
16.1 Which of the following products do you use to prepare specimens  for
histology/cytology?
16.1.1. Formalin 10% in normal saline
___ Yes (1)      ___No (2)      ___Don't know (3) 7
16.1.2 Fencott cytological fixative spray
___ Yes (1)      ___No (2)      ___Don't know (3) 8
16.1.3. Any stains and dyes such as hematoxylin and eosin stains?
___ Yes (1)      ___No (2)      ___Don't know (3) 9
16.1.4. Any solvents such as xylene and toluene to fix tissue specimens and 
      rinse stains? ___ Yes (1)      ___No (2)      ___Don't know (3) 10
16.1.5. If Yes to any  of the above in question 16.1, complete a separate sheet 
              of paper for each product
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Exposure to Products Used on Patients
Thinking about your current job and what you have done in this job in the 
last 12 months:
17. Do you use chemical products on patients? 
         Examples: 
Antiseptics : alcohols, iodine, acetic acid, silver compounds, chlorhexidine,  
                       povidone iodine
Adhesives : glues, acrylates, bone cements
Adhesive removing solvents : alcohols, acetone, ether
___ Yes (1)      ___No (2)      ___Don't know (3) 11
IF RESPONDENT DOESN’T KNOW, PROBE: This is to the best of their knowledge.
If YES, go on to Question 17.1
If NO, skip to Question 18
17.1 Which tasks do you perform when you apply or use chemicals, antiseptics,
adhesives, alcohols, or solvents on patients? 
Tasks:
17.1.1. Disinfect skin areas on patients prior to procedure  using wipes, gauze or
swabs with antiseptics such as Biotane in alcohol, povidone iodine, alcohols, 
acetic acid. ___ Yes (1)      ___No (2)      ___Don't know (3) 12
17.1.2. Clean and disinfect wounds  using antiseptics such as silver compounds,
Biotane in alcohol, povidone iodine, or cadexomer iodine
___ Yes (1)      ___No (2)      ___Don't know (3) 13
17.1.3. Apply wound dressing  such as polyurethane based hydrogel, hydrocolloid, 
or hydrocellular foam 
___ Yes (1)      ___No (2)      ___Don't know (3) 14
17.1.4. Use adhesives  such as glues, acrylates, bone cements, benzoin tincture 
such as Opsite, 3M® Steri-Strip® for surgery, skin closure, bone repair, 
ostomy bags, and other applications
___ Yes (1)      ___No (2)      ___Don't know (3) 15
17.1.5. Use adhesive removing solvents  such as ether, alcohols or acetone with
 wipes, gauze, or swabs
___ Yes (1)      ___No (2)      ___Don't know (3) 16
17.1.6. Apply or remove synthetic fiberglass orthopaedic casts 
___ Yes (1)      ___No (2)      ___Don't know (3) 17
17.1.7. If Yes to any  of the above in question 17.1, complete a separate sheet 
              of paper for each task
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Exposure to Aerosolized Medicines Used on Patients
Thinking about your current job and what you have done in this job 
in the last 12 months :
18. Do you administer aerosolized medications  such as bronchodilators or 
       anaesthetics?
___ Yes (1)      ___No (2)      ___Don't know (3) 18
IF RESPONDENT DOESN’T KNOW, PROBE: This is to the best of their knowledge.
If YES, go on to Question 18.1
If NO, skip to the next section (Previous employment)
18.1   Which tasks do you perform when you administer aerosolized medications? 
Tasks
18.1.1. Administer aerosolized medications with a small volume nebulizer (SVN)
___ Yes (1)      ___No (2)      ___Don't know (3) 19
18.1.2. Use continuous aerosol delivery system  for bronchodilators and other
              medicines
___ Yes (1)      ___No (2)      ___Don't know (3) 20
18.1.3. Administer aerosolized medications with a metered-dose inhaler (MDI)
___ Yes (1)      ___No (2)      ___Don't know (3) 21
18.1.4. Administer aerosolized medications with a dry powder inhaler (DPI)
___ Yes (1)      ___No (2)      ___Don't know (3) 22
18.1.5. If Yes to any  of the above in question 18.1, complete a separate sheet 
              of paper for each task
Page 38
I. PREVIOUS EMPLOYMENT
Now I am going to ask some questions about your previous jobs  in this hospital:
1. Name all the previous jobs  that you have had in this hospital:
Start with the first job that you had 
Department/ Job Title Start End How many Were you regularly
Section/ (what did date date hours/day exposed to vapours,
Area you do?) (year) (year) did you gases, gases, dusts,
work? or fumes?
Now I am going to ask some questions about your previous employment in the 
healthcare industry, but not in this hospital
2. Name all the previous healthcare facilities  where you have worked,
     when not working in this hospital, or before coming to work in this hospital:
Start with the first job that you had 
Name Type Job Title Start End How many Were you regularly
of the (what did date date hours/day exposed to vapours,
work- you do?) (year) (year) did you gases, gases, dusts,
place work? or fumes?
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Now I am going to ask some questions about your previous employment (outside
the healthcare industry)
3. Name all the previous workplaces where you have worked (outside the
healthcare industry):
Start with the most recent job and work backwards (including all other healthcare
 facilities and the jobs done)
Name of Industry Job Title (what Start Date End Date Total 
workplace did you do?)  (year)  (year) (years)
Page 40
Changing Jobs
4. Have you ever had to change or leave a job or position because it affected your
breathing? This would include changing jobs or positions within the same  
workplace.
___ Yes (1)      ___No (2)      ___Don't know (3) 23
If YES, go on to Question 4.1
If NO, skip to the next section (Work-related symptoms)
Please answer the following questions about the most recent time you changed or 
left a job or position because it affected your breathing.
4.1. In which year did you change or leave this job or position?    
Year: __ __ __ __ 24-27
4.2. What kind of job or position did you change or leave?
_________________________________________________________________ 28-29
_________________________________________________________________
4.3. What were you doing in the job or position you changed or left? __________
_____________________________________________________________________ 30-31
_____________________________________________________________________
_____________________________________________________________________
4.4. What exposure or activity affected your breathing in the job or position you 
changed or left? ___________________________________________________ 32-33
_____________________________________________________________________ 34-35
4.5. Concerning the job  or position  you went to: What kind of job or position did 
           you go to? ______________________________________________________ 36-37
____________________________________________________________________
4.6. What did you do in this new job or position?
_________________________________________________________________ 38-39
_________________________________________________________________
4.7. What was the name of the company where you worked at this new job?
_______________________________________________________________ 40-41
4.8. Did your symptoms improve when you changed job or position?
___ Yes (1)      ___No (2) 42
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J. WORK-RELATED SYMPTOMS
Work-related chest symptoms
Thinking about all your working life and asthma symptoms at work:
1. Does being at work ever  make your chest tight, wheezy, or short of breath?
  ___ Yes (1)      ___No (2) 43
If YES, go on to Question 1.1 
If NO, skip to Question 2
1.1 When did you first notice having these chest symptoms at work? 
Date:     Month ______  Year _____ 44-47
1.2. What do you think is causing or triggering these symptoms?
As I read each response, tell me if it applies to you
Workplace triggers
Don't know __Y(1) __N(2) 48
Ortho-phthalaldehydes such as Cidex OPA®, Cidex OPA® C __Y(1) __N(2) 49
Glutaraldehydes such as Cidex® __Y(1) __N(2) 50
Enzymatic cleaners, such as Endozime®, Biozyme® __Y(1) __N(2) 51
Chlorhexidine containing products such as Bioscrub, D-germ, __Y(1) __N(2) 52
     Biotane in alcohol, or Steriscrub
Quaternary ammonium compounds such as MEDDIS® __Y(1) __N(2) 53
Bleach or chlorine, such as Domestos®, Medisure®, Biocide D®, Clorox® __Y(1) __N(2) 54
Ammonia, such as Handysan, Ammonia cleaner (cleaner all purpose) __Y(1) __N(2) 55
Other cleaning products for sterilisation/high-level disinfection of __Y(1) __N(2) 56
     medical instruments
Other cleaning products for cleaning fixed surfaces __Y(1) __N(2) 57
Floor strippers or waxes __Y(1) __N(2) 58
Other liquid hand soaps/sanitisers __Y(1) __N(2) 59
Adhesives, glues, or removers of surgical dressings __Y(1) __N(2) 60
Aerosolised medicines __Y(1) __N(2) 61
Gases or vapour __Y(1) __N(2) 62
Latex rubber products __Y(1) __N(2) 63
Very cold or very hot temperatures __Y(1) __N(2) 64
Dust, please specify (paper dust, etc.): ___________________________ __Y(1) __N(2) 65
Other, please specify: __Y(1) __N(2) 66
a)  ____________________________ 67
b)  ____________________________ 68
c)  ____________________________ 69
d)  ____________________________ 70
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Thinking about the last 12 months:
1.3. In the last 12 months , have you experienced these chest symptoms while
           you were at work at any time?
  ___ Yes (1)      ___No (2) 71
If YES, go on to Question 1.3.1
If NO, skip to Question 1.4
1.3.1. While you were away  from work (for e.g. on weekends, off-shift, or on
       vacations) at any time in the last 12 months,  did your chest symptoms seem
       better, worse, or the same?
Give all options at once (3)
Insert a cross (X) next to one answer only
72
a)  Stay the same ______
b)  Get better ______
c)  Get worse ______
1.3.2. After returning  to your work  at any time in the last 12 months , did your
              chest symptoms seem better, worse, or the same?
Give all options at once (3)
Insert a cross (X) next to one answer only
73
a)  Stay the same ______
b)  Get better ______
c)  Get worse ______
1.4. Were you ever  told by a doctor that your asthma was related to any job
           you ever had?   ___ Yes (1)      ___No (2) 74
If YES, go on to Question 1.4.1
If NO, skip to Question 2
1.4.1. At approximately what age or year  did the doctor first diagnosed it? 
Enter approximate age: _______   years old 75-76
OR
Enter approximate year: Year     ___________ 77-80
1.4.2. Where were you working at time of the first symptoms? Card 9
1
____ 1. Employed in the healthcare industry      
____ 2. Employed outside of the healthcare industry      
____ 3. Student, please specify: ____________________________________ 2
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Work-related nose & eye symptoms
Thinking about all your working life and nose & eye symptoms at work:
2. Does being at work ever  cause you to have sneezy/itchy/runny nose or
          red/itchy/watery eyes?
  ___ Yes (1)      ___No (2) 3
If YES to any one of the above, go on to Question 2.1
If NO, skip to Question 3
2.1. Since when have you been having these symptoms at work?
Date:     Month ______  Year _____ 4-7
2.2. What do you think is causing or triggering these symptoms?
As I read each response, tell me if it applies to you
Workplace triggers
Don't know __Y(1) __N(2) 8
Ortho-phthalaldehydes such as Cidex OPA
®
, Cidex OPA® C __Y(1) __N(2) 9
Glutaraldehydes such as Cidex® __Y(1) __N(2) 10
Enzymatic cleaners, such as Endozime®, Biozyme® __Y(1) __N(2) 11
Chlorhexidine containing products such as Bioscrub, D-germ, __Y(1) __N(2) 12
     Biotane in alcohol, or Steriscrub
Quaternary ammonium compounds such as MEDDIS® __Y(1) __N(2) 13
Bleach or chlorine, such as Domestos®, Medisure®, Biocide D®, Clorox® __Y(1) __N(2) 14
Ammonia, such as Handysan, Ammonia cleaner (cleaner all purpose) __Y(1) __N(2) 15
Other cleaning products for sterilisation/high-level disinfection of __Y(1) __N(2) 16
     medical instruments
Other cleaning products for cleaning fixed surfaces __Y(1) __N(2) 17
Floor strippers or waxes __Y(1) __N(2) 18
Other liquid hand soaps/sanitisers __Y(1) __N(2) 19
Adhesives, glues, or removers of surgical dressings __Y(1) __N(2) 20
Aerosolised medicines __Y(1) __N(2) 21
Gases or vapour __Y(1) __N(2) 22
Latex rubber products __Y(1) __N(2) 23
Very cold or very hot temperatures __Y(1) __N(2) 24
Dust, please specify (paper dust, etc.): ___________________________ __Y(1) __N(2) 25
Other, please specify: __Y(1) __N(2) 26
a)  ____________________________ 27
b)  ____________________________ 28
c)  ____________________________ 29
d)  ____________________________ 30
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Thinking about the last 12 months:
2.3. In the last 12 months , have you experienced these symptoms while
           you were at work at any time?
  ___ Yes (1)      ___No (2) 31
If YES, go on to Question 2.3.1
If NO, skip to Question 2.4
2.3.1. While you were away  from work (for e.g. on weekends, off-shift, or on
       vacations) at any time in the last 12 months,  did your symptoms seem
       better, worse, or the same?
Give all options at once (3)
Insert a cross (X) next to one answer only
32
a)  Stay the same ______
b)  Get better ______
c)  Get worse ______
2.3.2. After returning  to your work  at any time in the last 12 months , did your
              symptoms seem better, worse, or the same?
Give all options at once (3)
Insert a cross (X) next to one answer only
33
a)  Stay the same ______
b)  Get better ______
c)  Get worse ______
2.4. Were you ever  told by a doctor that your nose & eye symptoms were
              related to any job you ever had?   ___ Yes (1)      ___No (2) 34
If YES, go on to Question 2.4.1
If NO, skip to Question 3
2.4.1. At approximately what age or year  did the doctor first diagnosed it? 
Enter approximate age: _______   years old 35-36
OR
Enter approximate year: Year     ___________ 37-40
2.4.2. Where were you working at time of the first symptoms? 
41
____ 1. Employed in the healthcare industry      
____ 2. Employed outside of the healthcare industry      
____ 3. Student, please specify: ____________________________________ 42
Page 45
Work-related skin symptoms
Thinking about all your working life and skin symptoms at work:
3. Does being at work ever  cause you to have skin problems?
  ___ Yes (1)      ___No (2) 43
If YES, go on to Question 3.1
If NO, END THE INTERVIEW
3.1. Since when have you been having these skin problems at work?
Date:     Month ______  Year _____ 44-47
3.2. What do you think is causing or triggering these symptoms?
As I read each response, tell me if it applies to you
Workplace triggers
Don't know __Y(1) __N(2) 48
Ortho-phthalaldehydes such as Cidex OPA®, Cidex OPA® C __Y(1) __N(2) 49
Glutaraldehydes such as Cidex
®
__Y(1) __N(2) 50
Enzymatic cleaners, such as Endozime®, Biozyme® __Y(1) __N(2) 51
Chlorhexidine containing products such as Bioscrub, D-germ, __Y(1) __N(2) 52
     Biotane in alcohol, or Steriscrub
Quaternary ammonium compounds such as MEDDIS® __Y(1) __N(2) 53
Bleach or chlorine, such as Domestos®, Medisure®, Biocide D®, Clorox® __Y(1) __N(2) 54
Ammonia, such as Handysan, Ammonia cleaner (cleaner all purpose) __Y(1) __N(2) 55
Other cleaning products for sterilisation/high-level disinfection of __Y(1) __N(2) 56
     medical instruments
Other cleaning products for cleaning fixed surfaces __Y(1) __N(2) 57
Floor strippers or waxes __Y(1) __N(2) 58
Other liquid hand soaps/sanitisers __Y(1) __N(2) 59
Adhesives, glues, or removers of surgical dressings __Y(1) __N(2) 60
Aerosolised medicines __Y(1) __N(2) 61
Gases or vapour __Y(1) __N(2) 62
Latex rubber products __Y(1) __N(2) 63
Very cold or very hot temperatures __Y(1) __N(2) 64
Dust, please specify (paper dust, etc.): ___________________________ __Y(1) __N(2) 65
Other, please specify: __Y(1) __N(2) 66
a)  ____________________________ 67
b)  ____________________________ 68
c)  ____________________________ 69
d)  ____________________________ 70
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Thinking about the last 12 months:
3.3. In the last 12 months , have you experienced these symptoms while
           you were at work at any time?
  ___ Yes (1)      ___No (2) 71
If YES, go on to Question 3.3.1
If NO, skip to Question 3.4
3.3.1. While you were away  from work (for e.g. on weekends, off-shift, or on
       vacations) at any time in the last 12 months,  did your symptoms seem
       better, worse, or the same?
Give all options at once (3)
Insert a cross (X) next to one answer only
72
a)  Stay the same ______
b)  Get better ______
c)  Get worse ______
3.3.2. After returning  to your work  at any time in the last 12 months , did your
              symptoms seem better, worse, or the same?
Give all options at once (3)
Insert a cross (X) next to one answer only
73
a)  Stay the same ______
b)  Get better ______
c)  Get worse ______
3.4. Were you ever  told by a doctor that your skin symptoms were
              related to any job you ever had?   ___ Yes (1)      ___No (2) 74
If YES, go on to Question 3.4.1
If NO, END THE INTERVIEW
3.4.1. At approximately what age or year  did the doctor first diagnosed it? 
Enter approximate age: _______   years old 75-76
OR
Enter approximate year: Year     ___________ 77-80
3.4.2. Where were you working at time of the first symptoms? Card 10
1
____ 1. Employed in the healthcare industry      
____ 2. Employed outside of the healthcare industry      
____ 3. Student, please specify: ____________________________________ 2
THANK YOU FOR ANSWERING THE QUESTIONNAIRE
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SABABU ZINAZOHUSIANA NA UGONJWA WA PUMU UNAOHUSIANA NA KAZI KWA
WATUMISHI WA AFYA WAFANYAO KAZI NA KEMIKALI MBALIMBALI ZA KUFANYIA
USAFI KATIKA SEKTA YA AFYA YA NCHI MBILI ZA AFRICA – 2017
DODOSO
Card 1
Namba ya utafiti  ________________ 1-3
A. TAARIFA ZA MSHIRIKI
1. Jina la kwanza __________________________________________
2. Jina la ukoo _______________________________________________
3. Mahali unapoishi ________________________________________________
________________________________________________
________________________________________________
4. Namba ya kitambulisho cha kazi: ____________________________
5. Tarehe ya kuzaliwa:    Siku _____  Mwezi ______  Mwaka  ________ 12-17
6. Jinsia:          ___  Mwanamme (1)          ___  Mwanamke (2) 18
7. Lugha unazoongea: ____ English (1) 19-20
____ Kiswahili (2)
____ Nyingine (3)   ________________________
8. Namba za simu: Nyumbani     _____________________________
Kazini     _________________________________
Simu ya mkononi     _______________________
9. Barua pepe:          _________________________________________
10. Herufi za kwanza za majina ya anaehoji   ______________________ 21-22
11. Siku ya mahojiano:         Siku_______Mwezi_________Mwaka_________ 23-28
12. Hospitali: ____________________________ 29
13. Idara / Kitengo / eneo la kazi: ______________________________ 30-31
14.1 Siku ya shifti ya mwisho               Siku____Mwezi_________Mwaka___________ 32-37
14.2. Umefanya kazi leo?               ___ Ndio (1)      ___Hapana (2) 38
Kama NDIO, endelea na Swali la 14.3
Kama HAPANA, nenda kwenye kipengele kinachofatia (Matatizo ya kiafya)
14.3. Shifti gani umefanya leo?
Kutoka _____________ mpaka _____________ 39
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Appendix B2: Swahili Questionnaire
B. MATATIZO YA KIAFYA
Sauti kama za filimbi na kubanwa kifua
1. Je, ulishawahi kusikia sauti kama za filimbi kutoka kwenye kifua chako katika
    kipindi cha nyuma?   ____ Ndio (1)      ____Hapana (2) 40
Kama NDIO, endelea na Swali la 1.1
Kama HAPANA, nenda Swali la 2
1.1. Kama ndio, ni lini ilikuwa mara yako ya kwanza kupata hizi dalili?
Mwezi __________ Mwaka _____________ 41-44
1.2. Je, umewahi kusikia sauti kama za filimbi kutoka kwenye kifua chako wakati
  wowote ule katika kipindi cha miezi 12 iliyopita?   ____ Ndio (1)    ____Hapana (2) 45
Kama NDIO, endelea na Swali la 1.2.1
Kama HAPANA, nenda Swali la 2
1.2.1. Umeshawahi kupata shida kupumua wakati ukiwa na hizo sauti kama za
            filimbi?   ____ Ndio (1)      ____Hapana (2) 46
1.2.2. Umeshawahi kuwa na hizi sauti kama za filimbi wakati ukiwa hauna mafua?
  ____ Ndio (1)      ____Hapana (2) 47
2. Umeshawahi kuamka usingizini kwa sababu ya kubanwa kifua wakati wowote ule
katika kipindi cha miezi 12 iliyopita?   ____ Ndio (1)      ____Hapana (2) 48
Kupumua kwa shida
3. Umeshawahi kupata shida ya kupumua wakati wowote ule  katika kipindi cha 
     miezi 12 iliyopita?   ____ Ndio (1)      ____Hapana (2) 49
4. Umeshawahi kupata shida ya kupumua muda wa mchana wakati ukiwa
     umepumzika katika kipindi cha miezi 12 iliyopita?
  ____ Ndio (1)      ____Hapana (2) 50
5. Umeshawahi kupata shida ya kupumua kwasababu ya kukimbia au mazoezi 
     wakati wowote ule katika kipindi cha miezi 12 iliyopita?
  ____ Ndio (1)      ____Hapana (2) 51
6. Umeshawahi kuamka usingizini kwasababu ya shida ya kupumua wakati wowote
ule katika kipindi cha miezi 12 iliyopita?   ____ Ndio (1)      ____Hapana (2) 52
Kikohozi na makohozi toka kifuani
7. Umeshawahi kuamka usingizini kwa sababu ya kikohozi wakati wowote ule 
    katika kipindi cha miezi 12 iliyopita?   ____ Ndio (1)      ____Hapana (2) 53
8. Kwa kawaida huwa unakohoa asubuhi na mapema?
  ____ Ndio (1)      ____Hapana (2) 54
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9. Kwa kawaida huwa unakohoa wakati wa mchana au usiku?
  ____ Ndio (1)      ____Hapana (2) 55
Kama NDIO, endelea na Swali la 9.1
Kama HAPANA, nenda Swali la 10
9.1. Huwa unakohoa kama hivi mchana au usiku kwa siku nyingi zaidi mpaka kufikia
        miezi 3 au zaidi  kwa kila mwaka katika kipindi cha miaka hii miwili iliyopita?
  ____ Ndio (1)      ____Hapana (2) 56
10. Kwa kawaida huwa unapata makohozi toka kifuani kwako asubuhi  na mapema?
  ____ Ndio (1)      ____Hapana (2) 57
11. Kwa kawaida huwa unapata makohozi toka kifuani kwako wakati wa mchana
       au usiku?   ____ Ndio (1)      ____Hapana (2) 58
Kama NDIO, endelea na Swali la 11.1
Kama HAPANA, nenda Swali la 12
11.1. Huwa unapata makohozi kama hivi mchana au usiku kwa siku nyingi zaidi
           mpaka kufikia miezi 3 au zaidi  kwa kila mwaka katika kipindi cha miaka hii
           miwili iliyopita?   ____ Ndio (1)      ____Hapana (2) 59
Upumuaji
12. Umewahi kuwa na shida na upumuaji wako?
  ____ Ndio (1)      ____Hapana (2) 60
Kama NDIO, endelea na Swali la 12.1
Kama HAPANA, nenda Swali la 13
12.1. Shida hii ya kupumua:
Toa majibu yote matatu kwa wakati mmoja
Weka alama ya (X) mbele ya jibu sahihi
61
a) Inakuwepo muda wote, kwahiyo upumuaji wako unakuwa hauko sawa
     hata mara moja? ______
b) Inajirudiarudia, lakini kuna kipindi inakuwa haipo kabisa? ______
c) Inatokea mara chache sana? ______
13. Una elemavu wa kushindwa kutembea kwa sababu nyingine isipokuwa ugonjwa
      wa moyo au mapafu?   ____ Ndio (1)      ____Hapana (2) 62
Kama NDIO, itaje ni sababu gani ___________________________________ 63
              na endelea na kipengele kinachofuata (Ugonjwa wa pumu)
Kama HAPANA, endelea na Swali la 13.1
13.1. Unapata shida kupumua ukiwa unatembea kwa haraka  katika sehemu
           tambarare  isiyokuwa na kilima AU wakati ukitembea kupanda kilima kidogo?
  ____ Ndio (1)      ____Hapana (2) 64
Kama NDIO, endelea na Swali la 13.1.1
Kama HAPANA, nenda katika kipengele kinachofuata (Ugonjwa wa pumu)
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13.1.1. Unapata shida kupumua ukiwa unatembea na watu wa umri wako katika
              sehemu tambarare?
  ____ Ndio (1)      ____Hapana (2) 65
13.1.2. Huwa inabidi usimame kwa sababu ya shida ya kupumua ukiwa
               unatembea kwa kasi yako mwenyewe katika sehemu tambarare?
  ____ Ndio (1)      ____Hapana (2) 66
Ugonjwa wa pumu
1. Umeshawahi kuwa na shida ya kupumua wakati ukiwa umepumzika na muda huo
     huo ukawa na sauti kama za filimbi kutoka kifuani kwako?
  ____ Ndio (1)      ____Hapana (2) 67
2. Umeshawahi kuumwa ugonjwa wa pumu?
  ____ Ndio (1)      ____Hapana (2) 68
3. Umeshawahi kupata shambulizi la pumu?
  ____ Ndio (1)      ____Hapana (2) 69
"Shambulizi la pumu" ni wakati dalili zako za pumu (sauti kama za filimbi, shida ya
kupumua, kubanwa kifua au kikohozi) zinakuwa mbaya kuliko kawaida yake
Kama jibu ni NDIO kwa aidha swali la 1,2 au 3, endelea na Swali la 4
Kama jibu ni HAPANA kwa swali 1,2 na 3, nenda kwenye kipengele
kinachofuata (Historia ya matibabu)
4. Je, ugonjwa wako wa pumu umeshawahi kuthibitishwa na daktari?
  ____ Ndio (1)      ____Hapana (2) 70
5. Ulikuwa na umri gani wakati ulivyoambiwa na daktari kwamba una pumu?
Toa majibu yote matatu kwa wakati mmoja
Weka alama ya (X) mbele ya jibu moja tu
71
a)  Kabla hujafikisha miaka 17     ____
b)  Ukiwa na miaka 17 au zaidi   ____
c)  Mara zote                                    ____
6. Umepata shambulizi la pumu katika kipindi cha miezi 12 iliyopita?
  ____ Ndio (1)      ____Hapana (2) 72
Kama NDIO, endelea na Swali la 6.1
Kama HAPANA, nenda Swali la 7
6.1. Umepata mashambulizi ya pumu mangapi katika kipindi cha miezi 12 iliyopita?
Andika kadirio la namba: mashambulizi        ________ 73-74
6.2. Umepata mashambulizi ya pumu mangapi katika kipindi cha miezi 3 iliyopita?
Andika kadirio la namba: mashambulizi        ________ 75-76
7. Ulikuwa una umri gani ulivyopata shambulizi lako la pumu la kwanza kabisa? Card 2
Andika kadirio la umri: Miaka        _______ 1-2
AU
Andika kadirio la mwaka: Mwaka     ___________ 3-6
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8. Ulikuwa na umri gani ulivyopata shambulizi lako la pumu la hivi karibuni?
Andika kadirio la umri: Miaka        _______ 7-8
AU
Andika kadirio la mwaka: Mwaka     ___________ 9-12
9. Ulikuwa umeajiriwa wakati ulivyopata shambulizi lako la pumu la kwanza kabisa?
  ____ Ndio (1)      ____Hapana (2) 13
Kama NDIO, endelea na Swali la 9.1
Kama HAPANA, nenda Swali la 10
Wakati ulivyopata shambulizi lako la pumu la kwanza kabisa:
9.1. Ni kazi gani ulikuwa unafanya?
Cheo cha kazi:  ________________________________________________________ 14-15
9.2. Ulikuwa unafanya shughuli gani katika kazi hii?
Shughuli: ______________________________________________________________ 16-17
9.3. Ni aina gani ya kampuni uliyokuwa unafanya kazi?
Sekta: ____________________________________________________________ 18-19
10. Baada ya pumu kuanza, kuna kipindi ulikuwa haupati dalili za pumu?
   ____ Ndio (1)      ____Hapana (2) 20
Usirekodi kama mshiriki alikuwa anatumia dawa za pumu katika kipindi hicho
Kama NDIO, endelea na Swali la 10.1
Kama HAPANA, nenda Swali la 11
10.1. Dalili zako za pumu zilipotea ukiwa una umri gani?
Andika kadirio la umri: Miaka        _______ 21-22
AU
Andika kadirio la mwaka: Mwaka     ___________ 23-26
10.2. Dalili zako za pumu zilirudi tena?   ____ Ndio (1)      ____Hapana (2) 27
Kama NDIO, endelea na Swali la 10.2.1
Kama HAPANA, nenda Swali la 11
10.2.1. Dalili zako za pumu zilirudi ukiwa na umri gani?
Andika kadirio la umri: Miaka        _______ 28-29
AU
Andika kadirio la mwaka: Mwaka     ___________ 30-33
10.2.2. Ulikuwa umeajiriwa wakati dalili zako za pumu zilivyorudi?
  ____ Ndio (1)      ____Hapana (2) 34
Kama NDIO, endelea na Swali la 10.2.2.1
Kama HAPANA, nenda Swali la 11
Page 5
Wakati dalili zako za pumu zilivyorudi:
10.2.2.1. NI kazi gani ulikuwa unafanya?
Cheo cha kazi:  ____________________________________________ 35-36
10.2.2.2. Ulikuwa unafanya shughuli gani katika kazi hii?
Shughuli: ____________________________________________________ 37-38
10.2.2.3. Ni aina gani ya kampuni uliyokuwa unafanya kazi?
Sekta: _____________________________________________________________ 39-40
11. Ni msimu gani wa mwaka huwa unapata mashambulizi ya pumu?
11.1. Msimu wa baridi ___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 41
11.2. Spring ___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 42
11.3. Msimu wa joto ___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 43
11.4. Autumn ___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 44
12. Dalili zako za pumu zinasababishwa au zinakuwa mbaya zaidi kwa sababu ya
       yoyote yafuatayo:
Jibu maswali yote
12.1. Ukiwa karibu na wanyama   ____ Ndio (1)      ____Hapana (2) 45
12.2. Majani au maua   ____ Ndio (1)      ____Hapana (2) 46
12.3. Zoezi kubwa   ____ Ndio (1)      ____Hapana (2) 47
12.4. Kupumua hewa yenye baridi   ____ Ndio (1)      ____Hapana (2) 48
12.5. Moshi wa tumbaku   ____ Ndio (1)      ____Hapana (2) 49
12.6. Mabadiliko ya hali ya hewa   ____ Ndio (1)      ____Hapana (2) 50
12.7. Kemikali za kufanyia usafi nyumbani   ____ Ndio (1)      ____Hapana (2) 51
12.8. Manukato   ____ Ndio (1)      ____Hapana (2) 52
13. Ilishawahi kukulazimu kukosa kwenda kazini kwa sababu ya pumu katika kipindi
       cha miezi 12 iliyopita?   ____ Ndio (1)      ____Hapana (2) 53
Kama NDIO, endelea na Swali la 13.1 
Kama HAPANA, nenda Swali la 14
13.1. Ni siku ngapi za kazi ilikulazimu kuzikosa kwa sababu ya pumu katika kipindi
          cha miezi 12 iliyopita?
Andika kadirio la namba: Siku _______ 54-56
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14. Katika kipindi cha miezi 12 iliyopita,  uliwahi kwenda kazini  ingawa dalili zako
       za pumu zilikuwa mbaya kabisa?   ____ Ndio (1)      ____Hapana (2) 57
Kama NDIO, endelea na Swali la 14.1
Kama HAPANA, nenda Swali la 15
14.1 Katika kipindi cha miezi 12 iliyopita,  ni siku ngapi ulienda kazini ingawa dalili
        zako za pumu zilikuwa mbaya kabisa?
Andika kadirio la namba: Siku   _______ 58-60
15. Ulishawahi kulazwa hospitalini usiku kucha kwa sababu ya pumu?
  ____ Ndio (1)      ____Hapana (2) 61
Kama NDIO, endelea na Swali la 15.1
Kama HAPANA, nenda Swali la 16
15.1. Katika kipindi cha miezi 12 iliyopita,  umewahi kulazwa hospitalini usiku kucha
          kwa sababu ya pumu?   ____ Ndio (1)      ____Hapana (2) 62
16. Katika kipindi cha miezi 12 iliyopita,  umewahi kupata matibabu ya dharura kwa
      sababu ya shambulizi la pumu aidha kwenye ofisi ya daktari, au kituo cha
      huduma ya haraka, au idara ya magonjwa ya dharura na majeruhi?
  ____ Ndio (1)      ____Hapana (2) 63
Usihesabu zile tarehe za kawaida za kupangiwa kuja kiliniki
Kama NDIO, endelea na Swali la 16.1
Kama HAPANA, nenda Swali la 17
16.1. Katika kipindi cha miezi 12 iliyopita,  ni mara ngapi umepata matibabu ya
         dharura kwa sababu ya shambulizi la pumu aidha kwenye ofisi ya daktari, au
         kituo cha huduma ya haraka, au idara ya magonjwa ya dharura na majeruhi?
Usihesabu zile tarehe za kawaida za kupangiwa kuja kiliniki     Mara  _______ 64-65
17. Unatumia dawa zozote zile za pumu au matatizo ya kupumua, kama dawa
       za kuvuta (inhalers), nebulaiza, dawa za maji za kunywa au vidonge?
  ____ Ndio (1)      ____Hapana (2) 66
Kama NDIO, endelea na Swali la 17.1, huku ukiwa unaonyesha mifano ya dawa
Kama HAPANA, nenda Swali la 18
17.1. Ni dawa gani hizo? 
______________________________________________________________ 67
______________________________________________________________ 68
______________________________________________________________ 69
17.2. Utumia dawa hizi kila siku hata wakati ukiwa hauna shida ya kupumua?
  ____ Ndio (1)      ____Hapana (2) 70
17.3. Katika kipindi cha miezi 12 iliyopita , umetumia fast-acting or rescue 
           bronchodilators, kama Asthalin au Ventolin, kwa sababu ya pumu?
  ____ Ndio (1)      ____Hapana (2) 71
Kama NDIO, endelea na Swali la 17.3.1
Kama HAPANA, nenda Swali la 18
17.3.1. Katika kipindi cha miezi 12 iliyopita, kuna wakati uliongeza matumizi ya
             fast-acting or rescue bronchodilators kwa muda mfupi, kama kwa
             siku 2 had wiki 2 hivi?
  ____ Ndio (1)      ____Hapana (2) 72
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17.4. Katika kipindi cha miezi 12 iliyopita , umetumia dawa za steroids za kuvuta,
            kama Budecort, Ibicar au Alvesco, kwa sababu ya pumu?
  ____ Ndio (1)      ____Hapana (2) 73
Kama NDIO, endelea na Swali la 17.4.1
Kama HAPANA, nenda Swali la 17.5
17.4.1. Katika kipindi cha miezi 12 iliyopita,  kuna wakati uliongeza matumizi ya
         dawa za steroids za kuvuta kwa muda mfupi, kama kwa siku 2 hadi wiki 2 hivi?
  ____ Ndio (1)      ____Hapana (2) 74
17.5. Katika kipindi cha miezi 12 iliyopita,  umetumia dawa za steroids za kumeza,
          kama Prednisone, kwa sababu ya pumu?
  ____ Ndio (1)      ____Hapana (2) 75
Kama NDIO, endelea na Swali la 17.5.1
Kama HAPANA, nenda Swali la 18
17.5.1. Katika kipindi cha miezi 12 iliyopita,  kuna wakati uliongeza matumizi ya
        dawa za steroids za kumeza kwa muda mfupi, kama kwa siku 2 hadi wiki 2 hivi?
  ____ Ndio (1)      ____Hapana (2) 76
Current asthma control test
Sasa nitakuuliza maswali kuhusu hali ya pumu yako katika kipindi cha 
wiki 4 zilizopita:
18. Katika kipindi cha wiki 4 zilizopita,  ni muda kiasi gani pumu yako imekuzuia
       kufanya kazi ukiwa kazini au nyumbani? 77
______ Mara zote (1)
______ Mara nyingi (2)
______ Wakati fulani (3)
______ Mara chache tu (4)
______ Hata mara moja (5)
19. Katika kipindi cha wiki 4 zilizopita,  ni mara ngapi umepata shida kupumua? 78
______ Zaidi ya mara moja kwa siku (1)
______ Mara moja kwa siku (2)
______ Mara 3 hadi 6 kwa wiki (3)
______ Mara moja au mbili kwa wiki (4)
______ Hata mara moja (5)
20. Katika kipindi cha wiki 4 zilizopita,  ni mara ngapi dalili zako za pumu (sauti
       kama za filimbi, kukohoa, kupumua kwa shida, kubanwa kifua au maumivu
       kifuani) zimekuamsha usiku au asubuhi ya mapema kuliko kawaida? 79
______ Usiku 4 au zaidi kwa wiki (1)
______ Usiku 2 hadi 3 kwa wiki (2)
______ Mara moja kwa wiki (3)
______ Mara moja au mbili (4)
______ Hata mara moja (5)
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21. Katika kipindi cha wiki 4 zilizopita,  ni mara ngapi umetumia rescue inhaler yako
       au dawa zako za nebulaiza (kama Asthalin au Ventolin)? 80
______ Mara 3 au zaidi kwa siku (1)
______ Mara 1 au 2 kwa siku (2)
______ Mara 2 au 3 kwa wiki (3)
______ Mara 1 kwa wiki au chini ya hapo (4)
______ Hata mara moja (5)
Card 3
23. Ni kwa kiwango gani unaweza kusema mwili wako umeihimili pumu yako katika 1
       kipindi cha wiki 4 zilizopita?
______ Haujaihimili kabisa (1)
______ Haujaihimili vizuri (2)
______ Umeihimili kiasi fulani (3)
______ Umeihimili vizuri (4)
______ Umeihimili vizuri kabisa (5)
Historia ya matibabu
1. Ulishawahi kutibiwa kwa ajili ya haya yafuatayo?
Jibu maswali yote
1.1. Chronic bronchitis ___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 2
1.2. Kifua kikuu (TB) ___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 3
1.3. Maambukizi ya kifuani ya mara kwa mara  wakati ukiwa mdogo
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 4
Matatizo ya pua na macho
1. Umeshawahi kuwa na "allergies" za pua na macho kama "hay fever"?
  ____ Ndio (1)      ____Hapana (2) 5
Kama NDIO, endelea na Swali la 1.1.   Jibu maswali yote
Kama HAPANA, nenda Swali la 1.4
1.1. Ulikuwa na umri gani wakati ulivyoanza kupata hizi dalili kwa mara ya kwanza?
Andika kadirio la umri: Miaka        _______ 6-7
AU
Andika kadirio la mwaka: Mwaka     ___________ 8-11
1.2. Katika kipindi cha miezi 12 iliyopita,  je umepata dalili zifuatazo kwa
        mara mbili au zaidi:
1.2.1. Kupiga chafya au pua kuwasha au kutokwa na makamasi wakati ukiwa
           hauna mafua?   ____ Ndio (1)      ____Hapana (2) 12
1.2.2. Macho kuwa mekundu au kuwasha au kutoa machozi
  ____ Ndio (1)      ____Hapana (2) 13
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1.2.3. Kuna kipindi fulani cha mwaka ambapo huwa unapata dalili hizi za 
           pua na macho?   ____ Ndio (1)      ____Hapana (2) 14
1.2.3.1. Kama NDIO, je ni kipindi gani huwa kibaya zaidi?
Toa majibu yote manne kwa wakati mmoja
Weka alama ya (X) mbele ya jibu moja tu
1.2.3.1.1. Kipindi cha baridi ___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 15
1.2.3.1.2. Spring ___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 16
1.2.3.1.3. Kipindi cha joto ___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 17
1.2.3.1.4. Autumn ___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 18
1.3. Unatumia dawa zozote kwa ajili ya dalili zako za pua au macho, kama dawa za
       kupulizia puani, za matone puani, vidonge au sindano?
  ____ Ndio (1)      ____Hapana (2) 19
Kama NDIO, endelea na Swali la 1.3.1
Kama HAPANA, nenda Swali la 1.4
Onyesha karatasi yenye aina mbali mbali za dawa za "allergy" 
(N.B. mshiriki anaweza kukuonyesha dawa zake) 
1.3.1. Ni dawa gani hizo? 
______________________________________________________________ 20
______________________________________________________________ 21
______________________________________________________________ 22
1.4. Ulikuwa na "hay fever" (pua kuwasha, kutokwa makamasi, macho kuwasha au
        kutoa machozi) wakati ukiwa mtoto?
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 23
Matatizo ya ngozi
1. Ushawahi kuwa na tatizo lolote la ngozi aidha ukiwa nyumbani au kazini?
  ____ Ndio (1)      ____Hapana (2) 24
Kama NDIO, endelea na Swali la 1.1 
Kama HAPANA, nenda Swali la 1.6
1.1. Kama NDIO, ilikuwa ni tatizo gani?
______________________________________________________________ 25-26
______________________________________________________________
1.2. Ulikuwa na umri gani wakati ulivyopata hilo tatizo la ngozi kwa mara ya kwanza?
Andika kadirio la umri: Miaka        _______ 27-28
AU
Andika kadirio la mwaka: Mwaka     ___________ 29-32
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1.3. Katika kipindi cha miezi 12 iliyopita,  umepata tatizo la ngozi ambalo limetokea
       mara 2 au zaidi?   ____ Ndio (1)      ____Hapana (2) 33
Kama NDIO, ni tatizo gani ulikuwa nalo kati ya haya yafuatayo?
Uliza kila swali hapa chini na uzungushie jibu sahihi
Mikono kuanzia
kwenye viwiko Mwili mzima
1.3.1.
Kuwashwa ngozi ___Ndio(1) ___Hapana(2) ___Ndio(1) ___Hapana(2) 34
35
1.3.2.
Hives (“bommels”) ___Ndio(1) ___Hapana(2) ___Ndio(1) ___Hapana(2) 36
37
1.3.3.
Ngozi kavu/magamba ___Ndio(1) ___Hapana(2) ___Ndio(1) ___Hapana(2) 38
39
1.3.4
Ngozi kuwa nyekundu ___Ndio(1) ___Hapana(2) ___Ndio(1) ___Hapana(2) 40
41
1.3.5.
Malengelenge/maji maji ___Ndio(1) ___Hapana(2) ___Ndio(1) ___Hapana(2) 42
kwenye ngozi 43
1.3.6.
Burning skin ___Ndio(1) ___Hapana(2) ___Ndio(1) ___Hapana(2) 44
45
1.3.7.
Upele ndani ya lisaa ___Ndio(1) ___Hapana(2) ___Ndio(1) ___Hapana(2) 46
limoja la kukutana na 47
mpira (latex)
1.3.8. ___Ndio(1) ___Hapana(2) ___Ndio(1) ___Hapana(2) 48
Mengine, yataje:_________________________________________________________ 49
______________________________________________________________________
______________________________________________________________________ 50
1.4. Ulipata matatizo ya kifua baada ya kupata matatizo haya ya ngozi?
  ____ Ndio (1)      ____Hapana (2) 51
1.5. Unatumia dawa zozote kwa matatizo yako ya ngozi kama creams au ointments?
  ____ Ndio (1)      ____Hapana (2) 52
Kama NDIO, endelea na Swali la 1.5.1
Kama HAPANA, nenda Swali la  1.6
1.5.1. Ni dawa gani hizo? 
_______________________________________________________________ 53
_______________________________________________________________ 54
_______________________________________________________________ 55
Page 11
1.6. Umeshawahi kuumia kwenye vidole au mikono wakati ukiwa unafanya kazi
       katika hospitali hii?   ____ Ndio (1)      ____Hapana (2)
56
1.7. Unaosha mikono yako mara ngapi kwa siku?
Andika kadirio la namba: Mara ________ kwa siku 57-58
1.8. Ulikuwa na pumu ya ngozi ulivyokuwa mtoto?
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 59
Matatizo mengine ya "allergy"
1. Unapata "allergy" uking'atwa na wadudu?
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 60
Kama NDIO, endelea na Swali la 1.1
Kama HAPANA, nenda Swali la 2
1.1. Ni madhara gani unapata uking'atwa na wadudu?
1.1.1. Shida kupumua, kuzirai, homa?
  ____ Ndio (1)      ____Hapana (2) 61
1.1.2. Wekundu, kuwashwa au kuvimba pale ulipong'watwa?
  ____ Ndio (1)      ____Hapana (2) 62
1.1.3. Mengine: _______________________________ 63
2. Umeshawahi kupata shida kupumua baada ya kumeza dawa au sindano
    ambayo ulikuwa hauna kabla ya hapo?
  ____ Ndio (1)      ____Hapana (2) 64
Kama NDIO, endelea na Swali la 2.1
Kama HAPANA, nenda Swali la 3
2.1. Ni dawa gani hizo? 
______________________________________________________________________ 65
______________________________________________________________________ 66
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3. Umeshawahi kupata dalili zozote zile zinazohusiana na vitu venye "latex" kama
gloves au catheters, n.k.?   ___ Yes (1)      ___No (2) 67
Kama NDIO, endelea na Swali la 3.1
Kama HAPANA, nenda Swali la 4
3.1. Kama NDIO, ni dalili gani ulipata?
3.1.1. Kuwashwa ngozi   ____ Ndio (1)      ____Hapana (2) 68
3.1.2. Hives ("bommels")   ____ Ndio (1)      ____Hapana (2) 69
3.1.3. Malengelenge/maji maji kwenye ngozi   ____ Ndio (1)      ____Hapana (2) 70
3.1.4. Kupumua kwa shida/kifua kubana/sauti
           kama za filimbi   ____ Ndio (1)      ____Hapana (2) 71
3.1.5. Kupiga chafya, pua kuwasha, kuziba au
           kutokwa na makamasi   ____ Ndio (1)      ____Hapana (2) 72
3.1.6. Macho kuwa mekundu, kuwasha au 
           kutokwa na machozi   ____ Ndio (1)      ____Hapana (2) 73
3.1.7. Kuzimia   ____ Ndio (1)      ____Hapana (2) 74
3.2. Ushawahi kuambiwa na wataalam kwamba una allergy ya latex?
  ____ Ndio (1)      ____Hapana (2) 75
Kama NDIO, endelea na Swali la 3.2.1
Kama HAPANA, nenda Swali la 4
3.2.1.Kama NDIO, ilikuwa ni lini hiyo? Card 4
Andika kadirio la umri: Miaka        _______ 1-2
AU
Andika kadirio la mwaka: Mwaka     ___________ 3-6
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4. Umeshawahi kuwa na ugonjwa, tatizo la afya au allergy iliyosababishwa na 
     kula chakula/tunda fulani?
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 7
Kama NDIO, endelea na Swali la 4.1
Kama HAPANA, nenda Swali la 5
4.1 Ilikuwa ni chakula/tunda aina gani? 
_________________________________________________________ 8-9
4.1. Ugonjwa huu au tatizo hili la afya lilikuwa ni pamoja na:
4.1.1. Kuwashwa ngozi au upele   ____ Ndio (1)      ____Hapana (2) 10
4.1.2. Kuharisha au kutapika   ____ Ndio (1)      ____Hapana (2) 11
4.1.3. Pua kuziba au kutokwa na makamasi   ____ Ndio (1)      ____Hapana (2) 12
4.1.4. Kichwa kuuma sana   ____ Ndio (1)      ____Hapana (2) 13
4.1.5. Kupumua kwa shida/kifua kubana/sauti
           kama za filimbi   ____ Ndio (1)      ____Hapana (2) 14
4.1.6. Mengine:________________________________________ 15
4.2. Hicho chakula kilikuwa na ni cha kopo au cha kuhifadhiwa?
  ____ Ndio (1)      ____Hapana (2) 16
4.3. Unapata matatizo haya ukinywa vinjwaji vyenye gesi kama soda?
  ____ Ndio (1)      ____Hapana (2) 17
5. Umeshawahi kufanyiwa upasuaji wa mwili au wa meno ambao ilibidi uingie
      chumba cha upasuaji (theatre)?   ____ Ndio (1)      ____Hapana (2) 18
6. Ukiwa karibu na wanyama (kama paka, mbwa au farasi), 
      AU  karibu na miti, majani au maua au kukiwa na poleni nyingi,
      AU  karibu na mito, mablanketi, au katika sehemu yenye vumbi nyumbani, huwa
6.1. Unaanza kukohoa?   ____ Ndio (1)      ____Hapana (2) 19
6.2. Unaanza kupata sauti kama za filimbi?   ____ Ndio (1)      ____Hapana (2) 20
6.3. Unabanwa kifua?   ____ Ndio (1)      ____Hapana (2) 21
6.4. Unaanza kupumua kwa shida?   ____ Ndio (1)      ____Hapana (2) 22
6.5. Unapiga chafya/pua kuziba/kutoa makamasi?   ____ Ndio (1)      ____Hapana (2) 23
6.6. Macho yanawasha au kutoa machozi?   ____ Ndio (1)      ____Hapana (2) 24
6.7. Ngozi inawasha au unapatwa na upele?   ____ Ndio (1)      ____Hapana (2) 25
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C. HISTORIA YA FAMILIA
1. Kuna ndugu wa damu katika familia yenu ambae alishakuwa/ana allergy
    yoyote ile?
Hii haimaanishi undugu wa kuoana
 Kama historia ya familia haijulikani, jaza jibu la 'SIJUI' na usijaze jedwali
 hapo chini. Nenda kipengele kinachofuata (Uvutaji Sigara)
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 26
Kama NDIO, jaza jedwali hapa chini. Weka alama ya (X) panapotakiwa 
kwenye kila swali
Kama HAPANA, nenda kipengele kinachofuata (Uvutaji Sigara)
Aina ya allergy:
Mzazi Kaka/dada Mtoto
1.1. Hay fever 1 2 3 27-29
1.2. Pumu ya ngozi 1 2 3 30-32
1.3. Pumu 1 2 3 33-35
1.4. Ya chakula (e.g. 1 2 3 36-38
tunda, samaki, viungo)
1.5. Allergy nyingine, 1 2 3 39-41
Zitaje: ______________________________
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D. UVUTAJI SIGARA
1. Umeshawahi kuvuta tumbaku (sigara au kiko) kwa kipindi kinachofika mwaka
     mmoja?
‘NDIO’ ina maana angalau pakiti 20 za sigara au gramu 360 za tumbaku maishani
 au angalau sigara moja kwa siku kwa mwaka mzima
  ____ Ndio (1)      ____Hapana (2) 42
Kama NDIO, endelea na Swali la 1.1
Kama HAPANA, nenda Swali la 2
1.1. Ulikuwa na umri gani wakati umeanza kuvuta mara kwa mara?
Andika kadirio la umri: Miaka        _______ 43-44
AU
Andika kadirio la mwaka: Mwaka     ___________ 45-48
1.2. Unavuta siku hizi?
‘NDIO’ ina maana kavuta tumbaku katika kipindi cha mwezi huu mmoja uliopita
au karibu zaidi
  ____ Ndio (1)      ____Hapana (2) 49
Kama NDIO, endelea na Swali la 1.2.1
Kama HAPANA, nenda Swali la 1.3
1.2.1. Kwa wastani, unavuta kiasi gani?
1.2.1.1. Sigara kwa siku ___________ 50-51
1.2.1.2. Kiko (gramu kwa wiki) ___________ 52-54
1.3. Ulishawahi kuacha kuvuta kabisa?   ____ Ndio (1)      ____Hapana (2) 55
Kama NDIO, endelea na Swali la 1.3.1
Kama HAPANA, nenda Swali la 1.4
1.3.1. Ulikuwa na umri gani ulivyoacha kuvuta kabisa?
Andika kadirio la umri: Miaka        _______ 56-57
AU
Andika kadirio la mwaka: Mwaka     ___________ 58-61
1.4. Ni miaka mingapi kwa ujumla uliyovuta tumbaku?
(Usihesabu ile miaka ambayo mshiriki alikuwa ameacha kuvuta kabla hajaanza tena)
Miaka  ____ ____ 62-63
1.5. Kwa wastani katika kipindi chote ulichovuta, umevuta kiasi gani?
1.5.1. Sigara kwa siku ___ ___ 64-65
1.5.2. Kiko (gramu kwa wiki)  ___ ___ ___ 66-68
1.6. Ulimeza/unameza moshi ukivuta?   ____ Ndio (1)      ____Hapana (2) 69
2. Umekuwa ukipata moshi wa tumbaku mara kwa mara  kutoka kwa watu wengine
    wanaovuta sigara au kiko katika kipindi cha miezi 12 iliyopita?
  ____ Ndio (1)      ____Hapana (2) 70
‘Mara kwa mara’ ina maana siku nyingi zaidi
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E. ELIMU NA MAFUNZO YA AFYA NA USALAMA MAHALA PA KAZI
1. Unajua madhara yoyote yanayosababishwa na kemikali unazofanya nazo kazi?
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 71
Kama NDIO, endelea na Swali la 1.1
Kama HAPANA, nenda Swali la 2
1.1. Kama NDIO, ni madhara gani hayo? ____________________________________ 72-73
____________________________________________________________________
____________________________________________________________________
2. Unajua hatua zozote zile za kuilinda afya yako na afya za watu wengine makazini?
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 74
Kama NDIO, endelea na Swali la 2.1
Kama HAPANA, nenda Swali la 3
2.1. Kama NDIO, ni hatua gani hizo? ____________________________________ 75-76
____________________________________________________________________ 77-78
____________________________________________________________________
3. Kuna hatua zozote zile zilizopo hapa hospitalini za kulinda afya zenu?
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 79
Kama NDIO, endelea na Swali la 3.1
Kama HAPANA, nenda Swali la 4 Card 5
3.1. Kama NDIO, ni hatua gani hizo? ____________________________________ 1-2
_____________________________________________________________________ 3-4
_____________________________________________________________________
3.2. Utazipa kiwango gani hatua hizi za kulinda afya zilizopo hapa, kati ya 1 - 5? 5
_____ 3.2.1. Hazitoshi kabisa (1)
_____ 3.2.2. Hazitoshi (2)
_____ 3.2.3. Zinatosha (wastani) (3)
_____ 3.2.4. Nzuri (4)
_____ 3.2.5. Nzuri sana (5)
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4. Umepata mafunzo yoyote kuhusu afya na usalama wa kufanya kazi na kemikali
    hospitalini? ___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 6
Kama NDIO, endelea na Swali la 4.1
Kama HAPANA, nenda kipengele kinachofuata (Mazingira ya Nyumbani)
4.1. Ulipata mafunzo haya mara tu ulipoanza kazi?
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 7
4.2. Ni mara ngapi kwa mwaka unapata mafunzo kuhusu afya na usalama wa
       kufanya kazi na kemikali? 8
_____ 4.2.1. Chini ya mara moja kwa mwaka
_____ 4.2.2. Mara moja kwa mwaka
_____ 4.2.3. Zaidi ya mara moja kwa mwaka
4.3 Utayapa kiwango gani mafunzo haya ya afya na usalama uliyoyapata, kati ya 1-5? 9
_____ 4.3.1. Hayatoshi kabisa (1)
_____ 4.3.2. Hayatoshi (2)
_____ 4.3.3. Yanatosha (wastani) (3)
_____ 4.3.4. Mazuri (4)
_____ 4.3.5. Mazuri sana (5)
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F. MAZINGIRA YA NYUMBANI
Maswali yanayofuata yanahusu nyumba unayoishi sasa
1. Katika kipindi cha miezi 12 iliyopita,  umeona yoyote yafuatayo nyumbani kwako?
 
1.1. Maji kuvuja au uharibifu wa maji ndani ya nyumba kama kwenye kuta, sakafu
        au dari? ___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 10
1.2. Fangasi zinazoonekana ndani ya nyumba (sio kwenye chakula) kama kwenye
       kuta, sakafu, au dari? ___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 11
1.3. Harufu ya fangasi (sio kwenye chakula)?
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 12
2. Katika kipindi cha miezi 12 iliyopita,  kumekuwa na matengenezo au ujenzi
    wowote nyumbani kwako?   ____ Ndio (1)      ____Hapana (2) 13
3. Katika kipindi cha miezi 12 iliyopita,  ni mara ngapi wewe mwenyewe umefanya
    usafi nyumbani kwako?
     Sijafanya < siku 1 Siku 1-2 Siku 3-4 Siku 5-7
/wiki /wiki / wiki / wiki
(a) (b) (c) (d) (e) 14
Kama 'SIJAFANYA': nenda kipengele kinachofuata (Ajali za kemikali 
kumwagika au gesi kutoka)
Kwa majibu mengine isipokuwa 'SIJAFANYA': nenda Swali la 4
4. Katika kipindi cha miezi 12 iliyopita,  ni mara ngapi kwa wiki umetumia kemikali
    hizi kufanyia usafi nyumbani kwako?
Weka alama (X) kwenye jibu sahihi kwa kila kemikali
Sijatumia < Siku 1 Siku 1-2 Siku 3-4 Siku 5-7
/wiki /wiki / wiki / wiki
4.1. Bleach kama Domestos, 1 2 3 4 5 15
       Jik
4.2. Kemikali zenye ammonia 1 2 3 4 5 16
        kama Handy Andy
4.3. Kemikali za kuoshea 1 2 3 4 5 17
    madirisha kama Windolene
4.4. Air freshener ya kupuliza 1 2 3 4 5 18
        kama Glade
4.5. Kemikali yoyote ya 1 2 3 4 5 19
    kufanyia usafi ya kupuliza
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G. AJALI ZA KEMIKALI KUMWAGIKA AU GESI KUTOKA
1. Umeshawahi kupata au kukaribia kupata ajali ya kemikali kumwagika au gesi
    kutoka ukiwa nyumbani, kazini au mahali pengine ambapo ilibidi upate matibabu?
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 20
Kama NDIO, endelea na Swali la 1.1
Kama HAPANA, nenda kipengele kinachofuata (Historia ya Ajira)
1.1. Ni mwaka gani lilitokea tukio la mwisho (la hivi karibuni)?
       Mwaka  __  __  __  __  21-24
1.2. Ni wapi lilitokea tukio la mwisho (la hivi karibuni)?
Tafadhali weka alama (X) kwenye jibu moja tu
____Nyumbani (1) ____Kazini (2) ____Mahali pengine (3) 25
1.3. Ni kemikali gani ilikufikia kwenye mwili wako?
Taja jina/majina ya kemikali
_____________________________________________________________________ 26-27
1.4. Katika masaa 24 ya kwanza tangu tukio la mwisho kutokea, ulipata matatizo
       yoyote ya kifua kama shida kupumua, sauti kama za filimbi, kikohozi, au 
       kubanwa kifua?
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 28
Kama NDIO, endelea na Swali la 1.5
Kama HAPANA, nenda kipengele kinachofuata (Historia ya Ajira)
1.5. Haya matatizo ya kifua uliyoyapata yalikaa mpaka muda gani? 
       (kipindi ulivyopata matatizo ya kifua ndani ya masaa 24 ya kwanza tangu 
       tukio la mwisho kutokea) 29
Sijui < Wiki 1 Wiki 1 - > Mwezi 1 Miezi 3 
Mwezi 1 lakini au zaidi
< Miezi 3
1 2 3 4 5
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H. HISTORIA YA AJIRA
Historia ya kufanya kazi za kutoa huduma ya afya
1. Tafadhali nitajie umri uliyoanza kufanya kazi katika sekta ya afya AU umri
     ulioanza kusoma masomo ya huduma za afya
Andika cha kwanza kutokea
Andika kadirio la umri: Miaka        _______ 30-31
AU
Andika kadirio la mwaka: Mwaka     ___________ 32-35
2. Ni miaka mingapi umefanya kazi za kutoa huduma ya afya? Hii ni pamoja na miaka
    uliyokuwa unasoma masomo ya hududma za afya
Miaka  _______  36-37
Ajira ya sasa
3. Unafanya kazi gani? 38-39
_____ 3.1. Registered nurse
_____ 3.2. Enrolled nurse
_____ 3.3. Health attendant
_____ 3.4. Cleaner
_____ 3.5. Admin., mtaje:______________________________________________
_____ 3.6. Porter (mbeba mizigo)
_____ 3.7. Technician/mteknologia, mtaje: _________________________________
4. Unafanya kazi idara/kitengo/eneo gani? ___________________________ 40-41
5. Umefanya kazi muda gani katika idara/kitengo hiki?
Miaka ______ 42-43
Miezi _______ 44-45
6. Unafanya kazi masaa mangapi kwa wiki katika kazi yako hii?
Masaa kwa wiki _____ _____ 46-47
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7. Katika kazi yako hii, unapatwa na vitu vifuatavyo mara kwa mara : mivuke, gesi,
     vumbi, au fumes? ___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 48
‘Mara kwa mara’ ina maana siku nyingi zaidi
Kama NDIO, endelea na Swali la 7.1
Kama HAPANA, nenda Swali la 8
7.1. Ni mivuke, mavumbi na fumes gani ambazo zinakupata mara kwa mara?
_____________________________________________________________ 49-50
_____________________________________________________________ 51-52
8. Katika kipindi cha miezi 12 iliyopita,  umeona lolote kati ya haya katika sehemu
    unazofanyia kazi?
8.1. Maji kuvuja au uharibifu wa maji ndani ya nyumba kama kwenye kuta, sakafu
        au dari? ___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 53
8.2. Fangasi zinazoonekana ndani ya nyumba (sio kwenye chakula) kama kwenye
       kuta, sakafu, au dari? ___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 54
8.3. Harufu ya fangasi (sio kwenye chakula)?
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 55
9.Katika kipindi cha miezi 12 iliyopita,  umeona matengenezo au ujenzi wowote ule
    ufuatao katika au karibu na maeneo unayofanyia kazi?   
9.1. Upakaji rangi kwenye ukuta?  
___ Yes (1)      ___No (2)      ___Don't know (3) 56
9.2. Kubandua na kurudishia kuta, mbao, au partitions?   
___ Yes (1)      ___No (2)      ___Don't know (3) 57
9.3. Kubandua na kurudishia sakafu, mazulia, au samani za kudumu?  
___ Yes (1)      ___No (2)      ___Don't know (3) 58
9.4. Mwingine, utaje: __________________________________________________
_____________________________________________________________ 59
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Matumizi ya sabuni za maji maji za kunawia mikono / Sanitizers
Fikiria kuhusu kazi yako ya sasa na nini umefanya katika kazi hii kwa kipindi cha
 miezi 12 iliyopita :
10. Unatumia sabuni za maji maji za kunawia mikono/sanitisers kuosha au
       kudisinfect mikono yako?   ____ Ndio (1)      ____Hapana (2) 60
Kama NDIO, endelea na Swali la 10.1
Kama HAPANA, nenda Swali la 11
10.1. Ni sabuni/sanitiser gani unatumia kazini?
10.1.1. JET hand wash liquid soap (pink)   ____ Ndio (1)      ____Hapana (2) 61
10.1.2. TARMOL all pupose cleaner   ____ Ndio (1)      ____Hapana (2) 62
10.1.3. REGLYD solution (90%) handrub   ____ Ndio (1)      ____Hapana (2) 63
10.1.4. ANIOSGEL 800 handrub   ____ Ndio (1)      ____Hapana (2) 64
10.1.5. Sabuni/sanitiser nyingine _________________________________________ 65
                    _____________________________________________________________ __________ 66
10.1.1. Ni mara ngapi kwa siku unatumia hizi sabuni/sanitiser katika siku ya
             kawaida kazini?
10.1.1.1. JET hand wash liquid soap (pink) mara _____   /siku 67-68
10.1.1.2. TARMOL all pupose cleaner mara _____   /siku 69-70
10.1.1.3. REGLYD solution (90%) handrub mara _____   /siku 71-72
10.1.1.4. ANIOSGEL 800 handrub mara _____   /siku 73-74
10.1.1.5. Sabuni/sanitiser nyingine ___________________ mara _____   /siku 73-74
               ____________________________________________ mara _____   /siku 75-76
10.2. Ni sabuni/sanitiser gani unatumia nyumbani?
__________________________________________________________________ 77-78
__________________________________________________________________ 79-80
10.2.1. Ni mara ngapi kwa siku unatumia hizi sabuni/sanitiser katika siku ya kawaida Card 6
            ukiwa nyumbani?
________________________________________________ mara _____   /siku 1-2
________________________________________________ mara _____   /siku 3-4
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Kemikali za kusafishia / kusterilize vifaa tiba
Fikiria kuhusu kazi yako ya sasa na nini umefanya katika kazi hii kwa kipindi cha
 miezi 12 iliyopita :
11. Ukiwa kazini, unasafisha, kusterilize au kufanya high-level disinfection  ya vifaa
     tiba kama bronchoscopes, laryngoscopes, endoscposes, cystoscopes, 
    AU  vyombo vya chuma kama needle holder, forceps, n.k.,
   AU  vyombo vya plastiki kama ear specula za kufanyia uchunguzi sikio?
  ____ Ndio (1)      ____Hapana (2) 5
KAMA MSHIRIKI HAJUI, mjaribu jaribu ili kupata kile anachokijua vizuri
Kama NDIO, endelea na Swali la 11.1
Kama HAPANA, nenda Swali la 11.2
11.1. Ukiwa kazini, ni kemikali gani kati ya zifuatazo unazotumia kusterilize au
kufanya high-level disinfection ya vifaaa tiba?
Jina la kemikali
11.1.1. Ortho-phthalaldehydes kama Cidex OPA
® 
au Shieldex OPA® au Cidex OPA® C 
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 6
11.1.2. Glutaraldehydes kama Steranios 2% NG® au Cidex
®
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 7
11.1.3. Enzymatic cleaners kama Cidezyme® au Sanizyme®
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 8
11.1.4. Kemikali zenye chlorhexidine kama Bioscrub® au D-germ®
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 9
11.1.5. Quaternary ammonium compounds kama MEDDIS®
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 10
11.1.6. Hydrogen peroxide ___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 11
11.1.7. Alcohols, kama ethyl alcohol 96% (ethanol), isopropanol, methylated
    spirits, alcohol 50%, or 70%
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 12
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11.1.8. Bleach au chlorine, kama CLORITE BLEACH®, PRESEPT®, CHLOROCIDE® au
ZAP BLEACH® ___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 13
11.1.9. TARMOL all pupose cleaner®
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 14
11.1.10. Olympus EndoDet® ___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 15
11.1.11. Olympus EndoDis® ___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 16
11.1.12. Olympus EndoAct® ___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 17
11.1.13. Citrosteril® ___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 18
11.1.14. Unatumia kemikali nyingine  kusterilize au kufanya high level-disinfection ya
               vifaa tiba?    ____ Ndio (1)      ____Hapana (2)
Kama HAPANA, nenda Swali la 11.2
Kama NDIO, endelea na Swali la 11.1.14.1
11.1.14.1. Ni kemikali gani nyingine unazotumia?
(i) ______________________________________________________ 24-25
(ii) _____________________________________________________ 26-27
11.1.15. Kama NDIO kwa swali lolote hapo juu (swali la 11.1), jaza karatasi nyingine
                pembeni kwa kila kemikali
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Tasks
11.2. Katika miezi 12 iliyopita,  umeandaa vifaa tiba kwa ajili ya sterilization kwa
kuvifungua/tenganisha vifaa tiba, kuvisafisha ili kuondoa uchafu mkubwa mkubwa 
au kuflush uchafu kutoka kwenye vifaa tiba
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 28
Kama HAPANA, nenda Swali la 11.3
Kama NDIO, endelea na Swali la 11.2.1
11.2.1. Wakati ukisafisha vifaa tiba hivi, tafadhali niambie ni siku ngapi kwa wiki,
 mara ngapi kwa siku na ni muda gani unatumia kufanya shughuli hii
11.2.1.1
.
Ni siku ngapi kwa wiki  unafanya shughuli hii? __________
29
11.2.1.2
. 
Ni mara ngapi kwa siku  unafanya shughuli hii? __________
30-31
11.2.1.3
.
Ni muda  gani unatumia kufanya shughuli hii?      Masaa __________ 
32-33
11.2.1.4
.
Unatumia gloves? Ndio (1) Hapana(2) 
34
11.2.1.4
.1.
Aina gani?
Latex 
(1)
Nitrile (2) Vinyl (3) Yellow/black domestic (4)
35
11.2.1.5
.
Unatumia respirator? Ndio (1) Hapana(2) 
36
11.2.1.5
.1. Aina gani ya respirator? 37
Surgical mask 1
Particulate respirator such as an N95 2
Air purifying half mask 3
Air purifying full face piece 4
Powered air purifying 5
11.2.1.6
.
Kuna aina gani ya uingizaji hewa katika sehemu yako ya kazi wakati 
ukiwa unafanya shughuli hii?
11.2.1.6
.1.
Local exhaust ventilation yenye hood na duct
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 38
11.2.1.6
.2.
Feni za kutoa hewa kwenye dari
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 39
11.2.1.6
.3.
Feni zinazosukuma hewa chafu kuitoa pale alipo mfanyakazi
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 40
11.2.1.6
.4.
Uingizaji hewa wa kawaida (madirisha/milango iliyo wazi)
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 41
11.2.1.6
.5. Kiyoyozi ___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 42
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11.3. Katika kipindi cha miezi 12 iliyopita,  umeandaa kemikali za kuoshea au za
 kufanyia high-level disinfection kwa kuzichanganya  na maji au kuchanganya 
 kemikali moja na nyingine? ___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 42
Kama HAPANA, nenda Swali la 11.4
Kama NDIO, endelea na Swali la 11.3.1
11.3.1. Wakati ukiwa unaandaa kemikali hizi, tafadhali niambie ni siku ngapi kwa
wiki, mara ngapi kwa siku, na ni muda gani unatumia kufanya shughuli hii
11.3.1.1
.
Ni siku ngapi kwa wiki  unafanya shughuli hii? __________
43
11.3.1.2
. 
Ni mara ngapi kwa siku  unafanya shughuli hii? __________
44-45
11.3.1.3
.
Ni muda  gani unatumia kufanya shughuli hii?      Masaa __________ 
46-47
11.3.1.4
.
Unatumia gloves? Ndio (1) Hapana(2) 
48
11.3.1.4
.1.
Aina gani?
Latex 
(1)
Nitrile (2) Vinyl (3) Yellow/black domestic (4)
49
11.3.1.5
.
Unatumia respirator? Ndio (1) Hapana(2) 
50
11.3.1.5
.1. Aina gani ya respirator? 51
Surgical mask 1
Particulate respirator such as an N95 2
Air purifying half mask 3
Air purifying full face piece 4
Powered air purifying 5
11.3.1.6
.
Kuna aina gani ya uingizaji hewa katika sehemu yako ya kazi wakati 
ukiwa unafanya shughuli hii?
11.3.1.6
.1.
Local exhaust ventilation yenye hood na duct
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 52
11.3.1.6
.2.
Feni za kutoa hewa kwenye dari
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 53
11.3.1.6
.3.
Feni zinazosukuma hewa chafu kuitoa pale alipo mfanyakazi
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 54
11.3.1.6
.4.
Uingizaji hewa wa kawaida (madirisha/milango iliyo wazi)
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 55
11.3.1.6
.5. Kiyoyozi ___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 56
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11.4. Katika kipindi cha miezi 12 iliyopita,  umefanya kazi ya kubadilisha  kemikali za
 kuoshea au za kufanyia high-level disinfection kwa kuondoa zilizotumika na kuweka
 nyingine? ___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 56
Kama HAPANA, nenda Swali la 11.5
Kama NDIO, endelea na Swali la  11.4.1
11.4.1. Wakati ukiwa unabadilisha kemikali hizi, tafadhali niambie ni siku ngapi kwa
wiki, mara ngapi kwa siku na ni muda gani unatumia kufanya shughuli hii
11.4.1.1
.
Ni siku ngapi kwa wiki  unafanya shughuli hii? __________
57
11.4.1.2
. 
Ni mara ngapi kwa siku  unafanya shughuli hii? __________
58-59
11.4.1.3
.
Ni muda  gani unatumia kufanya shughuli hii?      Masaa __________ 
60-61
11.4.1.4
.
Unatumia gloves? Ndio (1) Hapana(2) 
62
11.4.1.4
.1.
Aina gani?
Latex 
(1)
Nitrile (2) Vinyl (3) Yellow/black domestic (4)
63
11.4.1.5
.
Unatumia respirator? Ndio (1) Hapana(2) 
64
11.4.1.5
.1. Aina gani ya respirator? 65
Surgical mask 1
Particulate respirator such as an N95 2
Air purifying half mask 3
Air purifying full face piece 4
Powered air purifying 5
11.4.1.6
.
Kuna aina gani ya uingizaji hewa katika sehemu yako ya kazi wakati 
ukiwa unafanya shughuli hii?
11.4.1.6
.1.
Local exhaust ventilation yenye hood na duct
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 66
11.4.1.6
.2.
Feni za kutoa hewa kwenye dari
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 67
11.4.1.6
.3.
Feni zinazosukuma hewa chafu kuitoa pale alipo mfanyakazi
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 68
11.4.1.6
.4.
Uingizaji hewa wa kawaida (madirisha/milango iliyo wazi)
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 69
11.4.1.6
.5. Kiyoyozi ___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 70
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11.5. Katika kipindi cha miezi 12 iliyopita,  umetumia vyombo vya kutumbukizia 
 vifaa (mabeseni au mabakuli makubwa) ili kusterilize au kufanya high-level 
disinfection  ya vifaa tiba kwa kutumia mikono?  
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 70
Kama HAPANA, nenda Swali la 11.6
Kama NDIO, endelea na Swali la 11.5.1
11.5.1. Wakati ukitumia vyombo hivi kusterilize au kufanya high-level disinfection
ya vifaa tiba kwa kutumia mikono, tafadhali niambie ni siku ngapi kwa wiki, mara
ngapi kwa siku, na ni muda gani unatumia kufanya shughuli hii
11.5.1.1
.
Ni siku ngapi kwa wiki  unafanya shughuli hii? __________
71
11.5.1.2
. 
Ni mara ngapi kwa siku  unafanya shughuli hii? __________
72-73
11.5.1.3
.
Ni muda  gani unatumia kufanya shughuli hii?      Masaa __________ 
74-75
11.5.1.4
.
Unatumia gloves? Ndio (1) Hapana(2) 
76
11.5.1.4
.1.
Aina gani?
Latex 
(1)
Nitrile (2) Vinyl (3) Yellow/black domestic (4)
77
11.5.1.5
.
Unatumia respirator? Ndio (1) Hapana(2) 
78
11.5.1.5
.1. Aina gani ya respirator? 79
Surgical mask 1
Particulate respirator such as an N95 2
Air purifying half mask 3
Air purifying full face piece 4
Powered air purifying 5
11.5.1.6
.
Kuna aina gani ya uingizaji hewa katika sehemu yako ya kazi wakati 
ukiwa unafanya shughuli hii?
11.5.1.6
.1.
Local exhaust ventilation yenye hood na duct
Card 7
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 1
11.5.1.6
.2.
Feni za kutoa hewa kwenye dari
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 2
11.5.1.6
.3.
Feni zinazosukuma hewa chafu kuitoa pale alipo mfanyakazi
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 3
11.5.1.6
.4.
Uingizaji hewa wa kawaida (madirisha/milango iliyo wazi)
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 4
11.5.1.6
.5. Kiyoyozi ___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 5
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11.6. Katika kipindi cha miezi 12 iliyopita, umesterilize  vifaa tiba kwa kutumia
mashine/mitambo ya kujiendesha yenyewe ?
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 5
Kama HAPANA, nenda Swali la 12
Kama NDIO, endelea na Swali la 11.6.1
11.6.1. Ni kazi gani unafanya ukiwa unasterilize vifaa tiba kwa kutumia
mashine/mitambo ya kujiendesha yenyewe ?
Unafanya kazi hizi?
11.6.1.1. Kuendesha mashine/mtambo wa Olympus
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 6
11.6.1.2. Kuendesha mashine/mitambo mingine 
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 7
Itaje: _____________________________________________________ 8
11.6.2. Unafanya matengenezo kwenye mashine/mitambo hii, kama kuisafisha au
 kubadilisha vifaa vyake kama screens na filters?
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 9
Tafadhali niambie ni siku ngapi kwa wiki, mara ngapi kwa siku, na ni muda gani
unatumia kufanya shughuli hii na kama kuna kifaa kinachonasa na kuondoa gesi
na mivuke inayotoka katika mashine/mitambo hii
11.6.3. Mashine/mtambo wa Olympus 10
11.6.3.1
.
Ni siku ngapi kwa wiki  unafanya shughuli hii? __________ 11
11.6.3.2
. 
Ni mara ngapi kwa siku  unafanya shughuli hii? __________ 12-13
11.6.3.3
.
Ni muda  gani unatumia kufanya shughuli hii?      Masaa __________ 14-15
11.6.3.4
.
Unatumia gloves? Ndio (1) Hapana(2) 16
11.6.3.4
.1.
Aina gani?
Latex 
(1)
Nitrile (2) Vinyl (3) Yellow/black domestic (4) 17
11.6.3.5
.
Unatumia respirator? Ndio (1) Hapana(2) 18
11.6.3.5
.1. Aina gani ya respirator? 19
Surgical mask 1
Particulate respirator such as an N95 2
Air purifying half mask 3
Air purifying full face piece 4
Powered air purifying 5
11.6.3.6
.
Kuna aina gani ya uingizaji hewa katika sehemu yako ya kazi wakati 
ukiwa unafanya shughuli hii?
11.6.3.6
.1.
Local exhaust ventilation yenye hood na duct
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 20
11.6.3.6
.2.
Feni za kutoa hewa kwenye dari
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 21
11.6.3.6
.3.
Feni zinazosukuma hewa chafu kuitoa pale alipo mfanyakazi
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 22
11.6.3.6
.4.
Uingizaji hewa wa kawaida (madirisha/milango iliyo wazi)
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 23
11.6.3.6
.5. Kiyoyozi ___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 24
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11.6.4. Mashine/mitambo mingine: ________________________________________ 24
11.6.4.1
.
Ni siku ngapi kwa wiki  unafanya shughuli hii? __________
25
11.6.4.2
. 
Ni mara ngapi kwa siku  unafanya shughuli hii? __________
26-27
11.6.4.3
.
Ni muda  gani unatumia kufanya shughuli hii?      Masaa __________ 
28-29
11.6.4.4
.
Unatumia gloves? Ndio (1) Hapana(2) 
30
11.6.4.4
.1.
Aina gani?
Latex 
(1)
Nitrile (2) Vinyl (3) Yellow/black domestic (4)
31
11.6.4.5
.
Unatumia respirator? Ndio (1) Hapana(2) 
32
11.6.4.5
.1. Aina gani ya respirator? 33
Surgical mask 1
Particulate respirator such as an N95 2
Air purifying half mask 3
Air purifying full face piece 4
Powered air purifying 5
11.6.4.6
.
Kuna aina gani ya uingizaji hewa katika sehemu yako ya kazi wakati 
ukiwa unafanya shughuli hii?
11.6.4.6
.1.
Local exhaust ventilation yenye hood na duct
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 34
11.6.4.6
.2.
Feni za kutoa hewa kwenye dari
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 35
11.6.4.6
.3.
Feni zinazosukuma hewa chafu kuitoa pale alipo mfanyakazi
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 36
11.6.4.6
.4.
Uingizaji hewa wa kawaida (madirisha/milango iliyo wazi)
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 37
11.6.4.6
.5. Kiyoyozi ___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 38
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Kemikali za kusafishia / kudisinfect Fixed Surfaces au vifaa
Fikiria kuhusu kazi yako ya sasa na nini umefanya katika kazi hii kwa kipindi cha
 miezi 12 iliyopita :
12. Ukiwa kazini, unasafisha au kudisinfect fixed surfaces au vifaa?
     Mifano ya fixed surfaces are: countertops, sakafu, vitanda and mabafu
     Mifano ya vifaa: stendi za kutundikia dripu, matoroli, kompyuta
                                 mashine za kupimia presha na stethoscopes
  ____ Ndio (1)      ____Hapana (2) 38
KAMA MSHIRIKI HAJUI, mjaribu jaribu ili kupata kile anachokijua vizuri
Kama NDIO, endelea na Swali la 12.1
Kama HAPANA, nenda Swali la 15
12.1. Ukiwa kazini, ni kemikali gani unatumia kusafisha au kudisinfect fixed surfaces
          au vifaa?  
Jina la kemikali
12.1.1. Alcohols, kama ethyl alcohol 96% (ethanol), isopropanol, methylated
  spirits, alcohol 50%, or 70% ___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 39
12.1.2. Ammonia, kama Handysan® au Ammonia cleaner 
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 40
12.1.3. Bleach au chlorine, kama CLORITE BLEACH®, PRESEPT®, CHLOROCIDE® au
ZAP BLEACH® ___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 41
12.1.4. TARMOL all pupose cleaner®
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 42
12.1.5. Glass cleaner ___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 43
12.1.6. LIT® household cleaner & disinfectant
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 44
12.1.7. HARPIC® Power Plus ___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 45
12.1.8. PLANITOL® ___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 46
12.1.9. LYSOL® (Cresol saponated liquid 50%)
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 47
12.1.10. Air freshener ___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 48
12.1.11. Enzymatic cleaners kama Cidezyme® au Sanizyme®
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 49
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12.1.12. Floor wax strippers, kama Multistrip®
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 50
12.1.13. Floor sealer/wax, kama buff spray (diluted floor sealer/wax) au Vision gold®
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 51
12.1.14. Carpet shampoo ___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 52
12.1.15. Furniture polish ___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 53
12.1.16. Stainless steel cleaner
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 54
12.1.17. Unatumia kemikali nyingine kusafishia fixed surfaces au vifaa?
  ____ Ndio (1)      ____Hapana (2) 55
Kama NDIO, endelea na Swali la 12.1.16.1
Kama HAPANA, nenda Swali la 13
12.1.17.1. Ni kemikali gani nyingine unatumia?
1. ______________________________________________________ 59-60
2. ______________________________________________________ 61-62
12.1.18. Kama NDIO kwa swali lolote hapo juu (swali la 12.1), jaza karatasi nyingine
                pembeni kwa kila kemikali
Tasks
Sasa nitakuuliza kuhusu kazi unazofanya ukiwa kazini
13. Unatumia kemikali kwa kupulizia zaidi au kwa kufuta zaidi, au unatumia njia
       zote sawa ukiwa kazini?
 Chagua jibu MOJA tu
13.1 Natumia kwa kupulizia zaidi ya kufuta 1 63
Natumia kwa kufuta zaidi ya kupulizia 2
Natumia njia zote sawa 3
Sina uhakika natumia njia ipi zaidi 4
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14. Ukiwa kazini, ni kazi  gani unafanya ukiwa unaosha au kudisinfect fixed surfaces,
       au vifaa?  
14.1. Kufuta vitanda, samani, counters, kuta, n.k.
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 64
14.2. Kusafisha damu zilizomwagika na maji maji mengine yaliyomwagika
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 65
14.3. Kuchanganya, kujazia, au kumwaga kemikali za kuoshea au za kudisinfect
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 66
14.4. Kuosha mabafu, choo, na masinki
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 67
14.5. Kupulizia kemikali na kufuta vioo na madirisha
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 68
14.6. Kupolish samani za mbao
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 69
14.7. Kupolish sehemu zenye chuma (stainless steel surfaces)
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 70
14.8. Kupulizia dawa za kuondoka harufu/disinfectant
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 71
14.9. Kufagia sakafu ___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 72
14.10. Kusafisha kwa kutumia vacuum
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 73
14.11. Kukung'uta zulia ___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 74
14.12. Kudeki ___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 75
14.13. Kusafisha vifaa kama mikasi, stethoscopes, kipima joto, stendi za kutundikia
             dripu, matoroli na kompyuta
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 76
14.14. Kufanya "terminal cleaning" ya vyumba vya wagonjwa
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 77
14.15. Kutumia vifaa vinavyotoa ukungu na hydrogen peroxide au peracetic acid
kufanyia "terminal cleaning" ya vyumba vya wagonjwa
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 78
14.16. Kusafisha au kudisinfect kwa sababu ya methicillin-resistant staphylococcus
aureus, vancomycin-resistant enterococci au kwa sababu ya vimelea sugu vingine 
kwenye vyumba vya wagonjwa
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 79
14.17. Kufanya "end of shift cleaning" kwenye vyumba vya upasuaji, vitengo vya
dialysis au sehemu nyingine za kuhudumia wagonjwa
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 80
14.18. Kama NDIO kwa swali lolote hapo juu (swali la 14), jaza karatasi nyingine
                pembeni kwa kila kemikali
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15. Katika kipindi cha miezi 12 iliyopita,  umesafisha na kung'arisha sakafu kwa Card 8
       kutumia strippers  na buffers?
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 1
Kama NDIO, endelea na Swali la 15.1
Kama HAPANA, nenda Swali la 16
15.1. Ni kazi gani unafanya wakati ukisafisha na kung'arisha sakafu kwa kutumia
         strippers na buffers?
15.1.1. Kustrip sakafu
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 2
15.1.2. Kukangua sakafu
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 3
15.1.3. Kubuff sakafu
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 4
15.1.4. Kung'arisha (kuwax) sakafu
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 5
15.1.5. Kama NDIO kwa swali lolote hapo juu (swali la 15.1), jaza karatasi nyingine
                pembeni kwa kila kemikali
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Kemikali zinazotumika kuandaa specimens
16. Huwa unaandaa specimens  kwa ajili ya histology au cytology?
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 6
Kama NDIO, endelea na Swali la 16.1
Kama HAPANA, nenda Swali la 17
16.1. Ni kemikali gani unazotumia kuaandaa specimens kwa ajili ya 
          histology/cytology?
16.1.1. Formalin 10% in normal saline
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 7
16.1.2 Fencott cytological fixative spray
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 8
16.1.3. Stains na dyes kama hematoxylin and eosin stains?
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 9
16.1.4. Solvents kama xylene and toluene za kufix specimens na kusuuza stains
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 10
16.1.5. Kama NDIO kwa swali lolote hapo juu (swali la 16.1), jaza karatasi nyingine
                pembeni kwa kila kemikali
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Kemikali za kutumia kwa wagonjwa
Fikiria kuhusu kazi yako ya sasa na nini umefanya katika kazi hii kwa kipindi cha
 miezi 12 iliyopita :
17. Unatumia kemikali kwa wagonjwa? 
         Mifano: 
Antiseptics : alcohols kama methylated spirit, povidone iodine, Planitol, 
                      chlorhexidine, iodine, silver compounds
Adhesives : glues, acrylates, bone cements
Kemikali za kutolea adhesives : alcohols, acetone, ether
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 11
KAMA MSHIRIKI HAJUI, mjaribu jaribu ili kupata kile anachokijua vizuri
Kama NDIO, endelea na Swali la 17.1
Kama HAPANA, nenda Swali la 18
17.1. Ni kazi gani unafanya wakati ukiwa unatumia hizi kemikali kwa wagonjwa?
Tasks:
17.1.1. Kudisinfect ngozi za wagonjwa kabla ya procedure  kwa kutumia wipes, gauze,
           au swabs zenye antiseptics kama povidone iodine au methylated spirit au
           Planitol ___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 12
17.1.2. Kusafisha na kudisinfect vidonda  kwa kutumia antiseptics kama kemikali
             zenye silver, Biotane in alcohol, povidone iodine, au Planitol
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 13
17.1.3. Kufunga vidonda  kwa kutumia polyurethane based hydrogel, hydrocolloid, 
            au hydrocellular foam 
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 14
17.1.4. Kutumia adhesives  kama gundi, acrylates, simenti za mifupa, benzoin tincture
            mfano Opsite, 3M Steri-Strip® wakati wa upasuaji, kuziba sehemu ya ngozi,
            kuunga mfupa, ostomy bags, na matumizi mengine
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 15
17.1.5. Kutumia kemikali za kutolea adhesives  kama ether, alcohols au acetone
             kwenye wipes, gauze, au swabs
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 16
17.1.6. Kuweka au kutoa synthetic fiberglass orthopaedic casts 
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 17
17.1.7. Kama NDIO kwa swali lolote hapo juu (swali la 17.1), jaza karatasi nyingine
                pembeni kwa kila kemikali
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Dawa za kuvuta (aerosolized medicines) zinazotumiwa na wagonjwa
Fikiria kuhusu kazi yako ya sasa na nini umefanya katika kazi hii kwa kipindi cha
 miezi 12 iliyopita :
18. Huwa unatoa kwa wagonjwa dawa za kuvuta  kama bronchodilators au 
       dawa za usingizi?
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 18
KAMA MSHIRIKI HAJUI, mjaribu jaribu ili kupata kile anachokijua vizuri
Kama NDIO, endelea na Swali la 18.1
Kama HAPANA, nenda kipengele kinachofuata (Ajira za kipindi cha nyuma)
18.1. Ni kazi gani huwa unafanya wakati ukiwa unatoa dawa za kuvuta? 
Tasks
18.1.1. Kutoa dawa za kuvuta kwa kutumia small volume nebulizer (SVN)
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 19
18.1.2. Kutumia continuous aerosol delivery system  kwa ajili ya bronchodilators 
              na dawa nyingine
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 20
18.1.3. Kutoa dawa za kuvuta kwa kutumia metered-dose inhaler (MDI)
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 21
18.1.4. Kutoa dawa za kuvuta kwa kutumia dry powder inhaler (DPI)
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 22
18.1.5. Kama NDIO kwa swali lolote hapo juu (swali la 18.1), jaza karatasi nyingine
                pembeni kwa kila kemikali
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I. AJIRA ZA KIPINDI CHA NYUMA
Sasa ntakuuliza maswali kuhusu kazi ulizokuwa unafanya kipindi cha nyuma hapa
hospitalini:
1. Nitajie kazi zote za nyuma  ulizowahi kuwa nazo hapa hospitalini:
Anza na kazi ya kwanza kabisa uliyowahi kuwa nayo
Idara/ Jina la kazi Mwaka Mwaka Ni masaa Ulikuwa unapata
Kitengo/ (ulifanya  ulioanza wa mwi- mangapi mivuke, gesi,
Eneo kazi gani?) kazi sho kufa- kwa siku mavumbi, fumes
nya kazi ulifanya? mara kwa mara?
Sasa nitakuuliza maswali kuhusu ajira zako za nyuma katika sekta ya afya,
lakini sio katika hospitali hii:
2. Nitajie sehemu zote ulizowahi kufanya kazi, wakati ukiwa hufanyi hapa hospitalini,
     au kabla hujaanza kazi hapa hospitalini:
Anza na kazi ya kwanza kabisa uliyowahi kuwa nayo
Jina Aina Jina la kazi Mwaka Mwaka Ni masaa Ulikuwa unapata
la sehe- (ulifanya  ulioanza wa mwi- mangapi mivuke, gesi,
mu ya kazi gani?) kazi sho kufa- kwa siku mavumbi, fumes
kazi nya kazi ulifanya? mara kwa mara?
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Sasa nitakuuliza maswali kuhusu ajira zako za nyuma (nje ya sekta ya afya)
3. Nitajie sehemu zote ulizowahi kufanya kazi (nje ya sekta ya afya):
Anza na kazi ya kwanza kabisa uliyowahi kuwa nayo
Jina la sehe- Sekta Jina la kazi Mwaka Mwaka Jumla ya
mu ya kazi (ulifanya  ulioanza wa mwi- miaka
kazi gani?) kazi sho kufa-
nya kazi
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Kubadilisha kazi
4. Umeshawahi kuacha au kubadilisha kazi au eneo la kazi kwasababu iliathiri
upumuaji wako? Hii ni pamoja na kubadilisha kazi au eneo la kazi lakini bado
ukiwa hospitali ile ile / mahali pale pale pa kazi
___ Ndio (1)      ___ Hapana (2)      ___ Sijui (3) 23
Kama NDIO, endelea na Swali la 4.1
Kama HAPANA, nenda kipengele kinachofuata (Work-related symptoms)
Tafadhali jibu maswali yafuatayo kuhusu mara yako ya mwisho kabisa  kuacha au
kubadilisha kazi au eneo la kazi kwasababu imeathiri upumuaji wako.
4.1. Ni mwaka gani uliacha au kubadili kazi au eneo la kazi?    
Mwaka: __ __ __ __ 24-27
4.2. Ni aina gani ya kazi au eneo la kazi uliloondoka au kubadili?
_________________________________________________________________ 28-29
_________________________________________________________________
4.3. Ni shughuli gani ulikuwa unafanya katika kazi hiyo au eneo hilo la kazi
uliloondoka au kubadili?  _______________________________________________ 30-31
_____________________________________________________________________
_____________________________________________________________________
4.4. Ni kitu gani kiliathiri upumuaji wako hapo kwenye hiyo kazi au eneo hilo la kazi 
uliloondoka au kubadili? _________________________________________________ 32-33
_____________________________________________________________________ 34-35
4.5. Kuhusu kazi au eneo la kazi uliloenda:  Ni kazi gani au eneo gani la kazi
uliloenda? __________________________________________________________ 36-37
____________________________________________________________________
4.6. Ulifanya shughuli gani katika kazi hii au eneo hili jipya la kazi?
_________________________________________________________________ 38-39
_________________________________________________________________
4.7. Naomba nitajie jina la kampuni hii mpya uliyoenda kufanya kazi
_______________________________________________________________ 40-41
4.8. Matatizo (yako ya upumuaji) yalipungua ulivyobadili kazi au eneo la kazi?
  ____ Ndio (1)      ____Hapana (2) 42
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J. MATATIZO YA KIAFYA YANAYOHUSIANA NA KAZI
Matatizo ya kifua yanayohusiana na kazi
Fikiria kuhusu maisha yako yote ukiwa unafanya kazi na matatizo yako ya pumu 
ukiwa kazini:
1. Je, kuwa kwako kazini kunasababisha/kulisababisha kifua chako kubana, kusikia
    sauti kama za filimbi, au kupumua kwa shida?
  ____ Ndio (1)      ____Hapana (2) 43
Kama NDIO, endelea na Swali la 1.1 
Kama HAPANA, nenda Swali la 2
1.1. Ni tangu lini ulianza kupata matatizo haya ya kifua ukiwa kazini?
Mwezi ______   Mwaka __________ 44-47
1.2. Unafikiri ni nini kinasababisha/kilisababisha haya matatizo?
Workplace triggers
Sijui __Y(1) __N(2) 48
Ortho-phthalaldehydes, kama Cidex OPA
®
, Shieldex OPA®, Cidex OPA® C __Y(1) __N(2) 49
Glutaraldehydes, kama Steranios® au Cidex® __Y(1) __N(2) 50
Enzymatic cleaners, kama Cidezyme® au Sanizyme® __Y(1) __N(2) 51
Kemikali zenye chlorhexidine kama Savlon®, Bioscrub®, D-germ®, __Y(1) __N(2) 52
Quaternary ammonium compounds kama MEDDIS® __Y(1) __N(2) 53
Bleach au chlorine, kama Clorite®, ZAP®, Presept®, Chlorocide® __Y(1) __N(2) 54
Ammonia, kama Handysan, Ammonia cleaner (cleaner all purpose) __Y(1) __N(2) 55
TARMOL all purpose cleaner® __Y(1) __N(2) 56
Kemikali nyingine za kusterilise au kufanya high-level disinfection __Y(1) __N(2) 57
     ya vifaa tiba
Kemikali nyingine za kuoshea fixed surfaces __Y(1) __N(2) 57
Strippers au waxes za sakafu __Y(1) __N(2) 58
Sabuni nyingine za maji maji za kunawia mikono/sanitisers __Y(1) __N(2) 59
Adhesives, gundi, au kemikali za kuondoa adhesives __Y(1) __N(2) 60
Dawa za kuvuta (aerosolised medicines) __Y(1) __N(2) 61
Gesi au mivuke __Y(1) __N(2) 62
Vitu venye latex __Y(1) __N(2) 63
Hali ya ubaridi sana au joto sana __Y(1) __N(2) 64
Vumbi, tafadhali taja aina ya vumbi (vumbi la karatasi, n.k.): _________ __Y(1) __N(2) 65
Nyingine, tafadhali zitaje: __Y(1) __N(2) 66
a)  ____________________________ 67
b)  ____________________________ 68
c)  ____________________________ 69
d)  ____________________________ 70
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Fikiria kuhusu miezi 12 iliyopita:
1.3. Katika kipindi cha miezi 12 iliyopita,  umepata matatizo haya ya kifua wakati
        ukiwa kazini muda wowote ule?   ____ Ndio (1)      ____Hapana (2) 71
Kama NDIO, endelea na Swali la 1.3.1
Kama HAPANA, nenda Swali la 1.4
1.3.1. Wakati ukiwa haupo kazini  (kwa mfano wikiendi au ukiwa likizo) katika
           kipindi hiki cha miezi 12 iliyopita,  matatizo yako ya kifua huwa 
           yanapungua, au yanakuwa mabaya zaidi au yanakuwa vile vile?
Uliza maswali yote matatu (3) kwa wakati mmoja
Weka alama ya (X) mbele ya jibu moja sahihi
72
a)  Yanakuwa vile vile ______
b)  Yanapungua ______
c)  Yanakuwa mabaya zaidi ______
1.3.2. Baada ya kurudi kazini  katika kipindi hiki cha miezi 12 iliyopita,  matatizo yako
           ya kifua huwa yanapungua, au yanakuwa mabaya zaidi au yanakuwa vile vile?
Uliza maswali yote matatu (3) kwa wakati mmoja
Weka alama ya (X) mbele ya jibu moja sahihi
73
a)  Yanakuwa vile vile ______
b)  Yanapungua ______
c)  Yanakuwa mabaya zaidi ______
1.4. Ulishawahi kuambiwa na daktari kwamba pumu yako inahusiana na kazi yoyote
        uliyowahi kufanya?   ____ Ndio (1)      ____Hapana (2) 74
Kama NDIO, endelea na Swali la 1.4.1
Kama HAPANA, nenda Swali la 2
1.4.1. Ulikuwa una umri gani au ni mwaka upi daktari aligundua hilo kwa mara ya 
           kwanza kabisa? 
Andika kadirio la umri: Miaka        _______ 75-76
AU
Andika kadirio la mwaka: Mwaka     ___________ 77-80
1.4.2. Ulikuwa unafanya kazi wapi wakati ulipopata haya matatizo kwa mara ya Card 9
 kwanza? 1
____ 1. Ajira kwenye sekta ya afya
____ 2. Ajira nje ya sekta ya afya
____ 3. Mwanafunzi, tafadhali fafanua: ____________________________________ 2
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Matatizo ya pua na macho yanayohusiana na kazi
Fikiria kuhusu maisha yako yote ukiwa unafanya kazi na matatizo yako ya pua na
macho ukiwa kazini:
2. Je, kuwa kwako kazini kunasababisha/kulisababisha wewe kupiga chafya/ pua
    kuwasha/ kutokwa makamasi au macho kuwa mekundu/kuwasha/kutoa machozi?
  ____ Ndio (1)      ____Hapana (2) 3
Kama NDIO kwa mojawapo ya hayo, endelea na Swali la 2.1
Kama HAPANA, nenda Swali la 3
2.1. Ni tangu lini ulianza kupata matatizo haya ukiwa kazini?
Mwezi ______   Mwaka __________ 4-7
2.2. Unafikiri ni nini kinasababisha/kilisababisha haya matatizo?
Workplace triggers
Sijui __Y(1) __N(2) 8
Ortho-phthalaldehydes, kama Cidex OPA
®
, Shieldex OPA®, Cidex OPA® C __Y(1) __N(2) 9
Glutaraldehydes, kama Steranios® au Cidex® __Y(1) __N(2) 10
Enzymatic cleaners, kama Cidezyme® au Sanizyme® __Y(1) __N(2) 11
Kemikali zenye chlorhexidine kama Savlon®, Bioscrub®, D-germ®, __Y(1) __N(2) 12
Quaternary ammonium compounds kama MEDDIS® __Y(1) __N(2)
Bleach au chlorine, kama Clorite®, ZAP®, Presept®, Chlorocide® __Y(1) __N(2) 13
Ammonia, kama Handysan, Ammonia cleaner (cleaner all purpose) __Y(1) __N(2) 14
TARMOL all purpose cleaner® __Y(1) __N(2) 15
Kemikali nyingine za kusterilise au kufanya high-level disinfection __Y(1) __N(2) 16
     ya vifaa tiba
Kemikali nyingine za kuoshea fixed surfaces __Y(1) __N(2) 17
Strippers au waxes za sakafu __Y(1) __N(2) 18
Sabuni nyingine za maji maji za kunawia mikono/sanitisers __Y(1) __N(2) 19
Adhesives, gundi, au kemikali za kuondoa adhesives __Y(1) __N(2) 20
Dawa za kuvuta (aerosolised medicines) __Y(1) __N(2) 21
Gesi au mivuke __Y(1) __N(2) 22
Vitu venye latex __Y(1) __N(2) 23
Hali ya ubaridi sana au joto sana __Y(1) __N(2) 24
Vumbi, tafadhali taja aina ya vumbi (vumbi la karatasi, n.k.): _________ __Y(1) __N(2) 25
Nyingine, tafadhali zitaje: __Y(1) __N(2) 26
a)  ____________________________ 27
b)  ____________________________ 28
c)  ____________________________ 29
d)  ____________________________ 30
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Fikiria kuhusu miezi 12 iliyopita:
2.3. Katika kipindi cha miezi 12 iliyopita,  umepata matatizo haya wakati ukiwa
        kazini muda wowote ule?   ____ Ndio (1)      ____Hapana (2) 31
Kama NDIO, endelea na Swali la 2.3.1
Kama HAPANA, nenda Swali la 2.4
2.3.1. Wakati ukiwa haupo kazini  (kwa mfano wikiendi au ukiwa likizo) katika
           kipindi hiki cha miezi 12 iliyopita,  haya matatizo yako huwa 
           yanapungua, au yanakuwa mabaya zaidi au yanakuwa vile vile?
Uliza maswali yote matatu (3) kwa wakati mmoja
Weka alama ya (X) mbele ya jibu moja sahihi
32
a)  Yanakuwa vile vile ______
b)  Yanapungua ______
c)  Yanakuwa mabaya zaidi ______
2.3.2. Baada ya kurudi kazini  katika kipindi hiki cha miezi 12 iliyopita,  matatizo yako
           huwa yanapungua, au yanakuwa mabaya zaidi au yanakuwa vile vile?
Uliza maswali yote matatu (3) kwa wakati mmoja
Weka alama ya (X) mbele ya jibu moja sahihi
33
a)  Yanakuwa vile vile ______
b)  Yanapungua ______
c)  Yanakuwa mabaya zaidi ______
2.4. Ulishawahi kuambiwa na daktari kwamba matatizo yako ya pua na macho
        yanahusiana na kazi yoyote uliyowahi kuifanya?
  ____ Ndio (1)      ____Hapana (2) 34
Kama NDIO, endelea na Swali la 2.4.1
Kama HAPANA, nenda Swali la 3
2.4.1. Ulikuwa una umri gani au ni mwaka upi daktari aligundua hilo kwa mara ya 
           kwanza kabisa? 
Andika kadirio la umri: Miaka        _______ 35-36
AU
Andika kadirio la mwaka: Mwaka     ___________ 37-40
2.4.2. Ulikuwa unafanya kazi wapi wakati ulipopata haya matatizo kwa mara ya
 kwanza? 41
____ 1. Ajira kwenye sekta ya afya
____ 2. Ajira nje ya sekta ya afya
____ 3. Mwanafunzi, tafadhali fafanua: ____________________________________ 42
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Matatizo ya ngozi yanayohusiana na kazi
Fikiria kuhusu maisha yako yote ukiwa unafanya kazi na matatizo yako ya ngozi
ukiwa kazini:
3. Je, kuwa kwako kazini kunasababisha/kulisababisha wewe kupata matatizo 
     ya ngozi?   ____ Ndio (1)      ____Hapana (2) 43
Kama NDIO, endelea na Swali la 3.1
Kama HAPANA, hapa ndio mwisho wa mahojiano
3.1. Ni tangu lini ulianza kupata matatizo haya ya ngozi ukiwa kazini?
Mwezi ______   Mwaka __________ 44-47
3.2. Unafikiri ni nini kinasababisha/kilisababisha haya matatizo?
Workplace triggers
Sijui __Y(1) __N(2) 48
Ortho-phthalaldehydes, kama Cidex OPA®, Shieldex OPA®, Cidex OPA® C __Y(1) __N(2) 49
Glutaraldehydes, kama Steranios® au Cidex® __Y(1) __N(2) 50
Enzymatic cleaners, kama Cidezyme® au Sanizyme® __Y(1) __N(2) 51
Kemikali zenye chlorhexidine kama Savlon®, Bioscrub®, D-germ®, __Y(1) __N(2) 52
Quaternary ammonium compounds kama MEDDIS® __Y(1) __N(2)
Bleach au chlorine, kama Clorite®, ZAP®, Presept®, Chlorocide® __Y(1) __N(2) 53
Ammonia, kama Handysan, Ammonia cleaner (cleaner all purpose) __Y(1) __N(2) 54
TARMOL all purpose cleaner® __Y(1) __N(2) 55
Kemikali nyingine za kusterilise au kufanya high-level disinfection __Y(1) __N(2) 56
     ya vifaa tiba
Kemikali nyingine za kuoshea fixed surfaces __Y(1) __N(2) 57
Strippers au waxes za sakafu __Y(1) __N(2) 58
Sabuni nyingine za maji maji za kunawia mikono/sanitisers __Y(1) __N(2) 59
Adhesives, gundi, au kemikali za kuondoa adhesives __Y(1) __N(2) 60
Dawa za kuvuta (aerosolised medicines) __Y(1) __N(2) 61
Gesi au mivuke __Y(1) __N(2) 62
Vitu venye latex __Y(1) __N(2) 63
Hali ya ubaridi sana au joto sana __Y(1) __N(2) 64
Vumbi, tafadhali taja aina ya vumbi (vumbi la karatasi, n.k.): _________ __Y(1) __N(2) 65
Nyingine, tafadhali zitaje: __Y(1) __N(2) 66
a)  ____________________________ 67
b)  ____________________________ 68
c)  ____________________________ 69
d)  ____________________________ 70
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Fikiria kuhusu miezi 12 iliyopita:
3.3. Katika kipindi cha miezi 12 iliyopita,  umepata matatizo haya wakati ukiwa
        kazini muda wowote ule?   ____ Ndio (1)      ____Hapana (2)
Kama NDIO, endelea na Swali la 3.3.1 71
Kama HAPANA, nenda Swali la 3.4
3.3.1. Wakati ukiwa haupo kazini  (kwa mfano wikiendi au ukiwa likizo) katika
           kipindi hiki cha miezi 12 iliyopita,  haya matatizo yako huwa 
           yanapungua, au yanakuwa mabaya zaidi au yanakuwa vile vile?
Uliza maswali yote matatu (3) kwa wakati mmoja
Weka alama ya (X) mbele ya jibu moja sahihi
72
a)  Yanakuwa vile vile ______
b)  Yanapungua ______
c)  Yanakuwa mabaya zaidi ______
3.3.2. Baada ya kurudi kazini  katika kipindi hiki cha miezi 12 iliyopita,  matatizo yako
           huwa yanapungua, au yanakuwa mabaya zaidi au yanakuwa vile vile?
Uliza maswali yote matatu (3) kwa wakati mmoja
Weka alama ya (X) mbele ya jibu moja sahihi
73
a)  Yanakuwa vile vile ______
b)  Yanapungua ______
c)  Yanakuwa mabaya zaidi ______
3.4. Ulishawahi kuambiwa na daktari kwamba matatizo yako ya ngozi yanahusiana
        na kazi yoyote uliyowahi kuifanya? 74
  ____ Ndio (1)      ____Hapana (2)
Kama NDIO, endelea na Swali la 3.4.1
Kama HAPANA, hapa ndio mwisho wa mahojiano
3.4.1. Ulikuwa una umri gani au ni mwaka upi daktari aligundua hilo kwa mara ya 
           kwanza kabisa? 
Andika kadirio la umri: Miaka        _______ 75-76
AU
Andika kadirio la mwaka: Mwaka     ___________ 77-80
Card 10
3.4.2. Ulikuwa unafanya kazi wapi wakati ulipopata haya matatizo kwa mara ya 1
 kwanza? 
____ 1. Ajira kwenye sekta ya afya
____ 2. Ajira nje ya sekta ya afya 2
____ 3. Mwanafunzi, tafadhali fafanua: ____________________________________
ASANTE SANA KWA USHIRIKI WAKO
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RISK FACTORS FOR WORK-RELATED ASTHMA IN HEALTH CARE
WORKERS WITH EXPOSURE TO DIVERSE CLEANING AGENTS – 2014
LUNG FUNCTION TESTS--Pretest Questionnaire
a. Survey Number  ________________ 1-3
b. Staff Number  _________________________ 4-11
c. Interviewer's initials: ______________________ 12-13
d. Date of interview:
 Day____Month_________Year___________ 14-21
1. Have you had any recent operation (in the last 12 months)?
Yes (1) No (2) 22
     1.1 If Yes , what type and how many months ago? 23
     __________________________________________________
     __________________________________________________
     1.2 How many months ago?  ________ 24-25
2. Have you had a heart attack or stroke in the last 3 months?
Yes (1) No (2) 26
3. Do you have epilepsy? 
Yes (1) No (2) 27
If YES to any  of the above no. 1-3, indicate to the person that
the lung function tests will not be done.   
Otherwise proceed with the questions below.
4. Are you being treated for Tuberculosis (TB)?
Yes (1) No (2) 28
  4.1 If Yes, for how long?       ________months  ________weeks 29-32
5. Have you had the flu or sinusitis or a lung infection in the
past 3 weeks? Yes (1) No (2) 33
If YES, to question no. 4 or 5, indicate to person that the tests
will not be done today. Schedule another appointment in
three weeks from the end of their illness or 
three months time from the start of their TB medication. 
6.For women:
     6.1 Are you Pregnant?    
Yes (1) No (2) Don't know (3) 34
     6.2 If Don't know: Would you like to perform a 
     urinary pregnancy test to make sure?
Yes (1) No (2) 35
 1
Appendix C: Lung function test and exhaled nitric oxide pre-test questionnaire
     6.3 Are you Breastfeeding? Yes (1) No (2) 36
If Pregnant, indicate to the person that the spirometry and
methacholine tests will NOT be done today, but proceed with
the exhaled nitric oxide test.
If Breastfeeding, proceed with spirometry test with post-
bronchodilator. Otherwise proceed with the questions below.
ALCOHOL CONSUMPTION
7. Do you drink alcohol? Yes (1) No (2) 37
     7.1 If Yes, when have you last consumed alcohol? 38
1-2 hours ago (1)
1 day ago (2)
1 week ago (3)
     7.2 How much alcohol did you consume? Units: _________ 39-40
     (1 unit = 1 beer, 1 glass of wine, 1 tot of spirits)
GREEN VEGETABLE CONSUMPTION
8. How often do you eat the following vegetable products?
Type of product Daily 1 to 3 1 to 3 Never
 times a times a
  week month
8.1. Green salad 1 2 3 4 41
8.2. Spinach & other 1 2 3 4 42
   green leafy vegetables
9. When did you last consume green salad and/or spinach/
other green leafy vegetables?
1-2 hours ago (1) 43
1 day ago (2)
1 a week ago (3)
PHYSICAL ACTIVITY
10. Do you exercise? Yes (1) No (2) 44
11. When was the last time you exercised? 
1-2 hours ago (1) 45
1 day ago (2)
1 week ago (3)
SPIROMETRY/LUNG FUNCTION TEST
12. Have you ever had a spirometry/lung function test?
Yes (1) No (2) 46
     12.1 If yes, when last did you blow into a lung function
     machine? 1-2 hours ago (1) 47
1 day ago (2)
1 week ago (3)
> a week ago (4)  2
RECENT ORAL INTAKE
13. Did you have anything to eat or drink in the last hour?
Yes (1) No (2) 48
14. Have you smoked in the last hour?          Yes (1)      No (2) 49
If YES to no. 13 or 14, reschedule nitric oxide test for
at least 1 hour later the same day or for another date. 
15. Have you had asthma in the past?            Yes (1)      No (2) 50
16. Do you have asthma now?                          Yes (1)      No (2) 51
17. Are you taking any medicine(s) from a doctor or clinic
at the moment for your chest OR any heart condition 
OR for your eyes? Yes (1) No (2) 52
     17.1 If YES, what are you taking and when did you last
     take them?
Names: Hours since last dose:
_______________________________ _______ 53-54
_______________________________ _______ 55-56
_______________________________ _______ 57-58
_______________________________ _______ 59-60
If Beta-Blockers such as Atenolol, Carvedilol etc. are being
used—DO NOT perform methacholine challenge test.
Additionally, if anti-cholinesterase medication such as
Pyridostigmine for Myasthenia gravis is being used
—DO NOT perform methacholine challenge test.
If short-acting beta-2-agonist or anti-cholinergic inhalers have 
been used in the last 4 hours or long-acting MDI or
theophylline have been used in last 8 hours, reschedule and
counsel accordingly.
18. Do you currently have any of these symptoms?
     18.1 chest tightness  Yes (1) No (2) 61
     18.2 shortness of breath Yes (1) No (2) 62
     18.3 wheezing or whistling in your chest Yes (1) No (2) 63
     18.4 dry cough Yes (1) No (2) 64
19. If YES to any of the above: 
     19.1 Are you feeling very unwell today?
Yes (1) No (2) 65
If YES to no. 19.1: Consult with the doctor on site whether to 
proceed with spirometry and methacholine challenge test.
END
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RISK FACTORS FOR WORK-RELATED ASTHMA IN HEALTH CARE 
WORKERS WITH EXPOSURE TO DIVERSE CLEANING AGENTS – 2014 
 
LUNG FUNCTION TESTS—DATA COLLECTION SHEET 
 
 
                                                                                            
 
                                                                                          Card 1 
     Survey Number     1-3 
     Staff number           4-11 
     Date        12-17 
           DAY           MONTH        YEAR 
                     
 
1. Subject’s blood pressure      systolic 
           
[DO NOT PROCEED WITH MCT IF BP >180/110]      diastolic 
 
           YEARS 
2. Subject's age    18-19 
         MALE  FEMALE 
3. Subject's gender    20 
 
     CENTIMETRES 
4.1 Subject's height  .   21-23 
         KILOGRAMS 
4.2 Subject's weight    24-26 
 
5. When did you last work? Date         27-32 
 
 
 
BASELINE SPIROMETRY 
  
 
6. PREDICTED FEV1 
    33-35 
 
 
7. INITIAL FEV1 and FVC                     FEV1                    FVC                  
    (up to 8 attempts)       1                                     36-41 
       2                                     42-47 
       3                                     48-53 
       4                                     54-59 
       5                                     60-65 
   
         
 7.1 Number of rejected attempts 
               66 
 
 
8. Best INITIAL FEV1 as % of predicted FEV1         67-69 
    (divide best results from No. 7 by results from No. 6) 
 
Appendix D: Lung function test data collection sheet
  2 
IF BEST INITIAL FEV1 IS:  a) less than 70% PREDICTED or 
   b) less than 1.5 LITRES or   
the individual is: c) Breastfeeding 
 
GO TO BRONCHODILATOR CHALLENGE—DO NOT DO METHACHOLINE CHALLENGE 
 
BRONCHODILATOR CHALLENGE ONLY (following 4 puffs of 100 mcg) 
 
9. FEV1 and FVC  
                                                                       FEV1                 FVC               Card 2 
         9.1 Record Best two technically satisfactory                           1-6 
         Manoeuvres (up to 8 attempts)                                         7-12 
                                                                                                                                                                     
         9.2 Number of rejected attempts                13 
                
METHACHOLINE CHALLENGE TEST      
    
10. CONTROL FEV1 following inhalation of diluent 
  
                                                                                                                                                                        
         10.1 Record two technically satisfactory manoeuvres                        1     14-16 
                (up to 3 attempts)                                                                                                                              17-19 
      
         10.2 Number of rejected attempts    20 
 
11. BEST CONTROL (post-diluent) FEV1 as % of INITIAL FEV1    21-23 
        (divide best results from No. 10 by best results from No. 7) 
 
 
 
IF BEST CONTROL FEV1 <90% OF BEST INITIAL FEV1 STOP METHACHOLINE CHALLENGE AND  
 
GO TO REVERSAL OF BRONCHOCONSTRICTION 
 
 
Choice of methacholine short, medium, long protocol, standard 
 
STOP METHACHOLINE CHALLENGE if FEV1 falls to <80% of CONTROL FEV1  
 (multiply no. 10 by 0.8) 
 
         80% of CONTROL FEV1                 
        
 
12. DID THE SUBJECT ANSWER 'YES' TO QUESTIONS 9, 11 & 12  NO YES 
         OF THE LFT Pre-Test?     
      
12.1 Which protocol will the subject follow?   24 
  
 
13. METHACHOLINE BATCH NUMBER        25-26 
 
 
 
 
  3 
    DOSE                                                                            Best      2
nd
 Best    Rejected 
LEVEL    DOSE (mg of 32 mg/ml)                                           FEV1                      FEV1                     attempts  
 
1 Diluent                27-33 
2 0.0256                34-40 
 
3 0.032                41-47 
4 0.064                48-54 
 
5 0.128                55-61 
6 0.256                62-68 
                                                                                                                                                         Card 3 
7 0.512                1-7 
8 1.024                8-14 
 
9 2.048                15-21 
         
                                                                                                                                    
14. Why was methacholine challenge stopped?    TICK ONE 
      BOX ONLY 
a) best CONTROL FEV1 < 90% of best INITIAL FEV1    22  
b) end of test reached (2.048mg of 32 mg/ml inhaled)    23  
c) >/= 20% fall in FEV1 occurred    24  
d) subject asked to stop: reason; _______________________________    25  
e) other: _______________________________________________________    26  
 
All participants will have a bronchodilator at the completion of the test with post-bronchodilator LFT 
results recorded below. 
 
Reversal of bronchoconstriction 
 
ADMINISTER 4 PUFFS OF SALBUTAMOL, WAIT FOR 10 MINUTES, AND THEN PERFORM PFT’S TO 
RESTORE BASELINE LUNG FUNCTION  
 
15. FEV1 and FVC  
                                                                       FEV1                 FVC              
         15.1 Record Best two technically satisfactory                       27-32 
                 manoeuvres (up to 3 attempts)                                     33-38 
 
         15.2 Number of rejected attempts                39 
 
16. Best POST-BRONCHODILATOR FEV1 as % of initial FEV1    40-42 
 (divide best results from No.15 by best results from No.7) 
         NO YES 
 
17. Has subject's FEV1 returned to within 10% of baseline spirometry? 
   43 
 
IF 'YES' THE SUBJECT MAY LEAVE THE CENTRE 
IF 'NO' ADMINISTER ANOTHER 4 PUFFS OF SALBUTAMOL AND WAIT ANOTHER 10 MIN, THEN 
PERFORM PFT’S TO RESTORE BASELINE LUNG FUNCTION  
 
  4 
 
 
 
 
18. FEV1 and FVC  
                                                                       FEV1                 FVC              
         18.1 Record Best two technically satisfactory                       44-49 
                 manoeuvres (up to 3 attempts)                                     50-55 
 
         18.2 Number of rejected attempts                56 
 
19. Best 2nd POST-BRONCHODILATOR FEV1 as % of initial FEV1    57-59 
 (divide best results from No. 18 by best results from No. 7) 
         NO YES 
20. Has subject's FEV1 returned to within 10% of baseline spirometry?    60 
 
 
All participants to answer questions below. Tick the relevant box. 
 
21. Did the subject experience any of the following symptoms during the challenge test? 
         NO YES 
21.1 Dry or sore throat / hoarse voice    61 
21.2 Cough    62 
21.3 Chest tightness/wheeze/shortness of breath    63 
21.4 Headaches/dizziness    64 
21.1 Other    65 
           Specify  __________________________________________     
 
22. General comments: 
 
_________________________________________________________________________
_________________________________________________________________________ 
 
 
 
23. Technologist initials: ______________  66              13 
 
24. Room temperature (C°): ______________   67-68              13 
         
     NO YES 
25 Lung function record attached?    69 
 
RISK FACTORS FOR WORK-RELATED ASTHMA IN HEALTH CARE
WORKERS WITH EXPOSURE TO DIVERSE CLEANING AGENTS – 2014
       EXHALED NITRIC OXIDE--Data Collection Sheet
Survey Number ________________________ 1-3
Date: _____________________________
Time __________________
Ambient NO concentration (ppb) _________________ 4-6
Ambient temperature (degrees celcius) __________________ 7-8
1. Subject's height (in centimetres) ___________________ 9-11
2. Subject's weight (in kilograms) ___________________ 12-14
3. Subject's blood pressure systolic ___________ 15-17
diastolic ___________ 18-20
4. Effort number (start) ____________ 21-23
4.1 FeNO measurement (ppb) 1st effort ____________ 24-26
4.2 FeNO measurement (ppb) 2nd effort ____________ 27-29
If there is a discrepancey of > 10 ppb between 1st & 2nd efforts, perform
 a 3rd effort
4.3 FeNO measurement (ppb) 3rd effort _____________ 30-32
5. FeNO measurement record attached? Yes (1) No (2) 33
Appendix E: Exhaled nitric oxide data collection sheet
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RISK FACTORS FOR WORK-RELATED ASTHMA IN HEALTH CARE WORKERS
 WITH EXPOSURE TO DIVERSE CLEANING AGENTS - 2014
CHECKLIST FOR EXPOSURE ASSESSMENT
INTERVIEW WITH THE PERSON IN CHARGE
CHECKLIST NUMBER __________
1. Date Day______Month______Year________
2. Interview done by _______________________________________
3. Name of the person interviewed _______________________________________
4. Job title: ____________________________________________
5. Department / Section / Area:
Insert a cross (X) next to the correct answer
OUT-PATIENT CLINICS
____1. Respiratory 
____2. Cardiac 
____3. GIT
____4. Urology
____5. ENT
____6. Eye
____7. Surgery
____8. Oral & Maxillofacial
____9. Gynae colposcopy
WARDS
____10. ENT ward (F8)
____11. Hemodialysis Lab/ward (E13)
TRAUMA &EMERGENCY
____12. Trauma (C14)
____13. Emergency (C15)
____14. Gynae. Emergency (C24)
OTHER:
____15. ICU, specify ___________________________________________
____16. Theatre, specify _______________________________________
____17. Vascular radiology (C8)
____18. Other, specify: _________________________________________
6. How many health care workers are working in this area?
           1. Nurses _____________
           2. Clerks ______________
           3. Cleaners ____________
           4. Porters _____________
           5. Technicians __________
           6. Other _________________________________________________________________
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Appendix F: Workplace observation checklist
27. In the last 12 months, has there been an adverse health effect/s reported by your
     workers related to the cleaning agents? 1.     Yes 2.     No
IF 'NO' GO TO QUESTION 8
IF 'YES' CONTINUE WITH QUESTION 7.1
  7.1. How many health care workers reported these health effects over this period?     ______
  7.2. What health effect/s were reported by affected workers?
No. of events
1. Itchy / red / watery eyes 1.     Yes 2.     No ______________
2. Sneezing / runny / itchy / stuffy nose 1.     Yes 2.     No ______________
3. Itchy throat 1.     Yes 2.     No ______________
4. Wheezing 1.     Yes 2.     No ______________
5. Shortness of breath / chest tightness 1.     Yes 2.     No ______________
6. Cough 1.     Yes 2.     No ______________
7. Itchy skin 1.     Yes 2.     No ______________
8. Redness of the skin 1.     Yes 2.     No ______________
9. Hives ("bommels") 1.     Yes 2.     No ______________
10. Blisters or weeping skin 1.     Yes 2.     No ______________
11. Dry, scaly skin 1.     Yes 2.     No ______________
12. "Collapsed" 1.     Yes 2.     No ______________
13. Other ________________________________________________ ______________
  7.3. Which cleaning agents were suspected as being responsible for these adverse 
          health effects?
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
______________________________________________________________________________
  7.4. Was there any medical evaluation of these workers who experienced adverse
         health effects associated with cleaning agents? 1.     Yes 2.     No
IF 'NO' GO TO QUESTION 8
IF 'YES' CONTINUE WITH QUESTION 7.4.1
    7.4.1. How were they evaluated? 
            1. Referred to GSH Staff Health Clinic 1.     Yes 2.     No
            2. Referred to GSH Occupational Medicine Clinic (E16) 1.     Yes 2.     No
            3. Referred to their own medical practitioner/specialist 1.     Yes 2.     No
            4. Other: __________________________________________________________________
                ________________________________________________________________________
     7.4.2. What were the final outcome/s for these workers?
           1. Continued with similar tasks in the same work area 1.     Yes 2.     No
           2. Performed different tasks in the same work area 1.     Yes 2.     No
           3. Work area modified to accommodate the worker/s 1.     Yes 2.     No
           4. Moved to a different work area with different tasks 1.     Yes 2.     No
           5. Resigned/Dismissed due to these health problems 1.     Yes 2.     No
           6. Other _________________________________________________________
                ______________________________________________________________
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3     7.4.3. Are there workers who are not required to work in certain areas because
                of their preexisting  health problems? 1.     Yes 2.     No
8. In the last 12 months, has there been any new cleaning agent/s introduced in this area?
1.     Yes 2.     No
IF 'NO' GO TO QUESTION 9
IF 'YES' CONTINUE WITH QUESTION 8.1
  8.1. Which cleaning agent/s were introduced in this period?
          __________________________________________________________________________
          __________________________________________________________________________
          __________________________________________________________________________
  8.2. Why were they introduced? _________________________________________________
          __________________________________________________________________________
          __________________________________________________________________________
9. In the last 12 months, has there been any cleaning agent/s discontinued from use in
    this area? 1.     Yes 2.     No
IF 'NO' GO TO QUESTION 10
IF 'YES' CONTINUE WITH QUESTION 9.1
  9.1. Which cleaning agent/s were discontinued from use in this period?
          __________________________________________________________________________
          __________________________________________________________________________
          __________________________________________________________________________
  9.2. Why were they discontinued from use? _______________________________________
          __________________________________________________________________________
          __________________________________________________________________________
10. How do you order your cleaning agents?
           1. Through GSH supplies
           2. Outsource/Private/Buyout supplies, specify _________________________________
          __________________________________________________________________________
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411. Do the workers receive training on how to prepare (diluting, mixing etc.)
       cleaning agents? 1.     Yes 2.     No
IF 'NO' GO TO QUESTION 12
IF 'YES' CONTINUE WITH QUESTION 11.1
  11.1. How often do the workers receive this training per year ? ________________
12. Do the workers receive training on how to use the cleaning agents they work with?/ the 
      actual cleaning/disinfection 1.     Yes 2.     No
IF 'NO' GO TO QUESTION 13
IF 'YES' CONTINUE WITH QUESTION 12.1
  12.1. How often do the workers receive this training per year ? ________________
13. Do the workers receive training on how to discard cleaning agents?
       1.     Yes 2.     No
IF 'NO' GO TO QUESTION 14
IF 'YES' CONTINUE WITH QUESTION 13.1
  13.1. How often do the workers receive this training per year ? ________________
14. Do the workers receive training regarding adverse health effects associated with 
       cleaning agents? 1.     Yes 2.     No
IF 'NO' GO TO QUESTION 15
IF 'YES' CONTINUE WITH QUESTION 14.1
  14.1. How often do the workers receive this training per year ? ________________
15. Do the workers working with cleaning agents undergo medical surveillance/
       biological monitoring on a regular basis? 1.     Yes 2.     No
IF 'NO' GO TO NEXT STEP (OBSERVATION)
IF 'YES' CONTINUE WITH QUESTION 15.1
  15.1. How often is the biological monitoring conducted on these workers?    _______________
             
15.1.1. Please specify for which cleaning agent   ______________________________________
  15.2. How often do these workers undergo these medical surveillances?   ________________
15.2.1. Please specify for which cleaning agent   ______________________________________
Page 4
      UNIVERSITY OF CAPE TOWN
RISK FACTORS FOR WORK-RELATED ASTHMA IN HEALTH CARE WORKERS 
 WITH EXPOSURE TO DIVERSE CLEANING AGENTS - 2014
CHECKLIST FOR EXPOSURE ASSESSMENT
OBSERVATION
CHECKLIST NUMBER __________
1. Date Day______Month______Year________
2. Department / Section / Area:
Insert a cross (X) next to the correct answer
OUT-PATIENT CLINICS
____1. Respiratory 
____2. Cardiac 
____3. GIT
____4. Urology
____5. ENT
____6. Eye
____7. Surgery
____8. Oral & Maxillofacial
____9. Gynae colposcopy
WARDS
____10. ENT ward (F8)
____11. Hemodialysis Lab/ward (E13)
TRAUMA &EMERGENCY
____12. Trauma (C14)
____13. Emergency (C15)
____14. Gynae. Emergency (C24)
OTHER:
____15. ICU, specify ___________________________________________
____16. Theatre, specify _______________________________________
____17. Vascular radiology (C8)
____18. Other, specify: _________________________________________
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CLEANING / STERILISING MEDICAL INSTRUMENTS
3. In this department, do the workers clean, sterilise or conduct high-level disinfection  of medical instruments  such as bronchoscopes, laryngoscopes,
     endoscposes, cystoscopes, OR metal  instruments (needle holder, forceps, etc.), OR plastic  instruments such as ear specula for ear examination?
   1.     Yes 2.     No
IF 'NO' GO TO QUESTION 4
IF 'YES' CONTINUE WITH QUESTION 3.1
3.1. Which of the following products are used to clean, sterilise  or to conduct high-level disinfection of medical instruments?
Insert a cross (X) next to the correct answer AND underline a specific product if applicable
Please also insert the appropriate codes where applicable
Ventila- Gloves Respirator Other
Products In the last 12 months, Spray? tion % of % of PPEs
Days/week Hours/day time time
1. Ortho-phthalaldehydes such as Cidex OPA®, 
    Cidex OPA C 1.     Yes 2.     No __________ _________ ________ ______ ______ ____ ____________ _____
2. Glutaraldehyde such as Cidex® 1.     Yes 2.     No __________ _________ ________ ______ ______ ____ ____________ _____
3. Enzymatic cleaners such as Endozime, or Biozyme
1.     Yes 2.     No __________ _________ ________ ______ ______ ____ ____________ _____
4. Chlorhexidine containing products such as Bioscrub
    D-germ, Biotane in alcohol or Steriscrub
1.     Yes 2.     No __________ _________ ________ ______ ______ ____ ____________ _____
5. Quaternary ammonium compounds such as MEDDIS
1.     Yes 2.     No __________ _________ ________ ______ ______ ____ ____________ _____
6. Peracetic acid 1.     Yes 2.     No __________ _________ ________ ______ ______ ____ ____________ _____
7. Acetic acid 1.     Yes 2.     No __________ _________ ________ ______ ______ ____ ____________ _____
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Ventila- Gloves Respirator Other
In the last 12 months, Spray? tion % of % of PPEs
Days/week Hours/day time time
8. Hydrogen peroxide 1.     Yes 2.     No __________ _________ ________ ______ ______ ____ ____________ _____
9. Surgislip 1.     Yes 2.     No __________ _________ ________ ______ ______ ____ ____________ _____
10. Surgistain 1.     Yes 2.     No __________ _________ ________ ______ ______ ____ ____________ _____
11. Alcohols, such as ethyl alcohol 96% (ethanol), 
      isopropanol, methylated spirits, alcohol 50%, or 70%
1.     Yes 2.     No __________ _________ ________ ______ ______ ____ ____________ _____
12. Bleach or chlorine, such as Domestos®, Medisure, 
       Biocide D®, or Clorox® 1.     Yes 2.     No __________ _________ ________ ______ ______ ____ ____________ _____
13. Bicarbonate concentrate 8.4% 1.     Yes 2.     No __________ _________ ________ ______ ______ ____ ____________ _____
14. Citric acid 50% 1.     Yes 2.     No __________ _________ ________ ______ ______ ____ ____________ _____
15. Citrosteril 1.     Yes 2.     No __________ _________ ________ ______ ______ ____ ____________ _____
16. Renalin 100 1.     Yes 2.     No __________ _________ ________ ______ ______ ____ ____________ _____
17. Tiutol KF 1.     Yes 2.     No __________ _________ ________ ______ ______ ____ ____________ _____
18. Scop'anios 1.     Yes 2.     No __________ _________ ________ ______ ______ ____ ____________ _____
19. Other products ___________________________________________ _________ ________ ______ ______ ____ ____________ _____
____________________________________________________________ _________ ________ ______ ______ ____ ____________ _____
____________________________________________________________ _________ ________ ______ ______ ____ ____________ _____
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3.2. Which of the following tasks  do the workers perform when cleaning, sterilising or conducting high-level disinfection of medical instruments?
Tasks In the last 12 months, Ventila- Gloves Respirator Other
Days/ Times Task dura- tion % of % of PPEs
week /day tion(hrs) time time
4. Do the workers prepare medical instruments  for sterilization
     by manually disassembling instruments, removing gross
     contaminants, or flushing gros scontaminants and waste?
     1.     Yes 2.     No _____ ________ _________ ______ ______ ____ ____________ _____
5. Do the workers prepare medical instruments  for sterilization
    by changing sterilization solutions? 
1.     Yes 2.     No _____ ________ _________ ______ ______ ____ ____________ _____
6. Do the workers prepare cleaning solutions  for example by
    diluting or  mixing cleaning agents? 
1.     Yes 2.     No _____ ________ _________ ______ ______ ____ ____________ _____
7. Do the workers use sterilants immersion container to
    manually sterilize/high-level disinfect  medical instruments?
    1.     Yes 2.     No _____ ________ _________ ______ ______ ____ ____________ _____
8. Do the workers sterilize/high-level disinfect  medical
    instruments using   automated systems?
1.     Yes 2.     No
  8.1. If Yes, which system do they operate?
Cidex OPA system 1.     Yes 2.     No _____ ________ _________ ______ ______ ____ ____________ _____
Other ________________ _____ ________ _________ ______ ______ ____ ____________ _____
  8.2. Do the workers conduct maintenance on the automated
           system,  such as cleaning or replacing screens and filters?
          1.     Yes 2.     No _____ ________ _________ ______ ______ ____ ____________ _____
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CLEANING FIXED SURFACES, EQUIPMENT OR INSTRUMENTS
10. In this department, do the workers clean or disinfect fixed surfaces,  equipment, or instruments?
     Examples of fixed surfaces are: countertops, floors, beds and bathrooms
     Examples of equipment are: IV poles, monitors, carts and computers
     Examples of instruments are: blood pressure cuffs and stethoscopes
1.     Yes 2.     No
IF 'NO' GO TO QUESTION 13
IF 'YES' CONTINUE WITH QUESTION 10.1
10.1. Which of the following products are used to clean and disinfect fixed surfaces, equipment, or instruments?
Insert a cross (X) next to the correct answer AND underline a specific product if applicable
Please also insert the appropriate codes where applicable
Ventila- Gloves Respirator Other
Products In the last 12 months, Spray? tion % of % of PPEs
Days/week Hours/day time time
1. Alcohols, such as ethyl alcohol 96% (ethanol), 
      isopropanol, methylated spirits, alcohol 50%, or 70%
1.     Yes 2.     No __________ _________ ________ ______ ______ ____ ____________ _____
2. Ammonia, such as Handysan, or Ammonia cleaner
    (cleaner all purpose) 1.     Yes 2.     No __________ _________ ________ ______ ______ ____ ____________ _____
3. Bleach or chlorine, such as Domestos®, Medisure, 
       Biocide D®, or Clorox® 1.     Yes 2.     No __________ _________ ________ ______ ______ ____ ____________ _____
4. Utensils cleaning products such as SPARKLE 
  dishwashing liquid, or Liquid soap 1.     Yes 2.     No __________ _________ ________ ______ ______ ____ ____________ _____
5. Phenolics, such as MEDIFEN Phenolic disinfectant
1.     Yes 2.     No __________ _________ ________ ______ ______ ____ ____________ _____
6. Enzymatic cleaners such as Endozime®, or Biozyme
1.     Yes 2.     No __________ _________ ________ ______ ______ ____ ____________ _____
7. Floor wax strippers, such as Multistrip®, or RADICAL
    Non-ammoniated floor stripper 1.     Yes 2.     No __________ _________ ________ ______ ______ ____ ____________ _____
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Ventila- Gloves Respirator Other
In the last 12 months, Spray? tion % of % of PPEs
Days/week Hours/day time time
8. Floor sealer/wax, such as buff spray (diluted floor
    sealer/wax), Vision gold®, or Claro-cote®
1.     Yes 2.     No __________ _________ ________ ______ ______ ____ ____________ _____
9. Glass cleaning products such as Liquid soap, or 
     Windex® 1.     Yes 2.     No __________ _________ ________ ______ ______ ____ ____________ _____
10. SPARKEM Scouring paste 1.     Yes 2.     No __________ _________ ________ ______ ______ ____ ____________ _____
11. Air freshener, such as Biocidol disinfectant (Ocean
      Cherry), air freshener without disinfectant, or DUX
1.     Yes 2.     No __________ _________ ________ ______ ______ ____ ____________ _____
12. Carpet shampoo 1.     Yes 2.     No __________ _________ ________ ______ ______ ____ ____________ _____
13. Furniture polish 1.     Yes 2.     No __________ _________ ________ ______ ______ ____ ____________ _____
14. M4 paste 1.     Yes 2.     No __________ _________ ________ ______ ______ ____ ____________ _____
15. Stainless steel cleaner 1.     Yes 2.     No __________ _________ ________ ______ ______ ____ ____________ _____
16. Sumasan 1.     Yes 2.     No __________ _________ ________ ______ ______ ____ ____________ _____
17. Terrazzo cleaner 1.     Yes 2.     No __________ _________ ________ ______ ______ ____ ____________ _____
18. Wall cleaner 1.     Yes 2.     No __________ _________ ________ ______ ______ ____ ____________ _____
19. Washing powder for cleaning floor mops
1.     Yes 2.     No __________ _________ ________ ______ ______ ____ ____________ _____
20. Other products ______________________________ __________ _________ ________ ______ ______ ____ ____________ _____
______________________________________________ __________ _________ ________ ______ ______ ____ ____________ _____
______________________________________________ __________ _________ ________ ______ ______ ____ ____________ _____
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11. Which of the following tasks do the workers perform when cleaning or disinfecting fixed surfaces, equipment, or instruments?
Tasks In the last 12 months, Ventila- Gloves Respirator Other
Days/ Times Task dura- tion % of % of PPEs
week /day tion(hrs) time time
1. Wipe down beds, furniture, counters, 1.     Yes 2.     No _____ ________ _________ ______ ______ ____ ____________ _____
     walls, etc.
2. Cleanup blood or cleanup other spills 1.     Yes 2.     No _____ ________ _________ ______ ______ ____ ____________ _____
3. Manually mix, refill, or empty cleaning or disinfecting
     products 1.     Yes 2.     No _____ ________ _________ ______ ______ ____ ____________ _____
4. Clean bathrooms including toilet, sink, 1.     Yes 2.     No _____ ________ _________ ______ ______ ____ ____________ _____
     shower
5. Spray then wipe glass, windows, mirrors 1.     Yes 2.     No _____ ________ _________ ______ ______ ____ ____________ _____
6. Polish wood furniture 1.     Yes 2.     No _____ ________ _________ ______ ______ ____ ____________ _____
7. Polish stainless steel surfaces 1.     Yes 2.     No _____ ________ _________ ______ ______ ____ ____________ _____
8. Spray deodorant/ disinfectant 1.     Yes 2.     No _____ ________ _________ ______ ______ ____ ____________ _____
9. Floor sweeping 1.     Yes 2.     No _____ ________ _________ ______ ______ ____ ____________ _____
10. Hoovering / vacuum cleaning 1.     Yes 2.     No _____ ________ _________ ______ ______ ____ ____________ _____
11. Rug beating 1.     Yes 2.     No _____ ________ _________ ______ ______ ____ ____________ _____
12. Mop floors 1.     Yes 2.     No _____ ________ _________ ______ ______ ____ ____________ _____
13. Clean instruments such as scissors, stethoscopes, and
      thermometers or equipment such as IV poles, carts,
      monitors, and computers 1.     Yes 2.     No _____ ________ _________ ______ ______ ____ ____________ _____
14. Conduct terminal cleaning of patient rooms
1.     Yes 2.     No _____ ________ _________ ______ ______ ____ ____________ _____
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In the last 12 months, Ventila- Gloves Respirator Other
Days/ Times Task dura- tion % of % of PPEs
week /day tion(hrs) time time
15. Use fogging equipment with hydrogen peroxide or
       peracetic acid vapors to conduct terminal cleaning
      of patient rooms 1.     Yes 2.     No _____ ________ _________ ______ ______ ____ ____________ _____
16. Clean or disinfect for MRSA, VRE or other drug resitant
       bacteria in patient rooms 1.     Yes 2.     No _____ ________ _________ ______ ______ ____ ____________ _____
17. Conduct end of shift cleaning of operating rooms,
       dialysis units or other patient care areas 1.     Yes 2.     No _____ ________ _________ ______ ______ ____ ____________ _____
    
13. Do the workers use more sprays or more wipes,  or do they use both equally often when cleaning fixed surfaces,  equipment or intsruments?
SELECT THE ONE BEST ANSWER
____1. Use more sprays than wipes ____2. Use more wipes than sprays ____3. Use sprays and wipes about equally
14. Do the workers clean and wax floors using strippers and buffers?
1.     Yes 2.     No
IF 'NO' GO TO QUESTION 15
IF 'YES' CONTINUE WITH QUESTION 14.1
  14.1. Which tasks  do the workers perform when cleaning and waxing floors using strippers and buffers?
          
Tasks In the last 12 months, Ventila- Gloves Respirator Other
Days/ Times Task dura- tion % of % of PPEs
week /day tion(hrs) time time
1. Strip floors 1.     Yes 2.     No _____ ________ _________ ______ ______ ____ ____________ _____
2. Scrape floors 1.     Yes 2.     No _____ ________ _________ ______ ______ ____ ____________ _____
3. Buff floors 1.     Yes 2.     No _____ ________ _________ ______ ______ ____ ____________ _____
4. Wax floors 1.     Yes 2.     No _____ ________ _________ ______ ______ ____ ____________ _____
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USE OF HAND SANITISERS / HAND WASHING PRODUCTS
15. Do the workers use liquid hand soaps/sanitisers  to wash or disinfect their hands?
1.     Yes 2.     No
IF 'NO' GO TO QUESTION 16
IF 'YES' CONTINUE WITH QUESTION 15.1
15.1. Which of the following products are used for washing/sanitising workers' hands?
Insert a cross (X) next to the correct answer AND underline a specific product if applicable
Products In the last 12 months, Spray?
Days/week Times/day
1. Chlorhexidine containing products such as 
     Bioscrub, Steriscrub, D-germ, or Biotane in alcohol 1.    Yes 2.      No __________ __________ _________
2. FRESH liquid hand soap 1.    Yes 2.      No __________ __________ _________
3. SPARKEM hand soap liquid 1.    Yes 2.      No __________ __________ _________
4. Other products _______________________________ 1.    Yes 2.      No __________ __________ _________
______________________________________________ 1.    Yes 2.      No __________ __________ _________
______________________________________________ 1.    Yes 2.      No __________ __________ _________
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EXPOSURE TO PRODUCTS USED ON PATIENTS
Examples:
16. Do the workers use chemical products on patients? Antiseptics : alcohols, iodine, acetic acid, silver compounds, chlorhexidine, povidone iodine
1.     Yes 2.     No Adhesives : glues, acrylates, bone cements
          Adhesive removing solvents : alcohols, acetone, ether
IF 'NO' GO TO QUESTION 17
IF 'YES' CONTINUE WITH QUESTION 16.1
16.1. Which tasks do the workers perform when applying or using chemicals, antiseptics, adhesives, alcohols, or solvents on patients?
           
Tasks In the last 12 months, Ventila- Gloves Respirator Other
Days/ Times Task dura- tion % of % of PPEs
week /day tion(hrs) time time
1. Disinfect skin areas on patients prior to procedure using
wipes, gauze or swabs with antiseptics such as Biotane in
alcohol, povidone iodine, alcohols, acetic acid
 1.     Yes 2.     No ____ ________ _________ ______ ______ ____ ____________ _____
2. Clean and disinfect wounds  using antiseptics such as silver
compounds, Biotane in alcohol,  povidone iodine, or
cadexomer iodine 1.     Yes 2.     No ____ ________ _________ ______ ______ ____ ____________ _____
3. Apply wound dressing  such as polyurethane based
hydrogel, hydrocolloid, or hydrocellular foam
1.     Yes 2.     No ____ ________ _________ ______ ______ ____ ____________ _____
4. Use adhesives  such as glues, acrylates, bone cements,
   benzoin tincture such as Opsite, 3M® Steri-Strip® for surgery,
   skin closure, bone repair, ostomy bags, and other
   applications 1.     Yes 2.     No ____ ________ _________ ______ ______ ____ ____________ _____
5. Use adhesive removing solvents  such as ether, alcohols or
acetone with wipes, gauze, or swabs
1.     Yes 2.     No ____ ________ _________ ______ ______ ____ ____________ _____
6. Apply or remove synthetic fiberglass casts 
1.     Yes 2.     No ____ ________ _________ ______ ______ ____ ____________ _____
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EXPOSURE TO AEROSOLIZED MEDICINES USED ON PATIENTS
17. Do the workers administer aerosolized medications such as bronchodilators or anaesthetics?   
       1.     Yes 2.     No
IF 'NO' GO TO QUESTION 18
IF 'YES' CONTINUE WITH QUESTION 17.1
17.1. Which tasks do the workers perform when administering aerosolized medications? 
Insert a cross (X) next to the correct answer AND underline a specific product if applicable
Please also insert the appropriate codes where applicable
Tasks In the last 12 months, Ventila- Gloves Respirator Other
Days/ Times Task dura- tion % of % of PPEs
week /day tion(hrs) time time
1. Administer aerosolized medications with a small 
    volume nebulizer (SVN) 1.     Yes 2.     No ____ ________ _________ ______ ______ ____ ____________ _____
2. Use continuous aerosol delivery system for 
    bronchodilators and other medicines ______ ______ ____ ____________ _____
1.     Yes 2.     No ____ ________ _________
3. Administer aerosolized medications with a 
    metered-dose inhaler (MDI) 1.     Yes 2.     No ______ ____ ________ _________ ______ ______ ____ ____________ _____
4. Administer aerosolized medications with a 
    dry powder inhaler (DPI) 1.     Yes 2.     No ______ ____ ________ _________ ______ ______ ____ ____________ _____
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EXPOSURE TO CHEMICALS USED FOR SPECIMEN PREPARATION
18. Do the workers prepare specimes for histology/cytology?
1.     Yes 2.     No
IF 'NO' GO TO QUESTION 19
IF 'YES' CONTINUE WITH QUESTION 18.1
18.1. Which of the following products are used for specimen preparation?
Insert a cross (X) next to the correct answer AND underline a specific product if applicable
Please also insert the appropriate codes where applicable
Products Ventila- Gloves Respirator Other
In the last 12 months, Spray? tion % of % of PPEs
Days/week Hours/day time time
1. Formalin 10% in normal saline ______ ______ ____ ____________ _____
1.     Yes 2.     No ___________ ________ ________
2. Fencott cytological fixative spray ______ ______ ____ ____________ _____
1.     Yes 2.     No ___________ ________ ________
3. Stains and dyes such as 
     hematoxylin and eosin stains 1.     Yes 2.     No ___________ ________ ________ ______ ______ ____ ____________ _____
4. Solvents such as xylene and 
     toluene 1.     Yes 2.     No ___________ ________ ________ ______ ______ ____ ____________ _____
5. Other products ______________________________ ___________ ________ ________ ______ ______ ____ ____________ _____
                                    ______________________________ ___________ ________ ________ ______ ______ ____ ____________ _____
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CLEANING PRODUCTS STORAGE
19. What is the condition of the containers storing cleaning products?
   1. Uncovered 1.     Yes 2.     No
   2. Partially covered (lid not tightly fitting) 1.     Yes 2.     No
   3. Covered with a tight fitting lid 1.     Yes 2.     No
CHEMICAL SPILL / RELEASE
20. Is there any chemical spill or release observed?
1.     Yes 2.     No
IF 'NO' GO TO QUESTION 21
IF 'YES' CONTINUE WITH QUESTION 20.1
20.1. If Yes, which chemicals were spilled or released? _____________________________
           ________________________________________________________________________
           ________________________________________________________________________
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ADMINISTRATIVE CONTROLS
21. Which of the following administrative controls are in place for cleaning agents?
Job rotation 1.   Yes 2. No
Restricted access to the high exposure areas 1.   Yes 2. No
Good house keeping 1.   Yes 2. No
Good supervision and management 1.   Yes 2. No
22. Is there a Standard Operating Procedures (SOP) document on how to handle cleaning agents? 1.     Yes 2.     No
IF 'NO' GO TO QUESTION 23
IF 'YES' CONTINUE WITH QUESTION 22.1
  22.1. For which cleaning agents? ________________________________________________
             ________________________________________________________________________
             ________________________________________________________________________
  22.2. Where is it placed?
1. Posted on the wall 1.     Yes 2.     No
2. Placed in the drawer 1.     Yes 2.     No
3. Placed elsewhere ________________________________________________________
  22.3. When was it last updated? _______________________________________________
23. Which of the following emergency facilities / items are present in the work area? 
1. Emergency showers / eye wash stations 1.     Yes 2.     No
2. First aid kit 1.     Yes 2.     No
3. Others __________________________________________________________________
AIR MEASUREMENTS FOR OPA
24. Is OPA air measurement indicated in this area? 1.  Yes 2.  No
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      UNIVERSITY OF CAPE TOWN
RISK FACTORS FOR WORK-RELATED ASTHMA IN HEALTH CARE WORKERS 
 WITH EXPOSURE TO DIVERSE CLEANING AGENTS - 2016/2017
OPA DATA COLLECTION SHEET 1
WORKER INFORMATION
TO BE COMPLETED FOR EACH WORKER SAMPLED
SURVEY NUMBER __________
Day 1 Day 2
1. Date Day______Month______Year________ Day______Month______Year________
2. Surname ____________________________________
3. First name/s ____________________________________
4. Gender:          ___ Male (1)          ___ Female (2)
5. Contact telephone no: Cell     _________________________
6. Hand of preference * Left (1)
Right (2)
No preference (3)
*side where the sampling head should be positioned
7. Department / Section / Area: ____________________________________________
8. Shift: 
From _____________ to _____________
9. Job title:  
_____ 11.1. Registered nurse
_____ 11.2. Enrolled nurse
_____ 11.3. Nurse assistant
_____ 11.4. Cleaner
_____ 11.5. Admin staff such as Clerks, etc.
_____ 11.6. Porter
_____ 11.7. Technician/technologist, specify: ______________________________________
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Appendix G: Environmental sampling data collection sheet
      UNIVERSITY OF CAPE TOWN
RISK FACTORS FOR WORK-RELATED ASTHMA IN HEALTH CARE WORKERS 
WITH EXPOSURE TO DIVERSE CLEANING AGENTS - 2016/2017
OPA DATA COLLECTION SHEET 2
PASSIVE SAMPLING
TO BE COMPLETED FOR EACH WORKER SAMPLED
SURVEY NUMBER ________________
Day 1 Day 2
Date:      Day______Month______Year________ Day______Month______Year_______
Temperature:  ____________ Temperature:  ____________
Humidity:   _______________ Humidity:   _______________
MONITOR NO. MONITOR NO.
START TIME START TIME
END TIME END TIME
DURATION (mins) DURATION (mins)
ONE COVER REMOVED ONE COVER REMOVED
TWO COVERS REMOVED TWO COVERS REMOVED
GENERAL COMMENTS:
____________________________________________________________
____________________________________________________________
____________________________________________________________
____________________________________________________________
____________________________________________________________
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      UNIVERSITY OF CAPE TOWN
RISK FACTORS FOR WORK-RELATED ASTHMA IN HEALTH CARE WORKERS 
 WITH EXPOSURE TO DIVERSE CLEANING AGENTS - 2016/2017
OPA DATA COLLECTION SHEET 3
OBSERVATION 
TO BE COMPLETED FOR EACH WORKER SAMPLED
SURVEY NUMBER _______________
Date Day______Month______Year________
1. Does the workers clean, sterilise or conduct high-level disinfection  of medical instruments  such as bronchoscopes, laryngoscopes, endoscposes, cystoscopes,
    OR metal  instruments (needle holder, forceps, etc.), OR plastic  instruments such as ear specula for ear examination? 1.     Yes 2.     No
IF 'NO' GO TO QUESTION 3 IF 'YES' CONTINUE WITH QUESTION 1.1
1.1. Which of the following tasks  does the worker perform when cleaning, sterilising or conducting high-level disinfection of medical instruments?
Tasks Products used Task dura- Times/ Days/ Ventila- Gloves Respirator Other
for specific task tion (mins) day week tion % of % of PPEs
time time
1. Does the worker prepare medical instruments  for sterilization
     by manually disassembling instruments, removing gross 1.     Yes 2.     No ___________ ______ ______ _______________ ______ ____ ________ ____ ______
     contaminants, or flushing gross contaminants and waste? ___________ ______ ______ _______________ ______ ____ ________ ____ ______
     ___________ ______ ______ _______________ ______ ____ ________ ____ ______
2. Does the worker prepare medical instruments  for sterilization ___________ ______ ______ _______________ ______ ____ ________ ____ ______
    by changing sterilization solutions? 1.     Yes 2.     No ___________ ______ ______ _______________ ______ ____ ________ ____ ______
___________ ______ ______ _______________ ______ ____ ________ ____ ______
3. Does the worker prepare cleaning solutions  for example by ___________ ______ ______ _______________ ______ ____ ________ ____ ______
      diluting or  mixing cleaning agents? 1.     Yes 2.     No ___________ ______ ______ _______________ ______ ____ ________ ____ ______
___________ ______ ______ _______________ ______ ____ ________ ____ ______
4. Does the worker use sterilants immersion container to ___________ ______ ______ _______________ ______ ____ ________ ____ ______
     manually sterilize/high-level disinfect  medical instruments? 1.     Yes 2.     No ___________ ______ ______ _______________ ______ ____ ________ ____ ______
    ___________ ______ ______ _______________ ______ ____ ________ ____ ______
5. Does the worker sterilize/high-level disinfect  medical ___________ ______ ______ _______________ ______ ____ ________ ____ ______
        instruments using   automated systems? 1.     Yes 2.     No ___________ ______ ______ _______________ ______ ____ ________ ____ ______
2. Which of the following products does the worker use to clean, sterilise  or to conduct high-level disinfection
     of medical instruments?
Insert a cross (X) next to the correct answer AND underline a specific product if applicable
Please also insert the appropriate codes where applicable
Products Spray Mins/ Days/ Products
(Y=1/N=2) day week storage
1. Ortho-phthalaldehydes such as Cidex OPA®
    or Cidex OPA C 1.     Yes 2.     No ________ ______ _____ ________
    
2. Glutaraldehyde such as Cidex® 1.     Yes 2.     No ________ ______ _____ ________
3. Enzymatic cleaners such as Endozime, Biozyme
     or Sanizyme 1.     Yes 2.     No ________ ______ _____ ________
4. Chlorhexidine containing products such as Bioscrub
     or Steriscrub 1.     Yes 2.     No ________ ______ _____ ________
5. Quaternary ammonium compounds such as MEDDIS 1.     Yes 2.     No ________ ______ _____ ________
6. Peracetic acid 1.     Yes 2.     No ________ ______ _____ ________
7. Acetic acid 1.     Yes 2.     No ________ ______ _____ ________
8. Hydrogen peroxide 1.     Yes 2.     No ________ ______ _____ ________
9. Surgislip 1.     Yes 2.     No ________ ______ _____ ________
10. Surgistain 1.     Yes 2.     No ________ ______ _____ ________
11. Alcohols, such as ethyl alcohol 96% (ethanol)
       isopropanol, methylated spirits, alcohol 50%, or 70% 1.     Yes 2.     No ________ ______ _____ ________
12. Bleach or chlorine, such as Domestos®, Medisure
        , Biocide D®, or Clorox® 1.     Yes 2.     No ________ ______ _____ ________
13. Scop'anios 1.     Yes 2.     No ________ ______ _____ ________
14. Other products ____________________________ ________ ______ _____ ________
_______________________________________________________ ________ ______ _____ ________
Codes for product storage
Uncovered (1)
Partially covered (lid not tightly fitting) (2)
Covered with a tight fitting lid (3)
OTHER CLEANING PRODUCTS USED BY THE WORKER
3. Does the worker use cleaning products for cleaning fixed surfaces ,
     equipment or instruments? 1.     Yes 2.     No
IF 'NO' GO TO QUESTION 5 IF 'YES' CONTINUE WITH QUESTION 3 BELOW
Products Spray Mins/day
(Y=1/N=2)
Fixed surfaces cleaning products
3.1. Alcohols, such as ethyl alcohol 96% (ethanol),  isopropanol,
     methylated spirits, alcohol 50%, or 70% 1.     Yes 2.     No ________ ________
3.2. Ammonia, such as Handysan, Sumasan or Ammonia cleaner
     (cleaner all purpose) 1.     Yes 2.     No ________ ________
3.3. Bleach or chlorine, such as Domestos®, Medisure, Biocide D®
        or Clorox® 1.     Yes 2.     No ________ ________
3.4. Utensils cleaning products such as SPARKLE dishwashing
     liquid, or Liquid soap 1.     Yes 2.     No ________ ________
3.5. Phenolics, such as MEDIFEN Phenolic disinfectant 1.     Yes 2.     No ________ ________
3.6. Glass cleaning products such as Liquid soap, or Windex® 1.     Yes 2.     No ________ ________
3.7. SPARKEM Scouring paste 1.     Yes 2.     No ________ ________
3.8. Air freshener, such as Biocidol disinfectant (Ocean Cherry),
      air freshener without disinfectant, or DUX 1.     Yes 2.     No ________ ________
3.9. Carpet shampoo 1.     Yes 2.     No ________ ________
3.10. Furniture polish 1.     Yes 2.     No ________ ________
3.11. M4 paste 1.     Yes 2.     No ________ ________
3.12. Stainless steel cleaner 1.     Yes 2.     No ________ ________
3.13. Terrazzo cleaner 1.     Yes 2.     No ________ ________
3.14. Wall cleaner 1.     Yes 2.     No ________ ________
3.15. Washing powder for cleaning floor mops 1.     Yes 2.     No ________ ________
Floor strippling and waxing products Spray Mins/day
(Y=1/N=2)
3.16. Floor wax strippers, such as Multistrip®, or RADICAL
       Non-ammoniated floor stripper 1.     Yes 2.     No ________ ________
3.17. Floor sealer/wax, such as buff spray (diluted floor sealer/wax)
       Vision gold®, or Claro-cote® 1.     Yes 2.     No ________ ________
4. Does the worker use more sprays or more wipes,  or does he/she use both equally often when cleaning
  fixed surfaces, equipment or instruments?
SELECT THE ONE BEST ANSWER
____1. Use more sprays than wipes  ____2. Use more wipes than sprays  ____3. Use sprays and wipes about equally
5. Does the worker use chemical products on patients? 1.     Yes 2.     No
IF 'NO' GO TO QUESTION 6 IF 'YES' CONTINUE WITH QUESTION 5 BELOW
Products for use on patients Spray Mins/day
(Y=1/N=2)
5.1. Chlorhexidine  containing products for skin disinfection/wound care
        such as Biotane in alcohol 1.     Yes 2.     No ________ ________
5.2. Iodinated  products for skin disinfection/wound care such as 
     povidone iodine, cadexomer iodine 1.     Yes 2.     No ________ ________
5.3. Silver  compounds for skin disinfection/wound care such as
       Flamazine, Silvadene, etc. 1.     Yes 2.     No ________ ________
5.4. Alcohols  with wipes, gauze or swabs for skin disinfection/adhesives removal
      such as ethyl alcohol 96% (ethanol), isopropanol, methylated spirits, 1.     Yes 2.     No ________ ________
      alcohol 50%, or 70%
5.5. Ether  for adhesives removal 1.     Yes 2.     No ________ ________
5.6. Acetone  for adhesives removal 1.     Yes 2.     No ________ ________
5.7. Adhesives  such as Opsite, 3M® Steri-Strip® for skin closure, etc. 1.     Yes 2.     No ________ ________
6. Does the worker use chemical products for specimen preparation? 1.     Yes 2.     No
IF 'NO' GO TO QUESTION 7 IF 'YES' CONTINUE WITH QUESTION 6 BELOW
Products for specimen preparation Spray Mins/day
(Y=1/N=2)
6.1. Formalin 10% in normal saline 1.     Yes 2.     No ________ ________
6.2. Fencott cytological fixative spray 1.     Yes 2.     No ________ ________
7. Hand sanitisers/washing products Spray Times/day
(Y=1/N=2)
7.1. Chlorhexidine containing hand washing products such as Bioscrub/Steriscrub 1.     Yes 2.     No ________ ________
7.2. Chlorhexidine containing sanitisers such as D-germ or Sterisol 1.     Yes 2.     No ________ ________
7.2. FRESH liquid hand soap 1.     Yes 2.     No ________ ________
8. Other cleaning products Spray Mins/day
(Y=1/N=2)
8.1. Other products _________________________________________ ________ ________
OTHER WORKERS PRESENT IN THE SAME AREA / CHEMICAL SPILL OR RELEASE
9. Please mention relevant  cleaning products used by other workers  in the same area (bystander exposures)
Products Any spill/release
(Y=1/N=2)
9.1. Ortho-phthalaldehydes such as Cidex OPA®, Cidex OPA C 1.     Yes 2.     No ________________
9.2. Glutaraldehyde such as Cidex® 1.     Yes 2.     No ________________
9.3. Formalin 10% in normal saline 1.     Yes 2.     No ________________
9.4. Enzymatic cleaners such as Endozime or Biozyme 1.     Yes 2.     No ________________
9.5. Other relevant product/s  _______________________________________ ________________
__________________________________________________________________ ________________
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Introduction
Previous studies have shown that the proportion of adult 
asthma cases attributable to occupational exposure is between 
10-15% of the population.1 More recent studies indicate that 
the population-attributable risk of 10-25% for adult asthma 
related to occupation exceeds that of previously reported 
studies.2,3 Occupational exposure as a cause of adult onset 
asthma may therefore be more common than is appreciated. 
In the South African setting, a population attributable fraction 
of 13% has previously been estimated4 with occupational 
asthma ranked as the second most common occupational lung 
disease after pneumoconiosis.5 
 Health care workers are among the high risk occupational 
groups for developing work-related asthma (WRA), and 
accounting for 16% of WRA patients in a US surveillance 
study.6 It is well known that natural rubber latex (NRL) has 
historically been a common cause of WRA in health care 
workers.7 Recent studies have reported a decrease in NRL 
allergy among health care professionals due to substitution 
with less allergenic alternatives or a reduction in powder and 
protein content of gloves8-11 with the incidence of sensitisation 
to NRL allergens having decreased to 1% in countries that 
have promoted latex avoidance.7 
 With the global decline in the incidence of NRL allergic 
asthma, cleaning agents have increasingly been considered 
a major risk factor for WRA in the health care setting.11,12 
Cleaning agents have been shown to cause work-related 
asthma-like symptoms, new onset asthma with or without 
latency and may also exacerbate asthma symptoms in 
asthmatic individuals.13 It is estimated that 12% of WRA 
is related to the use of cleaning products among patients 
reported in a US surveillance registry.14 Furthermore, among 
the causes of work-related reactive airways dysfunction 
syndrome (RADS), cleaning agents constituted the largest 
group (15% of the cases) reported by the same surveillance 
program for WRA.15
 In population-based studies, workers exposed to cleaning 
agents have been identified as a high risk occupational 
group for developing WRA.16 More specifically, in health 
care settings, health care workers are required to adhere to 
strict procedures when performing general cleaning duties 
including sterilizing medical equipment in order to comply 
with high infection control standards.17 As a result, numerous 
chemicals are being used, some known to be potent respiratory 
sensitisers and irritants. 
 The aim of this review is to focus on the recent literature 
pertaining to WRA associated with cleaning agents in the 
health care setting.
Search strategy
Several electronic literature sources were searched including 
PubMed, Google Scholar and Embase for relevant articles 
using various key words: allergy, asthma, occupational 
asthma, cleaning agents, cleaning products, disinfectants, 
chlorhexidine, ortho-phthalaldehyde (OPA), glutaraldehyde 
(GTA). Reference lists from the articles obtained were also 
screened for relevant publications.
Epidemiology of asthma related to cleaning 
agents 
Few epidemiological studies have investigated the magnitude 
of asthma among health care workers (Table 1). In an 
international prospective population-based study [(European 
Community Respiratory Health Survey-II (ECRHS-II)], 
Kogevinas et al2 demonstrated a two-fold (risk ratio (RR) 
= 2.22; 95% CI: 1.25 to 3.96) increased risk for asthma in 
nurses compared to a reference group (general population 
of professional, clerical and administrative workers). In this 
ECRHS-II study,2 the prevalence of asthma among nurses 
was found to be 4.8%.2 Another ECRHS-II study18 reported 
a slightly higher asthma prevalence of 6%, most likely due 
to different case definitions used for asthma in nurses. This 
is similar to a US study among health care workers,10 which 
demonstrated an overall prevalence of doctor-diagnosed 
asthma with onset after entry into the healthcare profession 
to be 6.6%, with the highest prevalence observed among 
nurses (7.3%) followed by respiratory therapists (5.6%), 
occupational therapists (4.5%) and doctors (4.2%). However, 
a recently published study from the same population of 
health care workers in US reported a much higher prevalence 
of asthma (9.8%) among nurses.11 The difference in asthma 
prevalence between the two studies from the same population 
is likely to be due to the sampling differences in the two 
studies. While the earlier study10 included a total of 941 
nurses with active professional licenses, the later study11 only 
selected 448 nurses based on their longest job held. Asthma 
definition was similar in both studies (Table 1).
Working populations at risk
 
Based on occupations in the health care sector, workers 
considered to be potentially at increased risk include nurses, 
cleaners, physicians, respiratory therapists and occupational 
therapists.11,19–22 Nursing professions typically consist of a 
number of sub-groups, such as registered nurses, licensed 
practical nurses, licensed vocational nurses, nurses’ aides, 
nurse practitioners and nurse trainers.11 Delclos et al10 
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demonstrated that, among nurses, registered nurses had the 
highest prevalence of reported asthma (10,2%), followed by 
licensed vocational nurses (8%) and nurse practitioners and 
nurse aides (6,9%). 
 Other studies also demonstrate that cleaners in hospitals 
also have a higher odds (odds ratio (OR) = 2.1; 95% CI: 1.1 
to 4.2) of current asthma when compared to those who have 
never done a cleaning job or those who were cleaners but 
had not worked in any listed high risk workplaces (industries, 
hospitals, kitchens, laboratories, schools, outdoors, private 
homes, common areas in apartment buildings, other 
healthcare settings).22 
Workplace environmental risk factors and 
causative agents
The extent of exposure to substances in the health care 
setting for substances other than NRL and its association 
with WRA is not well characterised. However, there are a 
few recent studies in the US and Europe that have attempted 
to address this issue.17,18 Cross-sectional studies in the US 
report that aside from powdered latex glove usage (pre-
2000), occupational exposure to cleaning substances (e.g. 
instrument cleaning, surface cleaning) and the use of 
adhesives / solvents are related to asthma after entry into the 
health care profession.10,11
Potential hazardous workplace activities
Patient care activities performed by nurses include drawing 
blood, mixing and administering medications, providing 
wound care and respiratory care, cleaning surgical and 
non-surgical instruments, mopping floors, assisting with 
invasive and other medical procedures and assisting with 
anaesthesia.11 These activities often involve the handling of 
chemical products or the release of air contaminants, which 
may pose a potential health risk. 
 Population based studies have generally applied a job 
exposure matrix (JEM) to categorise chemical agents and 
workplace activities in the health care sector.2,10,11,23 These 
studies have identified a number of broad categories of 
chemical exposures associated with cleaning related activities 
(e.g. patient care, cleaning and disinfection; instrument 
cleaning and disinfection; surface cleaning and disinfection); 
exposure to aerosolized medications such as pentamidine and 
use of adhesives / solvents (i.e. patient care, on surfaces).11 
Furthermore, accidental chemical exposures and spills may 
also result in irritant-induced asthma, another sub-group of 
WRA.11
Potential causative agents (asthmagens)
Various studies indicate that the development of occupational 
asthma is primarily related to the level of exposure to a specific 
agent in the workplace, and less so to individual host factors 
such as atopy and smoking, which have produced inconsistent 
results in a number of studies.24 Broad groups of potential 
sensitisers and irritants present in health care settings include 
surface cleaning products (e.g. bleach); disinfectants and 
sterilants (e.g. GTA and OPA); adhesives/solvents and hand 
cleaners (e.g. chlorhexidine); aerosolized medications (e.g. 
pentamidine); methacrylates in dental and surgical cements; 
NRL products; micro-organisms and mildew.6,21,25 
 Health care workers are commonly exposed to cleaning 
products that contain respiratory irritants and sensitisers. Most 
cleaning agents are irritants however, some cleaning agents 
have both irritant and sensitizing properties. Some of the 
known irritants in cleaning agents include chlorine, ammonia, 
hydrochloric acid, monochloramine, sodium hydroxide, 
quaternary ammonium compounds (e.g. benzalkonium 
chloride), monoethanolamine.13 Sensitisers in cleaning 
agents include but are not limited to amine compounds (e.g. 
monoethanolamine), disinfectants (e.g. GTA and OPA), 
quaternary ammonium compounds, scents (e.g. pinene, 
d-limonene, eugenol), preservatives (e.g. isothiazolinones 
and formaldehyde).13 
 Delclos et al10 in their studies of asthma further classified 
chemical products and agents in the health care sector into 
three main groups, i.e. instrument cleaning agents, building 
surface cleaners and adhesives/solvents/gases (Table 1). 
However, while the specific inventories of chemical products 
used in the health care setting may not always be generalizable 
across hospitals in different countries, the active ingredients 
in these cleaning products could be similar across hospitals.
Instrument cleaning/ disinfecting agents
Health care workers, especially nursing personnel, are 
exposed to cleaning agents used for high-level disinfection 
of heat sensitive medical equipment such as endoscopes. Of 
particular importance are the two aldehydes, GTA and OPA. 
GTA has been used for over 40 years in health care settings 
not only in disinfection of medical equipment but also as 
a fixative for electron microscopy and x-ray films. Several 
clinical case reports have been reported in the literature 
linking GTA and various health effects such as occupational 
asthma26,27 and allergic contact dermatitis.28 In 1999, Food 
and Drug Administration (FDA) approved OPA to be used 
as a high-level disinfectant. Subsequently, OPA has been 
considered a safer replacement for GTA in some health care 
settings. However, OPA has also been recently reported to 
cause occupational asthma29 and anaphylaxis30–33 in various 
case reports, including patients undergoing instrument 
procedures. 
 The association between asthma and cleaning agents 
used for medical equipment disinfection has also been 
demonstrated in epidemiological studies and surveillance 
systems. A study by Arif et al11 reported a significantly 
higher odds of reported asthma among health care workers 
exposed to medical instrument cleaning agents (adjusted OR 
= 1.67; 95% CI: 1.06 to 2.62). Six percent of occupational 
asthma cases reported to a surveillance system in the United 
Kingdom were attributable to GTA.34 Although not specified 
in the article34 it can be assumed that most, if not all of 
these cases, were from heath care settings where GTA was 
commonly used. 
Surface cleaning agents
Building surface cleaning is an inherent aspect of activities 
performed in the health care setting. Cleaners and janitors are 
widely reported as high-risk occupations in both developed 
and developing countries.35–37 In a US surveillance study14 
janitors, cleaners and housekeepers formed the largest (22%) 
occupational group in which exposure to cleaning products 
was associated with WRA, followed by a group of nurses and 
nurses’ aides (20%). In this study14 the health sector had the 
highest number (39%) of patients with WRA due to cleaning 
products. While general  cleaning tasks have been specifically 
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Table 1: Recent epidemiological studies on work-related asthma associated with cleaning agents in the health care setting
Author/year Population (n) Prevalence of asthma 
phenotypes/symptoms
High risk activities 
significantly associated 
with asthma OR/RR 
(95% CI)
Cleaning agents significantly 
associated with asthma OR/
RR/MR (95% CI)
Diagnostic tools used
Arif and 
Delclos, 2012
Health care workers
 (n = 3650)
WRAS: 3.3%
WEA: 1.1% 
OA: 0.8%
Not specified Bleach:3.72(1.70-8.12); 
cleaners/abrasives: 2.50(1.19-
5.25); cleaners for rest rooms 
and toilets:4.60(2.12-9.95); 
detergents:2.84(1.33-6.08); 
ammonia:2.45(1.28-4.69); 
glutaraldehyde/OPA: 
2.18 (1.17-4.07); 
formaldehyde:2.66(1.03-6.86); 
Chloramines:4.81(1.28-18.06) 
and ethylene oxide: 2.97(1.21-
7.33)
Questionnaire
Dumas et al, 
2012
Health care workers
(n=724)
Asthma and report 
of asthma attacks, 
respiratory symptoms 
or
asthma treatment in the 
last 12 months:
Men: 39.5%  
Women: 31.6%
General cleaning/ 
disinfecting tasks: 
2.32(1.11-4.86)
Decalcifiers:2.32(1.01-5.31)
Ammonia:3.05(1.19-7.82)
Sprays:2.87(1.02-8.11)
Questionnaire
Expert assessment
Asthma-specific JEM
Vizcaya et al, 
2011
Professional cleaners 
including hospital 
cleaners
(n=917)
Doctor-diagnosed 
asthma: 9%
Asthma attack in the 
last 12 months or 
woken by an attack 
of shortness of breath 
in last 12 months or 
currently taking any 
medicine for asthma: 
11%
Asthma with the first 
asthma attack at the age 
of 16 years or later: 5%
Hospital cleaners: 
activities not specified 
2.1(1.1-4.2)
Hydrochloric acid:1.7(1.1-
2.6); multiple purpose 
products:1.6(1.0-2.5); 
ammonia:1.6(1.0-2.5); 
perfumed products:1.5(1.0-2.4); 
air fresheners:1.5(1.0-2.4), 
waxes:1.6(1.0-2.6), 
degreasers:1.6(1.0-2.4) and 
carpet cleaners:2.2(1.0-5.1)
Questionnaire
Arif et al, 
2009
Health care workers
(n=3634)
Doctor-diagnosed 
asthma with onset 
after entry into the 
healthcare profession: 
9.8% among nurses
BHR-related 
symptoms: 31.3% 
among nurses
Medical instrument 
cleaning:1.67(1.06-2.62)
Building surface 
cleaning:1.72(1.00-2.94) 
Adhesives, glues and/or solvents 
for patient care:1.51(1.08-2.12)
Questionnaire
Job exposure matrix
Delclos et al, 
2007
Health care workers
(n=3650)
Doctor-diagnosed 
asthma with onset 
after entry into the 
healthcare profession: 
Overall: 6.6%
Physicians: 4.2% 
Nurses: 7.3%
Respiratory therapists: 
5.6% 
Occupational 
therapists: 4.5% 
BHR-related 
symptoms: overall 
27.4%
Medical instrument 
cleaning:2.22(1.34-3.67)
Building surface cleaning: 
2.02(1.20-3.40)
Adhesives for patients 
care:1.65(1.22-2.24)
Chemical spills: 2.02(1.28-3.21)
Questionnaire
Job exposure matrix
Kogevinas et 
al, 2007
General population 
(n = 6837)
Asthma attack or taking 
asthma
medication in the 
past 12 months: 4.8% 
among nurses
Nursing: activities not 
specified 2.22(1.25-3.96)
Acute symptomatic 
inhalational 
event:3.33(1·00-11·13)
Questionnaire
Job exposure matrix
Expert assessment
Methacholine challenge 
test
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Table 1 cont: Recent epidemiological studies on work-related asthma associated with cleaning agents in the health care setting
Author/year Population (n) Prevalence of asthma 
phenotypes/symptoms
High risk activities 
significantly associated 
with asthma OR/RR 
(95% CI)
Cleaning agents significantly 
associated with asthma OR/
RR/MR (95% CI)
Diagnostic tools used
Mirabelli et al, 
2007
General population 
(n = 2813)
Asthma attack in the 
last 12 months or 
woken by an attack of 
shortness of
breath in last 12 months 
or currently
taking any medicine 
for asthma: 6% among 
nurses
Not specified Ammonia and/or Bleach: 
2.16(1.03-4.53)
Questionnaire
IgE test to common 
aeroallergens
Delcloset al, 
2006
Health care workers
(n=118)
Self-reported history of 
asthma: 22.9%
Prior physician 
diagnosis of asthma: 
20.3%
PC20 ≤8 mg/ml: 55.1%
PC20 ≤4 mg/ml: 48.3%
Not specified Not specified Questionnaire
Industrial hygienist 
interview
Methacholine challenge 
test
IgE test to common 
aeroallergens
IgE test to latex
Key:-
Bronchial hyper-responsiveness (BHR)-related symptoms: combination of eight questions on asthma and allergy symptoms that had exhibited the best 
combination of sensitivity and specificity when compared to non-specific bronchial challenge testing with methacholine
WRAS (work-related asthma symptom): wheezing or whistling OR shortness of breath at work that gets better when away from work or worsens on return to 
work
WEA (work exacerbated asthma): wheezing or whistling OR shortness of breath at work that gets better when away from work or worsens on return to work 
AND physician diagnosis of asthma AND onset of asthma before entry into health care profession
OA (occupational asthma): wheezing or whistling OR shortness of breath at work that gets better when away from work or worsens on return to work AND 
physician diagnosis of asthma AND onset of asthma after entry into health care profession
PC20: provocative concentration of methacholine that produced a 20% or greater decrease in forced expired volume in one second (FEV1) from the baseline
JEM: job exposure matrix
IgE: Immunoglobulin E
OR: odds ratio
RR: risk ratio
MR: mean ratio
Table 2: Cleaning agents associated with work-related asthma in health care workers
Instrument cleaning/disinfection Building surface cleaners Adhesive removers and hand cleaners/
disinfectants
Glutaraldehyde
Isopropanol
Ortho-phthalaldehyde
Sodium sesquicarbonate
Subtilisins (enzymatic cleaners)
Acetic acid/acetic acid anhydride
Ammonia/ammonium hydroxide
Bleach
Butyl paraben, ethyl paraben, methyl 
paraben
Diethanolamine
Diethylene-glycol n-butyl ether
Hydrochloric acid
Isoparaffinic hydrocarbons
Phosphoric acid
Quaternary ammonium compounds 
Sodium sulfate
Sulfuric acid
Adhesive removers
• Acetone
• Dipropylene glycol methyl ether
• Ethanol
• Isoparaffinic hydrocarbons
• Isopropanol
Stoma care products
• Carboxymethyl ether
• Hexane-based skin bond
• Methylbenzene
Hand cleaners / disinfectants
• Chlorhexidine
Other
• Methylene chloride
• Trichloroethane
Source: Modified from reference 10
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linked to asthma,16,38 cleaners who are at increased risk 
are often employed in industries other than the health care 
sector.9,39
 For general cleaning purposes, Midena-Ramon et al9 
found bleach, ammonia and hydrochloric acid as the most 
commonly used irritant cleaning products used in a diluted or 
undiluted form, with airborne chlorine and ammonia detected 
during cleaning activities. A recent study among cleaning 
workers in Spain reported an increased risk of asthma 
symptoms in workers who had used hydrochloric acid (mean 
ratio [MR] = 1.7; 95% CI: 1.1 to 2.6), degreasers (MR = 1.6; 
95% CI: 1.0 to 2.4), air fresheners (MR = 1.5; 95% CI: 1.0 to 
2.4) or ammonia (MR = 1.6; 95% CI: 1.0 to 2.5) in the last 
year.22 
 Cleaning agents comprised the most common agent 
reported (20.5%) among individuals with suspected 
occupational asthma presenting with acute asthma symptoms 
to the emergency units of the two large public hospitals in 
Cape Town.40 The study by Kogevinas et al2 demonstrated a 
1.8 fold (RR = 1.80; 95% CI: 1.01 to 3.18) increased relative 
risk for asthma with the use of cleaning products (including 
different occupations and sectors in the analysis). A similar 
finding was observed among nurses in a study by Arif et al11 
that showed a significantly higher odds of reported asthma for 
exposure to general building cleaning agents and disinfectants 
(adjusted OR = 1.72; 95% CI: 1.00 to 2.94). According to a 
large scale European based study, nurses who reported using 
ammonia and/or bleach were found to have a more than 
two-fold (RR = 2.16; 95% CI: 1.03 to 4.53) increased risk 
of developing new-onset asthma compared to referents.18 An 
increased relative risk for asthma (RR = 1.51; 95% CI: 1.36 – 
1.66) has also been reported among cleaners in the health care 
setting in Finland. 
 Apart from the effect of individual agents, some other 
asthmagens may be produced when different cleaning agents 
are mixed together.13 Chloramines may be released when 
hypochlorite from bleach is mixed with ammonium salts.13 
Chloramines have been reported to cause occupational 
asthma among pool workers.41 On the other hand, chlorine, a 
common respiratory irritant is generated when acid is mixed 
with bleach.14
 Application of some cleaning agents can yield high 
levels of volatile organic compounds (VOC) that can also 
act as airway irritants.13 This suggests that there is potential 
for multiple exposures among workers who are involved in 
cleaning-related tasks. 
Adhesives/solvents and hand cleaners
Pechter et al6 reported that exposure to solvents accounted 
for 7% of reported WRA, and various chemicals (including 
glues and solvents) were associated with asthma among 29% 
of aides and therapists in the US. Walk-through surveys 
performed by occupational hygienists in US hospitals 
revealed that routine patient care activities performed by 
nurses often included the use of adhesives and adhesive 
removers, particularly in surgical and intensive care units.10,11 
These compounds are used to apply and/or remove dressings 
and adhesive bandages, as well in case of stoma care. The 
compounds may contain respiratory irritants such as dimethyl 
ether, dipropylene glycol methyl ether and isoparaffinic 
hydrocarbons, and may be administered in an aerosolized 
form. Arif et al11 found an almost twofold increased odds 
of asthma for nursing professionals who were exposed to 
adhesives, adhesive removers and/or solvents.
 A recent study by Nagendran et al42 among health care 
workers in the wards and operating theatres of a UK district 
general hospital reported four cases of occupational allergy 
among 14 health care workers with symptoms associated 
with the use of chlorhexidine 4% hand wash. However a 
previous Danish study43 among 104 health care workers using 
0.5–1.0% chlorhexidine hand wash did not identify any cases 
of chlorhexidine allergy. Although there have been very few 
reported occupational chlorhexidine IgE-mediated allergic 
reactions, several case reports exist in the literature of these 
reactions observed in  patients.42
Other host-associated risk factors
Common host-associated factors that have been associated 
with asthma include age, gender, seniority, smoking status 
and atopy.10,11 Delclos et al10 demonstrated that increasing 
seniority was positively associated with reported asthma. 
The study by Kogevinas et al2 of workers across different 
industries, demonstrated that atopic individuals had a 
significantly higher relative risk (RR = 2.9; p-value = 0.019) 
for new-onset asthma than non-atopics. The study2 also 
demonstrated an increased risk for new-onset asthma in 
participants with a parental history of asthma (RR = 2.1) than 
those without and in non-smokers (RR = 1.8) compared to 
current smokers.
 Female health care workers appear to be more affected 
than men. In a recent study17 among health care workers in the 
USA, females were found to have a higher prevalence of all 
asthma phenotypes such as WRA symptoms (3.6% vs. 1.8%), 
work exacerbated asthma (1.3% vs. 0.3%) and occupational 
asthma (1.0% vs. 0.1%) than their male counterparts. Similar 
findings were reported in a large population European study2 
that found a slightly higher relative risk of new-onset asthma 
among women (RR = 1.13) compared to men. It is likely that 
the gender distribution of work plays a role.
Pathophysiological mechanisms
The pathophysiology of asthma associated with cleaning 
agents is not well characterized. It is widely accepted that 
high molecular weight (HMW) agents, which are commonly 
proteins such as NRL and proteolytic enzymes cause asthma 
through immunoglobulin E (IgE)-mediated mechanism.44 
IgE-mediated immunological mechanisms are also believed 
to play a major role in occupational asthma induced by some 
low molecular weight (LMW) agents such as acid anhydrides 
and platinum salts.44 However, only a small proportion of 
individuals with occupational asthma due to most LMW 
agents have specific IgE in the serum suggesting an IgE-
independent immunological mechanism (probably involving 
cell-mediated and mixed Th1 and Th2 responses) may be 
playing a greater role.44,45 The mechanism of asthma caused 
by non-immunological (irritant) mechanisms is not clearly 
understood. However, it is believed that irritants can destroy 
bronchial epithelium thereby exposing nerve endings and 
subsequently trigger a neurogenic inflammation characterized 
by bronchoconstriction, increased mucus secretion and 
oedema, which are typical features of asthma.44,46 It is likely 
that IgE-independent immunological and irritant mechanisms 
play a greater role in asthma associated with cleaning agents 
as most cleaning agents are of LMW. 
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 Some animal and human data are available for common 
disinfectants such as GTA and OPA. Experimental studies in 
mice have shown that GTA and OPA are both dermal and 
respiratory irritants and sensitisers. Interestingly, OPA was 
found to be more irritant than GTA in both in vitro EpiDerm 
Skin Irritation Test and in-vivo tests.47 The in vitro EpiDerm 
Skin Irritation Test is a test used to assess dermal corrosion 
potential of chemicals and utilizes a normal, human cell-
derived, metabolically active skin model closely mimicking 
the human epidermis.47 There was a concentration-dependent 
increase in lymphocyte proliferation in the draining lymph 
nodes (DLNs) of the mice in all three studies reported from 
the US,47–49 B lymphocytes being the majority in one study.49 
In addition, a population of B lymphocytes expressing IgE 
was also increased in all these studies, in which mice were 
exposed to GTA48 and OPA.47,49 Another finding supporting 
the immunological mechanism caused by OPA and GTA was 
a predominance expression of Th2 cytokines (IL-4, IL-5 and 
IL-13).47-49 The two mice studies reported from Japan also 
demonstrated the production of specific IgE to OPA.50,51 In 
the US studies, there was a significantly increase in specific 
IgE to OPA in mice that were dermally exposed,47 but they 
were not detected in those exposed through the inhalational 
route.49 Total serum IgE was also elevated in two studies.47,48
 In some clinical case reports of patients with anaphylaxis 
due to OPA, skin prick and intracutaneous tests have been 
used to confirm the presence of sensitisation.30-33 More 
importantly, OPA specific IgE was detected by ELISA in 
all three patients who developed anaphylaxis due to OPA.32 
Furthermore, histamine was released from the basophils 
of these patients but not from healthy controls.32 However, 
when basophils from the healthy controls were sensitized to 
the patient’s serum and then exposed to OPA, these cells also 
released histamine.31 This suggests the presence of an OPA 
specific heat sensitive component (OPA specific IgE) in the 
patient’s serum capable of sensitizing control basophils.31
 In addition to these immunological data, the clinical 
history in the case reports of asthma due to OPA and GTA also 
demonstrated a latency period between first exposure to these 
agents and development of symptoms implying immunologic 
response associated with these agents.32,52 Late reactions were 
also observed in patients who underwent specific inhalation 
challenge test to glutaraldehyde, alluding to an underlying 
allergic mechanism.52
Conclusion
With the decline in extensive use of high protein powdered 
latex gloves, cleaning agents are increasingly becoming a 
major causative agent of WRA in health care settings. Despite 
this pattern, cleaning agents continue to be widely used in 
health care settings globally due to widespread infection 
control policies. The substitution of one hazardous cleaning 
agent (GTA) by OPA in various settings has however resulted 
in OPA increasingly becoming a major risk factor to patients 
and health care workers.
 Future studies need to use more objective measures of 
exposure assessment and characterization of cleaning agents 
used in the health care setting. More reliable and valid data 
can be obtained through a combination of methods including 
self-reported information from questionnaires, job-exposure 
matrices, expert judgments and quantitative measurements.
 More efforts need to be directed towards conducting 
mechanistic studies to better understand the pathophysiological 
mechanisms underlying asthma and other respiratory 
health effects associated with cleaning agents in health care 
settings. Elucidation of exposure-response relationships and 
other host-associated risk factors may contribute towards 
developing preventive strategies for WRA among health care 
workers.
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 APPENDIX J 
Response rates obtained following stratified random sample selection in both hospitals  
South African Hospital (SAH) 
 
Tanzanian Hospital (TAH) 
 Study 
population 
Study 
participants 
Response 
rate (%) 
 Study 
population 
Study 
participants 
Response 
rate (%) 
Out-patient 
clinics 
104 53 51 Out-patient 
clinics 
72 54 75 
Intensive care 
units 
270 107 40 Intensive care 
units 
117 65 56 
Operating 
theaters 
205 92 45 Operating 
theatres 
193 117 61 
Emergency 
units 
103 36 35 Emergency unit 127 78 61 
ENT ward 16 14 88  
Vascular 
radiology 
26 25 96 Central Sterile 
Services 
Department 
24 22 92 
Hemodialysis 
unit 
35 19 54 Hemodialysis 
unit 
27 17 63 
Total 759 346 46 Total 560 353 63 
 
 
 
 
 
